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SAVE Survival and Ventricular Enlargement  
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 Summary 
 
Greater renin-angiotensin-aldosterone system (RAAS) activity, as reflected by higher levels 
of renin and aldosterone, has been associated with worse prognosis in patients with chronic 
heart failure (HF). These findings provided the basis for clinical trials with RAAS inhibitors 
in these patients. Similarly, higher levels of cortisol have been correlated with worse 
outcomes in chronic HF. However, there is lack of information with respect to the activity of 
RAAS and glucocorticoid secretion in patients with decompensated HF. Is RAAS universally 
activated in patients with worsening HF? Are cortisol levels elevated in these patients? 
Furthermore, the prognostic importance of RAAS mediators and plasma glucocorticoid levels 
in patients with decompensated HF remains unknown.  
 
Diuretic therapy is one of the initial therapeutic strategies in patients with decompensated HF 
and fluid congestion. Diuretics decrease the extracellular volume and suppress natriuretic 
peptide levels while they in parallel stimulate RAAS activity early after initiation of therapy. 
However, it is unknown if the dissociation between RAAS and natriuretic peptides after 
initiation of diuretic treatment persists over time. If that remains present in the long term, 
augmentation of the natriuretic peptide actions on top of RAAS inhibition might be of further 
benefit in patients with HF, given their suppressing effects on RAAS and sympathetic 
nervous system (SNS) and vasodilating and natriuretic properties. 
 
The late steps in corticosteroid synthesis are mediated by aldosterone synthase for 
aldosterone and 11beta-hydroxylase for cortisol respectively. These enzymes are highly 
homologous and are encoded by genes that lie in tandem in chromosome 8 in humans. A 
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 common single nucleotide polymorphism (-344T/C) in the promoter region of aldosterone 
synthase gene (CYP11B2) has been associated with aldosterone levels and the aldosterone to 
renin ratio in healthy subjects and patients with hypertension. Similar findings have been 
shown for another polymorphism in the same gene, the Intron 2 conversion (IC). Moreover, 
these polymorphisms have been correlated with the 11-deoxycortisol to cortisol ratio, which 
represents an index of 11beta-hydroxylase activity. In patients with severe HF of African-
American origin -344T/C polymorphism has been associated with prognosis. However, the 
data with regards to the -344T/C polymorphism (and the IC) in relation to gluco- and 
mineralo-corticoid secretion and survival in patients with HF of Caucasian origin remains to 
be elucidated. 
 
The hypothesis of the current thesis was that plasma levels of RAAS mediators and 
glucocorticoids are associated with markers of HF severity in patients with decompensated 
HF and in patients with stable HF. Moreover, the dissociation between RAAS activity and 
natriuretic peptides seen early after initiation of diuretic treatment persists in the medium to 
the long term. In addition, that higher levels of plasma renin, mineralo- and gluco- corticoids 
are associated with worse prognosis in patients with decompensated HF. Lastly, that 
CYP11B2 polymorphisms -344T/C and IC are associated with mineralo- and gluco-corticoid 
secretion and survival in these patients. In order to test these hypotheses, 722 patients with 
decompensated HF were enrolled in the current studies. Of these, 453 surviving patients 
returned for the follow-up visit 4-6 weeks after discharge. All these patients had detailed 
clinical and biochemical phenotyping and additionally genotyping of the -344T/C and IC 
CYP11B2 polymorphisms.  
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 In this thesis, it was shown that levels of RAAS mediators, plasma renin concentration (PRC) 
and aldosterone, are not on average elevated during hospital admission in patients with 
decompensated HF. RAAS activity has been previously shown to be activated in patients 
with advanced congestive HF. However, high doses of diuretics were used and a significant 
proportion of patients were taking an aldosterone blocker in these studies. The results of the 
current study are in accordance with early studies with small numbers of untreated patients 
with congestive HF that reported normal or low levels of renin and aldosterone.  
 
PRC and aldosterone levels were higher at follow-up compared with hospital admission 
likely due to a decline in the intravascular volume. In contrast, natriuretic peptide levels were 
lower at the follow-up visit and that is likely to contribute to the higher levels of RAAS 
mediators after discharge as these peptides exert suppressing effects on the RAAS and SNS.  
 
Similarly to PRC and mineralocorticoid levels, glucocorticoid concentrations were within the 
normal range in patients with decompensated HF. Furthermore, it was shown for the first 
time that cortisol levels during admission are associated with clinical status and prognostic 
markers of HF, such as B-type natriuretic peptide  (BNP) and troponin. That may represent 
an association reflecting the greater stress response due to HF severity. However, growing 
evidence supports that cortisol under conditions of altered intracellular redox state becomes a 
mineralocorticoid agonist and that might contribute to these associations. Overall, these 
findings call into question the “normal range” of cortisol levels in patients with HF. 
 
Moreover, 11-deoxycortisol to cortisol ratio was shown to be lower in patients with left 
ventricular (LV) remodeling, lower blood pressure and greater RAAS activity during hospital 
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 admission. 11-deoxycortisol to cortisol ratio represents an index of 11beta-hydroxylase, 
which is an enzyme regulated by adrenocorticotropic hormone (ACTH). Lower 11-
deoxycortisol to cortisol ratio represents higher enzyme activity and reflects a state of chronic 
ACTH stimulation. These findings indicate that patients with features of worse HF are 
characterised by activation of the hypothalamus-pituitary-adrenal (HPA) axis.  
 
PRC but not aldosterone was associated with an increased risk of all-cause mortality in 
patients with decompensated HF, even after adjustment for a combination of other variables 
shown to exert an independent prognostic value in the overall HF population. In contrast, 
cortisol was not an independent prognostic factor in patients with decompensated HF.  
 
Lastly, no association was seen between aldosterone levels and -344T/C or IC polymorphism 
in the current study. CYP11B2 -344TT genotype was associated with relative impairment of 
11beta-hydroxylase, as reflected by the higher 11-deoxycortisol to cortisol ratio, in keeping 
with previous studies in healthy subjects and patients with hypertension. However, no 
association was found between CYP11B2 polymorphisms and prognosis in the current 
studies. 
22
   
 
1. Chapter One – General introduction 
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 1.1 Epidemiology and pathophysiology of HF  
 
1.1.1 Definition 
HF is a complex clinical syndrome defined as an abnormality in the cardiac structure or 
function leading to heart inability to deliver oxygen to the tissues at a sufficient rate in 
relation to their metabolic needs (1). HF is characterised by symptoms such as breathlessness 
during exertion or at rest and fatigue and signs such as pulmonary congestion and peripheral 
oedema. It can present suddenly as acute HF, usually as a consequence of an acute coronary 
syndrome, or in a chronic fashion characterised by gradual worsening of HF symptoms and 
signs. Chronic HF can also be complicated by an acute on chronic deterioration requiring 
urgent treatment or hospitalisation due to decompensation. Depending on the ventricular 
systolic function, it can be also classified as HF with reduced systolic function (HFrSF) or as 
HF with preserved systolic function (HFpSF). The ejection fraction (EF), which refers to the 
ratio of stroke volume to end-diastolic ventricular volume, has been traditionally employed to 
describe HF according to systolic function. Although there is no clear cut-off, patients with 
HFrSF have left ventricular EF (LVEF) <35-40%; these are the patients who have been 
principally enrolled in the major trials in HF and gained benefit with regards to mortality risk 
reduction from the available therapeutic measures. On the other hand, patients with HFpSF 
have LVEF >40-45%; these are the patients with evidence of diastolic dysfunction and to 
date no treatments have improved clinical outcomes in this group of patients (2). 
 
1.1.2 Epidemiology 
The prevalence of HF in developed countries is estimated to be approximately 1-2% of the 
adult population (3). HF is predominantly a syndrome of the elderly and its prevalence 
increases markedly with age (4) (5). In addition, it is the most common cause of 
hospitalisation in patients over 65 years of age (6). There has been an increase in the 
prevalence of HF in the past decades, at least partially because of the overall increase in the 
24
 number of elderly people due to the longer life expectancy, as well as due to advances in the 
treatment of precipitating factors for the development of HF, such as the acute coronary 
syndromes (7). Similar to the prevalence, the incidence of HF increases with age and has 
been shown to be higher in males compared with females in all age groups (8).  
 
Apart from the data about the overall prevalence of HF, estimates of the prevalence of HF 
with preserved and reduced systolic function have been separately reported by studies, which 
assessed the LV systolic function. Among patients with symptomatic HF in population-based 
and hospital studies, approximately half of them have HF with systolic dysfunction and the 
other half have normal or near-normal systolic function (9) (10) (11). These studies also 
revealed differences in the characteristics of patients with HFpSF and HFrSF; patients of the 
former group are older, more likely to be female and have more frequently history of 
hypertension and diabetes. In contrast, patients of the latter group are younger and more 
likely to be male. 
 
HF is associated with poor prognosis; data based on population-based studies prior to the 
modern era of treatment showed that within 5 years of diagnosis, approximately 60-70% died 
(12). Similarly, mortality and morbidity following hospitalisation with HF is markedly high. 
Recent data suggest that advances in the prevention and management of HF have resulted in 
decline in HF hospitalisation rates; however, the improvement in long-term mortality, 
although statistically significant, is clinically modest (13). Interestingly, various studies 
reported similar prognosis between HFpSF and HFrSF (14) (15). Nevertheless, a meta-
analysis showed that patients with HFpSF had mortality approximately half that of patients 
with HFrSF (16). 
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 1.1.3 Aetiology - Pathophysiology of HF  
The aetiology and pathophysiology of HFrSF has been extensively investigated. The 
ventricular systolic dysfunction results from loss of a critical number of cardiomyocytes due 
to myocardial injury, or alternatively in response to a disruption of the myocardium ability to 
generate force, thereby altering the cardiac contractility (17). The predisposing factors may be 
of a sudden onset, as in the case of a myocardial infarction (MI); alternatively, they may have 
a gradual course with pressure or volume overloading, such as in hypertension or valvular 
heart disease. Moreover, hereditary factors related to genetic cardiomyopathies or exogenous 
factors with cardiotoxic effects can cause HF. Irrespective of the nature of the underlying 
aetiology, the damage to the myocytes and the extracellular matrix leads to changes in the 
morphology and structure of the ventricles (remodeling), resulting in deterioration in their 
systolic function (18) (19). The progression of the HF syndrome due to remodeling occurs in 
two main ways (20). Inter-current acute coronary events produce further damage and decline 
in the pumping capacity of the heart. Alternatively, compensatory mechanisms are activated 
due to the reduced systolic function with over-expression of biologically active molecules, 
which exert systemic effects. The above adaptive neurohumoral mechanisms, although 
beneficial for the maintenance of cardiovascular homeostasis in the short term, result in 
mechanical and electrical dysfunction of the heart in the long term; they also exert deleterious 
effects on other organs leading to a vicious cycle in which the heart is unable to provide 
adequate tissue perfusion with further progression of HF over time (Figure 1-1)  
 
In contrast to HFrSF, the pathophysiology of HFpSF remains to be fully elucidated. Diastolic 
dysfunction, with impairment of LV relaxation and compliance, is likely to exert a principal 
role in these patients (21). Moreover, other systemic factors, as the vascular distensibility 
(22), might also play a pathophysiological role; however, the significance of activated 
neurohumoral pathways remains unclear in patients with HFpSF
26
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 1.1.3.1 Neurohumoral activation and the RAAS in HF 
The neurohumoral adaptive responses that occur in HF due to LV systolic dysfunction 
(LVSD) include mainly the activation of the SNS (23) (24) and the RAAS (25) (26). In 
addition, other pathways related to the expression of cytokines and other inflammatory 
mediators are also up-regulated (27) (28). In parallel, counter-regulatory systems, such as 
natriuretic peptides, are stimulated antagonising the effects of the SNS and RAAS activation 
(29) (30).  
 
The adrenergic nervous system is one of the first adaptive pathways that are activated early in 
the course of HF with systolic dysfunction. The SNS exerts positive cardiac inotropic and 
chronotropic effects in order to restore the decrease in the cardiac output (25). It also leads to 
peripheral vasoconstriction and stimulation of the nonosmotic release of arginine vasopressin, 
which causes antidiuresis and further enhances vasoconstriction, aiming to maintain the 
organ and tissue perfusion. Furthermore, the SNS is a stimulator of the RAAS, which in turn 
by secreting angiotensin II and aldosterone, results in further vasoconstriction and increase in 
intra-vascular volume.  
 
The main mechanisms contributing to RAAS activation in HF include sympathetic adrenergic 
stimulation, decrease in intravascular volume and renal hypoperfusion, which promote renin 
release from a juxtaglomerular apparatus (JGA) in the kidneys (31). Renal perfusion pressure 
is principally involved in the regulation of renin secretion. Specific type of cells in the 
afferent arterioles sense changes in pressure and transmit signals to the juxtaglomerular 
apparatus, which in turn modifies the release of renin into the circulation. The JGA regulates 
also renin secretion through the macula densa cells, which are specific epithelial tubular cells 
at the renal distal tubule, lying in close proximity with the afferent arterioles. These cells 
sense Na
+
 flux through the Na
+
K
+
2Cl
-
 transporter and give constantly signals to the JGA to 
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 adapt the renin secretion (32). In addition, the sympathetic system exerts a dual effect, with 
beta-adrenergic receptors stimulating and alpha-adrenergic receptors suppressing renin 
release (33). Apart from these regulatory factors there is also a negative feedback mediated 
by angiotensin II, which suppresses the release of renin by the juxtaglomerular cells. The 
clinical importance of this negative feedback circuit has been fully manifested with the use of 
RAAS inhibitors which increase renin levels several-fold (34).  
 
The renin secreted by the JGA, acts on the circulating angiotensinogen, which is synthesised 
in the liver, to form the biologically inactive decapeptide angiotensin I. This is converted by 
angiotensin-converting enzyme (ACE) into the biologically active octapeptide angiotensin II. 
Angiotensin II effects are mediated through specific angiotensin II receptors on the cell 
membranes. Activation of angiotensin II type 1 (AT1) receptors promotes various effects 
including systemic and renal vasoconstriction and enhances the activity of the SNS (35) (36) 
(37). Angiotensin II also stimulates via the same receptors the release of sodium-retaining 
hormone aldosterone from the adrenal cortex. The actions of angiotensin via the AT1 receptor 
aim to restore the blood volume and renal perfusion and to maintain the circulatory 
homeostasis. However, the sustained activation of these receptors leads to adverse effects, 
including oxidative stress, vascular smooth muscle cell (VSMC) and cardiomyocyte 
hypertrophy with vascular and ventricular remodeling (38) (39) (40). In contrast, the effects 
of angiotensin II acting via angiotensin II type 2 (AT2) receptors have been less well 
characterised, but evidence suggests that activation of AT2 receptors attenuates some of the 
effects mediated by AT1 receptor by inhibiting cell growth and promoting vasodilation (41) 
(42).  
 
Apart from angiotensin II other peptides of the RAAS family have recently received 
increased attention in HF. Angiotensin 1-7 is a heptapeptide that is generated form 
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 angiotensin I and angiotensin II. ACE2, a homologue of ACE, is expressed mainly in the 
heart, kidneys and vasculature and degrades angiotensin I to angiotensin 1-9 and angiotensin 
II to angiotensin 1-7 (43) (44). Angiotensin 1-9 is further degraded to angiotensin 1-7 by 
ACE (44). The expression of angiotensin 1-7 has been shown to be up-regulated in failing 
human heart ventricles (45). Similarly, the expression of ACE2 in the myocardium has been 
found to be increased in patients following MI and in patients with HF (45) (46). Angiotensin 
1-7 is an active peptide and exerts its effects by binding to the receptor Mas (47). There is 
growing evidence that angiotensin 1-7 is part of an axis, which counterbalances some of the 
angiotensin II actions. ACE2 degrades angiotensin II to angiotensin 1-7, reducing the 
concentrations of the former and its vasoconstricting, proliferative and hypertrophic effects 
on myocardium. Moreover, angiotensin 1-7 prevents angiotensin II- induced cardiac 
hypertrophy and fibrosis independent of blood pressure (48) (49) (50). Furthermore, 
angiotensin 1-7 has also been shown to have vasodilatory properties in animals, however, that 
has not been replicated in healthy subjects or patients with HF (51) (52).  
 
1.1.3.2 Aldosterone secretion in HF 
The secretion of aldosterone, which is the main mineralocorticoid, is stimulated by RAAS 
activation in patients with HF. In healthy subjects, whose sodium intake is normal, 
aldosterone secretion ranges from 270 to 485 nmol per day; in patients with HF, aldosterone 
secretion may reach 1100 nmol per day (53). The secretion of aldosterone in HF per se, 
however, is difficult to be evaluated as most of the available data come from studies with 
patients taking diuretic therapy or some form of a RAAS inhibitor (54) (55) (56). Diuretics 
are well known to stimulate aldosterone synthesis, thus, raised concentrations of plasma 
aldosterone and renin in patients with HF may be due to the HF itself, to diuretic treatment or 
both. In contrast, ACE inhibitors or angiotensin receptor blockers (ARBs) suppress 
aldosterone secretion. A small number of early studies with untreated HF patients provided 
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 evidence with regards to aldosterone secretion in patients not treated with a diuretic or a 
RAAS inhibitor. In patients with mild to moderate HF, plasma concentrations of aldosterone 
were well within the normal range (57). In patients with untreated severe HF, aldosterone 
levels were not universally increased (58). The wide variation of aldosterone levels in the 
above studies has been attributed to the degree of compensatory expansion of the circulating 
volume, which in turn suppresses renin and consequently aldosterone secretion (59). Indeed, 
plasma renin was not universally increased in patients with untreated severe congestive HF 
(58). Moreover, normal renin levels were reported in patients with untreated mild congestive 
HF (60). In accordance, patients with untreated LVSD or HF had normal plasma renin 
activity (PRA) (61). Overall, plasma renin and aldosterone levels in HF reflect a dynamic 
interplay between pathways with stimulating and inhibiting effects on aldosterone secretion. 
In addition to these regulatory systems, other factors, such as the reduced aldosterone 
clearance due to hepatic hypoperfusion or congestion, further contribute to the great variation 
of aldosterone levels in patients with HF (62) (63). 
 
The effect of aldosterone in the kidneys is to promote mainly sodium retention.  In untreated 
patients with HF total body water content and extracellular volume are increased by more 
than 15% and 30% respectively (58). In HF, there is evidence of prolonged sodium-retaining 
action of aldosterone in kidneys. In healthy subjects, administration of aldosterone results in 
an initial increase in extracellular fluid volume; however, the excretion of sodium in urine 
gradually increases despite the aldosterone sodium retaining effects (64). The exact 
mechanisms of the above phenomenon have not been clearly elucidated, but it is generally 
agreed that the increase of sodium delivery to the distal nephron, overrides the sodium 
retaining capacity of aldosterone and contributes to the re-establishment of sodium balance 
(64).  In patients with HF, the activation of the SNS and RAAS enhances sodium absorption 
in the proximal tubules with subsequent decrease in sodium delivery in the distal nephron 
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 (65). Under these conditions mineralocorticoids exert sodium retaining effects at their 
maximum. Thus, the overall sodium absorption throughout the nephron segments is almost 
complete, promoting persistent fluid retention in patients with HF.  
 
Apart from the classic epithelial properties related to sodium and water retention, aldosterone 
has been increasingly recognised to exert other nonepithelial effects related to the 
cardiovascular system that contribute further to HF progression; these cardiovascular actions 
are described in detail in section 1.3. Moreover, aldosterone blockade has emerged as one of 
the principal treatment strategies in patients with HFrSF and the current evidence from 
clinical studies is described further in section 1.4. 
 
1.1.3.3 Cortisol secretion in HF 
Apart from the mineralocorticoid actions, there is growing evidence about potential 
detrimental effects that cortisol exerts on the cardiovascular system, indicating that 
glucocorticoids might play a distinctive role in HF pathophysiology (66) (67). Cortisol, 
which is the main glucocorticoid in humans, is secreted like aldosterone by the adrenal 
glands; in humans the daily cortisol secretion is 41- 110 mmol, approximately 200 to 300 
times higher than the daily aldosterone production (68). In contrast to mineralocorticoids, the 
secretion of glucocorticoids has not been extensively studied in patients with HF. Plasma 
cortisol levels were found to be higher in patients with acute decompensated HF, in a series 
of early studies that included a very small number of patients (69) (70). In patients with 
untreated severe HF, serum cortisol levels were within the normal range, albeit 2.5- fold 
higher compared with healthy control subjects (58). Another study reported higher serum 
cortisol levels in patients with chronic HF and cachexia compared with HF patients without 
cachexia (71); however, no difference in cortisol levels was elucidated between non-
cachectic patients with HF and healthy subjects in this study. Moreover, in patients with 
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 chronic HF morning cortisol levels were well within the normal range and no evidence of 
major activation of the HPA axis was present (72) (73). In these patients, cortisol levels were 
not associated with markers of disease severity, cardiac cachexia or inflammation status. 
Interestingly, cortisol but not ACTH, which is the principal regulator of glucocorticoid 
synthesis, was independently associated with cardiovascular outcomes. These findings 
suggest that cortisol is not merely a nonspecific indicator of cardiac cachexia or stress, but 
might exert specific deleterious effects on the cardiovascular system. Thus, the secretion of 
glucocorticoids in patients with HF merits further investigation.  
 
1.2 Synthesis and secretion of mineralo- and gluco- corticosteroids  
 
1.2.1 Synthesis of aldosterone and cortisol (Figure 1-2) 
The adrenal cortex consists of three zones. The outermost zone is the zona glomerulosa (ZG) 
where the cells are arranged in whorls. Zona fasciculata (ZF) lies just beneath ZG and zona 
reticularis (ZR), which is the innermost, surrounds the adrenal medulla. The cells in the last 
two regions are arranged in columns and produce glucocorticoids and sex steroids, while ZG 
is responsible for aldosterone biosynthesis. Unlike other hormones, the capacity of 
intracellular storage of corticosteroids is limited and the secretion rate is directly related to 
the activity of the steroidogenic pathways. The fundamental substrate for adrenal steroid 
synthesis is cholesterol. In human subjects, most of cholesterol used in the adrenal 
steroidogenic pathways is taken from circulation where it is mainly transported as low 
density lipoprotein (LDL) or high density lipoprotein (HDL) (74). In addition, de novo 
adrenal cholesterol synthesis may provide additional substrate for adrenal steroidogenesis but 
to a smaller extent. After intracellular deposition, cholesterol is transferred from the outer to 
the inner mitochondrial membrane, which is the rate-limiting step in steroidogenesis and is 
mainly mediated by the steroidogenic acute regulatory protein (StAR) (75). Following this 
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 step, cholesterol is subjected to a series of reactions to generate mineralo- and gluco-
corticoids. Most of the enzymes that mediate the above reactions belong to the P450 
cytochrome family of the haem-containing enzymes. In the inner mitochondrial membrane, 
the cytochrome P450 side chain cleavage enzyme, which is located in all three zones of 
adrenal cortex, performs successive hydroxylations of cholesterol to generate pregnenolone, 
which is transported to the cytosol. Subsequently, 17alpha-hydroxypregnenolone is 
synthesised from pregnenolone in the ZF/ZR by 17alpha-hydroxylase. Pregnenolone and 
17alpha-hydroxypregnenolone are converted by 3beta-hydroxysteroid 
dehydrogenase/isomerase in the endoplasmic reticulum to progesterone and 17alpha-
hydroxyprogesterone respectively, which are subsequently hydroxylated by 21-hydroxylase 
and converted to 11-deoxycorticosterone (DOC) and 11-deoxycortisol respectively. 21-
hydroxylase is located in the smooth endoplasmic reticulum and expressed in all three zones 
of the adrenal cortex (76).  
 
The newly synthesized DOC in ZG enters the mineralocorticoid-producing pathway 
responsible for aldosterone generation. DOC is converted to aldosterone by aldosterone 
synthase, which catalyses the final enzymatic reactions in ZG. Aldosterone synthase, a 
cytochrome P450 enzyme, is located in the inner mitochondrial membrane of the ZG and 
catalyses three consecutive steps, converting DOC into corticosterone (11beta-
hydroxylation), corticosterone to 18OH-corticosterone (18-hydroxylation) and finally 18OH-
corticosterone to aldosterone (18-oxidation) (77). These final steps are known as the ‘late 
pathway’ in aldosterone biosynthesis.  
 
Similar to DOC with regards to aldosterone secretion in ZG, 11-deoxycortisol is the main 
substrate for cortisol production in ZF, the main glucocorticoid in humans; 11-deoxycortisol 
diffuses to the inner mitochondrial membrane, where is hydroxylated by 11beta-hydroxylase  
34
 to generate cortisol (78). 11beta-hydroxylase, apart from catalysing the production of 
cortisol, also mediates the conversion of DOC to corticosterone in ZF, similar to aldosterone 
synthase’s enzymatic action in ZG. Nevertheless, 11beta-hydroxylase , which is principally 
controlled by ACTH, catalyses 18-hydroxylation poorly and in contrast with aldosterone 
synthase, which is mainly regulated by angiotensin II and potassium, does not catalyse 18-
oxidation. As a consequence, aldosterone secretion is exclusively restricted in ZG (77).  
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 1.2.2 Metabolism of corticosteroids 
The metabolism of corticosteroids is complex and mostly tissue dependent. The main cortisol 
metabolites are 5alpha-tetrahydrocortisol, 5beta-tetrahydrocortisol and cortisone (Figure 1-3). 
The 5-tetrahydro-compounds are formed in the liver and are conjugated with a glucuronide to 
form water-soluble compounds that are excreted by the kidneys. Cortisol, in addition, is 
converted by 11beta-hydroxysteroid dehydrogenase 2 (11beta-HSD2) to inactive cortisone in 
classic epithelial tissues (renal tubules, colon and salivary glands) (79). Cortisone, similarly to 
cortisol, is metabolised in the liver and excreted as tetrahydrocortisone in the urine. 
 
11beta-HSD2 enzyme plays a critical role in the metabolism and action of corticosteroids. 
11beta-HSD2 regulates the concentration of active glucocorticoids available to bind and 
activate the glucocorticoid receptors (GRs) by converting the active cortisol to biologically 
inactive cortisone (80). Additionally, by the same conversion, it mediates the aldosterone 
specificity for the mineralocorticoid receptors (MRs) in classic epithelial tissues (section 
1.3.1). An isoenzyme, 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1), is mainly 
found in liver and adipose tissue and preferentially converts cortisone to cortisol amplifying 
GR activation (81) (82). 
 
Similar to glucocorticoids, aldosterone is metabolised in the liver to form mainly tetrahydro-
aldosterone, which is mainly excreted in the urine as a glucuronide conjugate.  
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Figure 1-3. Metabolism of glucocorticoids 
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 1.2.3 Regulation of aldosterone secretion 
 
1.2.3.1 RAAS 
Renin is one of the principal regulators of aldosterone secretion. It is released by the 
juxtaglomerular cells in response to a decrease in the intravascular volume, sympathetic 
stimulation and reduced sodium concentration at the macula densa. As previously described, 
renin acts on angiotensinogen secreted by the liver into circulation to produce angiotensin I, 
which is converted into angiotensin II by ACE that is located mainly in the lungs and 
vascular tissue. Angiotensin II, apart from the potent vasoconstricting properties, stimulates 
aldosterone secretion from the adrenal cortex through the AT1 receptor. The expression of 
AT1 receptors exhibits zonal distribution, contributing to the regulation of CYP11B2 
expression in ZG by angiotensin II (77). The ZG cells are very sensitive to angiotensin II, 
especially under circumstances of sodium-depletion (83) (84). Moreover, the response of 
these cells to angiotensin II is rapid, within minutes, indicating that aldosterone is 
immediately synthesised from intermediate compounds or de novo from cholesterol with no 
new protein synthesis (85). On the other hand, chronic stimulation by angiotensin II up-
regulates CYP11B2 expression and induces ZG cell proliferation and hypertrophy (86) (87). 
The increased aldosterone secretion resulting from angiotensin II stimulates in turn the 
expression of tissue ACE and AT1 receptors (88) (89) (90). Thus, a positive feedback circuit 
is present in which angiotensin II binds to the AT1 receptors in ZG and stimulates the 
secretion of aldosterone, which in turn leads to up-regulation in ACE expression and 
angiotensin II synthesis, with further increase in aldosterone levels. That represents a vicious 
cycle with a distinctive role in patients with HF, as it is likely to contribute to the raised 
aldosterone levels in these patients despite inhibition of RAAS (section 1.5.1).  
 
Apart from angiotensin II the heptapeptide angiotensin III also stimulates aldosterone 
secretion. Angiotensin III is generated from angiotensin II by aminopeptidase A, a membrane 
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 bound enzyme that is highly expressed in the kidney and especially in glomerular cells 
(endothelial, mesangial and podocytes) and the renal proximal tubule cells (91) (92). 
Aminopeptidase A cleaves the N-terminal amino acid from angiotensin II, which is converted 
to angiotensin III. Angiotensin III increases aldosterone secretion both in vivo and in vitro 
(93) (94) (95). However, it is not fully elucidated whether angiotensin III exerts direct or 
indirect effects on aldosterone production or these effects are mediated by a specific receptor. 
It has been recently shown that aldosterone secreting effects of angiotensin III are partially 
mediated via the AT2 receptor and that might contribute to aldosterone escape in patients 
with HF despite treatment with ARBs (96).  
 
1.2.3.2 Potassium 
Extracellular potassium is a major regulator of aldosterone secretion and potassium excess 
directly stimulates aldosterone secretion, independently of other regulatory mechanisms. The 
ZG cells are sensitive to changes in the extracellular potassium and respond even to small 
increments with aldosterone secretion (97) (98). Although potassium and angiotensin II exert 
independent effects on aldosterone production, a synergism between the two agonists has 
been identified resulting in enhancement of the individual trophin effects (99) (100). Thus, a 
fluctuation in potassium levels modifies the stimulating effect of angiotensin II on 
aldosterone production (101). However, it has been proposed that acute stimulation by 
angiotensin II impedes the potassium regulatory pathway, switching the adrenal to an 
angiotensin II-dependent model (77). 
 
Potassium acutely stimulates aldosterone secretion by acting mainly in the early steps of the 
mineralocorticoid pathway (102). In addition, chronic potassium excess up-regulates the 
transcription of aldosterone synthase, stimulating the late pathway in aldosterone 
biosynthesis; increase in the dietary potassium results in up-regulation of aldosterone 
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 synthase mRNA transcription in ZG (103) (104). Overall, potassium and aldosterone are part 
of a feedback circuit where increased potassium levels in the extracellular compartment 
stimulate aldosterone, which then increases kaliuresis and lowers potassium levels. 
 
1.2.3.3 ACTH 
ACTH is the principal endogenous stimulus to the main glucocorticoids, and the ZG is less 
dependent than the ZF upon ACTH control. Animal studies have shown that the aldosterone 
synthase expression in ZG, but not the 11beta-hydroxylase expression in ZF, is maintained 
despite low circulating levels of corticotrophin (105). ACTH, however, plays an important 
role in the regulation of aldosterone secretion as a potent short-term secretagogue and 
increases aldosterone secretion in a dose-dependent manner (106). In contrast, during a 
continuous ACTH infusion at pharmacological doses, aldosterone levels return to normal in 
24-72 hours, while cortisol levels remain elevated (107). In addition, long term continuous 
infusion of high exogenous ACTH doses results in hyperplasia and hypertrophy of ZF and is 
associated with a marked decrease in aldosterone secretion (108) (109). The reduction of 
aldosterone secretion induced by ACTH is characterised by a sustained decrease in CYP11B2 
expression with suppression of the late steps in mineralocorticoid synthetic pathway (110) 
(111). The molecular mechanisms for the morphological and functional responses of ZG to 
chronic ACTH stimulation are not clear but it is generally accepted that there is a 
transformation of adrenal ZG to ZF cell function (109) (110) (112). Interestingly, the 
stimulation of ZG by an ACTH infusion is sustained if the infusion is pulsatile (113).  
 
Overall, apart from the short term effects, ACTH is considered to have a contributing role in 
the regulation of aldosterone synthesis in the long term. In humans with panhypopituitarism 
there was an impairment of aldosterone response to salt restriction and ACTH stimulation 
(114). Moreover, aldosterone secretion exhibits a diurnal variation with higher levels in the 
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 morning, indicating that an ACTH drive is at least partially involved in the regulation of 
mineralocorticoid synthesis (115). 
 
1.2.3.4 Other factors stimulating aldosterone secretion  
Apart from the three main aldosterone secretagogues, other substances have been reported to 
stimulate aldosterone secretion, variably and modestly compared to the main stimulators. 
Serotonin enhances mineralocorticoid synthesis in adrenal glomerulosa cells (116). In clinical 
studies, selective serotonin receptor agonists have been shown to stimulate aldosterone 
production in normal subjects (117). Other agonists include endothelin and vasopressin (118) 
(119). However, their exact role in the regulation of aldosterone secretion remains unclear.   
 
Oxidized endogenous fatty acids have been reported to exert a direct stimulatory effect on 
aldosterone secretion; an oxidized derivative of linoleic acid, has been shown to have a potent 
aldosterone stimulating action on rat adrenal cells in vitro (120). In addition, plasma levels of 
oxidised derivatives of linoleic acid have been found to correlate positively with plasma 
aldosterone levels and body mass index (BMI) in humans (121). More recently, human 
adipocytes have been shown to secrete mineralocorticoid-releasing factors, which directly 
stimulate aldosterone production from adrenocortical cells in vitro and may represent a 
potential link between obesity and increased aldosterone levels (122). Thus, obesity and 
increased adipocity may promote aldosterone synthesis at least partially through adipose 
tissue-produced factors and endogenous fatty acids. 
 
1.2.3.5 Factors attenuating aldosterone synthesis 
Atrial natriuretic peptide (ANP) has been shown to suppress aldosterone secretion from the 
adrenal glands (123). ANP is secreted mainly from myocardial atrial cells in response to 
atrial distension and enhances vasodilation and diuresis (29) (124). Apart from the direct 
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 effects on aldosterone levels, it also suppresses angiotensin II- and ACTH - induced 
aldosterone secretion in glomerulosa cells (125) (126). Moreover, it has been shown to inhibit 
the production of renin in juxtaglomerular cells reducing further angiotensin and aldosterone 
production (127) (128). The inhibiting effects on aldosterone secretion are not directly related 
to inhibition of steroidogenic enzymes and are mediated through intra-cellular signaling 
pathways that are activated through specific membrane receptors (129). The 
pathophysiological role of ANP becomes more prominent under circumstances of fluid 
overload, such as in patients with HF, where plasma natriuretic peptide levels are increased, 
exerting antagonistic effects to the actions of the RAAS mediators and the sympathetic nerve 
system.  
 
Adrenomedullin (ADM) is another peptide with inhibitory effects on aldosterone secretion 
that was originally isolated from phaeochromocytoma tissues and has been found in different 
tissues, such as the adrenal medulla and endothelial cells (130) (131). ADM has been shown 
to inhibit angiotensin II- and potassium- induced aldosterone secretion in animal and human 
adrenocortical cells (132) (133). In animal studies, ADM has been found to attenuate 
aldosterone secretion after a few days of sodium-repletion (134). In keeping with these 
findings, ADM has been shown to antagonise angiotensin II-induced but not basal 
aldosterone production in healthy subjects (135). Although the role of ADM with regards to 
aldosterone secretion has not been fully characterised, findings from the above studies 
indicate that ADM probably exerts an inhibitory effect on mineralocorticoid secretion under 
conditions characterised by RAAS activation. 
 
Other factors such as dopamine and somatostatin have also been shown to exert inhibiting 
effects on aldosterone secretion, however not as drastically as ANP and ADM (108). 
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 1.2.4 Regulation of Cortisol secretion 
ACTH is synthesised in the pituitary gland as part of a large precursor called 
proopiomelanocortin (POMC). ACTH synthesis requires proteolytic processing of POMC, 
which contains the sequences for other hormonal peptides, including the beta-endorphin and 
melanocyte-stimulating hormones (136). ACTH is released into the circulation and stimulates 
secretion of glucocorticoids in the adrenal cortex. 
 
The secretion of ACTH and therefore of cortisol is regulated by hormonal interactions within 
the HPA axis and by other stimuli that affect that circuit. The main secretagogue for ACTH 
secretion is the corticotropin releasing hormone (CRH), which is also synthesised as part of a 
larger precursor by neurons in the hypothalamus and is secreted into the pituitary portal blood 
(137). CRH increases the expression of POMC gene with subsequent increase in POMC and 
ACTH secretion by the hypophysis (138). CRH secretion and consequently plasma ACTH 
and cortisol levels can be influenced by neural stimuli in response to stress (139). While CRH 
is the major hypothalamic releasing factor for ACTH, other hormones such as vasopressin 
have the potential to stimulate ACTH release or to augment CRH-induced ACTH secretion, 
although at lower potencies (140). Additionally, other stimuli such as hypoglycaemia or fever 
stimulate CRH and ACTH levels and significantly contribute to the regulation of cortisol 
secretion (141) (142).  
 
Under normal conditions there is a negative feedback loop between cortisol, ACTH and 
CRH. Cortisol decreases hypothalamic transcription of the POMC gene (143), inhibiting 
consequently ACTH release into the circulation. Glucocorticoids also suppress the 
transcription of CRH receptor gene (144) and might also exert a negative feedback at higher 
brain centers to attenuate the neural inputs to the hypothalamus.  
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In addition to the above mechanisms, there is a circadian rhythm in ACTH and cortisol 
secretion; their release shows pulsatile rhythmicity, with bursts of different amplitude 
throughout a day. The pulses occur with a frequency of 1 per 60-90 minutes (145) and 
increase in amplitude in the early morning hours reaching a peak prior to waking (146). 
Subsequently, there is a decrease over the course of the day with minimum amplitude at 
midnight. This diurnal pattern occurs despite the negative feedback effects of cortisol on the 
hypothalamus and pituitary under normal circumstances. 
 
1.3 Mineralo- and gluco-corticoid actions and cardiovascular system 
 
1.3.1 Epithelial actions of aldosterone  
Aldosterone exerts its classical effects on epithelial cells in the kidneys, colon and salivary 
glands, where it increases sodium and water reabsorption. In parallel, it increases potassium 
and hydrogen excretion contributing to electrolyte homeostasis. Aldosterone-responsive 
sodium transport within the kidneys is primarily mediated by the amiloride-sensitive 
epithelial sodium channel (ENaC) at the apical membrane of the distal convoluted and 
cortical collecting tubules (147). Aldosterone induces up-regulation of ENaC activity through 
an increase in the number of channels in the apical membrane or alternatively by an increase 
in their open-probability (148) (149). It additionally increases the efflux of sodium from the 
epithelial cells to the intravascular compartment by a sodium-potassium ATPase (Na
+
- K
+
-
ATPase) located in the basolateral epithelial membrane (140) (150). This is an energy-
dependent process and generates a negative potential difference, which is counterbalanced 
with a concurrent reabsorption of Cl
-
 via the thiazide-sensitive Na
+
/Cl
-
 co-transporter and 
K
+
/H
+
 secretion into the lumen (151). Apart from the above effects to the sodium flux, 
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 aldosterone up-regulates H
+
-ATPase activity in the collecting duct and affects acid-base 
homeostasis (152).  
 
Overall, the effect of aldosterone in the renal tubule is to promote sodium retention with 
concomitant hydrogen and potassium excretion in urine. The above effects are important not 
only under normal conditions but also in syndromes associated with activation of aldosterone 
secretion. In HF, the activation of RAAS results in aldosterone stimulation with concomitant 
sodium and fluid retention and expansion of the extracellular compartment. On the other 
hand, aldosterone blockade has been associated with hyperkalaemia in patients with HF 
(153).  
 
1.3.1.1 Genomic actions  
The classical aldosterone epithelial effects on the kidneys, colon and salivary glands are 
mediated by the MR, a member of the steroid/ thyroid/ retinoid nuclear receptor family (154). 
The MRs bind the main glucocorticoids (cortisol for man and corticosterone for rodents) and 
aldosterone with equal affinity (155). Glucocorticoids circulate in plasma in 100- to 1000- 
fold higher concentrations than plasma aldosterone levels and thus the MRs would 
predominantly be occupied by glucocorticoids (67). The selectivity of MR for aldosterone at 
epithelial tissues, however, is mediated by 11beta-HSD2, which converts cortisol to cortisone 
and corticosterone to dehydro-corticosterone, which exert no affinity for the MR (156). In 
this way the MRs at collecting ducts and other aldosterone epithelial target tissues are 
activated by aldosterone.  
 
The MRs are located in the cytosol and are kept transcriptionally inactive in the absence of a 
ligand. Once activated by an agonist, the complex translocates to the nucleus where it binds 
to mineralocorticoid - responsive genes (157). The above interaction results in the induction 
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 of a number of aldosterone-induced proteins (AIPs), which exert a wide range of actions on 
apical membrane and basolateral Na
+
- K
+
-ATPase activity in epithelial cells.  
 
One of the best characterized AIPs is the serum glucocorticoid-regulated kinase 1 (SGK1). 
Aldosterone up-regulates the expression of SGK1 at the distal tubule of the kidneys and in the 
colon (158) (159). SGK1 in turn activates ENaC partially by up-regulating the expression of 
ENaC gene subunits (160). However, it has been recognised that SGK1 action on ENaC 
activity occurs mainly through an interaction with a regulatory protein also known as neuronal 
precursor cells-expressed developmentally down-regulated protein 4-2 (Nedd4-2), which 
mediates the ENaC turnover (161). This protein ligase interferes with the ENaC subunits at 
the apical membrane, promoting channel internalisation and degradation. SGK1 impairs 
Nedd4-2 interaction with ENaC and therefore increases the ENaC density in the distal 
nephrons (162) (Figure 1-4). Apart from the above actions on ENaC activity, SGK1 has also 
been shown to up-regulate the density of the inward rectifier K
+ 
channel, contributing to the 
kaliuretic effect of aldosterone (163). 
 
Other proteins related to aldosterone action in transporting epithelia include the Kirstten Ras 
GTP-binding protein 2a, the glucocorticoid induced leucine zipper protein (GILZ) and the 
corticosteroid hormone-induced factor (CHIF) (85). The precise actions of the proteins 
remain to be fully elucidated.  
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Figure 1-4. Genomic actions of aldosterone on epithelial tissues. Aldosterone binds to the 
mineralocorticoid receptor (MR) and the complex translocates in the nucleus where it 
increases the transcription of mineralocorticoid-responsive genes, resulting in the 
production of aldosterone -induced proteins. The activation of aldosterone-induced 
serum glucocorticoid-regulated kinase 1 (SGK1) requires phosphorylation by the 
phosphatidylinositol-3 kinase (PI3K). SGK1 impairs via phosphorylation the activity of 
the neuronal precursor cells-expressed developmentally down-regulated protein 4-2 
(Nedd4-2) and the Nedd4-2- induced degradation of ENaC increasing the number of 
ENaC channels in the apical membrane.  
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 1.3.2 Non genomic actions of aldosterone 
In addition to the classic aldosterone effects related to the interaction of the hormone/ 
receptor complex with the deoxyribonucleic acid (DNA) regulatory elements, aldosterone has 
been shown to exert rapid nongenomic effects. These actions are independent of transcription 
or translation, and thus are not prevented by agents inhibiting the above processes (164) 
(165). Moreover, they appear within 5-10 minutes, a time course that precludes any effects on 
protein synthesis (166). The nongenomic effects have been described in a wide range of 
epithelial and nonepithelial cells including kidney tubule cells, skeletal and VSMCs and 
cardiac myocytes. Aldosterone rapidly affects the Na
+
-K
+
 pump activity in rabbit ventricular 
myocytes and exerts a negative inotropic effect in human atrial and ventricular trabeculae 
(167). Other studies demonstrated a rapid increase in intracellular pH via the Na
+
-H
+
 
exchanger in human arteries (168) and in kidney distal tubule cells induced by aldosterone 
(169). They also showed and a rapid rise of intracellular calcium
 
in human mononuclear 
leucocytes and skeletal muscle cells in response to aldosterone (170) (171).  In healthy 
subjects aldosterone infusion induced rapid reductions in forearm blood flow (172) (173), 
although these findings have not always been replicated (174). In addition, aldosterone 
blunted the baroreflex response in healthy individuals (175) and decreased the heart rate 
variability in HF patients (176). Overall, the above effects are rather modest and may act by 
sensitising physiological responses to other synergistic stimuli, representing a cardiovascular 
fine-tuning system (177).  
 
Similarly to the genomic MR effects, some of the nongenomic effects are prevented by a 
classical MR blockers, indicating that the MR contributes partially to aldosterone-induced 
non-transcriptional effects (178); However, several of aldosterone-induced rapid effects are 
not attenuated by classical MR blockers; spironolactone had no effect on aldosterone’s 
negative inotropic effect in human ventricular trabeculae (167). Moreover, spironolactone did 
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 not prevent the deterioration of myocardial contractile function due to coronary 
vasoconstriction following aldosterone infusion in canine hearts (179). It has been 
hypothesised that some effects may be mediated by the classic MR in a non-transcriptional 
pattern and some others by a specific receptor; however, attempts to isolate a specific 
aldosterone receptor have been unsuccessful. Interestingly, there is evidence from other 
steroid pathways related to progesterone and oestrogens, that nongenomic effects are 
mediated via modulation of G-protein-coupled receptors (180). Similar mechanisms may 
occur for aldosterone (181).  
 
1.3.3 Non-epithelial actions of aldosterone  
MRs have also been isolated in cells of non-epithelial tissues, including the cardiomyocytes, 
VSMCs and endothelial cells, circulating monocytes and the hippocampus (182). In the 
myocardium and hippocampus the expression of 11beta-HSD2 is extremely low or absent 
(183) (184) (185). Thus, the MRs are mainly occupied by endogenous glucocorticoids in a 
tonic inhibition fashion, as the glucocorticoid-MR complex is not active under normal 
circumstances (186). In contrast, the VSMCs and endothelial cells express MRs and 11beta-
HSD2, facilitating aldosterone specificity for the MR (187) (188).
  
There is increasing 
evidence that aldosterone exerts deleterious non-epithelial effects on endothelial and vascular 
function, promotes myocardial fibrosis and has additional pro-arrhythmic effects (Figure 
1-5). 
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 1.3.3.1 Vascular Inflammation  
Aldosterone has been shown to activate nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases in vascular smooth muscle and endothelial cells and to produce reactive 
oxygen species (ROS) (189) (190). Although ROS may derive from different pathways 
(mitochondria, xanthine oxidase, cyclooxygenase, or peroxidases), NADPH oxidases are the 
main stimulators of ROS generation in vascular tissues (191) (192). The NADPH oxidase 
system comprises cytosolic and membrane-bound subunits that form an enzyme complex 
capable of producing superoxide anion (O2
-
) and other ROS; mineralocorticoids stimulate the 
transcription of various NADPH subunits, inducing up-regulation in ROS production (193). 
The ROS stimulate in turn the expression of pro-inflammatory factors, such the nuclear 
factor-kappa B (NF-kappa B) (194) (195), which in turn induce the generation of various 
adhesion molecules, chemokines and inflammatory cytokines (196) (197).
 
 
The oxidative stress and pro-inflammatory phenotype induced by mineralocorticoids in the 
vascular wall, appears to evolve to vascular inflammation under the synergistic effect of high 
salt diet (198) (199). Vascular and peri-vascular inflammation in the myocardium, with 
leukocyte infiltration, vasculitis and myocardial necrosis, was a common finding in animal 
models treated with aldosterone infusions and high salt diet. The aldosterone/salt 
combination in these studies increased the myocardial expression of various inflammatory 
markers, including osteopontin, intercellular adhesion molecule-1 and macrophage 
chemoattractant protein-1, which are not normally expressed in the heart. Similarly, in 
uninephrectomised rats that maintained on a high salt diet, peri-vascular macrophage 
infiltration and up-regulation of inflammatory cytokines were present following injections of 
subcutaneous mineralocorticoids (200). In all these studies, high salt intake was essential for 
aldosterone to exert its inflammatory effects on the vascular wall. The precise mechanisms by 
which high salt enables the inflammatory effects of aldosterone remain unclear. Activation of 
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 MR causes intracellular calcium (Ca
2+
) loading and a fall in cytosolic free-ionised 
magnesium (Mg
2+
) in monocytes in the presence of high sodium (Na
+
) (201). It has been 
suggested that the oxidative stress and a pro-inflammatory phenotype in mononuclear cells 
induced by intracellular calcium loading in the monocyte/macrophage system act as a 
substrate for aldosterone’s pre-inflammatory action (202).  
 
The vascular inflammation induced by aldosterone is reversed by MR blockade; 
spironolactone attenuated the effects of aldosterone on vascular oxidative stress in 
hypertensive rats (203). In addition, in heritable hyperlipidaemic rabbits, MR blockade 
resulted in down-regulation of ROS with reduction in free radical injury (204). Moreover, in 
a rat model with chronic pressure overload, treatment with eplerenone exerted beneficial 
effects on myocardial oxidative stress, suppressing the expression of the intercellular 
adhesion molecule-1 with concomitant reduction in macrophage infiltration and inflammation 
(205).  
 
In patients with diabetic nephropathy blood pressure was reduced in response to 
spironolactone or amlodipine. However, only spironolactone reduced the urinary levels of the 
inflammatory markers, suggesting that aldosterone blockade attenuated vascular 
inflammation irrespective of blood pressure (206). In another study, hypertensive patients 
were randomised to receive spironolactone or chlorothalidone on top of treatment with a 
calcium-channel blocker and ARB (207). A significant decrease in blood pressure was 
present in both treatment arms but only spironolactone reduced the high sensitivity C-reactive 
protein (CRP). However, aldosterone blockade had no effect on CRP levels in a cohort of 
patients with chronic HF (208).  
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 1.3.3.2 Endothelial dysfunction 
Endothelial dysfunction is the end result of different pathophysiological pathways. 
Experimental and clinical studies have shown that decrease in bioavailability of endothelial 
nitric oxide (NO) results in impairment of endothelium-dependent relaxation (209) (210). 
Aldosterone induces down-regulation of endothelial NO availability in vitro and also affects 
endothelium-dependent vasoregulatory mechanisms by increasing ROS and oxidative stress 
in vivo (211). The generation of ROS leads to the oxidation of the NO synthase (NOS) co-
factor tetrahydrobiopterin (BH4) and in the absence of BH4, endothelial NOS produces 
superoxide and hydrogen peroxide instead of NO, a process known as uncoupling (212) 
(213). This action of aldosterone on NO availability is similar to that of angiotensin II and 
there is evidence that a cross-talk occurs between the two RAAS mediators with regards to 
the endothelial NOS uncoupling (203). In addition, aldosterone has been shown to down-
regulate the endothelial expression of glucose-6-phosphate dehydrogenase (G6PD), which 
mediates via the pentose phosphate pathway the generation of NADPH (214). The latter 
contributes to the maintenance of reduced glutathione intra-cellular stores, which participate 
in the neutralisation of ROS (215). Thus, the aldosterone-induced decrease in antioxidant 
reserve in endothelial cells via the above pathway contributes futher to the decrease in NO 
biovailability under conditions of increased generation of ROS. Moreover, aldosterone 
impairs the endothelial function by increasing the volume and stiffness of endothelial cells, 
inducing intercellular gaps in vitro (216).  
 
The effects of mineralocorticoids on oxidative stress and endothelial function are attenuated 
by MR blockade. In a coronary ligation MI rat model, eplerenone normalised the production 
of ROS in the aorta and improved the endothelial function post-MI (217). In an experimental 
HF rat model, treatment with spironolactone on top of an ACE inhibitor reduced superoxide 
formation and up-regulated the endothelial NOS expression (218). In clinical studies, MR 
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 blockade improved endothelium-dependent vasodilation in hypertensive patients with 
hyperaldosteronism (219). Furthermore, in patients with HF, treatment with spironolactone 
on top of an ACE inhibitor increased NO bioactivity and improved the endothelial 
vasodilator function (220) (221). 
 
1.3.3.3 Myocardial Fibrosis 
Treatment of uninephrectomised rats with a combination of aldosterone and salt induced 
accumulation of collagen with associated interstitial and perivascular myocardial fibrosis 
(222). The above effects were only seen in rats maintained on high and not on low salt diet. 
Interestingly, collagen accumulation in the aldosterone/ salt treated rats affected both the left 
and right heart, indicating that cardiac fibrosis was humoral rather than a haemodynamic 
effect of mineralocorticoid/ salt treatment. In keeping with these findings, in animal models 
co-infused with aldosterone peripherally and intra-cerebroventricular MR antagonist 
centrally, in order to maintain the blood pressure at normotensive levels, the degree of 
cardiac fibrosis was similar to that induced by aldosterone infusion alone (223).  
 
Aldosterone-induced cardiac fibrosis may be due to direct effects on the heart fibroblasts. 
Indeed, aldosterone has been shown to stimulate collagen synthesis by cardiac fibroblasts in 
vitro (224) (225); the above findings, however, were not always replicated (226) (227). In 
addition, other studies showed that aldosterone increases cardiac fibroblast proliferation 
instead (228). Apart from the direct effects on cardiac fibroblasts, it has also been shown that 
vascular and perivascular inflammation precedes myocardial fibrosis in animal models 
treated with aldosterone and salt; specifically, the primary inflammatory cells involved in 
peri-vascular inflammation and myocardial necrosis were monocytes and macrophages (200) 
(229). Recent studies have further focused on the specific role of MR activation of the 
monocyte/macrophage system on inflammation and cardiac fibrosis using 
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 monocyte/macrophage-specific MR knockout mice (230). Wild-type mice developed 
vascular macrophage infiltration with concomitant inflammation and cardiac fibrosis in 
response to mineralocorticoid/salt treatment. MR-knockout mice showed macrophage 
infiltration in the myocardial tissue but did not develop inflammation or fibrosis in response 
to mineralocorticoid/salt combination, indicating that macrophage MR activation is necessary 
for myocardial fibrosis but not for macrophage chemoattraction (Figure 1-6). On the other 
hand, endothelial MR activation up-regulates the expression of intracellular adhesion 
molecules, resulting in macrophages attaching to the endothelium (231). Overall, it appears 
that MR activation in endothelium and monocyte/macrophage system is responsible for both 
chemoattracting the macrophages to the endothelium and controlling their activities on arrival 
at the vascular and perivascular space, promoting inflammation and collagen disposition. In 
keeping with these considerations is also the finding that MR overexpression in 
cardiomyocytes did not result in myocardial fibrosis (232). Moreover, when various 
components of inflammatory signaling pathways were targeted following aldosterone/salt 
treatment in animal models  the collagen accumulation was reversed, indicating that 
myocardial fibrosis is at least partially a consequence of vascular and peri-vascular 
inflammation induced by mineralocorticoids (233) (234) (235) (236).   
 
The antifibrotic effects of aldosterone blockers have been examined in both animal and 
clinical studies. MR antagonism prevented aortic inflammation and fibrosis in spontaneously 
hypertensive rats independent of blood pressure reduction (237). In a rat model of MI, 
aldosterone blockade reduced the reactive fibrosis in the viable myocardium without 
affecting the replacement collagen deposition in the infracted region (238). In rats with MI 
complicated with LVSD, eplerenone reduced collagen type I mRNA expression and collagen 
accumulation in the non-infarcted myocardium (239). In patients with HFrSF, spironolactone 
on top of ACE inhibitor therapy reduced plasma collagen turnover markers such as pro-
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 collagen type I carboxy-terminal peptide (PCIP), pro-collagen type I (PINP) and III (PIIINP) 
amino-terminal peptides (176) (240) (241). In addition, the impact of aldosterone blockade 
on myocardial fibrosis has additionally been investigated in patients with HFpSF. 
Eplerenone, on top of an ACE inhibitor or ARB and beta-blocker prevented the increase in 
PIIINP after one year in these patients (242).   
57
  
Figure 1-6. Specific deletion of the mineralocorticoid receptor (MR) in monocytes/ 
macrophages prevents perivascular inflamation and myocardial fibrosis but not 
adhesion of monocytes to the endothelium or infliltration of macrophages to the 
intramyocardial perivascular space in response to 11-deoxycorticosterone (DOC) and 
salt. Adapted from Dorrance (243). 
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 1.3.3.4 Pro-arrhythmic effects 
The myocardial collagen formation with fibrosis and interstitial remodeling induced by 
aldosterone is associated with electrical inhomogeneity and could potentially provide the 
substrate for potential arrhythmogenesis (244). However, there is growing, evidence that MR 
activation in cardiomyocytes exerts direct actions on their electrical properties increasing the 
risk of arrhythmias. Incubation of rat ventricular myocardial cells with aldosterone resulted in 
an up-regulation of sarcolemmal inward L-type calcium current (Ica) expression in vitro, 
which induced in turn a decrease in transient outward potassium current (Ito) in ventricular 
myocytes (245) (246).The increase in Ica density induced by aldosterone was attenuated by 
treatment with spironolactone, indicating a potential role of cardiomyocyte MR in the 
modulation of calcium cardiac ion currents (247). The effects of aldosterone on sarcolemmal 
calcium and potassium ionic currents prolong the ventricular action potential, providing the 
substrate for arrhythmias and increasing the risk for arrhythmic death (244).  
 
Consistent with the in vitro findings are also reports from in vivo studies. In a transgenic 
mouse model, conditional cardiomyocyte-specific MR overexpression resulted in ion channel 
remodeling with up-regulation of Ica, down-regulation of Ito and action potential duration 
prolongation (232). The electrical remodeling induced by cardiac MR over-expression was 
prevented by treatment with spironolactone, which reduced the high rate of ventricular 
arrhythmias observed in the above mouse model. Correspondingly, in a MI rat model, 
electrical remodeling was present early post-infarction, characterised by increased Ica and 
decreased the Ito expression with concomitant prolongation of action potential duration; MR 
blockade prevented the electrical remodeling post-MI in that model (248).  
In clinical studies, aldosterone infusion resulted in impairment of baroreflex response in 
healthy subjects (175).  In patients with HF, MR blockade improved parasympathetic 
activity, heart rate variability and QT dispersion (176) (249) and increased furthermore the 
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 cardiac neuronal uptake of norepinephrine, resulting in a decrease in ventricular arrhythmias 
(250). The overall benefit of MR blockade on arrhythmic death was shown in the Eplerenone 
Post Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), in which 
eplerenone, a selective MR blocker, reduced the risk of sudden cardiac death and all-cause 
mortality in 30 days after initiation of treatment in patients with HF and LVSD following MI 
(251) (section 1.5.3).  
 
1.3.4 Main effects of glucocorticoids 
Glucocorticoids exert their main actions by stimulation of the GRs; they bind to the GRs after 
entering into the cytoplasm, promoting dissociation of the GR from key heart shock proteins 
and translocation of the ligand – receptor complex to the nucleus. The binding of the complex 
to specific DNA sites results in the transcriptional activation of glucocorticoid-responsive 
genes (252). Apart from the GRs, cortisol binds to the MRs (155). However, as previously 
mentioned, in some but not in all tissues cortisol is converted to inactive cortisone by 11beta-
HSD2 (253). Thus, the glucocorticoid effects depend upon whether the target tissues express 
GRs, MRs or 11beta-HSD2 (254). 
 
Glucocorticoids exert their main biological effects on carbohydrate and protein metabolism 
as well as on the inflammatory and immune processes. In addition, glucocorticoids have 
weak mineralocorticoid activity under normal physiological conditions (255). It has been 
increasingly recognised that glucocorticoids exert detrimental effects on the cardiovascular 
system. 
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 1.3.5 Cardiovascular effects of glucocorticoids 
 
1.3.5.1 Endothelial dysfunction 
Glucocorticoids have been shown to affect the endothelial NO system. Hydrocortisone and 
dexamethasone inhibited the expression of inducible NO synthase in vascular endothelial 
cells via a GR-mediated mechanism in vitro (256). Dexamethasone decreased the availability 
of NO synthase cofactor tetrahydrobiopterin, promoting the synthesis of ROS in vitro (257). 
Moreover, in animal studies, endothelial NO synthase expression was down-regulated in the 
aorta of dexamethasone-treated rats resulting in a decrease of NO synthase activity (258). 
Dexamethasone is a synthetic glucocorticoid, which does not exert mineralocorticoid action, 
and its inhibiting effects on NO synthase expression were abrogated by a specific GR 
antagonist. In the same series of experiments, treatment with glucocorticoids attenuated the 
endothelium- dependent vasodilating effect of acetylcholine but not the endothelium-
independent vasodilation induced by penicillamine. Similarly, in studies of healthy subjects, 
oral cortisol impaired vasodilatation induced by acetylcholine but not sodium nitroprusside, 
indicating that glucocorticoids affect the endothelial NO system (259). 
 
1.3.5.2 Pro-arrhythmic effects 
Glucocorticoids have been increasingly recognised to affect the expression of ion channels in 
cardiomyocytes; dexamethasone increased the expression of the L-type calcium channels in 
rat ventricles (260). In another study, dexamethasone down-regulated the Ito density in mouse 
ventricular myocytes, resulting in prolongation of the action potential duration (261). 
Conditional cardiomyocyte GR overexpression in a transgenic mouse model was associated 
with the prolongation of QRS and QTc duration and chronic atrio-ventricular block on the 
electrocardiogram (ECG) (262). These findings were different from the ventricular 
arrhythmic events seen after conditional cardiomyocyte MR - overexpression in mice, 
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 indicating that different signaling pathways are activated by stimulation of MRs and GRs in 
cardiomyocytes. However, it should be noted that as cardiomyocytes lack 11beta-HSD2, 
MRs are likely to be occupied by endogenous glucocorticoids. Under conditions of oxidative 
stress and increased production of ROS, cortisol may exert MR agonist rather antagonist 
effects, mimicking aldosterone effects on ion channels in the myocardium. Indeed, the 
glucocorticoid corticosterone which binds equally the MR and GR, increased the Ica density 
of rat cardiomyocytes in vitro similarly to aldosterone when given at low doses (263). These 
effects were abolished in cardiomyocytes of MR-deficient mice but conserved in GR-
deficient mice, indicating that corticosterone (the cortisol equivalent in mice) exerts its 
effects on calcium current via the MR. 
 
1.3.5.3 Infarct Remodeling 
Given their anti-inflammatory effects and lysosomal membrane-stabilising actions, it has 
been proposed that glucocorticoids might be useful in reducing tissue damage after MI; pre-
treatment with methylprednisolone stabilised cardiomyocyte membranes and prevented the 
leakage of lysosomal enzymes and cell disruption in animals and patients with MI (264) 
(265). Other studies suggested that treatment with glucocorticoids after MI delays the 
accumulation of inflammatory cells at the sites of tissue injury; high doses of glucocorticoids 
after MI inhibited phagocytosis and removal of necrotic cells from the infarct area, resulting 
in scar thinning and infarct expansion in animal models (266) (267). Moreover, treatment 
with glucocorticoids has been shown to prevent angiogenesis and to down-regulate 
neovascularisation reducing the integrity of the scar tissue after MI (268) (269). In keeping 
with the above studies, in which high therapeutic doses of glucocorticoids were used, urinary 
levels of cortisol metabolites in patients following acute MI were related to larger infarct 
volumes and greater infract remodeling over time (270). Moreover, cortisol in doses 
representing physiological endogenous concentrations increased cardiomyocyte apoptosis 
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 rate and infarct size in an ex-vivo rodent model of MI (271). Interestingly, these effects were 
mitigated by spironolactone indicating that part of cortisol effects on cardiomyocyte necrosis 
and infarct size were mediated by MRs. 
 
1.4 Prognostic significance of mineralo- and gluco-corticoids in HF 
 
1.4.1 Aldosterone escape and clinical significance in HF 
The concept of aldosterone escape (or breakthrough) describes the failure of suppression of 
plasma aldosterone levels despite treatment with an ACE inhibitor or ARB (272). The 
incidence of the phenomenon in HF is variable, with estimates ranging from 10-51% mainly 
as a result of a lack of consensus on the definition of aldosterone escape (273). Aldosterone 
breakthrough has been defined as either plasma aldosterone levels above an absolute cut-off 
or any increase in plasma aldosterone levels from individual baseline levels three to twelve 
months after initiation of therapy with an ACE inhibitor or ARB. The mechanism of 
aldosterone escape is likely to be multifactorial and may reflect the importance of trophins 
other than angiotensin II, such as plasma potassium and ACTH, in the regulation of 
aldosterone production (274). Non ACE-dependent pathways may also be involved in the 
pathogenesis of the phenomenon; other proteases as chymase have been shown to generate 
angiotensin II from angiotensin I in human arteries (275) (276). Moreover, aldosterone 
escape may promote a vicious cycle in which angiotensin II initially activates aldosterone 
production, which subsequently up-regulates systematic and tissue ACE activity and 
furthermore increases aldosterone secretion (220) (277). Furthermore, genetic factors, as the 
DD genotype of the ACE gene insertion/deletion polymorphism, have also been associated 
with raised plasma aldosterone levels in patients with HF despite receiving treatment with an 
ACE inhibitor (278).  
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 It is generally accepted that aldosterone escape is associated with poor clinical outcomes. In 
patients with HF receiving long term therapy with an ACE inhibitor, aldosterone escape was 
associated with impaired exercise tolerance and increased ventilatory response during 
exercise (279). Moreover, in patients with hypertension receiving treatment with an ACE 
inhibitor or ARB, patients of the escape group showed significant reduction in the LV mass 
index although the reductions in blood pressure were similar between escape and non-escape 
groups (280). Aldosterone escape has also been found to be inversely correlated with arterial 
compliance in patients with HF treated with an ACE inhibitor (281). In addition, markers of 
insulin resistance were higher in the aldosterone escape compared to the non-escape group in 
a sub-study of the Aliskiren Observation of heart Failure Treatment (ALOFT) trial (282). 
 
1.4.2 Prognostic significance of plasma aldosterone in patients with HF and interaction 
with treatment  
Apart from the associations with intermediate phenotypes, studies have examined aldosterone 
levels in relation to mortality and morbidity. Increased levels of plasma aldosterone have 
been associated with worse prognosis in the Cooperative North Scandinavian Enalapril 
Survival Study (CONSENSUS) (55). In this trial, patients with severe HF were randomised 
to receive treatment with enalapril or placebo in addition to conventional therapy with 
diuretics, digoxin and aldosterone blockers. Aldosterone levels at baseline were significantly 
higher in non-survivors compared to survivors at 6 months in the placebo arm. In addition, 
aldosterone levels were positively correlated with mortality in patients taking placebo but not 
enalapril. Interestingly, the reduction in medium-term mortality risk with enalapril was 
prominent in patients with high, but not in patients with low angiotensin II and aldosterone 
levels at baseline.  
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 The prognostic significance of aldosterone was also examined in the Survival and Ventricular 
Enlargement (SAVE) study, where patients with an MI and LVSD were randomised to 
receive captopril or placebo (283). Higher plasma aldosterone levels at baseline were 
univariately associated with cardiovascular mortality during the follow-up period. Moreover, 
aldosterone levels were independently associated with the combined end point of 
cardiovascular mortality, development of HF or recurrent MI in these patients. Plasma 
neurohormone levels were further measured at three months, one and two years after the 
index MI in these patients (284). Aldosterone levels were significantly lower in the captopril 
compared with the placebo group in asymptomatic patients three months post-infarction. In 
addition, they were independently correlated with the development of severe HF and the 
combined end point of death or severe HF or recurrent MI during the follow-up period. 
Interestingly, plasma aldosterone levels remained elevated in patients randomised to placebo, 
especially in those who had a combined end point event within twenty-four months after the 
MI. In contrast, there was a decrease in aldosterone levels in patients treated with captopril, 
especially in those who did not have an event.  
 
In the modern era of HF treatment with an ACE inhibitor and beta-blocker, plasma 
aldosterone levels were lower in patients with chronic HF and LVSD receiving an ACE 
inhibitor or a beta-blocker compared with patients taking none of the previous agents in the 
Valsartan in Heart Failure Trial (Val-HeFT) study (285). Higher aldosterone levels at 
baseline were univariately associated with all-cause mortality and the combined end point of 
mortality and morbidity. In a multivariate analysis, a trend of higher mortality and morbidity 
was present in patients with higher aldosterone levels in this study. 
 
Unfortunately, the Randomised Aldactone Evaluation Study (RALES) (286) and the 
EPHESUS study (287), which examined the use of aldosterone antagonists in patients with 
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 HF, have not resulted in any publication with regards to aldosterone levels and outcomes so 
far. In a RALES substudy, plasma aldosterone levels were significantly higher in patients 
receiving spironolactone at three and six months (288). Conversely, there was a significant 
decrease in the levels of other neurohumoral markers including BNP in these patients. The 
reasons for the higher aldosterone levels following aldosterone blockade are not clear. 
Aldosterone increases via a positive feedback circuit tissue ACE activity, which in turn 
results in further angiotensin II generation and stimulation of aldosterone secretion (88) (89). 
Additionally spironolactone might increase directly aldosterone levels by blocking the 
binding of aldosterone to the MRs.  
 
1.4.3 Prognostic significance of plasma cortisol levels in HF 
The data with regards to cortisol secretion in patients with HF are sparse and the prognostic 
value of glucocorticoids in chronic HF has not been examined until recently. In a study of 
patients with HF serum cortisol levels were independently linked with all-cause mortality 
(72). This study also revealed complementary and incremental prognostic value of cortisol 
and aldosterone when these corticosteroids were examined in combination. In another study, 
serum levels of cortisol were significantly higher in patients with cardiac events, which were 
defined as cardiovascular mortality or hospitalisation for HF and were independently 
associated with worse prognosis (73). This study further examined the impact of oxidative 
stress, as reflected by plasma oxidised LDL (oxLDL) levels, on the prognostic value of 
cortisol; patients with high cortisol and oxLDL levels had higher risk of cardiac events 
compared with patients with high cortisol and low oxLDL levels. Interestingly, there was no 
significant difference in terms of risk prediction in patients with high cortisol and low oxLDL 
compared with patients with low cortisol levels.  
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 Overall, the worse outcomes in patients with raised cortisol levels in these studies were 
attributed to the activation of cardiomyocyte MRs by glucocorticoids, as under circumstances 
of altered redox state cortisol becomes MR agonist in tissues lacking 11beta-HSD2 (66).  
 
1.4.4 MR blocking in HF – Evidence from clinical trials 
In RALES, patients with severe HF and LVSD (LVEF ≤35%) were randomly assigned to 
receive, spironolactone or placebo, in combination with standard medical therapy (286). The 
study showed that MR blockade with spironolactone was associated with a 30% reduction in 
all-cause mortality, irrespective of the HF aetiology. That was due to a lower rate of death 
from progressive pump failure and sudden cardiac death. Various mechanisms are likely to 
contribute to the mortality benefit of aldosterone blockade as discussed in section 1.3. 
Spironolactone opposes the classic epithelial aldosterone effects on sodium retention, 
improves potassium and magnesium homeostasis and contributes to the reduction of 
arrhythmias related to potassium and magnesium loss (250) (289). Moreover, aldosterone 
blockade improves endothelial function and heart rate variability, suppresses vascular 
inflammation and exerts antifibrotic effects. The RALES study group, looking for a 
mechanistic link to explain the beneficial effects of aldosterone blockade, examined the 
associations between collagen turnover markers (PINP, PIIINP and PCIP) with all-cause 
mortality and the interaction between these markers and the effect of spironolactone on 
outcomes in a subgroup of the RALES cohort (241). Higher PIIINP levels at baseline were 
associated with increased risk of all-cause death. Moreover, aldosterone blockade 
significantly decreased PIIINP and PINP levels at six months. Finally, the mortality benefit 
with spironolactone was more prominent in patients with higher levels of collagen turnover 
markers at baseline, indicating that the attenuation of myocardial fibrosis contributes to the 
therapeutic benefit of aldosterone blockade in these patients. 
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 Aldosterone blockade with eplerenone, a selective MR blocker, was further examined in 
patients with MI complicated with LVSD in EPHESUS trial (287). In this study, the addition 
of eplerenone was examined on top of standard medical therapy with an ACE inhibitor and 
beta-blocker, aspirin, statin and coronary reperfusion, three to fourteen days after a 
complicated MI. Aldosterone blockade was associated with 15% decrease in all-cause 
mortality. There was also a decrease in sudden cardiac death and all-cause cardiovascular 
hospitalisation by 21% and 15% respectively. Similar to RALES, aldosterone antagonism 
with eplerenone reduced collagen turnover markers post-infarct (290). Moreover, much of the 
benefit of MR blockade in EPHESUS was due to a significant reduction of sudden cardiac 
death early after randomisation. At 30 days eplerenone reduced all-cause mortality by 31% 
and sudden cardiac death by 37% (251).  
 
The EMPHASIS (Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart 
Failure) trial in patients with mild to moderate HF and LSVD has recently filled the 
knowledge gap about use of aldosterone antagonists in patients with mild to moderate HF 
with LVSD (291). The EMPHASIS study recruited patients with New York Heart 
Association (NYHA) II functional class HF and LVEF of no more than 35%. In this study, 
eplerenone in addition to standard therapy with an ACE inhibitor or ARB and beta-blocker, 
resulted in 37% reduction in the primary end point of death from cardiovascular causes or 
hospitalisation for HF and a 35% reduction in the combined end point of all-cause mortality 
or HF hospitalisation. Additionally, there was also a 42% and 31% reduction in 
hospitalisation for HF and cardiovascular causes respectively. 
  
Evidence regarding the effects of aldosterone antagonists in chronic HF with preserved EF is 
substantially lacking at the moment. The Treatment of Preserved Cardiac Function Heart 
Failure with an Aldosterone Antagonist (TOPCAT) trial has been designed to examine the 
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 effects of MR blockade in patients with chronic HF and LVEF ≥ 45% (292). The results of 
the above trial are currently awaited.  
 
1.5 CYP11B2 polymorphisms and mineralo- and gluco-corticoid secretion 
 
1.5.1 CYP11B2 characteristics 
Aldosterone synthase is encoded by the CYP11B2 gene, which lies on chromosome 8q21-22, 
in close proximity with 11beta-hydroxylase gene (CYP11B1) approximately 40 kilobases 
apart (Figure 1-7). Both genes consist of 9 exons and 8 introns and share 95% and 90% 
sequence homology within their exonic and intronic regions, respectively (293). CYP11B1 
encodes the enzyme 11beta-hydroxylase, which mainly catalyses the formation of cortisol 
from 11-deoxycortisol in ZF. CYP11B2, encodes aldosterone synthase which catalyses the 
synthesis of aldosterone from DOC in the ZG. These enzymes are 93% identical, reflecting 
their shared 11beta-hydroxylase and 18-hydroxylation activity (78). However, differences in 
the promoter regulatory region of these genes, account for the different pattern of expression 
and distinct regulatory pathways (294). CYP11B1 is expressed throughout the adrenal cortex 
and its transcription is regulated by the ACTH. CYP11B2 is expressed only in the ZG in and 
its transcription is principally regulated by the angiotensin II.  
69
  
Figure 1-7. Aldosterone synthase gene(CYP11B2) and 11beta-hydroxylase gene 
(CYP11B1) 
 
 
 
1.5.2 CYP11B2 polymorphisms associated with aldosterone synthase activity and 
mineralocorticoid secretion 
Several polymorphisms have been described in CYP11B2 and two of them, one in the 
transcriptional regulatory region and the other in intron 2, have been extensively studied in 
relation to mineralocorticoid secretion. The -344C/T polymorphism is located in the 5’ 
promoter region of CYP11B2 and results in a cytosine/ thymine (C/T) amino acid substitution 
at position -344 (295). The above polymorphism is located within a putative steroidogenic 
factor-1(SF-1) binding site, which has been implicated in the expression of adrenocortical 
steroidogenic enzymes (293). The -344T allele disrupts the transcription binding site and has 
been shown to bind the SF-1 4 to 5 times less than the C allele (296). However, the T and C 
alleles exert similar transcription rates in vitro and the SF1 binding site can be deleted 
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 without having an effect on CYP11B2 transcription, indicating that SF-1 exerts a non-
dominant role in the regulation of CYP11B2 expression (297). Another well studied 
CYP11B2 polymorphism is IC, which is an intron conversion caused by an exchange of “wild 
type’’(Wt) intron 2 in CYP11B2 with the corresponding intron in CYP11B1 (Con).  
The -344T/C polymorphism and the IC have been found to be in tight linkage disequilibrium 
(LD), defining three different haplotypes (T/Con, C/Wt and T/Wt) (298). 
 
In clinical studies, aldosterone synthase activity has been indirectly examined by measuring 
aldosterone levels. Aldosterone synthase mediates the final three steps converting DOC to 
aldosterone in ZG and for that reason a more indicative marker of enzyme activity would be 
the DOC to aldosterone ratio. However, as DOC takes part in both mineralocorticoid and 
glucocorticoid synthesis pathways, plasma or urine aldosterone levels and plasma aldosterone 
to renin ratio have been extensively used to estimate aldosterone synthase activity in vivo 
instead. In these studies, the CYP11B2 -344T/C polymorphism has been associated with 
plasma aldosterone levels, aldosterone to renin ratio and urine excretion rates of aldosterone 
metabolites in healthy subjects and subjects with hypertension. In normotensive subjects of 
Caucasian origin 24-hour urine exertion rates of aldosterone metabolites were higher in 
carriers of the T allele compared with those lacking this allele (299). Correspondingly, in 
another study with healthy subjects, T allele carriers were found to have higher plasma 
aldosterone levels than CC homozygotes (300). In a multi-ethnic population of middle aged 
subjects with normal and high blood pressure, the T allele has been associated with higher 
plasma aldosterone levels (301). The C allele was more frequent in Caucasian and South 
Asian patients than individuals of African-American origin; the different allele frequencies 
between ethnic groups in this study, however, did not affect the associations between -344T 
allele and plasma aldosterone levels. Moreover, in another study, hypertensive individuals 
with a raised aldosterone to renin ratio had higher proportion of the T allele compared with 
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 hypertensive subjects with low aldosterone to renin ratio (302). Nevertheless, the associations 
between CYP11B2 -344T allele and mineralocorticoid levels have not always been 
consistent; the -344T/C polymorphism has been reported to have no relationship with 
aldosterone levels (303) or the C instead of the T allele has been associated with raised 
aldosterone levels (304). The same trend of discordant results has been reported in 
association studies with regard to the CYP11B2 IC. The intron conversion (Con) has been 
associated with higher plasma and urine aldosterone levels in some (298) (305) (306) but not 
in all studies (307).  
 
From the other CYP11B2 polymorphisms studied, a variant in exon 3, which results in a 
lysine/ arginine (L/A) amino acid substitution at residue 173 (K173R), has been shown to be 
in tight LD with -344T/C polymorphism; a haplotype including -344T and K173 was 
associated with higher CYP11B2 expression in adrenal tissue compared to other haplotypes, 
indicating that the K173R polymorphism may have a causative or a synergistic role with the -
344T/C polymorphism with regards to aldosterone synthase efficiency (308). However, 
although the K173R polymorphism has been associated with low renin hypertension in 
another population, no obvious effect on enzymatic activity, expressed as the ability to 
convert DOC to aldosterone, has been demonstrated in vitro (309).  
 
Despite the numerous studies with regards to CYP11B2 polymorphisms in relation to 
aldosterone secretion in healthy subjects and hypertensive subjects, little data exist on the 
interaction between CYP11B2 polymorphisms and aldosterone secretion in conditions related 
to activation of the RAAS; specifically, whether polymorphisms of the CYP11B2 have an 
impact on aldosterone synthesis in patients with HF remains unclear. 
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1.5.3 CYP11B2 and CYP11B1 polymorphisms associated with 11beta-hydroxylase 
activity and glucocorticoid secretion 
11beta-hydroxylase activity varies within normal subjects and part of this variability is 
genetically determined (310). Basal and ACTH-stimulated plasma levels of 11-deoxycortisol 
and DOC and DOC to corticosterone ratio were found to be significantly heritable in this 
study. 11beta-hydroxylase activity is usually defined by the ratio of plasma 11-deoxycortisol 
to cortisol or DOC to corticosterone or by the ratio of the urinary excretion rates of their 
metabolites respectively. An increased 11-deoxycortisol to cortisol ratio implies that more 
substrate is needed for the enzyme to synthesise the biologically required amounts of cortisol.  
 
The CYP11B2 promoter polymorphisms have been previously found to be associated with 
altered 11beta-hydroxylase efficiency in healthy subjects. In a study of male healthy subjects 
corticosteroid levels were not different at baseline (after a dexamethasone suppression test) 
between the -344T/C genotypes (295). Cortisol response to ACTH was also unaffected by the 
-344T/C genotype; however, 11-deoxycortisol levels were significantly higher in TT 
homozygotes compared to heterozygotes and CC homozygotes after ACTH stimulation, 
indicating a relative impairment of 11beta-hydroxylase efficiency in these subjects. A similar 
pattern was identified between the IC genotype groups in these patients; there was no 
difference in ACTH-stimulated cortisol levels between the genotypes, but 11-deoxycortisol 
levels increased significantly in response to ACTH in subjects with Con genotype compared 
to subjects with Wt genotype. Similar differences in corticosteroid levels according to the 
above CYP11B2 genotypes were seen in another study that included both male and female 
healthy subjects (299). Moreover, the above associations were further replicated in patients 
with essential hypertension. In a subgroup of unrelated subjects of the British Genetics of 
Hypertension (BRIGHT) study, cortisol and 11-deoxycortisol urine metabolite levels were 
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 not different between CYP11B2 genotypes (311). However, the ratio of 11-deoxycortisol to 
total cortisol urine metabolites was significantly higher in TT than CC homozygotes. Similar 
differences were found among TC compared to CC patients, however the differences among 
TT and TC patients were not statistically significant.   
 
The correlations between CYP11B2 polymorphisms and biomarkers of 11beta-hydroxylase 
efficiency found in these studies were somewhat unexpected at a first sight. Aldosterone 
synthase does not metabolise 11-deoxycortisol, which is converted to cortisol by the enzyme 
11beta-hydroxylase. The CYP11B1 gene encodes 11beta-hydroxylase and as previously 
mentioned lies in close proximity to CYP11B2 gene on chromosome 8 in humans. It was 
speculated that the quantitative trait locus for the corticosteroid intermediate phenotypes 
would probably lie within CYP11B1 gene and that LD across the CYP11B2/CYP11B1 locus 
could account for these observations (298). In view of this hypothesis, two groups were able 
to demonstrate the presence of LD between CYP11B1 and CYP11B2 promoter regions (312) 
(313). Both studies found a limited number of frequently occurring haplotypes and further 
demonstrated that the higher ratio of urinary 11-deoxycortisol to cortisol metabolite excretion 
rates was correlated with haplotypes carrying the CYP11B2 -344 T allele.  
 
Further evidence regarding the presence of LD across CYP11B1/CYP11B2 locus was 
provided by another study, which identified two novel polymorphisms (1889 G/T and 1859 
A/G) in the 5’ promoter region of the CYP11B1 (314); haplotype analysis demonstrated tight 
LD across the entire CYP11B locus revealing four common haplotypes. The -1889T and 
1859G alleles were associated with reduced CYP11B1 transcription in vitro in response to 
stimulation with agonists. Moreover, in subjects with hypertension a higher urine 11-
deoxycortisol to cortisol ratio was evident in homozygotes for the -1889T allele than 
heterozygotes or homozygotes for -1889G allele. A similar trend was found for the -1859G/T 
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 polymorphism, with the GG patients showing impaired 11beta-hydroxylase efficiency 
compared with the GT or TT patients.  Overall, that study identified novel CYP11B1 variants 
and provided strong evidence for LD between polymorphisms in the promoter region of 
CYP11B1/CYP11B2. These polymorphisms were also correlated with altered 11beta-
hydroxylase activity and might represent the causative loci for the associations seen between 
the -344T/C polymorphism and markers of 11beta-hydroxylation.   
 
1.6 Prognostic significance of CYP11B2 -344T/C polymorphism in patients 
with HF or patients with MI 
The association between the CYP11B2 promoter -344 T/C polymorphism and prognosis has 
been examined in patients with HF in the Genetic Risk Assessment of Heart Failure in 
African-Americans (GRAHF) (315), which was a genetic sub-study of the African-American 
Heart Failure Trial (A-HeFT) (316). In the A-HeFT study, African-Americans with HFrSF 
were randomised to receive either a fixed combination of isosorbide dinitrate and hydralazine 
or placebo, in addition to standard therapy with a beta-blocker, ACE inhibitor/ARB or 
aldosterone blocker. In the GRAHF study, apart from the association between CYP11B2        
-344T/C polymorphism and outcomes, a pharmacogenetic interaction between the above 
polymorphism and the treatment with regards to prognosis was additionally explored in 354 
of the A-HeFT patients. Subjects were followed-up to an end point of death or HF 
hospitalisation. A composite score, calculated from the combination of all-cause mortality, 
HF hospitalisation and change in quality of life at six months, was employed as the primary 
end point.  
 
The CYP11B2 -344C allele was associated with significantly poorer event-free survival 
(death or HF hospitalisation) during the course of follow-up in GRAHF (Figure 1-8), with TT 
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 homozygotes having better and CC homozygotes having the worse outcomes. Similarly, 
patients with the C allele had greater mortality than TT patients. Interestingly, in a 
pharmacogenetic sub-analysis, homozygotes for the T allele, responded significantly better to 
isosorbide dinitrate/hydralazine combination therapy with improvement in the composite 
score at six months than the C allele carriers (TC+CC) and that was mainly driven by 
improvement in the quality of life score. On the other hand, the -344C allele was linked to 
LV remodeling in placebo but not in the group treated with the isosorbide dinitrate/ 
hydralazine combination therapy; In the placebo group, C allele homozygotes had a greater 
LV end-diastolic diameter (LVEDD) compared with the TT homozygotes at six months. 
Similarly, a lower LVEF was present at 6 months in CC homozygotes compared with the TT 
homozygotes in the placebo group but not in patients treated with combination therapy. 
Overall, the effects of the C allele on LV remodeling and LVEF were diminished by the 
combination therapy, however, that was not translated in better survival in CC/CT compared 
with TT patients.  
 
Aldosterone levels were not measured in GRAHF study and a gene additive model based on 
previous studies in patients with hypertension (304) was a priori implemented to explain the 
associations between -344T/C polymorphism and outcomes in GRAHF. According to this 
model, aldosterone levels increase in a stepwise fashion as the number of the C allele 
increases, and patients with the CC genotype have higher aldosterone levels than patients 
with the TC and TT genotypes respectively. However, as mentioned in section 1.3.2, the C 
allele additive model has not always been replicated and several studies associated the T 
rather the C allele with higher levels of aldosterone (298) (300). Interestingly, the -344T 
allele has consistently been associated with higher 11-deoxycortisol to cortisol ratio 
compared with the -344C allele (section 1.3.2). Unfortunately, mineralo- and gluco-corticoid 
levels were not measured and aldosterone synthase or 11beta-hydroxylase activity was not 
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 assessed in GRAHF or other HF study. Whether CYP11B2 polymorphisms are associated 
with mineralo- or gluco-corticoid levels and additionally have an impact on outcomes in 
patients with HF is unknown. 
 
The association between -344 T/C polymorphism and survival has also been investigated in 
patients of predominantly Caucasian origin following an MI (317). At baseline TT 
homozygotes had a higher incidence of antecedent hypertension than TC + CC patients and 
that was more pronounced for males. Furthermore, patients with the TT genotype had higher 
levels of BNP, 24-96 hours after the onset of MI. Interestingly patients with the TT genotype 
had better survival compared to patients with CT and CC genotypes. Similar to the GRAHF 
study plasma mineralo- and gluco-corticoid levels were not measured in these patients and it 
was assumed that the association between -344T/C polymorphism and survival represents a 
pharmacogenetic response to background therapy. Nevertheless, in the absence of plasma or 
urine corticosteroid measurements, no definitive mechanistic link between CYP11B2 -344C 
allele and worse prognosis was identified. 
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Figure 1-8. Event free survival by CYP11B2 -344C/T genotypes in patients with severe 
HF. Adapted from McNamara et al. (315) 
 
 
 
1.7 Hypotheses and Aims 
 
The hypotheses tested in the experimental section of this thesis were that: 
 
 RAAS activity and glucocorticoid concentrations are associated with markers of HF 
severity in patients with acute decompensated and chronic HF.  
 The dissociation between RAAS and natriuretic peptide levels seen early after 
initiation of diuretic therapy in patients with decompensated HF is present in the medium- to 
long-term. 
 Increased RAAS activity and glucocorticoid levels measured during hospital 
admission are associated with worse prognosis in patients with HF. 
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  Variants in the CYP11B2 locus are associated with 11beta-hydroxylase efficiency, 
gluco- and mineralo-corticoid secretion and survival in patients with decompensated HF.  
 
The aims to test these hypotheses were: 
 
 Comparison studies examining patient characteristics according to renin and aldosterone 
levels, 11-deoxycortisol and cortisol levels, and aldosterone to renin and 11-deoxycortisol to 
cortisol ratio in patients with HF not taking a RAAS inhibitor during  hospital admission and 
at the follow-up visit.  
 Studies comparing RAAS activity and other laboratory and clinical variables between 
hospital admission and follow-up in patients not taking a RAAS inhibitor at both time points. 
 Survival studies examining the associations between plasma levels of RAAS mediators 
and glucocorticoid during hospital admission and all-cause mortality in patients with HF. 
 Comparison studies examining mineralocorticoid and glucocorticoid levels and other 
patient characteristics during hospital admission, according to CYP11B2 -344T/C and IC 
polymorphisms.  
 Survival studies examining associations between CYP11B2 -344T/C and IC 
polymorphisms and all-cause mortality in patients with HF. 
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2. Chapter Two - Methods 
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 2.1 Introduction 
 
In this chapter, I present the methods employed in the studies of this thesis. The identification 
of the participants, the study design and collection of the data as well as the laboratory 
analyses performed in these studies will be described in detail. 
 
2.2 Healthy Volunteers studies 
 
2.2.1  Recruitment of healthy subjects  
Eight healthy subjects were included in these studies. These were identified 
 
a) From a list of healthy volunteers who had already participated in previous studies in the 
British Heart Foundation (BHF) Glasgow Cardiovascular Research Centre and expressed an 
interest to be contacted for participation in future studies. 
b) Through advertisement within the University of Glasgow and the Western Infirmary in 
Glasgow (WIG). 
 
All subjects who expressed an interest in participating in the study were invited to attend the 
clinical research unit at the BHF Glasgow Cardiovascular Research Centre and an 
information leaflet was provided. Subjects were given time to decide whether they wished to 
take part in the study and those who remained agreeable were asked to sign a consent form in 
the presence of the research doctor at the BHF Glasgow Cardiovascular Research Centre. 
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 2.2.1.1 Screening Visit 
In the screening visit, a routine clinical examination was performed and a 12-lead ECG and a 
blood sample for routine kidney function tests were undertaken. Blood pressure 
measurements were performed after 5 minutes of rest in a sitting position. A standard 
sphygmomanometer was used and the correct cuff size was selected according to the arm 
circumference of the participant. Volunteers were asked to complete a questionnaire to ensure 
that they did not suffer from any significant chronic disease. 
 
Exclusion criteria for participation were as follows: 
 
1) Age less than 18 years or greater than 50 years 
2) Blood pressure >160/90 mmHg 
3) Cardiovascular or chronic disease 
4) Chronic medication 
5) History of allergy or asthma 
6) Drug abuse 
7) Pregnancy 
8) Abnormal kidney function, which was defined as eGFR < 60ml/min/1.73m
2
 and creatinine 
>98 µmol/L for women and >120 µmol/L for men.  
9) Inability to comply with the study instructions 
 
2.2.1.2 Study protocol 
The study included four visits and the time interval between the visits was around seven days. 
Visit 1 − Ambulatory blood sampling 
 
Healthy subjects attended the BHF Glasgow Cardiovascular Research Centre at 7.30 am. An 
intravenous (IV) cannula was inserted in a forearm vein on arrival and subjects rested supine 
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 for 30 minutes before the first blood samples were taken at 8.00am. Ambulatory blood 
samples were taken at 10.00am, 12.00pm, 4.00pm, 8.00pm and 10.00pm for PRC and plasma 
gluco- and mineralo-corticoid measurements. 
 
Visit 2 − ACTH stimulation test 
Subjects were asked to take 1 mg of oral dexamethasone (Pharmacy Unit, NHS Greater 
Glasgow and Clyde) twice daily on day 2 and 3 and to collect a 24-hour urine sample on day 
3 for urinary electrolyte measurements. On day 4, an ACTH stimulation test was performed. 
Subjects had an IV cannula inserted in a forearm vein at 7.00am, and rest supine for 60 
minutes. 1 μg of synthetic ACTH (Pharmacy Production Unit, NHS Greater Glasgow and 
Clyde) was slowly injected and blood samples were taken at 0, 10, 30 and 60 minutes for 
PRC and plasma mineralo- and gluco-corticoid measurements. 
 
Visit 3 − Low salt diet / Angiotensin II infusion 
Healthy subjects were given a diet sheet and advice to achieve controlled sodium diet (80 
mmol/day) for three days (day 1, 2, 3) before their visit to the BHF Glasgow Cardiovascular 
Research Centre for visit 3 (day 4). Subjects were asked to take a 40 mg once-only dose of 
oral furosemide (Pharmacy Unit, NHS Greater Glasgow and Clyde) and to collect a 24-hour 
urine sample for urinary electrolyte measurements on day 3. On day 4, an angiotensin II 
infusion study was performed. After 60 minutes of supine rest starting at 7.00am, angiotensin 
II (Merck, Läufelfingen, Switzerland) was infused via an indwelling IV cannula in the 
forearm at 1, 3 and 5 ng/kg/min for 20 minutes at each dose. Blood samples for PRC and 
plasma mineralo- and gluco-corticoid measurements were removed through an indwelling IV 
cannula in the opposite forearm at 0, 20, 40 and 60 minutes. The systolic blood pressure 
(SBP) and diastolic blood pressure (DBP), mean arterial pressure (MAP) and pulse rate were 
83
 recorded every 5 minutes. The infusion was discontinued if there was more than 20 mmHg 
increase in the MAP. 
 
Visit 4 − High salt diet / Angiotensin II infusion 
Healthy subjects were given a diet sheet and advice to follow controlled sodium  
diet (120 mmol/day) and take slow sodium tablets (100 mmol per day) for three days (day 1, 
2, 3) before their visit to the BHF Glasgow Cardiovascular Research Centre for visit 4 (day 
4). Subjects were asked to collect a 24-hour urine sample for urinary electrolyte 
measurements on day 3. On day 4, an angiotensin II infusion study was performed. After 60 
minutes of supine rest starting at 8.00am, angiotensin II was infused via an indwelling IV 
cannula in the forearm at 1, 3 and 5 ng/kg/min for 20 minutes at each dose. Blood samples 
for PRC and plasma mineralo- and gluco-corticoid measurements were removed through an 
indwelling IV cannula in the opposite forearm at 0, 20, 40 and 60 minutes. The SBP and 
DBP, MAP and pulse rate were recorded every 5 minutes. The infusion was discontinued if 
there was more than 20 mmHg increase in the MAP. 
 
The study protocol was approved by the West Glasgow Ethics Committee and all healthy 
volunteers provided a written informed consent. 
 
2.2.2 Laboratory measurements 
Plasma mineralo- and gluco-corticoids were measured by the MRC Blood Pressure Group 
(Ms M Ingram and Prof R Fraser) at the BHF Glasgow Cardiovascular Research Centre using 
a Liquid Chromatography Mass Spectrometry (LCMS) method. Three milliliters (ml) of 
plasma, containing an internal standard (16β-methylprednisone: 60 ng) were added to a Chem 
Elut SPE cartridge (Varian Inc.) and allowed to stand for at least 5 minutes. The steroids 
were eluted with dichloromethane (high-performance liquid chromatography [HPLC] grade: 
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 2 x 5 ml) and the eluate was evaporated until dry under nitrogen. The residue dissolved in 
10% acetonitrile (HPLC grade: 60 μl) of which 20μl was applied to the column (PolarisTM, 5 
μ C18-A, 150 x 20 mm), which was developed by gradient elution (acetonitrile:water 
containing 2 mmol ammonium acetate). Finally, the column was coupled to a mass 
spectrometer (Varian 1200L with a triple quadropole detector). 
 
PRC was analysed by the Diasorin chemiluminescent immunoassay using the Liaison 
platform (Diasorin S.p.A, Saluggia, Italy) at the Glasgow Royal Infirmary (GRI) (Prof M 
Wallace). Urinary sodium and potassium excretion rates were measured on 24-hour urine 
collections by the Department of Biochemistry at the WIG using an ion-selective electrode 
method. 
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 2.3 HF study – Hospital admission 
 
2.3.1 Study design and participants 
Almost all patients admitted to the WIG and GRI with decompensated HF between July 2007 
and January 2009 and the Royal Alexandra Hospital (RAH) in Paisley between April 2008 
and January 2009, were screened (Dr Y Tsorlalis at WIG, Dr C Jackson at GRI and research 
nurse team at RAH) prospectively for inclusion in this study. The majority of patients were 
screened in the acute medical assessment and coronary care unit or the cardiology ward of 
each hospital within 24 - 72 hours of hospital admission. Screening involved looking daily at 
the case notes of all the new admissions.  
 
The inclusion criteria for participation in the study were as follows: 
 
1. Admission with symptoms and signs of HF 
2. Radiological evidence of HF 
3. Response to IV diuretics 
 
Patients were eligible for screening and potential inclusion in the study, if they were admitted 
to hospital with symptoms and signs of HF and had radiological evidence of HF or responded 
to IVdiuretics. 
 
The principal exclusion criteria are listed below: 
 
- Acute coronary syndrome complicated by pulmonary oedema  
- Serious concurrent systemic disease 
- Cognitive impairment  
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 - Geographical or social reasons making study visit not feasible 
 
All the eligible patients were approached for enrollment in the study, which involved two 
stages. At the first stage, patients expressing an interest to participate in the study were 
provided with an information sheet and they were asked to give written permission for blood 
sampling to measure BNP, PRC and plasma corticosteroids and to extract DNA for 
identification of CYP11B2 polymorphisms. In addition, permission was given for access to 
the patients’ medical records in order information to be recorded by the medical and nursing 
stuff recruiting for the study. Finally, patients consented at this stage to be followed-up 
through the Information Services Division (ISD) of the National Scottish Health Service with 
regards to death recording. 
 
The BNP result was available within 24 hours after the blood sampling and patients were 
informed about that the following day. Patients with BNP <100 pg/ml were not asked to 
participate in the next stage of study and the measurements of PRC and corticosteroids and 
the genotyping for CYP11B2 polymorphisms were not performed. Patients with BNP ≥100 
pg/ml were invited to visit the BHF Glasgow Cardiovascular Research Centre in 
approximately 4 - 6 weeks following their discharge from hospital. Following the consent 
form for the second stage, an appointment with date and time was arranged for every 
surviving patient prior to discharge. The study was approved by the Greater Glasgow & 
Clyde Ethics Committee. 
 
Demographic data, medical history, physiological measurements, 12-lead ECG findings and 
transthoracic echocardiogram parameters, medication and laboratory measurements were 
recorded in all patients enrolled in the study during hospital admission. Demographic data 
included age and gender. The medical history involved history of previous HF, MI, angina, 
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 diabetes mellitus, hypertension, atrial fibrillation (AF) and cerebrovascular accident (CVA). 
The pulse rate, SBP and DBP measured on admission were also recorded as part of the 
physiological measurements. Every patient had their weight and height measured and their 
BMI was calculated. A 12-lead ECG was performed in all patients at the time of admission 
and the heart rhythm was recorded.  
 
Most of the patients had a transthoracic echocardiogram performed during the index 
admission or early after discharge. The LVEDD as well as the presence or absence of dilated 
left ventricle was recorded. In addition, the presence or absence of LV hypertrophy (LVH) 
was recorded according to the echocardiogram reports in each hospital (patients with 
interventricular septal thickness or LV posterior wall thickness  >12 mm at the end of diastole 
in 2-dimensional or M-mode measurements were classified as having LVH). Calculations of 
the LVEF were not regularly carried out during hospital admission. The assessment of LV 
systolic function was based on qualitative assessment instead and whether there was LVSD 
or not was documented.  
 
The cardiovascular and oral glucocorticoid therapy prior to admission and the HF medication 
during the first 24 hours of admission were documented for every patient enrolled in the 
study. 
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 2.3.2 Blood sampling and laboratory measurements 
Blood sampling for neurohumoral and corticosteroid measurements was undertaken within 
24 - 72 hours following hospital admission. Most of the patients admitted to hospital between 
Monday morning and Friday midday had blood samples collected within 24 hours and 
patients admitted to hospital between Friday midday and Monday morning had blood 
samples collected within 24-72 hours following the hospital admission. All blood samples 
were collected in the morning, between 8am and 11am, with the majority of patients resting 
in the semi-recumbent position for at least 20 minutes. Blood samples for BNP and PRC 
were collected in tubes containing potassium ethylenediaminetetraacetic acid (EDTA). Blood 
samples for aldosterone, cortisol and 11-deoxycortisol were collected in lithium-heparin 
tubes. The EDTA tubes for BNP were sent to Gartneval General Hospital in Glasgow and 
analysed (Dr R Spooner) using the Architect Assay (Abbott Laboratories, Abbott Park, IL, 
USA). The EDTA and lithium-heparin tubes for PRC and corticosteroid measurements were 
transferred to the BHF Glasgow Cardiovascular Research Centre within 4 - 6 hours of blood 
sampling and centrifuged at 4 
o
C for 20 minutes. The supernatant was immediately frozen 
and stored at -80 
o
C in the BHF Glasgow Cardiovascular Research Centre until later blinded 
batched analysis. All samples were subjected to one freeze-thaw cycle only. Frozen PRC 
aliquots were sent to the GRI and measured (Prof M Wallace) by the Diasorin 
chemiluminescent immunoassay using the Liaison automated platform (Diasorin S.p.A, 
Saluggia, Italy). The assay working range is 5 - 500 mIU/L and samples containing PRC 
above 500 mIU/L were diluted in a diluent supplied by Diasorin (code - Endo 31933) (318). 
PRC values below 5 mIU/L were recorded as 5 mIU/L for the purposes of analyses.  
 
Three milliliters of stored plasma were analysed for aldosterone, cortisol and 11-
deoxycortisol levels by LCMS in the BHF Glasgow Cardiovascular Research Centre (Ms M 
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 Ingram and Prof R Fraser). The methodology used for the analysis of corticosteroids by 
LCMS was described in section 2.2.2. 
 
Stored plasma aliquots for PRC and corticosteroids were available and adequate for analyses 
for most of the patients recruited in the study (Table 2-1 below). These aliquots were selected 
and analysed for PRC and corticosteroids only by availability and adequacy criteria and this 
selection was essentially random. 
 
 
Table 2-1. Number and percentage (%) of patients with each variable measured in the 
overall hospitalised cohort (n=722). 
Variable Number of patients 
with each variable 
measured 
Percentage (%) of 
patients with each 
variable measured 
PRC 689 95.4 
Aldosterone 551 76.3 
Cortisol 613 84.9 
11-deoxycortisol 600 83.1 
 
 
 
Blood samples for routine biochemical and haematological tests were taken during hospital 
admission and analysed as part of the routine practice in the Biochemistry and Haematology 
laboratories. All patients had urea and electrolytes (U&Es), and full blood count (FBC) 
analysed and the majority of patients had troponin measured at the time of hospital 
admission. The estimated glomerular filtration rate (eGFR) was calculated using the 
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 Modification of Diet in Renal Disease (MDRD) equation
1
. Troponin I was measured at the 
WIG and GRI by the Architect assay (Abbot Laboratories, Abbott Park, IL, USA) and 
troponin T was measured at the RAH by the Roche assay (Roche Diagnostics, Basel, 
Switzerland). Elevated troponin I and T results were reported as ≥ 0.04 μg/L and ≥ 0.05 μg/L 
respectively. 
 
CRP, thyroid stimulating hormone (TSH) and lipid profile measurements were additionally 
recorded if tests were performed during admission. 
 
2.3.3 Genotyping 
 
2.3.3.1 Extraction and quantification of genomic DNA  
10 ml of EDTA-preserved whole blood was added to 40 ml of cell lysis mix in a universal 
tube, which was left on ice for 10 minutes before centrifugation at 1660 x g for 10mins at 
4C. The resulting pellet was re-suspended in 3 ml of nucleic lysis mix. 200 l 10% sodium 
dodecyl sulphate (SDS) and 100 l proteinase K (10 mg/ml) were added and the tubes were 
left for incubation overnight at 37C. Following incubation, 1 ml of 6 M NaCl2 was added 
with vigorous shaking and after addition of 5 ml of phenol:chloroform:isoamyl alcohol 
(25:24:1) the tubes were centrifuged at 1660 x g for 20 minutes at 4C. The upper phase of 
the supernatant was removed and two volumes of ethanol were added. DNA was spooled out 
with a glass rod, washed in 70% (v/v) ethanol and allowed to air dry; it was then suspended 
in 100l Tris-HCL-EDTA buffer (TE) before storage at 4C. The extraction of DNAwas 
carried out by Dr G Inglis 
                                                 
 
 
1
 eGFR (ml/min/1.73m2) = 32788 x (serum creatinine in mmol/L)-1.154  x (Age) -0.203 x (0.742 if female) x 
(1.212 if African American/Caribbean) 
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1 µl of DNA solution was mixed with 1 ml of distilled water in a quartz cuvette, which was 
inserted in a dual beam spectrophotometer. DNA concentration was determined according to 
the following equation: 
[DNA] = 50 x Absorbance260nm  
 
Absorbance refers to the wavelength of light that is absorbed by DNA at 260nm and was 
used to determine the DNA concentration in each sample. The quantification of genomic 
DNA was performed by Dr Y Tsorlalis and Mrs C Holloway  
 
 
2.3.3.2 CYP11B2 IC Genotyping − Polymerase chain reaction (PCR) − amplification 
and automated sequencing 
 
PCR amplification protocol 
 
The reaction mix was prepared in sterile eppendorf tubes on ice. 
10 x Thermo-Start DNA polymerase buffer 250µl 
MgCl2 (25 mM) 200µl 
dNTPs  500µl 
Sense oligonucleotide primer (ICTAQMAN F)  
Sequence: 5'  GATGGCATGAAGCACAAAGCT 3' 
100µl 
Antisense oligonucleotide primer (ICTAQMAN R) 
Sequence: 5'  CCTTGGGCGACAGCACA  3' 
100µl 
Enzyme (Taq ABGene) 12.5 µl 
Nuclease free (NF) water (Ambion, UK) 337.5  
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The reagents were kept on ice and 15 l of this mastermix added to 10 l of DNA (5ng/µl), 
which had been pre-plated on to 96-well plate. A 96-well DNA Engine Dyad thermocycler 
(MJ Research, USA) was used for the amplification reaction according to the following 
thermocycling protocol: 
 
1. 95°C for 15 minutes 
2. 95°C for 15 seconds 
3. 62°C for 30 seconds 
4. 72°C for 2 minutes 
5. Repeat step 2–4 x 35 more cycles 
6. 72°C for 7 minutes 
7. Incubate at 4°C for ∞ 
 
Identification of PCR products - Agarose gel electrophoresis 
A 1 % (w/v) tris/borate/EDTA (TBE) - agarose gel was prepared by adding 1 g of agarose 
(Eurogentec, Belgium) in 100 ml of TBE buffer (Sigma-Aldrich, UK) and melting it in a 
950W microwave oven for 60 seconds. After cooling for a few minutes, the mix was 
transferred in a fume hood where 1 µl of ethidium bromide (EtBr) (Sigma-Aldrich, UK) was 
further added. Agarose, was then effused into a gel mould with Teflon combs and allowed for 
15 minutes for the gel to be formed. After removing the combs, the gel was placed in a 
standard electrophoresis tank containing TBE buffer (Bio-rad, UK). 10 µl of each PCR 
reaction product with 5 µl of loading dye were loaded in separate gel wells. Subsequently the 
gel was resolved at 80 volts for 50 minutes. DNA bands on the gel were visualised by an 
ultraviolet trans-illuminator (Fluor-S MultiImager, Biorad, UK) and images obtained with 
Multi-Analyst software (Biorad, UK) 
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PCR product clean-up 
The AMPure (Agencourt, USA) purification method was used for the PCR product clean-up. 
The PCR plates were carefully unsealed and 36 µl of AMPure was added to each well. The 
plate was then sealed and centrifuged at 210 x g for 30 seconds. After incubation for 3 
minutes at room temperature, it was placed on a solid phase reversible immobilisation (SPRI) 
magnet for 10 minutes. Afterwards the plate while being on magnet was inverted on a paper 
to remove the supernatant. Subsequently, 200 µl of 70% ethanol was added to each well and 
after 30 seconds of incubation the plate inverted on a paper tissue again to discard the 
solution before being centrifuged at 76 x g for 30 seconds. The magnet was removed from the 
plate, which was dried in room temperature for approximately 20 minutes. 40 µl of nuclease 
free water was added in each well and the plate was replaced on the magnet for 5 minutes. 10 
µl of the clear product was transferred to a new 96 well plate for the sequencing reaction. 
 
Sequencing reaction set-up 
The plate was used for the sequencing reactions containing the following in each well:  
 
PCR product (10.0 µl) 
Sequencing buffer (3.5 µl)  
Ready reaction mix (0.5 µl) 
Sequencing primer - INTCONR(B1B2) 
Sequence: 5' GTGTTCGAGCTGCAGCCTTTT 3' 
(1.0 µl)  
Nuclease free water (5.0 µl) 
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 The resultant reaction mix was subjected to cycle sequencing using a 96-well Dyad Disciple 
sample block powered by the PTC-0021 thermal cycler with heated lid (MJ Research 
Waltham, MA, USA.) according to the following thermocycling conditions: 
 
1. 96°C for 45 seconds 
2. 60°C for 4 minutes 
3. Repeat step 1–2 x 25 more cycles 
4. Incubate at 4°C for ∞ 
 
Sequencing reaction clean-up 
A second clean-up was performed using CleanSEQ (Agencourt, USA). Each sequencing 
reaction was mixed with 10 l of CleanSEQ and 62 l of 85% ethanol  and an adhesive paper 
lid used to seal the plate. After incubation at room temperature for 15 minutes, the plates 
were centrifuged for 30 seconds at 210 x g and placed on the SPRI magnet for 10 minutes. 
The seal was removed and the PCR plate was inverted onto a paper tissue to discard the 
solution. Subsequently 150 l of 85% ethanol was added to each well and after 30 seconds of 
incubation the plate was inverted again on paper tissue to remove the supernatant and 
centrifuged at 210 x g for 30 seconds. Afterwards, the plate was left at room temperature to 
dry for approximately 20 minutes. 40 µl of nuclease free water were added to each 
sequencing reaction and the plate was placed on a magnet again after being centrifuged at 
210 x g for 30 seconds. 20l of sequence product were transferred to each well of a barcoded 
plate for the Big Dye Sequencer. 
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 Automated Cycle Sequencing 
Sequencing was performed using the Applied Biosystems BigDye Terminator v3.1. cycle 
sequencing kit (PE Applied Biosystems, CA,USA).The sequencing reaction results were 
visualised using SeqScape Version 2.1.1. 
 
CYP11B2 IC genotyping was carried out by Dr Y Tsorlalis  and Mrs C Holloway 
 
2.3.3.3 CYP11B2 -344 T/C Genotyping: Taqman method  
1 μl of each DNA sample (5ng/μl) was plated on to a Micro Amp Optical 96-well reaction 
plate (Applied Biosystems, U.K.). 1 μl (concentration 5ng/μl) of DNA, genotyped for the  
-344 T/C polymorphism (positive controls) and 1 μl of nuclease free water (negative 
controls) were added to the designated locations in the plate. The plate was sealed and 
centrifuged at 210 x g for 1 minute. 
 
The reaction mix for the CYP11B2 -344 T/C genotyping with the Taqman method was 
prepared using probes and primers that were made to order by Life Technologies, CA, USA 
(Assay ID: C_8896484_10) 
 
TaqMan Genotyping Master Mix (Applied Biosystems 
CA, USA) 
560µl 
Primers & probes 14µl 
NF water (Ambion, UK) 434µl  
 
 
9 μl of master mix were added to the plate, which had been pre-plated with 1 μl of DNA. 
Therma seal RT film for Real-time PCR (Excel Scientific, Wrightwood CA, USA) used for 
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 the plate sealing, which was subsequently placed on the High-Speed Microplate Shaker 
(Illumina, USA) and pulsed at 480 x g for 10 seconds. Afterwards, the plate was centrifuged 
at 210 x g for 1 minute. 
 
The amplification reaction was performed on a 96-well AlphaTM sample block powered by 
the PTC-225 Engine Tetrad(R) Cycler with heated lid (MJ Research, Waltham, MA, USA) 
according to the following cycling parameters: 
 
1. 95°C for 15 minutes 
2. 95°C for 15 seconds 
3. 60°C for 1 minute 
4. Go to step 2, 49 times 
5. 10°C forever 
 
Following the PCR, the genotypes were analysed by the ABI Prism 7900 HT. Separate 
clusters corresponding to different genotypes were identified by the SDS 2.3 software 
(Applied Biosystems). Samples which either were not assigned clearly in a separate cluster or 
characterised by a quality value <95% were not analysed. Finally, in order to exclude any 
incorrect analyses by the software, the results were further read by the operator (Dr Y 
Tsorlalis and Mrs C Holloway) 
 
2.4 HF study – follow-up visit 
  
2.4.1 Study design  
Surviving patients returned for follow-up at the BHF Glasgow Cardiovascular Research 
Centre approximately 4 - 6 weeks following their discharge from hospital, in the afternoon 
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 between 12 - 3pm. The follow-up visits commenced in September 2007 and were completed 
in March 2009.  
 
Similar to the variables recorded during hospital admission, demographic data, physiological 
measurements and 12-lead ECG findings were recorded for all patients during follow-up. All 
the cardiovascular medications and the treatment with an oral glucocorticoid were 
documented during follow-up. All patients had a transthoracic echocardiogram (Acuson 
Sequoia C512) in the BHF Glasgow Cardiovascular Research Centre by a single operator (Dr 
C Jackson). The LVEF could be calculated for the majority of patients using the Simpson’s 
method by a single cardiac echocardiography physiologist (Mr T Cunningham). 
 
2.4.2 Blood sampling and laboratory measurements 
Blood sampling for neurohumoral and corticosteroid measurements was undertaken at the 
BHF Glasgow Cardiovascular Research Centre between 1pm and 4pm, with the patients 
resting in the sitting position for at least 20 minutes. Similar to the hospital admission, blood 
samples were collected for PRC, BNP, aldosterone and 11-deoxycortisol and cortisol. The 
same methodology (section 2.3.2) was employed with regards to the centrifugation, 
extraction of plasma and storage of aliquots as well as the assays used for the laboratory 
measurements.  
 
Stored plasma aliquots for PRC and corticosteroids were available for the majority of patients 
during the follow-up visit (Table 2-2 below).  
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 Table 2-2. Number and percentage (%) of patients with each variable measured in the 
overall study visit cohort (n=453). 
Variable Number of patients 
with each variable measured 
Percentage (%) of patients 
with each variable 
Measured 
PRC 445 98.2 
Aldosterone 428 94.4 
Cortisol 417 92 
11-deoxycortisol 427 94.3 
 
 
 
In addition to the neurohumoral and corticosteroid measurements, routine biochemical and 
haematological tests were undertaken during the follow-up visit. All patients had U&Es, 
troponin I, CRP, TSH, lipid profile, and haemoglobin measured. The assays for the 
aforementioned tests were described previously (section 2.3.2).  
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3. Chapter Three - Validation of LCMS method 
for plasma corticosteroid measurements  
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 3.1 Introduction 
 
The principal objective of the healthy volunteer studies was to validate a new method based 
on the LCMS technology for the assessment of plasma gluco- and mineralo-corticoid levels. 
The overall corticosteroid metabolite excretion rates (24-hour urine collections) rather than 
individual compounds have been previously assayed for the measurement of corticosteroids 
in large populations of patients with or without cardiovascular disease (311) (319) (320). 
Although urinary corticosteroid analysis provides a reliable index of average adrenal cortex 
activity over 24 hours, it is time-consuming and cumbersome to organise in large-scale 
population studies. Moreover, it is indirect as each steroid is represented by several 
metabolites rather than the hormone itself. Various immunoassays have been used 
alternatively in the research setting for the measurement of plasma corticosteroids. Although 
most of these assays are automated, rapid and sensitive, their specificity has been questioned 
due to interference by cross-reacting endogenous steroid compounds (321). In addition, 
immunoassays are not reliable with regards to corticosteroid analysis in normal and low 
concentrations (322). LCMS has become increasingly employed for plasma steroid 
measurements and has been characterised by its reliability properties compared with 
immunoassays, especially with regards to aldosterone measurements (323).  
 
In these series of healthy volunteer studies, my aim was to ascertain that the LCMS method 
successfully detected predictable changes in plasma corticosteroid levels, following 
manipulation of the adrenal metabolism, prior to applying this method in the studies with HF 
patients. 
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 3.2 Methods 
 
3.2.1 Study design and laboratory measurements 
The study design and laboratory measurements of the normal volunteer studies were 
described in sections 2.2.1 and 2.2.2. 
 
3.2.2 Statistical Analysis 
All statistical analyses were carried out using the Minitab 15 software. As not all variables 
were normally distributed, the data were log transformed before analysis. Student’s paired t-
test and repeated-measures analysis of variance (ANOVA) were used as appropriate to 
compare values between different time points. All values are presented as mean and standard 
deviation (SD). A value of p<0.05 was considered to be statistically significant. 
 
3.3 Results 
 
3.3.1 Visit 1  Diurnal rhythm 
Cortisol and 11-deoxycortisol levels were lower at 10.00pm compared to 8.00am, 12.00pm 
and 4.00pm (Table 3-1). Conversely, the 11-deoxycortisol to cortisol ratio was higher in the 
evening, but not significantly, compared with the morning and the afternoon. A trend for 
lower aldosterone levels was present in the evening compared with the morning, but no 
differences were seen in PRC and the aldosterone to PRC ratio. 
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 3.3.2 Visit 2 
 
3.3.2.1 Effects of oral glucocorticoid therapy on plasma renin and corticosteroid levels 
Cortisol levels were significantly lower at baseline in visit 2 compared with visit 1 (Table 3-2 
below). Correspondingly, 11-deoxycortisol levels were significantly suppressed at baseline in 
visit 2. Conversely, the 11-deoxycortisol to cortisol ratio was higher, but not significantly, in 
visit 2. Plasma aldosterone and renin concentrations and the aldosterone to PRC ratio were 
not significantly altered by oral glucocorticoid treatment. 
 
 
Table 3-2. Plasma corticosteroid and renin levels and 11-deoxycortisol to cortisol and 
aldosterone to PRC ratio at baseline in visit 1 and visit 2 
Variable 
 
Visit 1 
8.00am 
Visit 2 
8.00am 
p-value 
Aldosterone (pmol/L) 197.8 (138.7) 280.2 (362.8) 0.718 
PRC (mIU/L) 22.2 (7.1) 26.9 (18.9) 0.980 
Aldosterone/PRC 9.03 (5.24) 9.52 (10.09) 0.583 
11-deoxycortisol (pmol/L) 805.2 (447.3) 277.3 (355.0) 0.049 
Cortisol (nmol/L) 378.0 (173.8) 6.2 (5.1) <0.001 
11-deoxycortisol/cortisol (10
-3
) 2.29 (1.34) 82.5 (106.3) 0.130 
Data are expressed as mean (SD) 
  
104
 3.3.2.2 Effects of ACTH on plasma renin and corticosteroid levels 
A significant increase was seen in glucocorticoid levels at 30 minutes following ACTH 
injection (Table 3-3 below). Cortisol increased from the mean (SD) basal value of 6.2 (5.1) 
nmol/L to a maximum of 156.2 (53.8) nmol/L at 30 minutes and remained elevated at 60 
minutes. Similarly, 11-deoxycortisol levels increased in response to ACTH and reached a 
maximum of 1044.7 (1036) pmol/L at 10 minutes after ACTH injection (paired t= 2.97, p= 
0.021). At 30 minutes, 11-deoxycortisol levels were still higher compared with baseline. The 
11-deoxycortisol to cortisol ratio was lower, but not significantly, at 30 minutes after the 
ACTH injection.  
 
 
Table 3-3. Plasma corticosteroid and renin levels and 11-deoxycortisol to cortisol and 
aldosterone to PRC ratio at baseline and 30 minutes after ACTH injection in visit 2 
Variable 
 
Visit 2 
0 minutes 
Visit 2 
30 minutes 
p-value 
Aldosterone (pmol/L) 280.2 (362.8) 640.8 (613.1) 0.009 
PRC (mIU/L) 26.9 (18.9) 22.6 (12.6) 0.054 
Aldosterone/PRC 9.52 (10.1) 36.9 (31.1) 0.005 
11-deoxycortisol (pmol/L) 277.3 (355.0) 958.2 (637.8) 0.044 
Cortisol (nmol/L) 6.2 (5.1) 156.2 (53.8) <0.001 
11-deoxycortisol/cortisol (10
-3
) 82.5 (106.3) 5.22 (2.79) 0.220 
Data are expressed as mean (SD) 
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 ACTH injection resulted also in a significant increase in aldosterone levels with a peak at 10 
minutes (paired t= 4.94, P= 0.002). Aldosterone levels were still higher at 30 minutes 
compared to baseline. Conversely, there was a decrease in PRC at 30 minutes after ACTH 
injection although that was not statistically significant. Similar to aldosterone, the aldosterone 
to PRC ratio was higher at 30 minutes compared with baseline.   
 
3.3.3 Visit 3 & 4 
 
3.3.3.1 Effects of sodium intake on plasma renin and corticosteroid levels 
Urinary sodium excretion was higher following high salt diet and lower after low salt diet 
(Table 3-4). Conversely, urinary potassium excretion was lower after high salt compared with 
lower salt intake.   
 
The baseline plasma concentrations of gluco- and mineralo-corticoids, PRC and the 11-
deoxycortisol to cortisol and aldosterone to PRC ratio are displayed in Table 3-5. Plasma 
aldosterone levels were higher at baseline in visit 3 (low salt diet) compared with visit 4 (high 
salt diet). Similarly, PRC was significantly higher at baseline after low compared to high salt 
diet. The shift from low to high salt diet intake suppressed aldosterone concentration in 
proportion to the decrease in PRC and the aldosterone to PRC ratio was not different between 
the two visits.  
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 Table 3-4. Urinary electrolyte and corticosteroid excretion rates in visit 3 and 4 
 
 
Visit 3 
 
(low salt diet) 
Visit 4 
 
(high salt diet) 
p-value 
 
Urinary sodium (mmol/L) 87.4 (32.7) 155.9 (47.5) 0.043 
Urinary potassium (mmol/L) 79.6 (28.9) 54.2 (19.4) 0.021 
Data are expressed as mean (SD) 
 
 
 
No significant changes were seen in plasma glucocorticoid levels (cortisol and 11-
deoxycortisol) and the 11-deoxycortisol to cortisol ratio in response to salt diet manipulation. 
 
 
Table 3-5. Plasma corticosteroid and renin levels and 11-deoxycortisol to cortisol and 
aldosterone to PRC ratio at baseline in visit 3 and 4 
Variable 
 
Visit 3  
(low salt diet) 
0 minutes 
Visit 4  
(high salt diet) 
0 minutes 
p-value 
Aldosterone (pmol/L) 194.2 (127.6) 72.1 (66.6) 0.053 
PRC (mIU/L) 42.9 (30.2) 11.2 (5.9) <0.001 
Aldosterone/ PRC 7.20 (9.82) 8.99 (11.39) 0.572 
11-deoxycortisol (pmol/L) 467.5 (303.0) 718.6 (476.2) 0.222 
Cortisol (nmol/L) 251.1 (143.5) 251.1 (193.1) 0.534 
11-deoxycortisol/cortisol (10
-3
) 1.83 (1.13) 3.4 (2.65) 0.178 
Data are expressed as mean (SD) 
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 3.3.3.2 Effects of angiotensin II on blood pressure  
During visit 4, angiotensin II infusion was discontinued in one normal volunteer, 35 minutes 
from the baseline, as there was a more than 20 mmHg increase in the MAP. 
 
During angiotensin II infusion, a slight, but significant, increase in DBP and MAP occurred at 
both visits 3 and 4 confirming the biological activity of the peptide (Table 3-6). The DBP 
increased from the basal level of 69 (7) mmHg to 74 (9) mmHg at 60 minutes in Visit 3 and 
from 69 (3) mmHg to 77 (5) mmHg at 60 minutes in Visit 4. Similarly, the MAP increased 
from 80 (7) mmHg at baseline to 85 (8) mmHg at 60 minutes in Visit 3 and from 80 (2) 
mmHg to 88 (6) mmHg at 60 minutes in Visit 4. Correspondingly, the SBP increased from 
baseline in both visits 3 and 4 but that reached statistical significance only at 60 minutes in 
Visit 4. 
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 3.3.3.3 Effects of angiotensin II on plasma renin and corticosteroid levels  
Angiotensin II infusion induced a significant increase in aldosterone secretion at 60 minutes 
compared with baseline in visit 3 and 4 (Table 3-7). Conversely, infusion of angiotensin II 
resulted in a decrease of PRC at 60 minutes in both visit 3 and 4. Plasma cortisol levels were 
significantly lower at 60 minutes compared with baseline in both visits.  No significant 
differences were observed in 11-deoxycortisol levels or the 11-deoxycortisol to cortisol ratio 
between 60 minutes and baseline in visit 3 and 4.  
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 3.3.3.4 Effects of sodium intake on aldosterone responsiveness to angiotensin II  
Following low sodium diet in visit 3, angiotensin II increased plasma aldosterone by 79.3 
(163.4), 464.9 (372.8) and 582.5 (533.4) pmol/L at the incremental infusion rates of 1, 3 and 
5ng/kg/min respectively (Table 3-8 below). On the other hand, after high salt diet, 
angiotensin II produced an increase in aldosterone by 56.4 (76.8), 208.6 (152) and 450.8 
(527.1) pmol/L at the three incremental infusion rates. The increments of aldosterone were 
significantly greater after low than after high salt diet at the two higher angiotensin II 
infusion rates (3 & 5 ng/kg/min). No significant difference in aldosterone increment was 
evident at the lower angiotensin infusion rate (1ng/kg/min) between the two visits 
 
 
Table 3-8. Increments of plasma aldosterone levels at 20, 40 and 60 minutes from 
baseline in visit 3 and 4 
Angiotensin II infusion 
rate 
 
Visit 3 (low salt) 
 
Increments of 
aldosterone 
from baseline 
(pmol/L) 
Visit 4 (high salt) 
 
Increments of 
aldosterone 
from baseline 
(pmol/L) 
p-value 
20 min (1ng/kg/min) 79.3 (163.4) 56.4 (76.8) 0.367 
40 min (3ng/kg/min) 464.9 (372.8) 208.6 (152) 0.043 
60 min (5ng/kg/min) 582.5 (533.4) 450.8 (527.1) 0.041 
Data are expressed as mean (SD) 
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 3.4 Discussion 
 
In these series of healthy volunteer studies, the LCMS method effectively detected changes in 
plasma steroid levels, predictable from many previous studies, following manipulation of 
adrenal metabolism.  
 
3.4.1 Visit 1 & 2 – Diurnal rhythm, effects of oral glucocorticoid treatment and ACTH 
injection on plasma corticosteroid and renin levels   
In visit 1, a diurnal pattern in glucocorticoid secretion was clearly demonstrated in this small 
cohort of healthy subjects. The ACTH-dependent adrenal glucocorticoids (11-deoxycortisol 
and cortisol) were higher in the morning than in the afternoon and in the evening due to the 
greater release of ACTH by pituitary gland in the morning. ACTH stimulates cholesterol 
entry into mitochondria, increases the conversion of cholesterol to pregnenolone and up-
regulates the expression of the enzymes involved in the glucocorticoid pathway (section 
1.2.4). Conversely, there was a trend for lower 11-deoxycortisol to cortisol ratio, which is an 
index of 11beta-hydroxylase activity, in the morning, reflecting a higher enzyme activity, as a 
higher concentration of the end product is secreted into the circulation compared with the 
substrate used. 
 
Apart from the glucocorticoid levels, the circadian pattern was also evident in the secretion of 
mineralocorticoids, with aldosterone reaching minimum levels late in the evening, although 
the differences were not significant. Aldosterone secretion has been shown to exhibit a 
circadian variation with increasing levels in the morning and lower levels in the evening, due 
to the diurnal pattern of ACTH secretion (324) (325). 
 
Treatment with an oral glucocorticoid resulted, as expected, in a reduction of plasma 
glucocorticoid levels at baseline in visit 2 compared with visit 1. Dexamethasone suppresses 
113
 the endogenous ACTH production via a negative feedback circuit and results in a decrease of 
plasma glucocorticoid levels. Indeed, that was evident for both 11-deoxycortisol and cortisol 
levels. For each of the two glucocorticoids (11-deoxycortisol and cortisol) studied, significant 
increases in their plasma levels were seen in response to low dose of ACTH in visit 2. This is 
expected for adrenal steroids produced in ZF, which is under the ACTH control, and is in 
agreement with findings from early experiments with ACTH infusions in healthy subjects 
injected with standard (250μg) or low (1μg) dose of ACTH (326) (327) (328).   
 
Apart from the increase in glucocorticoid levels, an increase in plasma aldosterone 
concentration was evident in response to low ACTH dose in visit 2. That is consistent with 
the ACTH regulatory influence on the ZG cells in the short term (327) (329).  
 
3.4.2 Visit 3 & 4 – Effects of sodium intake and angiotensin II on plasma corticosteroid 
and renin levels  
A higher PRC and aldosterone concentration was manifested at baseline after low compared 
with high salt diet (Visit 3 versus Visit 4) in these studies. Sodium concentration at the renal 
distal tubule is one of the principal regulators of renin release by the juxta-glomerular 
apparatus in the kidneys and dietary sodium deprivation in man is followed by enhanced 
activity of the RAAS (section 1.2.3). Apart from the effect on renin secretion, sodium 
restriction has additionally been shown to directly increase the activity of aldosterone 
synthase and thereby the secretion of aldosterone (103) (330). In the Framingham offspring 
sub-study, urinary sodium, which is a measure of sodium intake, was the strongest 
independent determinant of serum aldosterone levels (331).  
 
With regards to the glucocorticoid secretion, no differences were found in 11-deoxycortisol 
and cortisol at baseline in visits 3 and 4. This is expected, as ZF is not sensitive to 
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 extracellular sodium levels and the enzymes involved in the synthesis of glucocorticoids are 
principally controlled by ACTH.  
 
Angiotensin II induced a significant increase in aldosterone release in both sodium-replete 
and sodium-deplete healthy subjects. Acute response to angiotensin II involves an increase of 
the conversion of cholesterol and other precursors to aldosterone (section 1.2.3). In contrast 
to aldosterone stimulation, angiotensin II suppressed PRC in both visit 3 and 4. The 
inhibitory effect of angiotensin on renin secretion represents a negative feedback mechanism; 
angiotensin directly suppresses renin release by JGA through a feedback loop, independent of 
changes in blood pressure, exerting in this way an auto-regulatory control on its own 
activation.  
 
Plasma cortisol concentrations did not rise, as expected, in response to angiotensin infusion in 
both visit 3 & 4. In contrast, plasma cortisol and 11-deoxycortisol levels fell during 
angiotensin infusion and that is likely to represent a decline due to circadian rhythm. In 
agreement with this finding, cortisol levels in visit 1 were significantly lower at 10.00am 
compared with 8.00am in the same visit.  
 
Finally, during angiotensin infusion there was a significant difference in the increments of 
aldosterone in response to increasing infusion rate between the two visits. Normal subjects 
responded to angiotensin, especially in the higher infusion rates, with greater increase in 
aldosterone levels after low compared with high salt diet. This is in agreement with previous 
studies in humans; the slope of aldosterone to AII regression curve was steeper in healthy 
subjects infused with angiotensin II after low than after high salt diet (83) (84). 
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 Overall, in this chapter, I successfully produced physiological responses of endogenous 
corticosteroids, which were analysed by the LCMS method, following manipulation of the 
HPA axis and RAAS. These studies confirmed the reliability of the LCMS method for 
corticosteroid measurements prior to application in the studies with HF patients.  
116
  
4. Chapter Four - Baseline patient 
characteristics during hospital admission 
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 4.1 Introduction 
 
The main purpose of this chapter is to describe the baseline characteristics in patients 
admitted to hospital with decompensated HF. These characteristics include demographic 
data, medical history, physiological measurements, 12-lead ECG findings and transthoracic 
echocardiogram parameters, laboratory measurements and medication prior to hospital 
admission. In this chapter, I also show the plasma levels of RAAS components and 
glucocorticoids in these patients. The markers of RAAS activity measured were PRC and 
plasma aldosterone. The glucocorticoids measured were plasma 11-deoxycortisol and 
cortisol. In addition, the aldosterone to PRC ratio and the 11-deoxycortisol to cortisol ratio 
were calculated. Lastly, I present the levels of RAAS components and glucocorticoids 
according to background therapy with a RAAS inhibitor and an oral glucocorticoid 
respectively.  
 
4.2 Methods 
 
4.2.1 Study design and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in sections 2.3.1 & 2.3.2. 
 
4.2.2 Statistical analysis 
All baseline characteristics were expressed as median (interquartile range, IQR) for 
continuous and as absolute number (percentage) for categorical variables. The inter-group 
comparisons were carried out by the Mann-Whitney and Kruskal-Wallis test for continuous 
variables as appropriate and by the χ2 test for categorical variables. A p-value <0.05 was 
considered significant for all analyses. Statistical analyses were performed with Minitab 
version 15.  
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 4.3 Results 
 
4.3.1 Baseline patient characteristics during hospital admission 
A total of 1631 patients with suspected HF were screened for inclusion in the study and 909 
of them were excluded (Figure 4.1).  
 
 
 
 
Figure 4-1. Flow of patients through the study 
 
 
 
1631 patients were 
screened for inclusion in 
the study 
722 patients enrolled 
in the study  
269 patients failed to 
attend the follow-up 
visit 
136 patients 
withdrew prior to 
follow-up 
74 patients deceased 
prior to follow-up 
59 patients 
experienced 
deterioration in health 
status prior to follow-
up 
453 patients 
completed the 
follow-up visit 
909 patients 
excluded from  the 
study  
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The breakdown of reasons for exclusion from participation in the study is presented in Figure 
4.2.  
 
 
Figure 4-2. Reasons for exclusion from participation into the study 
  
 
The most common reason was re-admission with HF, reflecting the high rate of 
rehospitalisation due to HF in these patients. The second most common single reason was 
refusal to participate. The other more common reasons for exclusion from participation were 
BNP <100 pg/ml and cognitive impairment. Moreover, patients who required ambulance for 
transfer to the BHF Glasgow Cardiovascular Research Centre for the follow-up visit (nursing 
home residents and homebound patients - under “Other” in Figure 4.2) were also excluded 
from the study. Finally, patients with BNP≥100 pg/ml but with alternative diagnosis, such as 
exacerbation of chronic obstructive pulmonary disease or pulmonary embolism who 
0
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 responded to treatment for the above conditions, were also excluded (under “Other” in Figure 
4.2). 
 
722 patients with decompensated HF were enrolled in the study. The baseline characteristics 
of the hospitalised cohort are presented in Table 4-1. The median age (IQR) of the study 
participants was 74 (68 - 81) years and forty-six percent were women. Approximately three 
quarters of patients during hospital admission, were in NYHA functional class III (60.2%) 
and IV (15.7%) and one quarter (24.1%) of patients were in NYHA II class. A previous 
history of HF was present in forty-four percent of patients and a similar proportion  had a 
history of previous MI. Sixty-six percent of patients had pre-existing hypertension and thirty-
one percent had history of diabetes. While just over half of patients (53.6%) had a history of 
AF, only forty-one percent had this arrhythmia on their screening ECG. 
 
The median (IQR) BMI was 27.9 (24 - 32.9) kg/m
2
. Twenty-nine percent of patients were 
overweight (defined as BMI 25-30 kg/m
2
) and thirty-nine percent were obese (BMI 
≥30.kg/m2). A small proportion of patients (2.6%) were underweight during admission (BMI 
<18.5kg/m
2
).  
121
  
The median (IQR) SBP was 134 (115 - 152) mmHg. More than a third (40.7%) of patients 
had SBP ≥ 140mmHg with more than half (50.4%) of these patients having isolated systolic 
hypertension (SBP ≥ 140mmHg and DBP <90 mmHg). A small proportion (1.8%) of patients 
presented with SBP <90 mmHg. Approximately twenty percent of patients had DBP > 
90mmHg and a similar proportion presented with DBP <60mmHg on admission. The median 
(IQR) pulse rate was 86 (71.8 - 106) beats per minute (bpm). One third of patients were 
tachycardic (pulse rate >100bpm) while less than ten percent were bradycardic (pulse rate 
<60bpm).   
 
Two thirds of patients had LVSD, while more than a third (37.3) had dilated left ventricle and 
less than half (44%) had LVH on the transthoracic echocardiogram.  
 
The median BNP (IQR) of the hospitalised cohort was raised at 871pg/ml (391 -1819). 
Sodium levels with a median of 138 mmol/L were at the lower normal levels. A higher 
proportion of patients had hyponatraemia (sodium <135 mmol/L) than hypernatraemia 
(sodium >145 mmol/L) during admission (19% vs 3.7%). The median eGFR was reduced at 
56 ml/min/1.73m
2
. More than half of the patients (56.1%) had an eGFR <60 ml/min/1.73m
2
 
and approximately a tenth (10.9 %) had an eGFR <30 ml/min/1.73m
2
. The median creatinine 
(106.5 µmol/L) was within the normal range. Despite this, the median urea (8.7 mmol/L) was 
raised.  
 
Of the 620 patients recruited at the Western and Royal Infirmaries, the majority (96.6%) had 
troponin measurements available during admission. Elevated troponin (defined as troponin I 
≥ 0.04 μg/L) was present in more than half of patients (53.2%). From the 102 patients 
recruited at the RAH, only a third had troponin measured and this was elevated (defined as 
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 troponin T ≥ 0.05 μg/L) in less than a quarter of these patients. The median CRP was raised 
at 13 mg/L with more than half of the patients (59.7%) having a CRP > 10 mg/L. TSH and 
lipids were generally within normal range.  
 
The median haemoglobin was 12.1g/dl with a minimum of 6 g/dl and maximum of 18.6 g/dl. 
More than half of males (56.9%) and females (55.1%) had anaemia, defined as haemoglobin 
<13g/dl and haemoglobin <12g/dl respectively (332).  
 
Just over two thirds of patients (69%) were taking an oral diuretic prior to hospital admission. 
Almost sixty percent (59.6%) were taking either an ACE inhibitor or ARB, while 
approximately half of patients (49.6%) were taking an ACE inhibitor prior to admission. A 
similar proportion of patients (47.9%) were taking a beta-blocker, while less than a tenth of 
patients (8.3%) were treated with an aldosterone antagonist. Only a small proportion of 
patients (3.6%) were receiving oral glucocorticoid therapy.  
 
The majority of patients (99.1%) were treated with IV or oral diuretic during the first 24 
hours following hospital admission. Other treatments given during admission are shown in 
Table 4-1. 
  
123
 Table 4-1. Baseline patient (n=722) characteristics during hospital admission 
Variable Median or number of patients Interquartile range 
(IQR) or % 
Age (years) 74 68 – 81 
Female gender 332 46 
NYHA class   
II 174 24.1 
III 435 60.3 
IV 113 15.7 
Medical history   
HF 320 44.3 
MI 322 44.6 
Angina 396 54.8 
Diabetes mellitus 227 31.4 
Hypertension 478 66.2 
AF 387 53.6 
CVA/TIA 155 21.5 
Physiological measurements   
BMI (kg/m
2
) 27.9 24 - 32.9 
Weight (kg) 76 60 - 90 
Pulse rate (bpm) 86 71.8 - 106 
SBP (mmHg) 134 115 - 152 
DBP (mmHg) 75 62 - 88 
Signs of fluid congestion   
Elevated JVP 512 79.4 
Peripheral oedema 542 75.1 
ECG rhythm   
SR 398 55.1 
AF 294 40.7 
Echocardiogram  measurements   
LVEDD (cm) 5.2 4.6 - 5.9 
Dilated left ventricle 191 37.3 
LVH 226 44 
LVSD 341 66.6 
Laboratory measurements (blood)   
BNP (pg/ml) 871 391 - 1819 
Troponin I ≥ 0.04 (μg/L)* 330 53.2 
Sodium (mmol/L) 138 135 - 141 
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 Variable Median or number of patients Interquartile range 
(IQR) or % 
Potassium (mmol/L) 4.2 3.8 - 4.5 
Urea (mmol/L) 8.7 6.3 - 12 
Creatinine (µmol/L) 106.5 85 - 137 
eGFR (ml/min/1.73m
2
) 56 41- 60 
eGFR <60ml/min/1.73m
2
 405 56.1 
Cholesterol (total) (mmol/L) 3.7 3.1- 4.6 
HDL (mmol/L) 1.0 0.8 - 1.3 
CRP (mg/L) 13 5.7 - 32 
TSH (mIU/L) 1.7 1.0 - 2.8 
Haemoglobin (g/dl) 12.1 10.6 - 13.5 
Cardiovascular medication prior to admission  
Diuretic 498 69 
Furosemide 421 58.3 
ACE inhibitor 358 49.6 
ACE inhibitor or ARB 430 59.6 
Aldosterone blocker 49 6.8 
Beta-blocker 346 47.9 
Digoxin 117 16.2 
Anti-arrhythmic 29 4.0 
Aspirin 388 53.7 
Statin 471 65.2 
Non-cardiovascular medication prior to admission  
Steroid tablets 26 3.6 
Cardiovascular medication during admission  
Diuretic 716 99.1 
IV nitrate 68 9.4 
IV inotropes 16 2.2 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
Abbreviations: NYHA, New York Heart Association; HF, Heart Failure; MI, myocardial infarction; AF, atrial 
fibrillation; CVA, cerebrovascular accident; TIA, transient ischaemic attack; BMI, body mass index; bpm, beats 
per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; SR, sinus rhythm; LVEDD, left 
ventricular end-diastolic diameter; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic 
dysfunction; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high density 
lipoprotein; CRP, C-reactive protein; TSH, thyroid stimulating hormone; ACE, angiotensin-converting enzyme; 
ARB, angiotensin receptor blocker IV, intravenous 
 
* measured at WIG and GRI  
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 4.3.2 Baseline levels of RAAS components during hospital admission  
Levels of plasma aldosterone and PRC and the aldosterone to PRC ratio during hospital 
admission are presented below.  
 
4.3.2.1 Aldosterone 
An aldosterone level measured during hospital admission was available in 551 of the 722 
patients. The median (IQR) aldosterone was 72.3 (31.7 – 151.6) pmol/L (Figure 4-3) and the 
mean (SD) aldosterone was 141 (289) pmol/L. A frequency distribution histogram of 
aldosterone levels during the hospital admission in these patients is displayed in Figure 4-4. 
The distribution of aldosterone concentrations was positively skewed. The minimum 
aldosterone concentration was 0.8 pmol/L and the maximum aldosterone concentration was 
5398.8 pmol/L. The normal range for aldosterone measured in a pool of normal plasma 
samples by LCMS in the BHF Glasgow Cardiovascular Research Centre laboratory was 0 – 
937 pmol/L. The majority of patients (98.9%) had aldosterone levels within the normal range 
and only six patients (1.1%) had aldosterone levels above the upper limit of normal. Review 
of the past medical history (that was documented for every patient enrolled in the study 
during recruitment) in patients with aldosterone levels above the normal range revealed the 
presence of Conn’s syndrome in one of these patients (patient with aldosterone concentration 
of 1045.2 pmol/l). PRC was at the lowest detectable level (5.0 mIU/L) and aldosterone to 
PRC ratio was markedly elevated (209.1) in that patient (see section 4.3.2.3). In all the other 
patients with aldosterone values higher than the upper limit of normal, PRC values were 
elevated (180.1 to 4898 mIU/L) resulting in aldosterone to PRC ratio ≤9.0. 
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Figure 4-3. Box and whisker plot of the aldosterone concentrations showing the 2.5, 25, 
50, 75 and 97.5 centiles  
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Figure 4-4. Frequency distribution histogram of aldosterone concentrations in patients 
during hospital admission 
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 4.3.2.2 PRC 
A PRC measured during hospital admission was available in 689 of the 722 patients. The 
median (IQR) PRC was 47.3 (13.0 - 177.3) mIU/L (Figure 4-5) and the mean (SD) PRC was 
408 (1268) mIU/L. A frequency distribution histogram of PRC levels during the hospital 
admission in these patients is displayed in Figure 4-6. The distribution of PRC levels was 
positively skewed. The minimum PRC was 5.0 mIU/L and the maximum PRC was 12668 
mIU/L. The normal range for PRC analysed by the Diasorin direct assay is 5.0 - 44.9 mIU/L 
(305). Approximately half of patients (48.4%) had PRC within the normal range. 
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Figure 4-5. Box and whisker plot of the PRC values showing the 2.5, 25, 50, 75 and 97.5
 
centiles 
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Figure 4-6. Frequency distribution histogram of PRC levels in patients during hospital 
admission 
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 4.3.2.3 Aldosterone to PRC ratio 
An aldosterone to PRC ratio could be calculated for 542 of the 722 patients studied. The 
median (IQR) aldosterone to PRC ratio was 1.53 (0.30-4.95) (Figure 4-7) and the mean (SD) 
aldosterone to PRC was 5.3 (14.4). A frequency distribution histogram of aldosterone to PRC 
ratio during hospital admission in these patients is displayed in Figure 4-8. The distribution of 
aldosterone to PRC values was positively skewed. The minimum aldosterone to PRC ratio 
was 0.001 and the maximum aldosterone to PRC ratio was 209.1. The highest aldosterone to 
PRC ratio calculated was found in the patient with history of Conn’s syndrome. No other 
patient in the group of extreme outliers with high aldosterone to PRC ratio values 
(aldosterone to PRC ratio value > 60) was found to have history of Conn’s syndrome or 
primary aldosteronism. These patients had PRC of 5mIU/L and aldosterone levels between 
478pmol/L and 784pmol/L. 
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Figure 4-7. Box and whisker plot of the aldosterone to PRC ratio showing the 2.5, 25, 50, 
75 and 97.5 centiles 
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Figure 4-8. Frequency distribution histogram of aldosterone to PRC ratio in patients 
during hospital admission 
  
131
 4.3.2.4 Baseline levels of RAAS components according to background therapy with a 
RAAS inhibitor 
Levels of the RAAS mediators were stratified according to background therapy with an ACE 
inhibitor/ARB or aldosterone blocker (Table 4-2). Plasma aldosterone at baseline was higher 
in patients taking an aldosterone blocker but not an ACE inhibitor or ARB and lower in 
patients taking an ACE inhibitor or ARB but not an aldosterone blocker prior to admission 
(Table 4-2). PRC was higher in patients taking an ACE inhibitor/ARB or aldosterone blocker 
and lower in patients taking neither an ACE inhibitor/ARB nor an aldosterone blocker prior to 
admission. Conversely, aldosterone to PRC ratio was lower in patients taking a RAAS 
inhibitor and higher in patients not taking a RAAS inhibitor.
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4.3.3 Baseline glucocorticoid levels during hospital admission  
Levels of plasma 11-deoxycortisol and cortisol and the 11-deoxycortisol to cortisol ratio 
during hospital admission are presented below.  
 
4.3.3.1 11-deoxycortisol 
An 11-deoxycortisol level measured during hospital admission was available in 600 of 722 
patients. The median (IQR) 11-deoxycortisol was 492.6 (275.5 – 929.6) pmol/L (Figure 4-9) 
and the mean (SD) 11-deoxycortisol was 917 (1716) pmol/L. A frequency distribution 
histogram of 11-deoxycortisol levels during the hospital admission in these patients is 
displayed in Figure 4-10. The minimum 11-deoxycortisol concentration was 3.7 pmol/L and 
the maximum 11-deoxycortisol concentration was 21666 pmol/L. The normal range for 11-
deoxycortisol analysed by LCMS is 0 - 2017 pmol/L. The majority of patients (91%) had 11-
deoxycortisol levels within the normal range. 
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Figure 4-9. Box and whisker plot of 11-deoxycortisol showing the 2.5, 25, 50, 75 and 97.5 
centiles 
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Figure 4-10. Frequency distribution histogram of 11-deoxycortisol levels in patients 
during hospital admission 
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4.3.3.2 Cortisol 
A cortisol level measured during hospital admission was available in 613 of 722 patients. The 
median (IQR) cortisol was 322.6 (226.0 - 444.4) nmol/L (Figure 4.11) and the mean (SD) 
cortisol was 358 (231) nmol/L. A frequency distribution histogram of cortisol levels during 
the hospital admission in these patients is displayed in Figure 4-12. The minimum cortisol 
concentration was 1.7 nmol/L and the maximum cortisol concentration was 3123.2 nmol/L. 
The normal range for cortisol analysed by LCMS is 0 - 823nmol/L. The majority of patients 
(98%) had cortisol levels within the normal range.   
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Figure 4-11. Box and whisker plot of cortisol showing the 2.5, 25, 50, 75 and 97.5
 
centiles 
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Figure 4-12. Frequency distribution histogram of cortisol levels in patients during 
hospital admission 
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4.3.3.3 11-deoxycortisol to cortisol ratio 
An 11-deoxycortisol to cortisol ratio could be calculated for 600 of the 722 patients during 
hospital admission. The median (IQR) 11-deoxycortisol to cortisol ratio was 1.65 (0.96-2.88) 
x10
-3
 (Figure 4-13) and the mean (SD) 11-deoxycortisol to cortisol ratio was 2.4 (2.8) x10
-3
. 
A frequency distribution histogram of 11-deoxycortisol to cortisol ratio in these patients 
during the hospital admission is displayed in Figure 4-14. The minimum 11-deoxycortisol to 
cortisol ratio was 0.009 x10
-3
 and the maximum 11-deoxycortisol to cortisol ratio was 34.8 
x10
-3
. 
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Figure 4-13. Box and whisker plot of 11-deoxycortisol to cortisol showing the 2.5, 25, 50, 
75 and 97.5
 
centiles 
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Figure 4-14. Frequency distribution histogram of 11-deoxycortisol to cortisol ratio in 
patients during hospital admission 
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4.3.3.4 Baseline levels of glucocorticoids according to background therapy with an oral 
glucocorticoid  
Of the 722 patients studied during hospital admission, 26 were taking an oral glucocorticoid 
and 696 were not taking an oral glucocorticoid prior to admission. Cortisol levels were 
significantly lower in the former compared with the latter group (Table 4-3). The 11-
deoxycortisol levels were not different between the two groups and the 11-deoxycortisol to 
cortisol ratio was lower in patients not taking oral glucocorticoid treatment compared with 
patients taking oral glucocorticoid therapy, but that failed to reach statistical significance.  
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4.3.4 Patient characteristics according to the levels of RAAS mediators and 
glucocorticoids during the hospital admission 
The characteristics of the overall hospitalised cohort according to the levels of aldosterone 
and PRC and the aldosterone to PRC ratio during hospital admission are presented in the 
Appendix (Table 13-1 to Table 13-3). Similarly, the patient characteristics according to the 
levels of 11-deoxycortisol and cortisol and the 11-deoxycortisol to cortisol ratio are presented 
in the Appendix (Table 13-4 to Table 13-6) 
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4.4 Discussion 
 
4.4.1 Baseline patient characteristics during hospital admission 
The patients enrolled in this study were elderly and predominantly male. The average age (73 
years) was similar to that reported in a large registry of patients with decompensated HF 
(333). Approximately half of the patients had a diagnosis of pre-existing HF prior to 
admission and a similar proportion of patients found to have history of previous MI. The 
latter is in accordance with previous findings, showing the predominance of ischaemic heart 
disease in patients with HF (334). The proportion of patients (approaching two thirds) with a 
history of hypertension, as well as the finding that the majority of patients on admission were 
normotensive or hypertensive is also consistent with previous findings (333). 
 
Three quarters of patients were in NYHA class III or IV; however, considerably more 
patients were in NYHA class III than in class IV, reflecting a cohort of patients with 
predominantly moderate HF during hospital admission. Most patients had qualitative 
echocardiographic assessment of LV systolic function during hospital admission, which 
showed LVSD in approximately two thirds of the study population. That is slightly different 
from previous findings in hospitalised patients, showing that approximately half of patients 
with decompensated HF have LVSD (11). Quantitative assessment of LV systolic function 
was not performed in the current study and possible classification of patients with LVEF 
between 40% and 50% as having HFrSF may account for the higher proportion of patients 
with LVSD compared with previous reports. The proportion of patients (41%), found to be in 
AF (on a 12-lead ECG) during admission  is similar to the EuroHeart Failure survey II 
reporting approximately thirty-nine percent of hospitalised patients for HF to be in AF prior 
to hospital admission (335). AF may cause or exacerbate the decompensation in HF patients 
by impairing the ventricular filling, either by loss of atrial contraction or by reducing the time 
of diastole when associated with rapid ventricular response.   
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A significant number of patients had abnormalities in their haematological and biochemical 
profile during hospital admission. More than half of the patients were anaemic according to 
World Health Organisation (WHO) criteria and had eGFR <60 ml/min/1.73m
2
 indicating that 
anaemia and mild renal dysfunction are comorbid characteristics of patients hospitalised with 
HF. However, no data were available in this study about the number of patients with acute or 
chronic renal failure. That is of importance as a degree of acute kidney injury due to cardiac 
decompensation in patients with prior normal kidney function is expected to improve or 
resolve following treatment for HF in a number of patients. Moreover, patients studied during 
hospital admission were elderly and someone would expect a decline in eGFR in participants 
of that age group irrespective of HF. In the current study, patients hospitalised for other 
reasons were not examined and any comparisons of renal function between a control group 
and my group of patients hospitalised with HF were not available. 
 
BNP levels on average were markedly elevated, reflecting high myocardial wall stress in 
these patients. In contrast, sodium levels were at the lower limit of normal, partially due to 
the water retention secondary to the activation of pathways with antidiuretic effects in 
patients with decompensated HF. In addition, more than half of patients had elevated 
troponin reflecting the degree of myocardial necrotic process. Myocardial stretch and 
neurohumoral activation have been suggested to contribute to myocardial injury and troponin 
release in patients with HF (336). Moreover, oxidative stress and inflammation have been 
linked with myocardial injury. In accordance with previous findings (337) (338), CRP levels 
were elevated during admission indicating that patients with decompensated HF manifest a 
systematic inflammatory response characterised by up-regulation in cytokine production.  
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Almost all patients in this cohort received diuretic therapy on admission to hospital. 
Interestingly, the proportion of patients taking an oral diuretic prior to hospital admission was 
higher than the proportion of patients with history of pre-existing HF. That may be due to 
empirical treatment of hypertension (previous history of hypertension was more prevalent 
than that of HF) or systemic congestion in patients with unconfirmed diagnosis of HF with a 
diuretic. More than half of the patients were taking a RAAS inhibitor (ACE inhibitor/ARB or 
aldosterone blocker) and approximately half of the patients were receiving a beta-blocker 
prior to admission. Finally, only a tiny minority were taking an oral glucocorticoid (2.2%). 
 
4.4.2 Levels of RAAS mediators during hospital admission  
Aldosterone levels were at the lower and PRC values at the upper limit of normal in my 
patients during hospital admission. Little is known about RAAS activation during worsening 
of HF and, especially, about activity of each of the components of this system during acute 
deterioration. What little prior information that has been published was obtained from 
patients treated with a RAAS blocker, confounding interpretation of the results (55) (339) 
(340). In my study, more than half of the patients were receiving an ACE inhibitor/ARB or 
aldosterone blocker prior to hospital admission. Treatment with a RAAS inhibitor has 
significant effects on the levels of RAAS mediators. In the current cohort, aldosterone levels 
were higher in patients treated with an aldosterone blocker but not with an ACE inhibitor or 
ARB and lower in patients treated with an ACE inhibitor or ARB but not with an aldosterone 
blocker. By contrast, PRC was higher in patients treated with an ACE inhibitor/ARB or 
aldosterone blocker and lower in patients taking neither an ACE inhibitor/ARB nor an 
aldosterone blocker. Aldosterone to PRC ratio was higher in patients not treated with a 
RAAS inhibitor and lower in patients taking a RAAS inhibitor i.e. the ratio was primarily 
determined by PRC but not by aldosterone.  
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The above findings are likely to be due to the discordant effects of the RAAS inhibiting 
agents on the levels of the RAAS components. ACE inhibitors and ARBs reduce aldosterone 
production by decreasing or antagonising angiotensin II; moreover, they increase PRC due to 
the absence of negative feedback of angiotensin II on renin production (34) (341). 
Aldosterone antagonists block the MR and increase aldosterone and PRC (288). Thus, in the 
presence of RAAS inhibitors the relationship between renin, which represents the main 
surrogate for the RAAS activity, and angiotensin II and aldosterone, which represent the 
main effectors of RAAS activity, becomes distorted. Clearly, even in the presence of RAAS 
inhibitors, higher levels of RAAS effectors do not lead to greater RAAS activity (i.e. greater 
receptor stimulation). Because of these observations, RAAS activity was further examined in 
relation to markers of HF severity in patients not taking a RAAS blocker prior to hospital 
admission and at the follow-up visit in chapter 6 & 7 respectively. 
 
The review of recorded data about past medical history in extreme outliers with aldosterone 
levels above the upper limit of normal and extreme outliers with higher aldosterone to PRC 
ratio values revealed a patient with Conn’s syndrome. This patient had the highest 
aldosterone to PRC ratio and elevated aldosterone levels both during hospital admission and 
the follow- up visit (see also section 5.3.2.1 & 5.3.2.3). The aldosterone to renin ratio is the 
most reliable screening tool for primary aldosteronism as a secondary cause of hypertension 
(342). Recently, the feasibility of using PRC instead of PRA for the calculation of 
aldosterone to renin ratio has been shown as a first-line screen in patients for primary 
aldosteronism  (318). In the current study, PRC was at the lowest detectable level and 
aldosterone was above the normal range despite treatment with an ACE inhibitor and 
aldosterone blocker in the HF patient with history of Conn’s syndrome. Autonomous 
aldosterone secretion due to adrenal adenoma is likely to explain the elevated aldosterone 
levels with secondary volume expansion-induced PRC suppression despite the use of RAAS 
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inhibition in that participant. Review of medical notes confirmed the presence of adrenal 
adenoma in that patient during enrolment in the study. History of Conn’s syndrome or 
primary aldosteronism was not present in the other extreme outliers with higher aldosterone 
to PRC ratio or with aldosterone levels above normal. In patients of the latter group, PRC 
values were elevated (apart from the patient with Conn’s syndrome) reflecting that the up-
stream RAAS components led to elevated aldosterone levels. On the other hand, in the group 
of extreme outliers with higher aldosterone to PRC ratio (apart from the patient with Conn’s 
syndrome), PRC was suppressed (5mIU/L) and aldosterone levels were high but within 
normal range. The majority of these patients had history of hypertension and some of them 
might have low renin hypertension due to primary aldosteronism, although that was not 
confirmed in the medical history. Finally, data entry errors cannot be totally excluded; hence, 
some of the extreme outliers might be due to that.   
 
4.4.3 Levels of glucocorticoids during hospital admission  
Levels of plasma cortisol levels were within the normal range during hospital admission. This 
was initially surprising and seemed to be in contrast to two prior studies of untreated patients 
with severe congestive HF (69) (70). However, these studies were small and additionally 
included patients with acute HF secondary to MI. Nevertheless, due to the fact that blood 
samples were collected 24 to 48 hours after hospital admission in the current study, the 
stimulation of the HPA axis may have subsided. Indeed, in patients with cardiogenic 
pulmonary oedema, cortisol was markedly raised an hour after the onset of symptoms and 
gradually returned within the normal range in 12 hours following hospital admission (343). 
Similarly, a decline in cortisol levels following 48 hours after admission has been reported in 
patients with an uncomplicated MI (344). These findings suggest that normal cortisol levels 
found in my study might be due to the time of blood sampling, as all patients had blood 
samples taken 24 to 48 hours following the initiation of in-hospital treatment. Interestingly, 
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cortisol levels in my patients are similar to the levels previously reported in patients with 
chronic HF (72) (73). Indeed, perhaps surprisingly, they are similar to ambulatory cortisol 
levels measured in morning hours in healthy volunteers (section 3.3.1). Cortisol is a non-
specific indicator of stress and the findings of this study indicate that no major activation of 
HPA axis in patients with decompensated HF was present within 48 hours after admission.  
 
Glucocorticoid levels during hospital admission will be further examined in relation to 
patient characteristics and features of HF severity in chapter 8. Finally, the prognostic 
importance of glucocorticoids in patients with decompensated HF will be studied in chapter 
10. 
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5. Chapter Five - Patient characteristics at the 
follow-up visit 
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5.1 Introduction 
 
The main aim of this chapter is to present the clinical characteristics of patients with HF at 
the follow-up visit. In this chapter, I also show the plasma levels of RAAS components and 
glucocorticoids in these patients. In addition, I present these levels according to background 
therapy with a RAAS inhibitor and oral glucocorticoid therapy respectively. Lastly, I 
compare the levels of glucocorticoids in the subgroup of patients who had blood samples 
collected in the morning both during hospital admission and at follow-up.  
 
5.2 Methods 
 
5.2.1 Study design and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in sections 2.4.1 & 2.4.2.  
 
5.2.1 Statistical analysis 
All patient characteristics are expressed as median (IQR) for continuous and absolute number 
(percentage) for categorical variables. The inter-group comparisons were carried out by the 
Mann-Whitney and Kruskal-Wallis test for continuous variables as appropriate and by the χ2 
test for categorical variables. For the comparisons of glucocorticoid levels and patient 
characteristics between hospital admission and the follow-up visit in the group of patients 
who had blood taken in the morning at both stages, Wilcoxon matched pairs test and 
McNemar test were employed for continuous and categorical variables respectively. A p-
value <0.05 was considered significant for all analyses. Statistical analyses were performed 
with Minitab version 15.  
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5.3 Results  
 
5.3.1 Baseline patient characteristics during follow-up 
Of the 722 patients enrolled in the study during hospital admission, 269 patients (37.3%) 
failed to attend the follow-up visit (Figure 4.1). Almost a fifth of patients included in the 
study (n=136) refused to return to the BHF Glasgow Cardiovascular Research Centre for the 
follow-up visit. Just above a tenth of the enrolled patients (n=74) died prior to the study visit 
appointment. Lastly, approximately eight percent (n=59) of patients included in the study 
were not in position to attend the follow-up visit due to deterioration in their health status.  
 
The characteristics of the 453 patients who attended the follow-up visit are presented in Table 
5-1. The median age (IQR) was 72 (66-78) years and forty percent were women. 
Approximately two thirds of patients (63.6%) were in NYHA class II and one third (32.9%) 
were in NYHA class III. These findings were in contrast to those of hospital admission, 
where the majority of patients were in NYHA class III and IV. Similar to the hospitalised 
cohort, over forty percent of patients had a history of MI (43%), two-thirds had pre-existing 
hypertension and almost a third of patients had history of diabetes after discharge. While over 
half of the patients (53%) at follow-up had a history of AF, only a third (34.4%) had this 
arrhythmia on their screening ECG.  
 
The median (IQR) BMI was 27.6 (23.8-32.6) kg/m
2
. Approximately two thirds of patients 
were overweight (BMI 25-30 kg/m
2
) or obese (BMI >30 kg/m
2
) and a small proportion        
(< 3%) of patients were underweight (BMI <18.5 kg/m
2
).  
 
The median (IQR) SBP was 129 (114-144) mmHg. Approximately a third (32.9%) of patients 
had SBP ≥ 140mmHg, proportion that was smaller compared with the proportion of patients 
(41%) with SBP ≥ 140mmHg during hospital admission. A similar proportion (2%) to 
151
  
hospitalised cohort had SBP <90mmHg after discharge. In contrast, a smaller percentage of 
patients (5%) at follow-up had DBP >90mmHg compared with hospital admission (20%). 
The median (IQR) pulse rate was 74 (65-86) bpm. Less than a tenth of patients (6.1%) were 
tachycardic (pulse rate >100 bpm), whilst a greater proportion (16.1%) of patients were 
bradycardic (pulse rate <60bpm). The above findings were markedly different from hospital 
admission, where the median pulse rate (86bpm) was higher and a third of patients were 
tachycardic.  
 
The median (IQR) LVEF of the post-discharge cohort was 40 (38 - 41) % and the mean (SD) 
LVEF was 39.7 (11.8) %. Almost eighty percent (78.9%) of patients had LVEF < 50% and 
approximately a third (32.7%) of patients had LVEF <35%. 
 
The median BNP (IQR) during follow-up was 396 (206 - 813) pg/ml. That was markedly 
decreased compared with the hospital admission, where the median (IQR) BNP was 
871pg/ml (391 - 1819). Sodium levels were well within the normal range after discharge. 
Approximately a tenth of patients were hyponatraemic and less than one percent were 
hypernatraemic in contrast with the hospitalised cohort, where approximately a fifth of 
patients were hyponatraemic and four percent were hypernatraemic. The median eGFR (IQR) 
was 59 ml/min/1.73m
2 
with half of the patients having eGFR <60 ml/min/1.73m
2
 and less 
than a tenth having an eGFR <30 ml/min/1.73m
2
. Similar to the hospitalised cohort, although 
the median creatinine (106 µmol/L) was within the normal range, the median urea (8.6 
mmol/L) was raised.  
 
A considerably smaller proportion of patients (18%) after discharge had elevated troponin 
compared with hospital admission. The median (IQR) CRP at the study visit was 5.2 (9.4) 
mg/L and the median of TSH and lipids were within the normal ranges.   
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The median (IQR) haemoglobin was 12.5 (11.2-13.6) g/dl. Just over half of the male 
participants (51%) and almost half of the female participants (46%) had anaemia, defined as 
haemoglobin <13g/dl and haemoglobin <12g/dl respectively. 
 
Almost all patients of the post-discharge cohort (98.2%) were taking an oral diuretic. More 
than seventy percent (72.8%) of patients were taking an ACE inhibitor and eighty percent 
were taking an ACE inhibitor or ARB during follow-up. More than two thirds of patients 
(68.2%) were taking a beta-blocker, while only fourteen percent were taking an aldosterone 
blocker. A minority of patients (3.1%) were treated with a steroid tablet after discharge.  
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Table 5-1. Patient (n=453) characteristics at the follow-up visit 
Variable Median or number of 
patients 
IQR or % 
Age (years) 72 66 - 78 
Female gender 181 40 
NYHA class   
I 12 2.6 
II 288 63.6 
III 149 32.9 
IV 4 0.9 
Medical history   
HF 188 41.5 
MI 195 43 
Angina 248 54.7 
Diabetes mellitus 227 50.1 
Hypertension 296 65.3 
AF 240 53 
CVA/TIA 91 20.1 
Physiological measurements   
BMI (kg/m
2
) 27.6 23.8 - 32.6 
Weight (kg) 75 62 - 89 
Pulse rate (bpm) 74 65 - 86 
SBP (mmHg) 129 114 - 144 
DBP (mmHg) 67 58 - 76 
ECG rhythm   
SR 269 59.4 
AF 165 34.4 
Echo measurements   
LVEF (%) 40 31 - 48 
Laboratory measurements (blood)  
BNP (pg/ml) 396 206 - 813 
Troponin I ≥ 0.04 (μg/L) 82 18.1 
Sodium (mmol/L) 139 137 - 141 
Potassium (mmol/L) 4.3 3.8 - 4.3 
Urea (mmol/L) 8.6 6.5 - 11.9 
Creatinine (µmol/L) 106 87 - 130.5 
eGFR (ml/min/1.73m
2
) 59 43 - 60 
eGFR <60ml/min/1.73m
2
 230 50.8 
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Variable Median or number of 
patients 
IQR or % 
Cholesterol (total) (mmol/L) 4.0 3.3 - 4.9 
HDL (mmol/L) 1.1 0.8 - 1.3 
CRP (mg/L) 5.2 2.6 - 12 
TSH (mIU/L) 1.5 0.9 - 2.4 
Haemoglobin (g/dl) 12.5 11.2 - 13.6 
Cardiovascular Medication   
Diuretic 445 98.2 
Furosemide 412 90.9 
ACE inhibitor 330 72.8 
ACE inhibitor or ARB 363 80.1 
Aldosterone blocker 64 14.1 
Beta-blocker 309 68.2 
Digoxin 115 25.4 
Anti-arrhythmic   26 5.7 
Aspirin 253 55.8 
Statin 335 74 
Non-cardiovascular medication  
Steroid tablets 14 3.1 
Continuous variables are presented as median (IQR). Categorical variables are presented as number percentage). 
 
Abbreviations: NYHA, New York Heart Association; HF, Heart Failure; MI, myocardial infarction; AF, atrial 
fibrillation; CVA, cerebrovascular accident; TIA, transient ischaemic attack; BMI, body mass index; bpm, beats 
per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; SR, sinus rhythm; LVEF, left 
ventricular ejection fraction; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, 
high density lipoprotein; CRP, C-reactive protein; TSH, thyroid stimulating hormone; ACE, angiotensin-
converting enzyme ARB, angiotensin receptor blocker 
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5.3.2 RAAS activation during follow-up  
Levels of plasma aldosterone and PRC and the aldosterone to PRC ratio at follow-up are 
presented below.  
 
5.3.2.1 Aldosterone 
An aldosterone level measured at the follow-up visit was available in 428 of 453 patients. The 
median (IQR) aldosterone concentration was 143 (76.7 - 267) pmol/L (Figure 5-1) and the 
mean (SD) aldosterone concentration was 215.8 (298.5) pmol/L. A frequency distribution 
histogram of aldosterone levels in these patients is displayed in Figure 5-2. The distribution of 
aldosterone concentrations was positively skewed. The minimum aldosterone value was 2.5 
pmol/L and the maximum aldosterone value was 3894.5 pmol/L. Almost all patients (98.5%) 
had aldosterone levels within the normal range and only six patients (1.5%) had aldosterone 
levels above the upper limit of normal (937 pmol/L). Review of information about the past 
medical history in the latter group revealed the presence of Conn’s syndrome in one of these 
patients (aldosterone level of 2056.4 pmol/L). That was the same participant who was 
previously identified to have Conn’s syndrome during hospital admission (see section 4.3.2.1 
and 4.3.2.3). PRC was low (5 mIU/L) and aldosterone to PRC ratio was markedly elevated 
(411.3) in that patient at the follow-up visit similar to the hospital admission.   
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Figure 5-1. Box and whisker plot of aldosterone concentrations showing the 2.5, 25, 50, 
75 and 97.5
 
centiles   
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Figure 5-2. Frequency distribution histogram of aldosterone concentrations in the 
overall cohort 
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5.3.2.2 PRC 
PRC measured at the follow-up visit was available in 445 of 453 patients. The median (IQR) 
PRC was 92.8 (26.1 - 327.8) mIU/L (Figure 5-3) and the mean (SD) PRC was 490 (1147.8) 
mIU/L. A frequency distribution histogram of PRC in these patients is displayed in Figure  
5-4. The distribution of PRC values was positively skewed. The minimum PRC was 5.0 
mIU/L and the maximum PRC was 8326 mIU/L. Approximately a third (33%) of patients had 
a PRC within the normal range and two-thirds had a PRC above the upper limit of normal 
(44.9 mIU/L).  
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Figure 5-3. Box and whisker plot of PRC showing the 2.5, 25, 50, 75 and 97.5
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Figure 5-4. Frequency distribution histogram of PRC in the overall cohort 
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5.3.2.3 Aldosterone to PRC ratio 
An aldosterone to PRC ratio could be calculated for 426 of the 453 patients. The median 
(IQR) aldosterone to PRC value was 1.51 (0.4 - 5.3) (Figure 5-5) and the mean (SD) 
aldosterone to PRC value was 6.8 (23.1). A frequency distribution histogram of aldosterone 
to PRC values in these patients is displayed in Figure 5-6. The distribution of aldosterone to 
PRC values was positively skewed. The minimum aldosterone to PRC ratio was 0.004 and 
the maximum aldosterone to PRC ratio was 411.3. The patient with the maximum 
aldosterone to PRC ratio was the participant with a history of Conn’s syndrome (see section 
5.3.2.1, 4.3.2.3 and 4.3.2.1).  
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Figure 5-5. Box and whisker plot of aldosterone to PRC ratio showing the 2.5, 25, 50, 75 
and 97.5
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Figure 5-6. Frequency distribution histogram of aldosterone to PRC ratio in the overall 
cohort 
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5.3.2.4 RAAS activation according to background therapy with a RAAS inhibitor 
Levels of RAAS mediators according to background therapy with a RAAS inhibitor are 
presented in Table 5-2. Similar to the hospitalised cohort, aldosterone levels were higher in 
patients taking an aldosterone blocker but not an ACE inhibitor or ARB and lower in patients 
taking an ACE inhibitor or ARB but not an aldosterone blocker prior to admission. PRC was 
higher in patients receiving an ACE inhibitor/ARB or aldosterone blocker and lower in 
patients receiving neither an ACE inhibitor/ARB nor an aldosterone blocker. Conversely, 
aldosterone to PRC ratio was lower in patients treated with a RAAS inhibitor and higher in 
patients not taking a RAAS inhibitor prior to hospital admission.  
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5.3.3 Levels of glucocorticoid during follow-up   
Levels of plasma 11-deoxycortisol and cortisol, and the 11-deoxycortisol to cortisol ratio at 
follow-up are presented below.  
 
5.3.3.1 11-deoxycortisol  
An 11-deoxycortisol level measured at the follow-up visit was available in 417 of 453 
patients. The median (IQR) 11-deoxycortisol concentration was 465.7 (291 - 730) pmol/L 
(Figure 5-7) and the mean (SD) 11-deoxycortisol concentration was 657.5 (935.3) pmol/L. A 
frequency distribution histogram of 11-deoxycortisol levels in these patients is presented in 
Figure 5-8. The minimum 11-deoxycortisol value was 10.8 pmol/L and the maximum 11-
deoxycortisol value was 14885 pmol/L. The majority of patients (96%) had 11-deoxycortisol 
levels within the normal range (0 - 2017 pmol/L). 
  
164
  
 
1 4 0 0 
1 2 0 0 
1 0 0 0 
8 0 0 
6 0 0 
4 0 0 
2 0 0 
0 
1
 1
 - d
 e
 o
 x
 y
 c
 o
 r t
 i s
 o
 l  
 ( p
 m
 o
 l /
 l )
 
4 6 5 . 7  
1
1
-
d
e
o
x
y
c
o
r
t
is
o
l 
(p
m
o
l/
L
) 
 
Figure 5-7. Box and whisker plot of 11-deoxycortisol showing the 2.5, 25, 50, 75 and 97.5 
centiles 
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Figure 5-8. Frequency distribution histogram of 11-deoxycortisol concentrations in the 
overall cohort 
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5.3.3.2 Cortisol 
A cortisol level measured at the follow-up visit was available in 427 of 453 patients. The 
median (IQR) cortisol concentration was 215.8 (149-295.6) nmol/L (Figure 5-9) and the mean 
(SD) aldosterone concentration was 236.6 (140.2) nmol/L. A frequency distribution histogram 
of cortisol levels in these patients is displayed in Figure 5-10. The minimum cortisol value 
was 3.3 nmol/L and the maximum cortisol value was 1166.4 nmol/L. Almost all patients 
(99.3%) had cortisol levels within the normal range (0 – 823nmol/L).   
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Figure 5-9. Box and whisker plot of cortisol concentrations showing the 2.5, 25, 50, 75 
and 97.5
 
centiles 
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Figure 5-10. Frequency distribution histogram of cortisol concentrations in the overall 
cohort 
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5.3.3.3 11-deoxycortisol to cortisol ratio 
An 11-deoxycortisol to cortisol ratio could be calculated for 415 of the 453 patients at the 
follow-up visit. The median (IQR) 11-deoxycortisol to cortisol was 2.33 (1.39 -3.76) x10
-3
 
(Figure 5-11) and the mean (SD) value was 3.71 (7.91) x10
-3
. A frequency distribution 
histogram of 11-deoxycortisol to cortisol ratio in these patients is presented in Figure 5-12. 
The minimum 11-deoxycortisol to PRC ratio was 0.07 x10
-3
 and the maximum 11-
deoxycortisol to cortisol ratio was 118.4 x10
-3
. 
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Figure 5-11. Box and whisker plot of 11-deoxycortisol to cortisol ratio showing the 2.5, 
25, 50, 75 and 97.5
 
centiles 
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Figure 5-12. Frequency distribution histogram of 11-deoxycortisol to cortisol ratio in 
the overall cohort 
  
169
  
5.3.3.4 Levels of glucocorticoids according to background therapy with an oral 
glucocorticoid 
Of the 453 patients studied during the hospital admission, 14 were taking an oral 
glucocorticoid and 439 were not taking an oral glucocorticoid during follow-up (Table 5-3). 
Cortisol and 11-deoxycortisol levels were significantly lower in the former compared with the 
latter group. The 11-deoxycortisol to cortisol ratio was lower in patients not taking oral 
glucocorticoid treatment compared with patients taking oral glucocorticoid therapy, but that 
did not reach statistical significance.   
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5.3.4 Patient characteristics according to the levels of RAAS components and 
glucocorticoids during follow-up 
The characteristics of the post-discharge cohort according to the levels of aldosterone and 
PRC and the aldosterone to PRC ratio at follow-up are presented in the Appendix (Table 13-7 
to Table 13-9). Similarly, the patient characteristics according to the levels of 11-
deoxycortisol and cortisol and the 11-deoxycortisol to cortisol ratio are presented in the 
Appendix (Table 13-10 to Table 13-12). 
 
5.3.5 Levels of glucocorticoids at follow-up measured in the morning – comparison with 
glucocorticoid levels during the hospital admission    
Of the 453 patients studied during follow-up, 31 had blood samples taken during morning 
hours and 422 had blood samples taken during afternoon hours (Table 5-4).  
 
Cortisol levels were higher in the group of patients studied in the morning compared with 
patients studied in the afternoon at follow-up. Patients of the former group were less likely to 
have previous history of hypertension and were more likely to have lower HDL compared 
with patients of the latter group.  
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The levels of glucocorticoids, the physiological and laboratory measurements in patients who 
had blood samples taken in the morning during hospital admission and at follow-up and the 
medication prior to admission and after discharge are presented in Table 5-5. 
 
Cortisol and 11-deoxycortisol levels were not significantly different but the 11-deoxycortisol 
to cortisol ratio was higher at follow-up compared with the hospital admission.  
 
The majority of patients were in NYHA functional class III during hospital admission and in 
NYHA functional class II at follow-up. The weight, pulse rate, SBP and BNP were lower and 
the PRC was higher at the follow-up visit compared with hospital admission. A higher 
proportion of patients were taking an ACE inhibitor or ARB, a beta-blocker or a diuretic after 
discharge. 
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Table 5-5. Clinical characteristics, physiological and laboratory measurements and 
medication in patients who had blood samples taken in the morning during hospital 
admission and at follow-up (n=31) 
Variable During admission  
(n=31) 
At follow-up  
(n=31) 
p-value† 
NYHA class    
I 0 (0) 1 (3) - ¥ 
II 6 (19) 19 (61) 0.004 
III 17 ((55) 11 (35.5) 0.210 
IV 8 (26) 0 (0) - ¥ 
Physiological measurements   
BMI (kg/m
2
) 26.8 (24.5 - 33.7) 25.6 (23.9 - 30.9) 0.001 
Weight (kg) 74.3 (65 -  96) 70 (63 - 88) 0.001 
Pulse rate (bpm) 90 (68 - 110) 74 (62 - 86) 0.005 
SBP (mmHg) 130 (110 - 161) 125 (107 - 140) 0.029 
DBP (mmHg) 70 (60 - 74) 68 (56 - 75) 0.060 
Laboratory measurements (blood)   
BNP (pg/ml) 1146 (337 -  1917) 423 (187 -  1015) <0.001 
Sodium (mmol/L) 139 (135 - 141) 140 (138 - 141) 0.177 
Potassium (mmol/L) 4.2 (3.8 - 4.5) 4.2 (3.8 - 4.4) 0.187 
Urea (mmol/L) 8.2 (5.8 - 10.1) 8.6 (6.4 - 11.6) 0.493 
Creatinine (µmol/L) 109 (91 - 137) 110 (87 - 137) 0.468 
eGFR (ml/min/1.73m
2
) 57 (45 - 60) 60 (44 - 60) 0.888 
eGFR <60ml/min/1.73m
2
 17 (55) 15 (48) 0.688 
Cholesterol (total) (mmol/L) 3.6 (2.9 - 4.3) 3.8 (3.2 - 4.9) 0.105 
HDL (mmol/L) 0.9 (0.7 - 1.3) 1.0 (0.8 - 1.1) 0.587 
CRP (mg/L) 14 (7.6 - 32) 5.9 (1.8 - 13) 0.001 
TSH (mIU/L) 1.8 (1.4 - 2.5). 1.6 (0.9 - 2.3) 0.879 
Cortisol (nmol/L) 281.8 (211.1 - 456.4) 274.5 (170.4 - 374.4) 0.637 
11-deoxycortisol (pmol/L) 455.7 (231 - 781.3) 542 (269 - 1041) 0.218 
11-deoxycortisol/cortisol (10
-3
) 1.61 (0.86 - 2.34)  2.38 (0.98 - 3.45) 0.035 
Aldosterone (pmol/L) 68.9 (16.4 - 216.6) 132.3 (61.4 - 270.6) 0.076 
PRC (mIU/L) 48 (15 - 103) 52 (9.0 - 265) 0.050 
Aldosterone/PRC 1.68 (0.06 - 3.34) 1.63 (0.58 - 6.96) 0.623 
Haemoglobin (g/dl) 12.5 (11 - 13.9) 12.3 (11.1 -  13.7) 0.380 
Cardiovascular medication*   
Diuretic  19 (61) 27 (87) 0.008 
ACE inhibitor 17 (55) 25 (81) 0.008 
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Variable During admission  
(n=31) 
At follow-up  
(n=31) 
p-value† 
ACE inhibitor or ARB 21 (68) 28 (90) 0.016 
Beta-blocker 13 (42) 21 (68) 0.008 
Aldosterone antagonist 3 (10) 7 (22.5) 0.219 
Digoxin 4 (13) 6 (19) 0.625 
Anti-arrhythmic   2 (6) 1 (3) 1 
Aspirin 16 (52) 18 (58) 0.625 
Statin 19 (61) 20 (64.5) 1 
Non-cardiovascular medication   
Steroid tables 1 (3.2) 1 (3.2) 1 
Continuous variables are presented as median (IQR). Categorical variables are presented as number 
(percentage). 
 
† Wilcoxon matched pairs test was used for continuous variables and McNemars’s test was used for categorical 
variables. 
 
* medication prior to hospital admission for patients studied during admission 
 
¥ Chi-Square approximation probably invalid 
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5.4 Discussion 
 
5.4.1 Baseline patient characteristics at study visit 
Just above three-fifths of the patients enrolled in the study during hospital admission returned 
for the follow-up visit, whilst almost a fifth of patients withdrew from the study following 
discharge from hospital due to refusal to participate. A similar proportion died or had 
deterioration in their health status prior to the follow-up visit, with the former subgroup 
consisting of more patients than the latter subgroup. The fact that a significant proportion of 
patients died prior to follow-up visit is in keeping with previous data showing an increased 
risk of in-hospital and post-discharge mortality in patients hospitalised with decompensated 
HF (345) (346). Hospitalised patients with worsening HF and worse short-term mortality or 
morbidity are likely to be older, have higher NYHA class and lower levels of sodium among 
other adverse prognostic markers in HF (347) (345) (346). In the current study, failure of 
patients to attend for the follow-up visit due to deterioration in health or death might have 
contributed to the improved patient characteristics seen during follow-up. 
 
In this chapter, I saw the anticipated changes in the clinical status and laboratory 
measurements between hospital admission and the follow-up visit. The study visit cohort 
represents a population of patients with predominantly stable HF in comparison to patients 
with decompensated HF during hospital admission. Patients at follow-up had lower body 
weight than during hospital admission, likely due to extracellular fluid volume reduction 
following diuretic treatment. BNP levels were lower, with the median BNP value after 
discharge being less than half of the median BNP during hospitalisation. Similarly, CRP 
levels and the proportion of patients with elevated troponin were lower at the follow-up visit. 
Patients had similar urea and creatinine levels at both stages; however, the eGFR was higher 
in the post-discharge compared to the hospitalised cohort. 
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Nearly all patients were taking a diuretic at the follow-up visit. Although a higher proportion 
of patients were taking an ACE inhibitor/ARB or beta-blocker at follow-up compared with 
hospital admission, a considerable proportion was still not receiving an ACE inhibitor or 
ARB (20%) or a beta-blocker (32%) after discharge. That may be because patients could not 
tolerate these treatments, due to other comorbidities e.g. renal dysfunction, reversible airways 
disease. Finally, although the aldosterone blocker use increased after discharge compared 
with hospital admission, still a surprisingly small proportion of patients were treated with 
these agents (only 14%). 
 
5.4.2 Levels of RAAS mediators during follow-up 
Aldosterone levels during follow-up were well within the normal range (median 143 pmol/L, 
IQR [76.7 - 267]). In Val-HeFT, the median (IQR) aldosterone concentration in patients with 
HFrSF was 280 (166.4 - 471.6) pmol/L (285). In ALOFT and in another single centre study, 
the median (IQR) aldosterone in patients with HFrSF and HFpSF was 222 (98.3 - 418.3) 
pmol/L and 277 (155.3 - 529.8) pmol/L respectively (72) (348). The reasons for the 
differences in aldosterone levels between these studies and the current study are likely to be 
multifactorial. Almost all my patients (98.2%) were treated with a diuretic at the follow-up 
visit and any difference in the diuretic use between the aforementioned studies is unlikely to 
account for the lower aldosterone levels in my patients. As discussed previously (section 
4.4.2), the study of RAAS and comparisons between different studies in terms of RAAS 
activity in patients taking a RAAS blocker is difficult. In the current study, 80% of patients 
were treated with an ACE inhibitor or ARB at follow-up compared with 99% of patients in 
ALOFT and 82% of patients in the single-centre study. ACE inhibitors and ARBs reduce 
aldosterone levels and the lower prescription rate of these agents in my patients, is unlikely to 
account for the lower levels of aldosterone. Aldosterone antagonists were used only by 14% 
of patients in the current study compared with 34% and 28.3% of patients in the other two 
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studies respectively. Aldosterone blockers increase aldosterone levels and the lower 
prescription rate of aldosterone blockers in the current study might contribute to the lower 
aldosterone levels I observed. Indeed, as shown in Table 5-2, aldosterone levels were 
markedly higher in patients taking an aldosterone blocker compared with patients not taking 
an aldosterone blocker. Alternatively, differences in terms of dosage of diuretics or RAAS 
inhibitors may additionally account for the differences in aldosterone levels; however, such 
information is not available. 
 
One other possibility for the lower mineralocorticoid levels seen in the current study is the 
different assays used. To my knowledge, this is the first study to report on aldosterone (and 
other corticosteroid) levels, which were measured by LCMS in patients with HF. Aldosterone 
was measured by immunoassays in the previous HF studies. The levels of aldosterone in 
plasma are in the picomolar range and immunoassays are often inaccurate, especially at low 
normal concentrations. Plasma aldosterone levels were reported to be on average 33% higher 
when measured by a commercial radioimmunoassay compared with LCMS in the same blood 
samples (349). Moreover, immunoassays are susceptible to interference by cross-reacting 
corticosteroids, potentially giving consequently falsely high results (321). Marked 
differences, approaching even 100%, were previously reported when aldosterone levels 
measured by different immunoassays (322). The high accuracy and specificity of LCMS 
assay over the immunoassays with regards to aldosterone measurements has been 
increasingly recognised (323) and might at least partially account for the lower aldosterone 
levels observed in this study.  
 
As previously discussed, aldosterone levels were higher in patients taking an aldosterone 
blocker; that was evident even in patients taking background therapy with an ACE inhibitor or 
ARB (Table 5-2). Aldosterone, apart from the activation of the MRs, exerts MR-independent 
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effects. Thus, higher levels of mineralocorticoids might be partially associated with worse 
cardiovascular effects due to their nongenomic actions. Inhibition of aldosterone synthase has 
been shown to decrease aldosterone levels; in patients with primary hyperaldosteronism, 
aldosterone synthase inhibitors decrease plasma aldosterone levels (350). Similar results with 
lowering of aldosterone levels following inhibition of aldosterone synthase were also reported 
in patients with essential hypertension (351). Thus, aldosterone synthase inhibitors might 
prevent the reactive increase in aldosterone levels in response to aldosterone blockers. That 
may provide further therapeutic benefit in combination with RAAS inhibitors in patients with 
HF. 
 
PRC was raised in the overall cohort at follow-up and was higher compared with admission 
levels. PRC in this study was markedly higher than PRC measured in healthy subjects by 
using the same assay (352). Similarly, PRC levels in my patients were higher than the PRC 
reported in patients with hypertension receiving antihypertensive treatment again measured 
using the same assay (352). RAAS is one of the main neurohumoral pathways activated in 
HF and that is likely to account for the differences in PRC between HF patients in the current 
study and healthy subjects or patients with hypertension. Moreover, treatment with a diuretic 
or RAAS inhibitor which both increase PRC, potentially contributes to the differences in 
PRC at the aforementioned studies. Furthermore, the higher prescription rate of a diuretic or 
RAAS inhibitor is also likely to contribute to the higher PRC levels observed at follow-up 
visit compared with hospital admission. 
 
The majority of previous studies in patients with HF analysed the PRA instead of PRC (353) 
(354). PRA refers to the rate of angiotensin I generation from angiotensinogen and is 
predominantly measured by radio-immunological assays. A significant correlation between 
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PRC and PRA has been recently reported in HF patients (354). Similar to the elevated PRA 
found in previous HF studies, PRC was raised in patients with chronic HF in my study.  
 
Finally, PRC levels were higher in patients taking a RAAS inhibitor compared with those not 
taking a RAAS inhibitor as displayed in Table 5-2. That is of clinical importance, as higher 
renin secretion in these patients might overcome RAAS inhibition and in turn lead to higher 
levels of RAAS downstream components. Indeed, as shown in Table 13-17 & Table 13-18 in 
the Appendix, aldosterone levels in the overall cohort at follow-up were higher in patients 
with higher PRC. Similarly, PRC was higher in patients with higher aldosterone levels. Thus, 
in the overall post-discharge cohort, renin continues to drive aldosterone secretion, likely 
through RAAS mediators despite the treatment with an ACE inhibitor/ARB or an aldosterone 
blocker. The above findings indicate that aldosterone escape observed in patients with chronic 
HF, could be partially attributed to greater activation of upstream components of the RAAS, 
which overcome the RAAS inhibition in later steps. They furthermore imply that renin 
inhibition can potentially be a therapeutic option in order to suppress aldosterone escape. 
Indeed, in the ALOFT study, treatment with the direct renin inhibitor aliskiren resulted in 
reduction of urinary aldosterone secretion in patients with chronic HF (348). 
 
5.4.3 Levels of glucocorticoids at follow-up   
Levels of plasma cortisol in patients with stable HF were well within the normal range and 
lower than during admission. Glucocorticoid secretion exhibits a diurnal rhythm and this is 
likely to contribute to the difference in cortisol levels between admission and follow-up, as 
the blood samples were predominantly taken in the afternoon at follow-up and exclusively in 
the morning during admission. Indeed, cortisol levels were higher in the small group of 
patients who had blood samples collected in the morning compared with the majority of 
patients who had blood samples collected in the afternoon at the follow-up visit. This is in 
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contrast to previous studies (70) suggesting that the circadian rhythm in glucocorticoid 
secretion is present in patients with HF.  
 
In order to examine further if the improvement in the clinical status contributed to the lower 
glucocorticoid levels after discharge, I compared the glucocorticoid levels at follow-up and 
admission in the subset of patients who had blood samples collected in the morning both on 
admission and at follow-up. Interestingly, no significant difference was present in cortisol 
levels at the two time points, indicating that the lower cortisol levels found at follow-up are 
probably due to the circadian rhythm. Nevertheless, although the levels of the cortisol were 
not different, a lower 11-deoxycortisol to cortisol ratio was found during admission compared 
with follow-up. It is accepted that lower 11-deoxycortisol to cortisol ratio is likely to reflect a 
higher activity of 11beta-hydroxylase, which converts the precursor 11-deoxycortisol to the 
end product cortisol (section 8.4.1). 11beta-hydroxylase is an ACTH dependent enzyme, and 
a lower 11-deoxycortisol to cortisol ratio indicates relatively higher HPA activity, however, 
that was not translated in higher levels of cortisol during admission.  
Overall, similar to hospital admission no major activation of HPA axis was present in patients 
studied 4 to 6 weeks after discharge.  
 
Glucocorticoid secretion at the follow-up visit will be further described in relation to RAAS 
mediators and other markers of HF severity in chapter 9. 
  
184
  
 
6. Chapter Six - PRC and aldosterone levels 
during hospital admission in patients not 
taking a RAAS blocker 
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6.1 Introduction 
 
Activation of the RAAS is thought to be fundamentally important in the pathophysiology of 
HF (25) (355). While there are many studies reporting RAAS activity in patients with 
decompensated HF, most of these included patients treated with some combination of an 
ACE inhibitor/ARB or aldosterone blocker (55) (339) (340). Treatment with a RAAS 
inhibitor affects the levels of RAAS components and this makes the interpretation of RAAS 
activity difficult. ACE inhibitors decrease the levels of angiotensin II and aldosterone and 
increase the levels of renin. ARBs eliminate the effects of angiotensin II, while they suppress 
the levels of aldosterone and stimulate the secretion of renin. Aldosterone blockers 
antagonise the aldosterone effects and increase both aldosterone and renin levels. Thus, in the 
presence of RAAS inhibitors the relationship between plasma components of RAAS, as well 
as the relationship between these mediators and the activation of their receptors, becomes 
distorted making consequently the study of RAAS activity in these patients difficult. 
 
There are few available data on RAAS activity in patients with decompensated HF not 
treated with a RAAS inhibitor. The few studies that do exist included only small number of 
patients and do not report consistent findings (57) (58) (60). The main purpose of this chapter 
is to describe RAAS activity in patients with decompensated HF and who were not treated 
with an ACE inhibitor/ARB or aldosterone blocker prior to hospitalisation. The markers of 
RAAS activity measured were plasma aldosterone and PRC. In addition, the aldosterone to 
PRC ratio was calculated. In this chapter, I also present the clinical characteristics of my 
patients according to RAAS activity.  
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6.2 Methods 
 
6.2.1 Study participants and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in sections 2.3.1 & 2.3.2. Only patients not receiving a RAAS inhibitor (ACE inhibitor/ARB 
or aldosterone blocker) prior to hospital admission were included in the current study. 
 
6.2.2 Statistical analysis 
All baseline characteristics were expressed as median (IQR) for continuous and as absolute 
number (percentage) for categorical variables. The inter-group comparisons were carried out 
by the Mann-Whitney and Kruskal-Wallis test for continuous variables as appropriate and by 
the χ2 test for categorical variables. A p-value <0.05 was considered significant for all 
analyses. Statistical analyses were performed with Minitab version 15.  
 
6.3 Results 
 
6.3.1 Patient characteristics during hospital admission stratified by treatment with a 
RAAS inhibitor 
Of the 722 patients enrolled, 278 received none of an ACE inhibitor/ARB or aldosterone 
blocker prior to hospital admission (Table 6-1). Patients not taking a RAAS inhibitor were 
more often women and were less likely to have a history of previous HF, MI, angina, diabetes 
or hypertension compared with patients taking a RAAS inhibitor and patients of the overall 
hospitalised cohort. The weight, urea and creatinine were significantly lower and the pulse 
rate, SBP and DBP, haemoglobin and cholesterol were significantly higher in the first group 
compared with the other two groups. Diuretics, beta-blockers, aspirin and statins were less 
often prescribed in patients not taking a RAAS inhibitor prior to admission. 
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6.3.2 RAAS activity during hospital admission  
Levels of plasma aldosterone and PRC, and the aldosterone to PRC ratio, during hospital 
admission are presented below. 
 
6.3.2.1 Aldosterone 
An aldosterone level measured during hospital admission was available in 210 of the 278 
patients. The median (IQR) aldosterone was 80.3 (41.8 - 184.7) pmol/L (Figure 6-1) and the 
mean (SD) aldosterone was 184.3 (421.5) pmol/L. A frequency distribution histogram of 
aldosterone levels during hospital admission in these patients is displayed in Figure 6-2. The 
distribution of aldosterone concentrations was positively skewed. The minimum aldosterone 
concentration was 2.5 pmol/L and maximum aldosterone concentration was 5399 pmol/L. 
Almost all patients (98%) had aldosterone levels within the normal range (0 - 937 pmol/L). 
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Figure 6-1. Box and whisker plot of the aldosterone concentrations showing the 2.5, 25, 
50, 75 and 97.5
 
centiles 
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Figure 6-2. Frequency distribution histogram of aldosterone levels in patients not 
receiving an ACE inhibitor/ARB or aldosterone blocker  
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6.3.2.2 PRC 
A PRC measured during hospital admission was available in 267 of the 278 patients. The 
median (IQR) PRC was 27.2 (9.2 - 78.6) mIU/L (Figure 6-3) and the mean (SD) PRC was 
115.8 (371.7) mIU/L. A frequency distribution histogram of PRC levels during hospital 
admission in these patients is displayed in Figure 6-4. The distribution of PRC values was 
positively skewed. The minimum PRC was 5.0 mIU/L and the maximum PRC was 4898 
mIU/L. Sixty-two percent of patients had PRC within the normal range (5.0 - 44.9 mIU/L). 
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Figure 6-3. Box and whisker plot of PRC values showing the 2.5, 25, 50, 75 and 97.5
 
centiles 
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Figure 6-4. Frequency distribution histogram of PRC in patients not receiving an ACE 
inhibitor/ARB or aldosterone blocker 
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6.3.2.3 Aldosterone to PRC ratio 
An aldosterone to PRC ratio could be calculated for 207 of the 278 patients. The median 
(IQR) aldosterone to PRC ratio was 3.11 (1.09 - 7.51) (Figure 6-5) and the mean (SD) 
aldosterone to PRC was 6.9 (14). A frequency distribution histogram of aldosterone to PRC 
levels during hospital admission in these patients is displayed in Figure 6-6. The distribution 
of aldosterone to PRC values was positively skewed. The minimum aldosterone to PRC ratio 
was 0.03 and the maximum aldosterone to PRC ratio was 140.1. 
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Figure 6-5. Box and whisker plot of the aldosterone to PRC ratio showing the 2.5, 25, 50, 
75 and 97.5
 
centiles 
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Figure 6-6. Frequency histogram of aldosterone to PRC ratio in patients not receiving 
ACE inhibitor/ARB or aldosterone blocker 
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6.3.3 Patient characteristics according to RAAS activity 
The characteristics of the 278 patients not taking a RAAS inhibitor were stratified according 
to the levels of aldosterone and PRC and the aldosterone to PRC ratio during the hospital 
admission.  
 
6.3.3.1 Patient characteristics according to aldosterone levels 
The group of 210 patients with measured aldosterone levels was divided into 4 subgroups, 
according to the median aldosterone and the 25
th
 and 75
th
 centiles. Such quartiles were 
respectively defined by aldosterone levels <41.8 pmol/L, 41.8 to 80.2 pmol/L, 80.3 to 184.6 
pmol/L and ≥ 184.7 pmol/L (Table 6-2).   
 
Compared with those in the lowest aldosterone quartile, participants in the highest quartile 
were more likely to be younger and female. Patients in the highest aldosterone quartile also 
had higher PRC and higher aldosterone to PRC ratio. Apart from the above differences, a 
trend for higher cortisol was also present in patients with higher aldosterone levels.  
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6.3.3.2 Patient characteristics according to PRC levels 
The group of 267 patients with measured PRC was divided into 4 subgroups, according to the 
median PRC and the 25
th
 and 75
th
 centiles. Such quartiles were respectively defined by PRC 
<9.2 mIU/L, 9.2 to 27.1 mIU/L, 27.2 to 78.5 mIU/L and ≥ 78.6 mIU/L (Table 6-3)  
 
Compared with those in the lowest PRC quartile, participants in the highest PRC quartile 
were more likely to have lower aldosterone to PRC and 11-deoxycortisol to cortisol ratio and 
higher aldosterone, CRP and elevated troponin. They also had had lower SBP and higher 
urea. Patients with higher PRC were also more likely to be in sinus rhythm (SR) on the 12-
lead ECG and less likely to have LVH on the transthoracic echocardiogram compared with 
patients with lower PRC, who were more likely to be in AF and have LVH on the 
transthoracic echocardiogram. In addition, a trend for lower DBP and sodium and higher 
creatinine and cortisol was present in patients with higher PRC. A trend for higher prevalence 
of dilated left ventricle and LVSD was also evident in these patients 
.  
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Patients were further stratified in 4 groups according to the median PRC and SBP values. The 
levels of creatinine according to PRC and SBP are displayed in Figure 6-7 below. Patients 
with PRC above median and SBP above median had higher creatinine and patients with PRC 
below median and SBP above median had lower creatinine. 
 
 
 
 
 
Figure 6-7. Levels of creatinine stratified by levels of PRC and SBP in patients not 
taking a RAAS inhibitor 
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The levels of eGFR according to PRC and SBP are displayed in Figure 6-8 below. Patients 
with PRC below median (with either SBP above or below median) had higher eGFR and 
patients with PRC above median and SBP below median had lower eGFR, however these 
differences did not reach statistical significance. 
 
 
 
 
 
Figure 6-8. Levels of eGFR stratified by levels of PRC and SBP in patients not taking a 
RAAS inhibitor 
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6.3.3.3 Patient characteristics according to aldosterone to PRC ratio  
The group of 207 patients was divided into 4 subgroups, according to the median aldosterone 
to PRC ratio and the 25
th
 and 75
th
 centiles. Such groups were respectively defined by 
aldosterone to PRC ratio <1.09, 1.09 to 3.10, 3.11 to 7.50 and ≥ 7.51 (Table 6-4). 
 
Compared with those in the highest aldosterone to PRC ratio quartile, participants in the 
lowest aldosterone to PRC quartile were more likely to have higher PRC, CRP and elevated 
troponin. Patients with lower aldosterone to PRC ratio were also more likely to have lower 
aldosterone and sodium and 11-deoxycortisol to cortisol ratio compared with patients with 
higher aldosterone to PRC ratio. Moreover, a trend for lower SBP and DBP and higher urea 
and BNP and for lower prevalence of LVH on the transthoracic echocardiogram was evident 
in patients with lower aldosterone to PRC ratio.  
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6.4 Discussion 
 
6.4.1 Levels of RAAS mediators during hospital admission 
In the current study, almost all patients had normal plasma aldosterone levels and 
approximately two thirds of patients had PRC within the normal range. That both aldosterone 
and PRC were not on average elevated appears somewhat paradoxical at first sight, given the 
fact that patients were admitted with decompensated HF and received treatment with 
diuretics early during hospital admission.  
 
Traditionally, it has been accepted that worsening HF is characterised by RAAS activation. 
Nevertheless, most of the data about RAAS activation in decompensated HF come from 
studies in patients taking some form of a RAAS inhibitor with a diuretic (55) (339) (340). In 
the CONSENSUS study both renin and aldosterone levels were markedly elevated in patients 
with severe congestive HF not treated with an ACE inhibitor or ARB (55). Almost all 
patients were taking a diuretic in a high dose (mean dose of furosemide was 210mg) and over 
forty percent were treated with a high dose of aldosterone blocker (mean dose 80mg) (356), 
which are likely to account for the high RAAS activity reported in this study. CONSENSUS 
was a landmark trial, demonstrating the benefit of ACE inhibitors in HF and led to a wide 
acceptance of the concept of RAAS activation in patients with congestive HF. On the other 
hand, the available data about renin and aldosterone secretion in untreated patients with 
decompensated HF are sparse. Early studies five decades ago suggested that aldosterone 
secretion in patients with advanced congestive HF receiving treatment only with digitalis was 
not consistently increased (53). Similarly, patients with untreated congestive HF have been 
shown to have normal or low PRA (58) (357). The same pattern of findings was replicated in 
further studies of untreated patients with moderate and severe HF, which showed that not all 
patients had raised PRA or aldosterone (57) (358). Overall, the common finding in these 
studies with untreated HF patients was the absence of a universal RAAS activation. In 
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contrast, a considerable proportion of patients had normal or suppressed RAAS activity. The 
findings of my study are in accordance with these reports raising the question “have we been 
misled about the undisputable concept of RAAS activation in patients with worsening HF?”  
 
The variation of RAAS activity in patients with HF has been attributed to the severity and 
state of cardio-circulatory decompensation as well as the extracellular fluid status (57). Organ 
and specifically renal perfusion is primarily involved in the regulation of RAAS. The MAP 
and extracellular volume determine renal perfusion and RAAS activation. Decline in cardiac 
output and in blood pressure in patients with decompensated HF lead to renal hypoperfusion 
and RAAS activation. Indeed, PRC was inversely related to SBP and DBP and patients with 
higher PRC were more likely to have LVSD and lower blood pressure in the current cohort 
(section 6.4.2). On the other hand, the activation of RAAS and other compensatory 
mechanisms lead to an expansion of the extracellular volume and an increase in MAP, which 
in turn exerts a negative feedback on renin and aldosterone secretion. Renin levels were 
lower in patients with decompensated HF with fluid overload compared with patients with 
decompensated HF without fluid congestion in a previous study (59). Moreover, low arterial 
blood pressure was a major stimulus for renin secretion in these patients. In the current study, 
the majority of patients had normal or high blood pressure and approximately three quarters 
had signs of fluid overload. Extracellular fluid overload increases the myocardial wall stress, 
which in turn stimulates the secretion of natriuretic peptides by the myocardium. Natriuretic 
peptides belong to the counter-regulatory pathways that are activated in HF and promote 
diuresis, vasodilatation and RAAS suppression (30) (124) (127). The raised natriuretic 
peptide levels during hospital admission along with the normal or high blood pressure are 
likely to account for the absence of gross RAAS activation in my cohort. In agreement with 
that view is also the finding that levels of RAAS mediators found in the current HF cohort 
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were similar to those reported in the healthy subjects following a high salt diet (section 
3.3.3). 
 
In summary, RAAS activity during hospital admission in patients not taking a RAAS 
inhibitor was not raised and the interplay between the haemodynamic status and the 
extracellular fluid volume and natriuretic peptides contributes to the variation of RAAS 
activity in these patients.  
 
6.4.2 Patient characteristics according to RAAS activity during hospital admission 
There were several significant differences present in patient characteristics according to the 
levels of RAAS mediators in this study. Aldosterone levels were higher in patients with 
higher PRC. Renin represents a surrogate of angiotensin II, which is one of the principal 
regulators of aldosterone synthesis in the adrenal glands. In addition, a trend for higher 
cortisol levels was present in patients with higher aldosterone levels; however, these 
differences were not statistically significant, indicating that the ACTH, which primarily 
regulates glucocorticoid secretion, is not a principal regulator of aldosterone biosynthesis in 
patients with decompensated HF. Moreover, the levels of serum potassium, which represents 
another major secretagogue for aldosterone, were not different among patients with different 
aldosterone levels. Overall, these findings suggest that aldosterone secretion in patients with 
decompensated HF is primarily regulated by the renin angiotensin system. 
 
PRC was higher in patients with lower SBP and DBP. This association represents one of the 
fundamental responses involved in the homeostasis of the cardiovascular system. Lower 
blood pressure, as mentioned previously, leads to RAAS activation in order to preserve the 
systemic arterial pressure and organ perfusion. Moreover, patients with higher PRC represent 
a group characterised by more severe HF in my study. A trend for greater LV dilatation and 
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systolic dysfunction was present in patients with higher PRC, in keeping with previous 
studies (353) (354). In addition, patients with higher PRC were more likely to have elevated 
troponin, reflecting the severity of HF due to myocardial injury. In summary, higher PRC in 
patients with decompensated HF not taking a RAAS inhibitor was associated with 
myocardial necrosis and trended towards an association with LV remodeling, which both 
contribute to a decline in the cardiac output and potentially a decrease in blood pressure.  
 
The decline in systemic perfusion due to low arterial pressure results in decreased renal blood 
flow, which has been reported as one of the strongest predictors of renal function in patients 
with HF (359). In the current study higher urea levels and a trend for higher creatinine levels 
were seen in patents with higher PRC. Traditionally, RAAS activation is considered to cause 
vasoconstriction to the glomerular arterioles in the context of a homeostatic mechanism to 
preserve filtration pressure and glomerular function in conditions characterised by low 
systemic and renal perfusion. That mechanism depends on different levels of constriction 
mediated by angiotensin II on the afferent and efferent arterioles and can potentially lead to 
lower filtration fraction and deterioration of kidney function in states of excessive 
vasoconstriction due to higher RAAS activity in patients with HF (360). In the current study, 
creatinine was higher in patients with higher PRC even in the subgroup with lower SBP, and 
that might indicate a negative influence of RAAS on renal function. However, no differences 
were seen in eGFR according to PRC and SBP levels. Moreover, the median SBP was well 
above 110mmHg in patients with lower SBP indicating that these patients were on average 
normotensive. Thus, no conclusions can be made about the association between PRC and 
renal function in relation to haemodynamic status in patients with decompensated HF in the 
current analyses.  
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A trend for lower sodium levels in patients with higher PRC was evident in patients with 
decompensated HF. Renin is synthesised in the JGA in kidneys and released in response to 
low sodium concentration at the macula densa, activation of the SNS and decrease of the 
intravascular volume (section 1.2.3). The differences in sodium levels according to PRC 
quartiles suggest that the above mechanism still operates in patients with decompensated HF 
in a pattern similar to that of a normal population. On the other hand, the RAAS activation 
due to low sodium in the macula densa reduces through angiotensin II the medullary blood 
flow and in turn increases the water reabsorption (361). Angiotensin II also stimulates the 
release of antidiuretic hormone and the thirst centre, resulting in further water reabsorption 
and an increase in water intake respectively (53). Thus, hyponatraemia in these patients, apart 
from a marker of hyper-reninaemia, represents a status of water excess in relation to 
extracellular sodium, indicating that the activation of water-retaining pathways becomes a 
predominant pathophysiological feature in patients with low serum sodium levels. 
RAAS activation was also associated with higher CRP during hospital admission in patients 
not taking a RAAS inhibitor. Plasma CRP reflects the systemic inflammatory response with 
up-regulation of cytokines production in patients with HF; previous studies demonstrated that 
pro-inflammatory cytokines are activated in response to hypoperfusion and hypoxia in these 
patients (362). In addition, CRP has also been associated with the haemodynamic and 
neurohumoral responses related to the LV remodeling (363) (364). Thus, lower blood 
pressure and organ hypoperfusion are associated with RAAS activation and up-regulation of 
cytokines production and that might account for the higher CRP levels in patients with higher 
PRC.  
 
Patients with lower PRC were more likely to have AF, a finding which appears somewhat 
unexpected in the first instance. AF is characterised by the loss of the atrial contraction, 
which itself contributes to decreased LV filling. The above effect potentially results in 
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reduction of the cardiac output and blood pressure with further reduction in renal perfusion 
and increase in RAAS activity. However, in this study, patients in AF were less likely to have 
LVSD compared with patients not in AF. Thus, patients with AF on admission represent a 
group with less severe HF, which potentially compensates for the aforementioned 
pathophysiological considerations and might partially explain why patients with lower PRC 
were more likely to have AF. 
 
The lack of association between BNP and PRC in the current study is in keeping with 
previous findings in patients with LVSD treated with diuretics (365). Natriuretic peptides 
inhibit RAAS resulting in an inverse relationship with renin in normal volunteers (128). This 
reciprocal relationship is abrogated in patients with LVSD treated with diuretics which 
decrease the extravascular volume and in parallel stimulate RAAS activity (365). However, 
in patients with advanced HF, a positive correlation between natriuretic peptides and renin 
has been reported in some but not in all studies (353) (366). Patients with worse HF require 
higher doses of diuretics which by activating RAAS might contribute to the positive 
correlation between BNP and renin levels. The lack of positive association between PRC and 
BNP in my study, along with the finding of normal on average PRC levels despite diuretic 
treatment during hospital admission, may indicate that renin levels were suppressed by the 
raised natriuretic peptides in these patients. Alternatively, lower doses of diuretics might have 
been used compared with previous studies, as most of my patients were in NYHA class III 
during hospital admission, resulting into a lower degree of RAAS activation and lack of 
association between PRC and BNP levels.  
 
Finally, the differences in baseline characteristics according to aldosterone to PRC ratio 
followed a similar pattern to that observed for PRC in an inverse fashion, indicating that the 
aldosterone to renin ratio is principally driven by renin in patients with HF. Interestingly, the 
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11-deoxycortisol to cortisol ratio was lower in patients with higher PRC and lower 
aldosterone to PRC ratio. To the best of my knowledge, this is a novel finding and is 
discussed further in chapter 8.  
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7. Chapter Seven - PRC and aldosterone levels 
at follow-up in patients not taking a RAAS 
blocker 
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7.1 Introduction 
 
Diuretic therapy has been firmly established as one of the initial treatment strategies in 
patients with HF and fluid congestion during hospitalisation. Initiation of diuretics in patients 
with HF is associated with activation of RAAS (358) (367). In parallel, a decrease in 
natriuretic peptide levels due to extravascular volume reduction is evident in these patients. It 
is less clear if the discordance between the RAAS and natriuretic peptides seen following 
diuretic therapy persists in the medium- to long-term. That may be of importance as RAAS 
mediators exert detrimental effects on the cardiovascular system. Moreover, if the 
disconnection between BNP and RAAS activity continues over time, it indicates that apart 
from RAAS inhibition, augmentation of natriuretic peptide actions might be of therapeutic 
benefit in patients with chronic HF. Natriuretic peptides exert inhibitory effects on RAAS 
and SNS activity as well as natriuretic and vasodilating actions (30) (124) (127). 
 
The main aim of this chapter is to describe the change in RAAS activity in relation to 
natriuretic peptide levels between hospital admission and the follow-up visit in patients not 
taking a RAAS inhibitor at both time points. Prior to this, I describe RAAS activity in 
patients not taking a RAAS inhibitor at follow-up. I also present the clinical characteristics 
according to RAAS mediators in these patients at the follow-up visit and examine if the 
associations seen between RAAS components and markers of HF severity during hospital 
admission continue to exist after discharge.  
  
219
  
7.2 Methods 
 
7.2.1 Study participants and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in sections 2.4.1 & 2.4.2. Only patients not receiving a RAAS inhibitor (ACE inhibitor/ARB 
or aldosterone blocker) at follow-up were included in the current study. For the comparisons 
of RAAS mediators between hospital admission and follow-up visit, the subgroup of patients 
not receiving a RAAS inhibitor prior to admission and at follow-up was included in the 
analyses.  
 
7.2.2 Statistical analysis 
All baseline characteristics are expressed as median (IQR) for continuous and absolute 
number (percentage) for categorical variables. The inter-group comparisons were carried out 
by the Mann-Whitney and Kruskal-Wallis test for continuous variables as appropriate and by 
the χ2 test for categorical variables. For the comparisons of baseline characteristics between 
hospitalised and post-discharge patients not receiving a RAAS inhibitor, Wilcoxon matched 
pairs test and McNemar test were employed for continuous and categorical variables 
respectively. A p-value <0.05 was considered significant for all analyses. Statistical analyses 
were performed with Minitab version 15. 
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7.3 Results 
 
7.3.1 Patient characteristics at follow-up stratified by treatment with a RAAS inhibitor  
Of the 453 patients who completed the follow-up, 79 were not treated with a RAAS inhibitor 
after discharge (Table 7-1).  
 
Patients not taking a RAAS inhibitor were older, more often women and more likely to have 
higher SBP and LVEF and less likely to have a history of previous angina and diabetes 
compared with patients taking a RAAS inhibitor or patients of the overall post-discharge 
cohort. Potassium and eGFR were lower in the former group compared with the other two 
groups. Patients not taking RAAS inhibitor were also less likely to be treated with a beta-
blocker at the follow-up visit compared with patients of the other groups.  
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7.3.2 RAAS activity during follow-up visit  
Levels of aldosterone, PRC and aldosterone to PRC ratio during follow-up are presented 
below.  
 
7.3.2.1 Aldosterone  
An aldosterone level measured during follow-up was available in 77 of the 79 patients. The 
median (IQR) aldosterone was 182.4 (92.6 - 329) pmol/L (Figure 7-1) and the mean (SD) 
aldosterone was 273.1 (363.7) pmol/L. A frequency distribution histogram of aldosterone 
levels in these patients is displayed in Figure 7-2. The distribution of aldosterone 
concentrations was positively skewed. The minimum aldosterone value was 21.1 pmol/L and 
the maximum aldosterone value was 2314.1 pmol/L. Almost all patients (97.5%) had 
aldosterone levels within the normal range (0 - 937 pmol/L). 
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Figure 7-1. Box and whisker plot of aldosterone levels showing the 2.5, 25, 50, 75 and 
97.5
 
centiles 
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Figure 7-2. Frequency distribution histogram of aldosterone concentrations in patients 
not receiving an ACE inhibitor/ARB or aldosterone blocker 
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7.3.2.2 PRC  
A PRC measured during follow-up was available in 78 of the 79 patients. The median (IQR) 
PRC was 47.5 (18.9 - 107.1) mIU/L (Figure 7-3) and the mean (SD) PRC was 77.6 (86.7) 
mIU/L. A frequency distribution histogram of PRC levels in these patients is displayed in 
Figure 7-4. The distribution of PRC values was positively skewed. The minimum PRC was 
5.0 mIU/L and the maximum PRC was 423.6 mIU/L. Approximately half of patients (48%) 
had PRC within the normal range (5.0 - 44.9 mIU/L). 
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Figure 7-3. Box and whisker plot of PRC levels showing the 2.5, 25, 50, 75 and 97.5
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Figure 7-4. Frequency distribution histogram of PRC in patients not receiving an ACE 
inhibitor/ARB or aldosterone blocker 
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7.3.2.3 Aldosterone to PRC  
An aldosterone to PRC ratio could be calculated for 76 of the 79 patients. The median (IQR) 
aldosterone to PRC was 3.74 (1.88 - 9.73) (Figure 7-5) and the mean (SD) aldosterone to 
PRC was 7.2 (8.2). A frequency distribution histogram of aldosterone to PRC levels in these 
patients is displayed in Figure 7-6. The distribution of aldosterone to PRC values was 
positively skewed. The minimum aldosterone to PRC was 0.33 and the maximum aldosterone 
to PRC was 36.5. 
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Figure 7-5. Box and whisker plot of aldosterone to PRC values showing the 2.5, 25, 50, 
75 and 97.5
 
centiles 
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Figure 7-6. Frequency histogram of aldosterone to PRC in patients not receiving an 
ACE inhibitor/ARB or aldosterone blocker 
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7.3.3 Patient characteristics according to RAAS activity  
The characteristics of patients not receiving a RAAS inhibitor during follow-up were 
stratified according to the levels of aldosterone and PRC and the aldosterone to PRC ratio. 
 
7.3.3.1 Patient characteristics according to aldosterone levels  
The cohort of 77 patients with measured aldosterone levels was divided into two groups 
according to the median aldosterone; patients with aldosterone levels <182.4 pmol/L and 
patients with aldosterone levels ≥ 182.4 pmol/L (Table 7-2).  
 
Patients with higher aldosterone levels were more likely to have higher PRC and cortisol and 
higher aldosterone to PRC ratio. These patients also had higher cholesterol and lower TSH 
and were more likely to have a history of hypertension compared to patients with lower 
aldosterone levels. 
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Table 7-2. Characteristics of patients not taking an ACE inhibitor/ ARB or aldosterone 
blocker according to the median aldosterone 
Variable Aldosterone 
< 182.4 pmol/L 
(n=39) 
aldosterone 
≥ 182.4 pmol/L 
(n=38) 
p-value† 
Age (years) 77 (71 – 83) 73 (68 – 79) 0.081 
Female gender 21 (53.8) 23 (60.5) 0.554 
NYHA class    
I 1 (2.6) 2 (5.3) 0.541 
II 27 (69.2) 25 (65.8) 0.747 
III 11 (28.2) 11 (29) 0.943 
Medical history    
HF 14 (35.9) 14 (36.8) 0.931 
MI 14 (35.9) 16 (42.1) 0.577 
Angina 13 (33.3) 20 (52.6) 0.087 
Diabetes mellitus 6 (15.4) 9 (23.7) 0.358 
Hypertension 25 (64.1) 32 (84.2) 0.044 
AF 25 (64.1) 21 (55.2) 0.429 
CVA/TIA 9 (23.1) 5 (13.2) 0.259 
Physiological measurements    
BMI (kg/m
2
) 25.1 (23.0 – 32.9) 26.8 (23.9 – 32.4) 0.575 
Pulse rate (bpm) 73 (64 – 84) 84 (67 – 94) 0.179 
SBP (mmHg) 138 (123 – 150) 141 (126 – 152) 0.658 
DBP (mmHg) 69 (60 – 75) 71 (57 – 81) 0.695 
Signs of fluid congestion    
Elevated JVP 4 (11.8) 3 (8.6) 0.660 
Peripheral oedema 15 (38.5) 14 (36.8) 0.883 
ECG rhythm    
SR 20 (51.3) 26 (68.4) 0.125 
AF 17 (43.6) 10 (26.3) 0.112 
Echocardiography  
measurements 
   
LVEF 46 (38 – 56) 45 (34 – 53) 0.720 
LVEF <45% 18 (46.2) 17 (46) 0.985 
Laboratory measurements 
(blood) 
   
BNP (pg/ml) 525 (260 – 800) 411 (196 – 758) 0.292 
Troponin I ≥ 0.04 (µg/L) 7 (18) 8 (21.1) 0.731 
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Variable Aldosterone 
< 182.4 pmol/L 
(n=39) 
aldosterone 
≥ 182.4 pmol/L 
(n=38) 
p-value† 
Sodium (mmol/L) 140 (138 – 141) 139 (138 – 140) 0.104 
Potassium (mmol/L) 4.0 (3.6 – 4.3) 3.9 (3.5 – 4.1) 0.129 
Urea (mmol/L) 9.3 (6.3 – 14.0) 9.8 (7.2 – 11.5) 0.992 
Creatinine (µmol/L) 118 (91 – 142) 112 (84 – 157) 0.915 
eGFR (ml/min/1.73m
2
) 52 (39 – 60) 50 (32 – 60) 0.768 
eGFR <60ml/min/1.73m
2
 24 (61.5) 24 (63.2) 0.883 
Cholesterol (total) (mmol/L) 3.8 (3.1 – 5.1) 4.6 (3.7 – 5.5) 0.030 
HDL (mmol/L) 1.2 (0.9 – 1.3) 1.1 (1.0 – 1.5) 0.337 
CRP (mg/L) 5.5 (3.2 – 19.3) 7.4 (4.3 – 23.0) 0.425 
TSH (mIU/L) 1.7 (1.1 – 3.8) 1.3 (0.7 – 2.4) 0.044 
Cortisol (nmol/L) 209.8 (149.0 – 288.7) 263.7 (172.3 – 343.7) 0.051 
11-deoxycortisol (pmol/L) 522.8 (295.3 – 794.7) 451.7 (311.4 – 643.8) 0.573 
11-deoxycortisol/cortisol (10
-3
) 2.67 (1.44 – 4.43) 1.69 (1.18 – 3.10) 0.163 
PRC (mIU/L) 28.5 (11.8 – 50.7) 68.1 (31.1 – 159.7) <0.001 
Aldosterone/PRC 3.11 (1.35 – 7.08) 4.63 (2.22 – 13.18) 0.042 
Haemoglobin (g/dl) 11.7 (11.0 – 13.1) 12.1 (11.4 – 13.4) 0.328 
Cardiovascular medication    
Diuretic  38 (97.4) 38 (100) - ¥ 
Beta-blocker 26 (66.7) 18 (47.4) 0.087 
Digoxin 10 (25.6) 7 (18.4) 0.445 
Anti-arrhythmic   2 (5.1) 5 (13.2) 0.220 
Aspirin 22 (56.4) 22 (57.9) 0.895 
Statin 29 (74.4) 27 (71.1) 0.745 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid. 
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7.3.3.2 Patient characteristics according to PRC 
The cohort of 78 patients with measured PRC was divided into two groups according to the 
median PRC; patients with PRC <47.5 and patients with PRC ≥ 47.5 (Table 7-3). 
Patients with higher PRC were more likely to have higher BMI, aldosterone and cortisol. 
These patients also had lower potassium and aldosterone to PRC ratio compared to patients 
with lower PRC. Beta-blockers were prescribed more often in patients with lower compared 
to patients with higher PRC. 
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Table 7-3. Characteristics of patients not taking an ACE inhibitor/ ARB or aldosterone 
blocker according to the median PRC 
Variable PRC < 47.5  
(n=39) 
PRC ≥ 47.5  
 (n=39) 
p-value† 
Age (years) 76 (69 – 83) 73 (67 – 79) 0.353 
Female gender 23 (59) 20 (51.3) 0.495 
NYHA class    
I 3 (7.7) 0 (0) 0.077 
II 26 (66.7) 25 (64.1) 0.812 
III 10 (25.6) 14 (35.9) 0.326 
Medical history    
HF 11 (28.1) 18 (46.2) 0.101 
MI 14 (35.9) 18 (46.2) 0.357 
Angina 14 (35.9) 20 (51.3) 0.171 
Diabetes mellitus 7 (18) 9 (23.1) 0.575 
Hypertension 27 (69.2) 31 (79.5) 0.300 
AF 22 (56.4) 23 (59) 0.819 
CVA/TIA 8 (20.5) 7 (18) 0.774 
Physiological measurements   
BMI (kg/m
2
) 24.6 (22.9 – 28.7) 28.9 (25.0 – 33.5) 0.024 
Pulse rate (bpm) 75 (63 – 90) 82 (67 – 93) 0.358 
SBP (mmHg) 143 (124 – 156) 134 (121 – 145) 0.185 
DBP (mmHg) 69 (64 – 82) 70 (58 – 76) 0.614 
Signs of fluid congestion    
Elevated JVP 2 (5.7) 6 (17.1) 0.133 
Peripheral oedema 11 (28.2) 18 (46.2) 0.101 
ECG rhythm    
SR 24 (61.5) 23 (59) 0.817 
AF 14 (35.9) 13 (33.3) 0.812 
Echocardiography  measurements   
LVEF 45 (35 – 57) 45.5 (33 – 50) 0.373 
LVEF <45% 19 (48.7) 18 (47.4) 0.906 
Laboratory measurements (blood)   
BNP (pg/ml) 505 (215 – 800) 457 (228 – 819) 0.772 
Troponin I ≥ 0.04 (µg/L) 7 (18) 9 (23.1) 0.575 
Sodium (mmol/L) 140 (138 – 141) 139 (137 – 140) 0.074 
Potassium (mmol/L) 4.0 (3.8 - 4.2) 3.7 (3.4 – 4.1) 0.029 
Urea (mmol/L) 9.4 (6.3 – 14.4) 9.8 (7.3 – 12.0) 0.857 
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Variable PRC < 47.5  
(n=39) 
PRC ≥ 47.5  
 (n=39) 
p-value† 
Creatinine (µmol/L) 111 (82 – 134) 118 (92 – 155) 0.299 
eGFR (ml/min/1.73m
2
) 55 (35 – 60) 45 (33 – 60) 0.221 
eGFR <60ml/min/1.73m
2
 21 (53.9) 28 (71.8) 0.101 
Cholesterol (total) (mmol/L) 3.9 (3.2 – 5.5) 4.1 (3.6 – 5.2) 0.697 
HDL (mmol/L) 1.2 (1.0 – 1.3) 1.2 (0.9 – 1.5) 0.930 
CRP (mg/L) 4.6 (3.1 – 17.8) 8.9 (4.6 – 19.5) 0.187 
TSH (mIU/L) 1.6 (0.9 – 2.9) 1.6 (1.0 – 3.1) 0.883 
Cortisol (nmol/L) 197.1 (130.0 – 294.2) 263.9 (191.0 – 328.6) 0.032 
11-deoxycortisol (pmol/L) 531 (256 – 715) 452 (316 – 779) 0.982 
11-deoxycortisol/cortisol (10
-3
) 2.46 (1.49 – 3.97) 1.74 (1.18 – 3.35) 0.165 
Aldosterone (pmol/L) 112.9 (58.7 – 236.6) 250.5 (172.4 – 457.3) <0.001 
Aldosterone/PRC 6.72 (3.21 – 15.15) 2.63 (1.42 – 4.34) <0.001 
Haemoglobin (g/dl) 11.9 (11.1 – 13.1) 12.1 (11.4 – 13.7) 0.439 
Cardiovascular medication   
Diuretic  38 (97.4) 39 (100) - ¥ 
Beta-blocker 27 (69.2) 18 (46.2) 0.039 
Digoxin 7 (18) 9 (23.1) 0.575 
Anti-arrhythmic   2 (5.1) 5 (12.8) 0.235 
Aspirin 26 (66.7) 20 (51.3) 0.167 
Statin 29 (74.4) 26 (66.7) 0.456 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid. 
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7.3.3.3 Patient characteristics according to aldosterone to PRC ratio  
The cohort of 76 patients with calculated aldosterone to PRC ratio was divided into two 
groups according to the median aldosterone to PRC; patients with aldosterone/PRC <3.74 and 
patients with aldosterone/PRC ≥ 3.74 (Table 7-4)  
 
Patients with lower aldosterone to PRC ratio were more likely to be in NYHA functional 
class III and less likely to be in NYHA functional class II compared to patients with higher 
aldosterone to PRC ratio. These patients were also more likely to have history of MI and 
angina and elevated troponin. PRC, BNP, urea and creatinine were higher in patients with 
lower aldosterone to PRC ratio compared with patients with higher aldosterone to PRC ratio. 
Conversely, aldosterone and eGFR were lower in the former compared with the latter group. 
Apart from the above differences, a trend for lower SBP and DBP and higher CRP was also 
present in patients with lower aldosterone to PRC ratio. 
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Table 7-4. Characteristics of patients not taking an ACE inhibitor/ARB or aldosterone 
blocker according to the median aldosterone to PRC ratio 
Variable Aldosterone to PRC  
< 3.74  
(n=38) 
Aldosterone to PRC  
≥ 3.74  
 (n=38) 
p-value† 
Age (years) 76 (71 – 82) 75 (68 – 81) 0.366 
Female gender 19 (50) 24 (63.2) 0.247 
NYHA class    
I 0 (0) 3 (7.8) 0.077 
II 21 (55.3) 30 (79) 0.028 
III 17 (44.7) 5 (13.2) 0.002 
Medical history    
HF 18 (47.4) 10 (26.3) 0.057 
MI 20 (52.6) 10 (26.3) 0.019 
Angina 21 (55.3) 12 (31.6) 0.037 
Diabetes mellitus 8 (21.1) 7 (18.4) 0.773 
Hypertension 27 (71.1) 29 (76.3) 0.602 
AF 20 (52.6) 25 (65.8) 0.243 
CVA/TIA 3 (7.9) 11 (29) 0.018 
Physiological measurements   
BMI (kg/m
2
) 27.1 (24.3 – 32.9) 26.1 (22.7 – 32.2) 0.406 
Pulse rate (bpm) 74 (67 – 89) 80 (65 – 93) 0.585 
SBP (mmHg) 133 (119 – 153) 143 (128 – 148) 0.314 
DBP (mmHg) 69 (58 – 74) 73 (59 – 82) 0.273 
Signs of fluid congestion    
Elevated JVP 4 (11.7) 3 (8.8) 0.690 
Peripheral oedema 17 (44.7) 11 (29) 0.154 
ECG rhythm    
SR 25 (65.8) 21 (55.3) 0.348 
AF 10 (26.3) 16 (42.1) 0.147 
Echocardiography measurements   
LVEF 45 (29 – 52) 46 (37 – 55) 0.346 
LVEF <45% 8 (57.2) 27 (44.3) 0.384 
Laboratory measurements (blood)   
BNP (pg/ml) 604 (296 – 1017) 386 (183 – 703) 0.040 
Troponin I ≥ 0.04 (µg/L) 11 (29) 4 (10.5) 0.044 
Sodium (mmol/L) 140 (138 – 141) 139 (137 – 141) 0.872 
Potassium (mmol/L) 3.8 (3.5 – 4.1) 4.0 (3.7 – 4.2) 0.149 
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Variable Aldosterone to PRC  
< 3.74  
(n=38) 
Aldosterone to PRC  
≥ 3.74  
 (n=38) 
p-value† 
Urea (mmol/L) 10.3 (7.4 – 14.4) 7.9 (6.3 – 10.7) 0.025 
Creatinine (µmol/L) 125 (96 – 155) 104 (82 – 129) 0.020 
eGFR (ml/min/1.73m
2
) 42 (33 – 60) 57 (42 – 60) 0.047 
eGFR <60ml/min/1.73m
2
 28 (73.7) 20 (52.6) 0.057 
Cholesterol (total) (mmol/L) 3.9 (3.3 – 4.5) 4.7 (3.7 – 5.9) 0.019 
HDL (mmol/L) 1.2 (0.8 – 1.5) 1.1 (1.0 – 1.3) 0.858 
CRP (mg/L) 9.1 (4.6 – 20.5) 4.7 (2.4 – 15.0) 0.083 
TSH (mIU/L) 1.6 (0.9 – 3.7) 1.6 (0.9 – 2.8) 0.553 
Cortisol (nmol/L) 229.8 (167.7 – 308.0) 222.6 (137.4 – 313.8) 0.670 
11-deoxycortisol (pmol/L) 468.7 (318.0 – 698.2) 447 (198.5 – 752.0)  0.374 
11-deoxycortisol/cortisol (10
-3
) 2.02 (1.29 – 3.51) 2.13 (1.31 – 3.84) 0.973 
Aldosterone (pmol/L) 135.1 (57.1 – 268.3) 241.9 (119.4 – 361.4) 0.012 
PRC (mIU/L) 88.2 (32.9 – 159.7) 23.1 (10.4 – 53.2) <0.001 
Haemoglobin (g/dl) 11.7 (10.7 – 13.2) 12.2 (11.4 – 13.5) 0.102 
Cardiovascular medication    
Diuretic  38 (100) 37 (97.4) - ¥ 
Beta-blocker 21 (55.3) 23 (60.5) 0.642 
Digoxin 8 (21.1) 8 (21.1) 1.000 
Anti-arrhythmic   5 (13.2) 2 (5.3) 0.234 
Aspirin 25 (65.8) 19 (50) 0.163 
Statin 30 (79) 25 (65.8) 0.200 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid. 
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7.3.4 RAAS activity during hospital admission and follow-up in patients not taking a 
RAAS inhibitor 
Of the 79 patients not taking an ACE inhibitor/ARB or aldosterone blocker at follow-up, 57 
patients were not taking the above agents prior to hospital admission. The demographic 
characteristics, medical history and LVEF of these patients are presented in Table 7-5. 
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Patients not taking a RAAS inhibitor during hospital admission and at follow-up were older, 
more often women and more likely to have higher LVEF compared with patients of the 
overall post-discharge cohort. These patients were also less likely to have a history of HF and 
diabetes compared with patients of the overall post-discharge and hospitalised cohort.  
 
The physiological and laboratory measurements of these patients and the medication during 
hospital admission and follow-up are presented in Table 7-6. 
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Table 7-6. Clinical characteristics, physiological and laboratory measurements and 
medication in patients not taking a RAAS inhibitor* during hospital admission and 
follow-up (n=57) 
Variable During admission  
(n=57) 
At follow-up  
(n=57) 
p-value† 
NYHA class    
I 0 (0) 2 (3.5) 0.500 
II 20 (35.1) 38 (66.7) 0.001 
III 30 (52.6) 17 (29.8) 0.026 
IV 7 (12.3) 0 (0) 0.016 
Physiological measurements   
BMI (kg/m
2
) 28 (24 - 34) 26.3 (23 - 33.3) <0.001 
Weight (kg) 73 (57 - 89.8) 69 (55.5 - 86) <0.001 
Pulse rate (bpm) 86 (72 - 99.5) 79 (67.5 - 92) 0.013 
SBP (mmHg) 140 (125 - 155) 142 (126 - 152.5) 0.720 
DBP (mmHg) 78 (65 - 89.5) 69 (58 - 79.5)  0.002 
Pulse pressure (mmHg) 58 (50 - 137) 72 (28 - 90) 0.080 
Signs of fluid congestion    
Elevated JVP 41 (79) 4  (8) <0.001 
Peripheral oedema 38 (66.7) 21 (36.8) <0.001 
ECG rhythm    
SR 37 (64.9) 37 (64.9) 1 
AF 18 (31.6) 19 (33.3) 1 
Laboratory measurements (blood)   
BNP (pg/ml) 647 (310 - 1792) 457 (211 - 784) <0.001 
Sodium (mmol/L) 138 (126 - 138) 139 (137.5 - 141) 0.040 
Potassium (mmol/L) 4.2 (3.8 - 4.5) 3.9 (3.7 - 4.2) 0.001 
Urea (mmol/L) 8.8 (5.7 - 10.9)  9.2 (6.8 - 11.8) 0.258 
Creatinine (µmol/L) 112 (75 - 142.5) 115 (88 - 150) 0.003 
eGFR (ml/min/1.73m
2
) 53 (35 - 60) 51 (32 - 60) 0.061 
eGFR <60ml/min/1.73m
2
 35 (61.4) 37 (64.9) 0.727 
Cholesterol (total) (mmol/L) 3.9 (3.3 - 5.1) 4.2 (3.6 - 5.5) 0.139 
HDL (mmol/L) 1.1 (0.9 - 1.4) 1.15 ( 1.0 - 1.4)  0.261 
CRP (mg/L) 11 (4.7 - 38) 6.3 (3.8 - 21) 0.001 
TSH (mIU/L) 2.3 (1.1 - 3.7) 1.6 (0.7 - 2.6) 0.393 
Cortisol (nmol/L) 358.2 (260.8 - 497.9) 222.9 (151.6 - 298.4) <0.001 
11-deoxycortisol (pmol/L) 536 (319 - 1068) 423.8 (257.9 - 772.8) 0.557 
11-deoxycortisol/cortisol (10
-3
) 1.68 (1.12 - 3.4) 2.03 (1.29 - 3.44) 0.174 
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Variable During admission  
(n=57) 
At follow-up  
(n=57) 
p-value† 
Aldosterone (pmol/L) 113.8 (53.5 - 250.8) 181.5 (93.7 - 293.6) 0.132 
PRC (mIU/L) 34.2 (9.1 - 67.6) 42.8 (17.9 - 104.2) 0.036 
Aldosterone/PRC 3.2 (1.7 - 8.1) 3.9 (2.1 - 12.6) 0.307 
Haemoglobin (g/dl) 12 (10.3 - 13.3) 12 (10.9 - 13.4) 0.380 
Cardiovascular medication¶   
Diuretic  30 (52.6) 56 (98.2) <0.001 
Beta-blocker 28 (49.1) 29 (50.9) 1 
Digoxin 8 (14) 9 (15.8) 1 
Anti-arrhythmic   5 (8.8) 5 (8.8) 1 
Aspirin 32 (56.1) 33 (57.9) 1 
Statin 34 (59.6) 39 (68.4) 0.267 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
*ACE inhibitor/ARB or aldosterone blocker. 
 
† Wilcoxon matched pairs test was used for continuous variables and McNemars’s test was used for categorical 
variables. 
 
¶ medication prior to hospital admission for patients studied during admission. 
  
244
  
7.3.4.1 Baseline characteristics stratified by aldosterone to PRC median 
PRC levels were higher at follow-up compared with hospital admission. There was a trend for 
higher aldosterone levels and higher aldosterone to PRC ratio after discharge but that failed to 
reach statistical significance. Higher proportion of patients was treated with a diuretic after 
discharge compared with hospital admission. Moreover, the BNP and weight were lower at 
follow-up. In addition, the majority of patients were in NYHA class III during hospital 
admission and in NYHA class II at the follow-up visit. Finally, the SBP, pulse rate, CRP, 
cortisol and potassium were also lower and creatinine and sodium levels were higher after 
discharge compared with hospital admission. The disconnection between BNP levels and 
RAAS activity in these patients between hospital admission and the follow-up visit is 
presented in Figure 7-7 & Figure 7-8. 
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Figure 7-7. BNP and PRC levels during hospital admission and at follow-up 
 
 
 
 
Figure 7-8. BNP and aldosterone levels during hospital admission and at follow-up 
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7.4 Discussion 
 
7.4.1 Patients characteristics according to RAAS activity during follow-up  
Patients studied in this chapter were not taking a RAAS inhibitor at the follow-up visit. These 
patients were older and more often female compared with patients taking these agents at 
follow-up. These characteristics are more often seen in patients with HFpSF. Indeed, this 
group had higher LVEF at the follow-up visit with a higher proportion of patients having 
LVEF>45% compared with the group of patients taking a RAAS inhibitor. Although RAAS 
inhibitors have been one of the cornerstone treatments in patients with HFrSF, no definitive 
prognostic benefit has been shown with these agents in patients with HFpSF (368) (369) 
(370). Similar results regarding prognostic benefit in patients with HFpSF have been reported 
for beta-blockers (371) although adequate trial data are not currently available. The higher 
prevalence of patients with HFpSF and probable treatment of these patients according to 
evidenced-based practice might explain the lack of treatment with a RAAS inhibitor and the 
lower prescription of beta blockers in the group studied in this chapter. Moreover, lower 
prevalence of ischaemic heart disease (as reflected by less angina) and diabetes in this group, 
underlying diseases in which treatment with an ACE inhibitor or ARB is beneficial, might 
further explain the lack of treatment with RAAS inhibitors in some of these patients. 
However, the possibility that ischaemic heart disease and diabetes had an impact on the 
decision with regards to treatment with a RAAS inhibitor might apply mainly to patients with 
HFpSF, as patients with HFrSF benefit from RAAS inhibitors irrespective of the underlying 
disease. On the other hand, kidney function was worse in patients not taking a RAAS 
inhibitor at follow-up. It is likely that a number of patients in this group never started taking a 
RAAS due to kidney dysfunction or were commenced on a RAAS inhibitor after hospital 
admission but the treatment was discontinued due to worsening kidney function or electrolyte 
disturbances. Finally, hypotension or other less frequent side effects might also played a role 
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in the decision towards no treating some of the patients studied in this chapter with a RAAS 
inhibitor.   
 
Similar to the patients not treated with a RAAS inhibitor during hospital admission, 
aldosterone levels were higher in patients with higher PRC at the follow-up visit, indicating 
that renin angiotensin system continues to play a principal role in the regulation of 
aldosterone secretion in patients with stable HF. Patients with higher aldosterone levels also 
had higher cortisol levels after discharge. That is in agreement with previous findings (72) 
and could indicate that the HPA axis plays a role in the aldosterone secretion in patients with 
chronic HF. However, PRC was also higher in patients with higher cortisol levels in the 
current study, making it uncertain that there is an independent role of the HPA in aldosterone 
secretion in these patients. Renin is not involved in glucocorticoid secretion and the higher 
RAAS activity in patients with higher HPA activity might be viewed more as an association 
reflecting the severity of HF rather than a direct pathophysiological relationship.  
 
Patients with lower aldosterone to PRC ratio had higher PRC. These patients had features of 
more severe HF compared with patients with higher aldosterone to PRC ratio, as reflected by 
the NYHA functional class, the levels of BNP and kidney function markers as well as the 
prevalence of elevated troponin. Moreover, ischaemic heart disease was more prevalent in 
this group as indicated by the history of MI and angina. Overall, it appears that a lower 
aldosterone to renin ratio is more discriminating than a higher PRC in distinguishing patients 
not taking a RAAS inhibitor according to HF severity. Interestingly, despite the higher renin 
levels, aldosterone levels were lower in patients with lower aldosterone to renin ratio 
compared with patients with higher aldosterone to PRC ratio, suggesting that the activation of 
the renin angiotensin system did not result into a higher aldosterone secretion in the former 
group. That indicates that potential antagonists might partially counteract the aldosterone 
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secreting effects of RAAS in that group. Natriuretic peptides have been shown to suppress 
aldosterone synthase in vitro as well as to inhibit angiotensin II- and ACTH-induced 
aldosterone secretion in healthy subjects (125) (127) (372). BNP was higher in patients with 
lower aldosterone to PRC ratio and that may account for the lower aldosterone levels in these 
patients. These findings suggest that natriuretic peptides may have a more suppressing effect 
on the downstream rather than the upstream RAAS components and are in accordance with 
the finding that although aldosterone levels were normal, approximately half of patients at 
follow-up visit had elevated PRC. Moreover, they imply that in patients not treated with a 
RAAS inhibitor lower aldosterone to renin ratio may be a better indicator of HF severity than 
higher PRC, as it encompasses information not only related with the greater RAAS activity, 
but also with the expansion of the extravascular volume and raised natriuretic peptide levels 
as reflected by the lower aldosterone levels (in relation to renin) in these patients  
 
7.4.2 Change in RAAS activity from admission to follow-up 
At follow-up, patients not taking a RAAS inhibitor did not on average show activation of 
RAAS. Almost all patients had aldosterone levels within the normal range and approximately 
half of patients had normal PRC. However, in the small subset of patients who were not 
treated with a RAAS inhibitor both prior to admission and after discharge, PRC and 
aldosterone were higher at follow-up compared with hospital admission, reflecting a greater 
RAAS activation after discharge. Almost all patients were taking a diuretic at follow-up and 
this is likely to contribute to the higher RAAS activity. My findings are consistent with a 
prior study in patients with moderate HF not treated with a RAAS inhibitor or diuretic, in 
which plasma renin and aldosterone levels were well within the normal range (57). In that 
study, treatment with low dose furosemide and amiloride for four weeks resulted in a 
significant increase in both renin and aldosterone levels. Similarly, plasma renin levels were 
reported to be normal in patients with mild HF and increased following administration of 
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diuretics (60). Likewise, PRC was elevated only in patients with LVSD with or without HF 
who were treated with diuretics in the SOLVD study (61).  
 
At follow-up, RAAS activation was present despite the improvement in clinical status and a 
fall in BNP levels. That is in accordance with previous findings in patients with HF following 
initiation of diuretic therapy (358) (367) (373) and shows that in my patients the 
disconnection between BNP and RAAS activity persists at least 4 to 6 weeks after diuretic 
therapy. Patients lost approximately 4kgs of weight after discharge due to the effective 
diuresis, which reduces the extracellular volume. That in turn increases RAAS activity and 
reduces BNP levels. Moreover, as natriuretic peptides suppress the secretion of renin and 
aldosterone (65), the decline in BNP levels might have additionally contributed to the greater 
RAAS activity seen 4 to 6 weeks after discharge. 
 
RAAS activation due to diuretics can be detrimental in the long term. Angiotensin II, apart 
from its vasoconstricting effects, promotes vascular and myocardial remodeling (374) (375). 
On the other hand aldosterone induces endothelial dysfunction, vascular inflammation and 
myocardial fibrosis. RAAS activity in patients not receiving an ACE inhibitor or ARB has 
been associated with worse prognosis in patients with HF (356). Conversely, the inhibition of 
the RAAS with an ACE inhibitor as monotherapy or in combination with an ARB or an 
aldosterone blocker has become one of the cornerstones of therapy in patients with HF and 
LVSD. However, over the course of HF, reactivation of the RAAS might override RAAS 
inhibition leading to further progression of HF. Thus, in patients with HF an additional 
treatment approach, which preferably inhibits renin on top of a RAAS inhibitor (and a beta-
blocker), might be of additional benefit. Aliskiren, a direct renin inhibitor, exerts favorable 
effects on neurohumoral activation and is currently being examined with respect to survival 
benefit, either as an alternative or in combination with another RAAS inhibitor, in patients 
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with chronic HF (376). Nevertheless, aliskiren on top of standard medical treatment in 
patients hospitalised with worsening HFrSF had no effect on cardiovascular mortality or HF 
hospitalisation at 6 or 12 months after discharge in the Aliskiren Trial on Acute Heart Failure 
Outcomes (ASTRONAUT) (377). Treatment with aliskiren reduced the natriuretic peptide 
levels, however, that did not translate in better outcomes. On the other hand, aliskiren 
increased the incidence of adverse events such as hypotension, hyperkalaemia and renal 
impairment. Interestingly, a subgroup analysis for the composite end point of cardiovascular 
mortality or HF hospitalisation and also for all-cause mortality at 12 months showed 
statistically significantly poorer outcomes in diabetics compared with non-diabetics treated 
with aliskiren. Future studies will reveal if non-diabetics with HF will benefit from add-on 
therapy with aliskiren in combination with other RAAS inhibitors.  
 
Augmentation of the action of natriuretic peptides might offer another therapeutic option in 
patients with chronic HF, as these peptides suppress RAAS and SNS besides the diuretic and 
vasodilating effects. Inhibition of the degradation of natriuretic peptides in combination with 
an ACE inhibitor was previously examined in HF patients and showed beneficial effects; 
however, it was not further developed due to adverse effects (angioedema) related to 
accumulation of bradykinin (378) (379). Blockade of natriuretic peptides breakdown in 
combination with an ARB instead of an ACE inhibitor is being currently tested in patients 
with HF and might provide an additional treatment approach (380). 
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8. Chapter Eight - 11-deoxycortisol and cortisol 
levels during hospital admission 
in patients not taking a RAAS inhibitor  
or oral glucocorticoid therapy  
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8.1 Introduction 
The glucocorticoid hormone cortisol, which plays a pivotal role in metabolism, inflammation 
and immunity has been increasingly recognised to participate in cardiovascular processes 
(381) and has also been associated with cardiovascular mortality in the general population 
(319). In the cardiovascular spectrum, the secretion of cortisol has been mainly studied in 
patients with hypertension and MI (320) (382). In patients with HF, cortisol has been 
independently associated with all-cause mortality, cardiovascular mortality or hospitalisation 
for HF (72) (73). Although the above relationships are generally considered to reflect the 
stress response in the context of the severity of HF, it has additionally been suggested that 
cortisol is involved in the pathophysiology of HF progression (section 1.5.1). The latter may 
gain additional importance in patients with HF as previous studies showed that aldosterone 
blockers increase cortisol levels in these patients (383).  
 
Despite the increasing evidence about the importance of cortisol in the prognosis and 
pathophysiology of HF, the secretion of glucocorticoids, has not been extensively examined, 
especially in relation to the RAAS and other components of the neurohumoral activation, in 
patients with HF. The main aim of this chapter is to examine the characteristics and markers 
of HF severity, including RAAS mediators, according to glucocorticoid levels in patients 
admitted with decompensated HF. The glucocorticoids measured were plasma 11-
deoxycortisol and cortisol. The 11-deoxycortisol to cortisol ratio was additionally calculated. 
Taking into account the inhibiting effects of oral glucocorticoids on cortisol levels and 
previous studies reporting that aldosterone blockers increase cortisol levels, I have included 
patients taking none of an oral glucocorticoid or a RAAS inhibitor in this study. In this way, 
the confounding effect of RAAS inhibitors on the levels of RAAS mediators has also been 
removed in the analyses of RAAS activity according to glucocorticoid levels in these 
patients.  
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8.2 Methods 
 
8.2.1 Study participants and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in sections 2.3.1 & 2.3.2. Only patients not taking a RAAS inhibitor (ACE inhibitor/ARB or 
aldosterone blocker) or oral glucocorticoid therapy prior to hospitalisation were included in 
the current study. All patients had blood samples taken during morning hours between 8-
11am.  
 
8.2.2 Statistical analysis 
All patient characteristics were expressed as median (IQR) for continuous and as absolute 
number (percentage) for categorical variables. The inter-group comparisons were carried out 
by the Mann-Whitney and Kruskal-Wallis test for continuous variables as appropriate and by 
the χ2 test for categorical variables. A p-value <0.05 was considered significant for all 
analyses. Statistical analyses were performed with Minitab version 15.  
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8.3 Results 
 
8.3.1 Patient characteristics during hospital admission stratified by treatment with a 
RAAS inhibitor or oral glucocorticoid therapy 
Of the 722 patients enrolled, 451 were taking a RAAS inhibitor or oral glucocorticoid therapy 
and 271 were not taking either a RAAS inhibitor or oral glucocorticoid therapy prior to 
hospital admission (Table 8-1). 
 
Patients not taking a RAAS inhibitor or an oral glucocorticoid were more often female and 
were less likely to have a history of previous HF, MI, angina, DM, or hypertension compared 
with patients taking a RAAS inhibitor or an oral glucocorticoid and patients of the overall 
hospitalised cohort. The weight, urea and creatinine were significantly lower and the pulse 
rate, SBP and DBP, haemoglobin and cholesterol were significantly higher in the first group 
compared with the other two groups. Diuretics, beta-blockers and statins were less often 
prescribed prior to admission in patients not taking a RAAS inhibitor or glucocorticoid 
therapy.  
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8.3.2 Levels of glucocorticoids during hospital admission  
Levels of plasma 11-deoxycortisol and cortisol, and the 11-deoxycortisol to cortisol ratio, 
during hospital admission are presented below.  
 
8.3.2.1 11-deoxycortisol 
An 11-deoxycortisol level measured during hospital admission was available in 220 of the 
271 patients.  The median (IQR) 11-deoxycortisol was 493.6 (290.1 – 946.5) pmol/L (Figure 
8-1) and the mean (SD) 11-deoxycortisol was 806.8 (977) pmol/L. A frequency distribution 
histogram of 11-deoxycortisol levels in these patients is displayed in Figure 8-2. The 
minimum 11-deoxycortisol concentration was 23.4 pmol/L and the maximum 11-
deoxycortisol concentration was 7008.7 pmol/L. The majority of patients (91%) had 11-
deoxycortisol levels within the normal range (0 – 2017 pmol/L). 
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Figure 8-1. Box and whisker plot of 11-deoxycortisol concentrations showing the 2.5, 25, 
50, 75 and 97.5
 
centiles 
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Figure 8-2. Frequency distribution histogram of 11-deoxycortisol concentrations 
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8.3.2.2 Cortisol 
A cortisol level measured during hospital admission was available in 225 of the 271 patients. 
The median (IQR) cortisol was 336.4 (246.5 – 450.0) nmol/L (Figure 8-3) and the mean (SD) 
cortisol was 354.6 (158.2) nmol/L. A frequency distribution histogram of cortisol levels in 
these patients is displayed in Figure 8-4. The minimum cortisol concentration was 6.6 nmol/L 
and the maximum cortisol concentration was 757.1 nmol/L. All patients (100%) had cortisol 
levels within the normal range (0 – 823nmol/L). 
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Figure 8-3. Box and whisker plot of cortisol concentrations showing the 2.5, 25, 50, 75 
and 97.5
 
centiles 
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8.3.2.3 11-deoxycortisol to cortisol ratio 
An 11-deoxycortisol to cortisol ratio could be calculated for 220 of the 271 patients studied. 
The median (IQR) 11-deoxycortisol to cortisol ratio was 1.64 (0.98 – 2.88) x10-3 (Figure 8-5) 
and the mean (SD) 11-deoxycortisol to cortisol ratio was 2.32 (2.39) x10
-3
. A frequency 
distribution histogram of 11-deoxycortisol to cortisol ratio in these patients is displayed in 
Figure 8-6. The minimum 11-deoxycortisol to cortisol ratio was 0.07 x10
-3
 and the maximum 
11-deoxycortisol to cortisol ratio was 22.33 x10
-3
. 
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Figure 8-5. Box and whisker plot of 11-deoxycortisol to cortisol ratio showing the 2.5, 25, 
50, 75 and 97.5 centiles 
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8.3.3 Patient characteristics according to glucocorticoid levels 
The characteristics of the 271 patients not taking a RAAS inhibitor or oral glucocorticoid 
therapy were stratified according to the levels of 11-deoxycortisol and cortisol and the 11-
deoxycortisol to cortisol ratio during hospital admission. 
 
8.3.3.1 Patient characteristics according to 11-deoxycortisol levels 
The group of 220 patients with measured 11-deoxycortisol levels was divided into four 
subgroups, according to the median 11-deoxycortisol and the 25
th
 and 75
th
 centiles. Such 
quartiles were respectively defined by 11-deoxycortisol levels <290.1 pmol/L, 290.1 to 493.5 
pmol/L, 493.6 to 946.4 pmol/L and ≥ 946.5 pmol/L (Table 8-2).   
 
Compared with those in the highest 11-deoxycortisol quartile, participants in the lowest 
quartile were more likely to have lower cortisol, 11-deoxycortisol to cortisol ratio and lower 
SBP. Patients in the lowest 11-deoxycortisol quartile were also more likely to have dilated 
left ventricle and larger LVEDD and were less likely to have LVH on the transthoracic 
echocardiogram. In addition, a trend for higher PRC and BNP and lower aldosterone was 
evident in these patients compared to patients with higher 11-deoxycortisol concentrations. 
  
266
  T
a
b
le
 8
-2
. 
C
h
a
ra
ct
er
is
ti
cs
 o
f 
p
a
ti
en
ts
 n
o
t 
ta
k
in
g
 a
 R
A
A
S
 i
n
h
ib
it
o
r*
 o
r 
o
ra
l 
g
lu
co
co
rt
ic
o
id
 t
h
er
a
p
y
 a
cc
o
rd
in
g
 t
o
 1
1
-d
eo
x
y
co
rt
is
o
l 
q
u
a
rt
il
es
 
V
a
ri
a
b
le
 
Q
1
 
(n
=
5
5
) 
Q
2
 
(n
=
5
5
) 
Q
3
 
(n
=
5
5
) 
Q
4
 
(n
=
5
5
) 
p
-v
a
lu
e†
 
A
g
e 
(y
ea
rs
) 
7
3
 (
6
2
 –
 8
0
) 
7
5
 (
6
4
 –
 8
3
) 
 
7
5
 (
6
7
 –
 8
2
) 
7
6
 (
6
9
 –
 8
6
) 
0
.3
0
4
 
F
em
al
e 
g
en
d
er
 
3
2
 (
5
8
.2
) 
3
1
 (
5
5
.4
) 
2
6
 (
4
7
.3
) 
2
7
 (
4
9
.1
) 
  
0
.6
2
5
 
N
Y
H
A
 c
la
ss
 
 
 
 
 
 
II
 
1
6
 (
2
9
.1
) 
1
4
 (
2
5
.5
) 
1
6
 (
2
9
.1
) 
1
5
 (
2
7
.3
) 
0
.9
6
9
 
II
I 
3
1
 (
5
6
.4
) 
3
7
 (
6
7
.3
) 
3
1
 (
5
6
.4
) 
2
8
 (
5
0
.9
) 
0
.3
6
4
 
IV
 
8
 (
1
4
.6
) 
4
 (
7
.3
) 
8
 (
1
4
.6
) 
1
2
 (
2
1
.8
) 
0
.1
9
7
 
M
ed
ic
a
l 
h
is
to
ry
 
 
 
 
 
 
H
F
 
1
1
 (
2
0
) 
1
8
 (
3
2
.7
) 
1
3
 (
2
3
.6
) 
1
6
 (
2
9
.1
) 
0
.4
3
8
 
M
I 
1
1
 (
2
0
) 
1
8
 (
3
2
.7
) 
1
9
 (
3
4
.6
) 
2
1
 (
3
8
.2
) 
0
.1
8
8
 
A
n
g
in
a 
2
1
 (
3
8
.2
) 
2
5
 (
4
5
.5
) 
2
5
 (
4
5
.5
) 
2
3
 (
4
1
.8
) 
0
.8
4
5
 
D
ia
b
et
es
 m
el
li
tu
s 
1
2
 (
2
1
.8
) 
9
 (
1
6
.4
) 
6
 (
1
0
.9
) 
1
4
 (
2
5
.5
) 
0
.2
2
1
 
H
y
p
er
te
n
si
o
n
 
2
8
 (
5
0
.9
) 
3
3
 (
6
0
) 
3
3
 (
6
0
) 
3
3
 (
6
0
) 
0
.7
0
6
 
A
F
 
2
3
 (
4
1
.8
) 
3
0
 (
5
4
.6
) 
2
9
 (
5
2
.7
) 
3
2
 (
5
8
.2
) 
0
.3
5
1
 
C
V
A
/T
IA
 
6
 (
1
0
.9
) 
1
2
 (
2
1
.8
) 
1
0
 (
1
8
.2
) 
1
5
 (
2
7
.3
) 
0
.1
7
6
 
P
h
y
si
o
lo
g
ic
a
l 
m
ea
su
re
m
en
ts
 
 
 
 
 
 
B
M
I 
(k
g
/m
2
) 
2
4
.6
 (
2
2
.1
 –
 3
0
.1
) 
2
8
.0
 (
2
4
.4
 –
 3
1
.5
) 
 
2
6
.5
 (
2
2
.7
 -
  
3
2
.8
) 
2
7
.1
 (
2
2
.6
 –
 3
3
.8
) 
 
0
.3
5
8
 
P
u
ls
e 
ra
te
 (
b
p
m
) 
9
3
 (
7
7
 –
 1
1
0
) 
9
6
 (
8
0
 –
 1
1
0
) 
 
9
4
 (
7
2
 -
 1
1
6
) 
8
8
 (
7
0
 -
 1
0
4
) 
 
0
.3
2
6
 
S
B
P
 (
m
m
H
g
) 
1
3
0
 (
1
1
4
 –
 1
4
0
) 
1
4
0
 (
1
1
8
 –
 1
6
0
) 
1
4
0
 (
1
2
5
 –
 1
6
2
) 
1
3
8
 (
1
2
2
 –
 1
5
6
) 
 
0
.0
0
8
 
D
B
P
 (
m
m
H
g
) 
7
2
 (
6
4
 –
 8
3
) 
8
1
 (
6
6
 –
 9
5
) 
8
6
 (
7
5
 –
 9
2
) 
7
7
 (
6
2
 –
 9
5
) 
0
.0
2
0
 
267
  V
a
ri
a
b
le
 
Q
1
 
(n
=
5
5
) 
Q
2
 
(n
=
5
5
) 
Q
3
 
(n
=
5
5
) 
Q
4
 
(n
=
5
5
) 
p
-v
a
lu
e†
 
S
ig
n
s 
o
f 
fl
u
id
 c
o
n
g
es
ti
o
n
 
 
 
 
 
 
E
le
v
at
ed
 J
V
P
 
 3
6
 (
7
3
.5
) 
  
 4
0
 (
8
0
) 
  
  
3
7
 (
7
8
.7
) 
  
4
2
 (
8
2
.4
) 
  
  
  
  
  
0
.7
4
0
 
P
er
ip
h
er
al
 o
ed
em
a 
 3
9
 (
7
0
.9
) 
  
 4
4
 (
7
8
.6
) 
  
  
4
1
 (
7
5
.6
) 
  
3
9
 (
7
0
.9
) 
  
  
  
  
  
0
.7
6
0
 
E
C
G
 r
h
y
th
m
 
 
 
 
 
 
S
R
 
3
2
 (
5
8
.2
) 
2
9
 (
5
2
.7
) 
3
0
 (
5
4
.6
) 
3
0
 (
5
4
.6
) 
0
.9
5
1
 
A
F
 
2
1
 (
3
8
.2
) 
2
3
 (
4
1
.8
) 
2
2
 (
4
0
.0
) 
2
4
 (
4
3
.6
) 
0
.9
4
5
 
E
ch
o
ca
rd
io
g
ra
p
h
y
 m
ea
su
re
m
en
ts
 
 
 
 
 
L
V
E
D
D
 (
cm
) 
5
.6
 (
4
.9
 –
 6
.2
) 
5
.2
 (
4
.4
 –
 5
.6
) 
5
.1
 (
4
.6
 –
 5
.9
) 
5
.0
 (
4
.5
 –
 5
.5
) 
 
0
.0
1
4
 
D
il
at
ed
 l
ef
t 
v
en
tr
ic
le
 
2
4
 (
5
4
.6
) 
1
6
 (
3
4
.8
) 
1
6
 (
3
4
.8
) 
1
0
 (
2
3
.8
) 
0
.0
2
8
 
L
V
H
 
1
1
 (
2
5
) 
2
4
 (
5
3
.3
) 
2
2
 (
4
7
.8
) 
2
2
 (
5
2
.4
) 
0
.0
2
4
 
L
V
S
D
 
3
1
 (
7
0
.5
) 
2
7
 (
5
8
.7
) 
3
4
 (
7
3
.9
) 
2
7
 (
6
4
.3
) 
0
.4
2
4
 
L
a
b
o
ra
to
ry
 m
ea
su
re
m
en
ts
 (
b
lo
o
d
) 
 
 
 
 
B
N
P
 (
p
g
/m
l)
 
1
0
3
2
 (
5
3
1
 –
 2
1
9
3
) 
 
8
4
1
 (
3
6
5
 –
 1
5
1
2
) 
 
9
5
6
 (
4
0
5
 –
 1
8
6
9
) 
6
9
4
 (
3
7
3
 –
 2
0
1
0
) 
0
.7
3
2
 
T
ro
p
o
n
in
 I
 ≥
 0
.0
4
 (
µ
g
/L
)*
*
 
2
5
 (
5
4
.4
) 
2
7
 (
5
7
.5
) 
2
7
 (
6
0
.0
) 
2
7
 (
5
8
.7
) 
0
.9
5
5
 
S
o
d
iu
m
 (
m
m
o
l/
L
) 
1
3
7
 (
1
3
3
 –
 1
4
1
) 
 
1
3
8
 (
1
3
5
 –
 1
4
0
) 
1
3
9
 (
1
3
6
 –
 1
4
1
) 
1
3
8
 (
1
3
5
 –
 1
4
1
) 
 
0
.6
0
6
 
P
o
ta
ss
iu
m
 (
m
m
o
l/
L
) 
4
.1
 (
3
.9
 –
 4
.5
) 
4
.2
 (
3
.9
 –
 4
.5
) 
 
4
.0
 (
3
.8
 –
 4
.3
) 
4
.1
 (
3
.7
 –
 4
.6
) 
 
0
.5
1
7
 
U
re
a 
(m
m
o
l/
L
) 
8
.0
 (
6
.2
 –
 1
0
.7
) 
7
.5
 (
5
.0
 –
 1
1
.0
) 
 
8
.4
 (
5
.9
 –
 1
0
.7
) 
 
8
.1
 (
6
.0
 –
 1
1
.8
) 
0
.5
4
0
 
C
re
at
in
in
e 
(µ
m
o
l/
L
) 
9
7
 (
7
9
 –
 1
3
0
) 
  
1
0
1
 (
8
5
 –
 1
3
3
) 
1
0
8
 (
7
9
 –
 1
3
9
) 
9
7
 (
8
2
 –
 1
2
9
) 
 
0
.8
6
7
 
eG
F
R
 (
m
l/
m
in
/1
.7
3
m
2
) 
6
0
 (
4
2
 –
 6
0
) 
5
6
 (
4
0
 –
 6
0
) 
5
7
 (
4
4
 –
 6
0
) 
6
0
 (
4
3
 –
 6
0
) 
0
.7
6
3
 
eG
F
R
 <
6
0
m
l/
m
in
/1
.7
3
m
2
 
2
7
 (
4
9
.1
) 
3
3
 (
6
0
) 
3
0
 (
5
4
.6
) 
2
6
 (
4
7
.3
) 
0
.5
3
4
 
268
  V
a
ri
a
b
le
 
Q
1
 
(n
=
5
5
) 
Q
2
 
(n
=
5
5
) 
Q
3
 
(n
=
5
5
) 
Q
4
 
(n
=
5
5
) 
p
-v
a
lu
e†
 
C
h
o
le
st
er
o
l 
(t
o
ta
l)
 (
m
m
o
l/
L
) 
4
.2
 (
3
.5
 –
 4
.9
) 
4
.3
 (
3
.5
 –
 5
.0
) 
3
.7
 (
3
.4
 -
 4
.4
) 
4
.4
 (
3
.2
 –
 5
.2
) 
0
.3
3
6
 
H
D
L
 (
m
m
o
l/
L
) 
1
.0
 (
0
.8
 –
 1
.4
) 
1
.1
 (
0
.9
 –
 1
.4
) 
 
1
.0
 (
0
.8
 –
 1
..
2
) 
1
.1
 (
0
.9
 –
 1
.5
) 
0
.6
0
5
 
C
R
P
 (
m
g
/L
) 
1
4
 (
7
 –
 3
8
) 
1
2
 (
7
 –
 2
9
) 
 
1
4
 (
6
 –
 2
6
) 
1
4
.5
 (
6
 –
 4
8
) 
0
.7
8
7
 
C
o
rt
is
o
l 
(n
m
o
l/
L
) 
2
6
5
.5
(1
4
1
.3
 –
 3
3
0
.9
) 
3
0
5
.8
 (
2
1
9
.1
 –
 3
8
9
.4
) 
3
6
2
.7
 (
3
0
4
.4
 –
 4
5
6
.0
) 
4
6
0
.9
 (
3
9
2
.2
 –
 5
9
5
.9
) 
<
0
.0
0
1
 
1
1
-d
eo
x
y
co
rt
is
o
l/
co
rt
is
o
l 
(1
0
-3
) 
0
.7
2
 (
0
.4
6
 –
 1
.1
1
) 
1
.3
5
 (
0
.9
6
 –
 1
.7
3
) 
1
.6
8
 (
1
.3
6
 –
 2
.5
2
) 
 
3
.7
2
 (
2
.8
5
 –
 4
.8
8
) 
<
0
.0
0
1
 
A
ld
o
st
er
o
n
e 
(p
m
o
l/
L
) 
6
2
.0
 (
2
8
.4
 –
 1
6
9
.2
) 
8
0
.1
 (
3
9
.0
 –
 1
9
0
.0
) 
 
1
0
0
.6
 (
5
1
.0
 –
 1
7
1
.4
) 
 
7
8
.4
 (
5
1
.9
 –
 2
2
2
.1
) 
0
.5
0
9
 
P
R
C
 (
m
IU
/L
) 
3
9
.5
 (
1
2
.4
 –
 9
1
.0
) 
2
8
.9
 (
1
0
.4
 –
 1
0
3
.3
) 
1
8
.9
 (
9
.0
 –
 4
8
.9
) 
2
3
.2
5
 (
7
.9
 –
 7
4
.8
) 
0
.2
1
5
 
A
ld
o
st
er
o
n
e/
P
R
C
 
2
.7
1
 (
0
.5
8
 –
 6
.1
7
) 
2
.3
5
 (
0
.9
1
 -
 4
.5
1
) 
3
.9
8
 (
1
.3
5
 –
 1
0
.6
6
) 
4
.0
 (
1
.4
7
 –
 1
0
.2
0
) 
0
.0
5
1
 
T
S
H
 (
m
IU
/L
) 
2
.0
 (
0
.9
 –
 3
.3
) 
1
.8
 (
1
.3
 –
 2
.5
) 
1
.9
 (
1
.2
 –
 3
.0
) 
 
1
.6
 (
1
.0
 –
 2
.1
) 
0
.5
3
2
 
H
ae
m
o
g
lo
b
in
 (
g
/d
l)
 
1
2
.2
 (
1
0
.4
 –
 1
3
.4
) 
1
3
.0
 (
1
1
.5
 –
 1
4
.5
) 
1
2
.5
 (
1
0
.7
 –
 1
4
.1
) 
1
2
.5
 (
1
0
.7
 –
 1
3
.6
) 
0
.2
3
9
 
C
a
rd
io
v
a
sc
u
la
r 
m
ed
ic
a
ti
o
n
 p
ri
o
r 
to
 a
d
m
is
si
o
n
 
 
 
 
 
D
iu
re
ti
c 
 
3
0
 (
5
4
.6
) 
3
0
 (
5
4
.6
) 
2
9
 (
5
2
.7
) 
2
9
 (
5
2
.7
) 
0
.9
9
5
 
B
et
a-
b
lo
ck
er
 
1
6
 (
2
9
.1
) 
2
0
 (
3
6
.4
) 
2
2
 (
4
0
.0
) 
2
6
 (
4
7
.3
) 
0
.2
6
1
 
D
ig
o
x
in
 
5
 (
9
.1
) 
1
2
 (
2
1
.8
) 
5
 (
9
.1
) 
9
 (
1
6
.4
) 
0
.1
5
6
 
A
n
ti
-a
rr
h
y
th
m
ic
  
 
0
 (
0
) 
3
 (
5
.5
) 
4
 (
7
.3
) 
3
 (
5
.5
) 
0
.2
8
7
 
A
sp
ir
in
 
2
1
 (
3
8
.2
) 
3
0
 (
5
4
.6
) 
2
4
 (
4
3
.6
) 
2
9
 (
5
2
.7
) 
0
.2
6
8
 
S
ta
ti
n
 
2
2
 (
4
0
) 
2
7
 (
4
9
.1
) 
2
8
 (
5
0
.9
) 
2
8
 (
5
0
.9
) 
0
.6
1
4
 
C
o
n
ti
n
u
o
u
s 
v
ar
ia
b
le
s 
ar
e 
p
re
se
n
te
d
 a
s 
m
ed
ia
n
 (
IQ
R
).
 C
at
e
g
o
ri
ca
l 
v
ar
ia
b
le
s 
ar
e 
p
re
se
n
te
d
 a
s 
n
u
m
b
er
 (
p
er
ce
n
ta
g
e)
. 
*
 A
C
E
 i
n
h
ib
it
o
r/
A
R
B
 o
r 
al
d
o
st
er
o
n
e 
b
lo
ck
er
 
†
 K
ru
sk
al
-W
al
li
s 
te
st
 w
a
s 
u
se
d
 f
o
r 
co
n
ti
n
u
o
u
s 
v
ar
ia
b
le
s 
an
d
 χ
2
 te
st
 f
o
r 
ca
te
g
o
ri
ca
l 
v
ar
ia
b
le
s.
 
*
*
m
ea
su
re
d
 a
t 
W
IG
 a
n
d
 G
R
I 
 
269
  
8.3.3.2 Patient characteristics according to cortisol levels 
The group of 225 patients with measured cortisol levels was divided into four subgroups, 
according to the median cortisol and the 25
th
 and 75
th
 centiles. Such quartiles were 
respectively defined by cortisol levels <246.5 nmol/L, 246.5 to 336.3 nmol/L, 336.4 to 449.9 
nmol/L and ≥ 450.0 nmol/L (Table 8-3).   
 
Compared with those in the lowest cortisol quartile, participants in the highest quartile were 
more likely to have higher 11-deoxycortisol. Patients in the highest cortisol quartile were also 
more likely to have elevated troponin I compared with patients in the lowest cortisol quartile. 
Apart from the above differences, a trend for higher BNP, urea, creatinine and CRP and 
smaller LVEDD was present in patients with higher cortisol levels. These patients were also 
more often in NYHA class IV and less often in NYHA class II compared to patients with 
lower cortisol levels.   
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8.3.3.3 Patient characteristics according to 11-deoxycortisol to cortisol ratio  
The group of 220 patients with calculated 11-deoxycortisol to cortisol ratio was divided into 
four subgroups, according to the median 11-deoxycortisol to cortisol ratio and the 25
th
 and 
75
th
 centiles. Such quartiles were respectively defined by 11-deoxycortisol to cortisol <0.98 
x10
-3
, 0.98 x10
-3
 to 1.63 x10
-3
, 1.64 x10
-3
 to 2.87 x10
-3
 and ≥ 2.88 x10-3 (Table 8-4). 
 
Compared with those in the highest 11-deoxycortisol to cortisol ratio quartile, participants in 
the lowest quartile were more likely to have lower 11-deoxycortisol, aldosterone to PRC 
ratio, SBP and sodium and higher PRC, BNP and CRP. Patients in the lowest 11-
deoxycortisol to cortisol quartile were also more likely to have dilated left ventricle and were 
less likely to have LVH on the transthoracic echocardiogram.  In addition, there was a trend 
for larger LVEED, higher prevalence of LVSD and elevated troponin in patients with lower 
11-deoxycortisol to cortisol ratio.  
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8.4 Discussion 
 
8.4.1 Patient characteristics according to glucocorticoid secretion during hospital 
admission 
The levels of 11-deoxycortisol, cortisol and the 11-deoxycortisol to cortisol ratio in the subset 
of patients not taking a RAAS inhibitor or oral glucocorticoid therapy were similar to the 
relevant glucocorticoid levels and their ratio in the overall hospitalised cohort. The levels of 
cortisol were higher in patients with higher 11-deoxycortisol concentrations. That is not 
surprising taking into account that the last step in cortisol synthesis in ZF involves the 
11beta- hydroxylation of 11-deoxycortisol, which is the immediate precursor of cortisol in 
adrenal steroidogenesis (section 1.2.1). Although cortisol levels in my patients were within 
the so called “normal range”, there was a clear gradient in severity of HF according to 
cortisol levels with patients with higher levels having worse clinical and prognostic features. 
Patients with higher cortisol were more likely to have elevated troponin during follow-up, 
which reflects the degree of myocardial necrosis. A direct link between glucocorticoids and 
myocardial necrosis in patients with HF has not been demonstrated and the above association 
may reflect the severity of HF in these patients. Indeed, patients in the highest cortisol 
quartile were more often in NYHA IV and less likely in NYHA class II compared to patients 
in the lowest cortisol quartile. Correspondingly, patients with higher cortisol levels were 
more likely to have, apart from elevated troponin, higher BNP and LVSD. In keeping with 
these findings, cortisol has been previously associated with norepinephrine in patients with 
HF (72), which is an independent prognostic indicator in HF (384).  
 
Whether some of the relationships between cortisol and established prognostic markers, 
however, represent a cause-and-effect relationship cannot be excluded. As described in 
section 1.3.5, glucocorticoids exert deleterious effects on the cardiovascular system either by 
activating the GRs or through the activation of the MRs under conditions of altered 
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intracellular redox state. Moreover, it has been suggested that normal cortisol levels are 
sufficient to activate MR and exert detrimental non-epithelial effects in patients with HF (72). 
MR activation is associated with peri-vascular inflammation, myocardial necrosis and 
apoptosis and these effects might represent a possible link for the observed association 
between cortisol and troponin. In addition, cortisol exerts mineralocorticoid epithelial effects 
under circumstances of impaired metabolism by 11beta-HSD2 (385) (386). A decline in the 
expression and activity of 11beta-HSD2 in the kidneys has been reported in patients with 
chronic kidney disease (387). More than half of patients in my study had eGFR <60 
ml/min/1.73m
2
; thus, a possible glucocorticoid-induced MR activation in kidneys may lead to 
an increase in the extravascular volume and potentially to higher natriuretic peptide levels.  
 
Overall, the associations between markers of HF severity and cortisol were present despite 
the normal on average glucocorticoid levels, providing, thus, the rationale to rethink what we 
mean by “normal” levels of cortisol in patients with HF. 
 
Interestingly, patients with lower 11-deoxycortisol to cortisol ratio were more likely to have 
higher PRC. In addition, these patients were more likely to have dilated left ventricle (and less 
likely to have LVH), representing a group of patients at a more progressed stage of LV 
remodeling. Moreover, similar to patients with higher PRC (section 6.3.3.2) they had lower 
SBP and sodium and higher BNP. The reasons for the above findings are not clear. It is 
generally accepted that 11-deoxycortisol to cortisol ratio represents an index of 11beta-
hydroxylase activity and a lower 11-deoxycortisol to cortisol ratio reflects a higher activity of 
this enzyme; 11-deoxycortisol under these circumstances is utilised more efficiently, with 
less leakage into the bloodstream, by 11beta-hydroxylase for the formation of the cortisol. 
Hence, greater amounts of cortisol, are secreted into the circulation in relation to 11-
deoxycortisol. 11beta-hydroxylase is an ACTH dependent enzyme and its activity reflects the 
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HPA axis stimulation. Indeed, chronic ACTH activation has been shown to up-regulate the 
late phase of cortisol biosynthesis with augmentation in the conversion of 11-deoxycortisol to 
cortisol (388) (389). Moreover, ACTH exerts trophic effects on 11beta-hydroxylase and also 
causes adrenocortical cell hypertrophy with increase in the number of mitochondria, where 
the conversion of 11-deoxycortisol to cortisol takes place (390) (391). In patients with 
chronic ACTH excess and Cushing disease, however, the levels of cortisol precursors were 
found to lie within or below the normal range (392). Likewise, in hypophysectomised rats 
models ACTH enhanced the conversion of DOC to corticosterone, indicating an up-
regulation of the 11beta-hydroxylase activity (393). In contrast, acute stimulation with ACTH 
produces elevation in both cortisol and its precursors (388) (394).  
 
These insights into the physiology of glucocorticoid secretion suggest that patients with 
higher 11beta-hydroxylase activity, which is likely due to chronic HPA axis activation, had 
higher RAAS activity, worse LV remodeling and lower blood pressure. It is important to note 
that the above associations were also present in the overall hospitalised cohort (Table 13-8 in 
the Appendix). Various pathways might contribute to the HPA activation in these patients. 
Haemodynamically stressful stimuli, such as low blood pressure, might contribute to ACTH 
stimulation (395). In addition, a general inflammatory state, as reflected by the higher CRP, 
is associated with up-regulation of cytokine expression, which in turn can potentially 
stimulate ACTH secretion (396) (397). Moreover, the SNS also participates in the regulation 
of cortisol secretion mainly through the autonomic innervation of the adrenal cortex (398). 
Thus, in patients with HF, apart from RAAS (and the SNS) activation, HPA axis activation 
may represent an additional pathway of the adaptive neurohumoral responses.  
 
The findings of the current study suggest that inhibition of 11beta-hydroxylase and lowering 
of cortisol levels might be of benefit in patients with HF. Aldosterone synthase inhibitors 
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apart from suppressing aldosterone levels, inhibit partially 11beta-hydroxylase (350) (351). 
The latter effect is not associated with lower cortisol levels but with suppression of ACTH-
induced release of cortisol in patients with essential hypertension. That might be of clinical 
benefit in patients with HF according to the findings in my study, as patients with features of 
worse HF had higher 11beta-hydroxylase activity, presumably due to chronic ACTH 
stimulation. Hence, suppression of both mineralocorticoid and glucocorticoid secretion with 
these agents may provide additional therapeutic opportunities in patients with HF. However, 
in contrast to the appealing theoretical effects, the safety of these agents may be 
compromised under acute conditions, where the stress response is clinically useful. A study 
examining the safety and efficacy of aldosterone synthase inhibitors in patients with HF will 
provide information with respect to theoretical benefits and concerns. 
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9. Chapter Nine - 11-deoxycortisol and cortisol 
levels at follow-up in patients not taking a 
RAAS inhibitor or oral glucocorticoid 
therapy  
  
282
  
9.1 Introduction 
 
The main aim of this chapter is to examine if the associations among glucocorticoid levels, 
RAAS activation and markers of HF severity seen in patients with decompensated HF are 
present in patients with stable HF not taking an oral glucocorticoid and a RAAS inhibitor at 
the follow-up visit. In this chapter, I also compare the levels of glucocorticoids measured 
during hospital admission and after discharge in patients not receiving oral glucocorticoid 
therapy or a RAAS inhibitor at both time points. 
 
9.2 Methods 
 
9.2.1 Study participants and laboratory measurements 
Details of the study participants and the laboratory measurements were presented previously 
in 2.4.1 & 2.4.2. Only patients not receiving a RAAS inhibitor or oral glucocorticoid therapy 
during follow-up were included in the current study. All blood samples were drawn during 
afternoon hours between 12 - 4 pm. For the comparisons of glucocorticoid levels between 
hospital admission and the follow-up visit, the subgroup of patients not receiving a RAAS 
inhibitor or oral glucocorticoid prior to admission and at follow-up was included in the 
analyses.  
 
9.2.2 Statistical analysis 
All baseline characteristics are expressed as median (IQR) for continuous and absolute 
number (percentage) for categorical variables. The inter-group comparisons were carried out 
by the Mann-Whitney and Kruskal-Wallis test for continuous variables as appropriate and by 
the χ2 test for categorical variables. For the comparisons of baseline characteristics between 
hospitalised and post-discharge patients not receiving a RAAS inhibitor or oral 
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glucocorticoid treatment, Wilcoxon matched pairs test and McNemar test were employed for 
continuous and categorical variables respectively. A p-value <0.05 was considered significant 
for all analyses. Statistical analyses were performed with Minitab version 15.  
 
9.3 Results 
 
9.3.1 Patient characteristics during follow-up stratified by treatment with a RAAS 
inhibitor or oral glucocorticoid. 
Of the 453 patients completed the follow-up visit, 378 were taking a RAAS inhibitor or oral 
glucocorticoid therapy and 75 were not taking a RAAS inhibitor or oral glucocorticoid 
therapy after discharge (Table 9-1). 
 
Patients not taking a RAAS inhibitor or oral glucocorticoid treatment were older, more often 
female and more likely to have higher SBP and LVEF and less likely to have a history of 
angina compared with patients not taking the above agents or patients of the overall post-
discharge cohort. Patients in the former group were also more likely to have lower potassium 
and eGFR and less likely to be treated with a beta-blocker at follow-up compared with 
patients in the other two groups.  
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9.3.2 Levels of glucocorticoids during follow-up 
 
Levels of plasma 11-deoxycortisol and cortisol, and the 11-deoxycortisol to cortisol ratio, 
during follow-up are presented below.  
 
9.3.3 11-deoxycortisol 
An 11-deoxycortisol level measured during follow-up was available in 68 of the 76 patients. 
The median (IQR) 11-deoxycortisol was 468.7 (305.4 – 739.3) pmol/L (Figure 9-1) and the 
mean (SD) 11-deoxycortisol was 589.7 (475.3) pmol/L. A frequency distribution histogram 
of 11-deoxycortisol levels in these patients is displayed in Figure 9-2. The minimum 11-
deoxycortisol concentration was 14.0 pmol/L and the maximum 11-deoxycortisol 
concentration was 3051.5 pmol/L. Almost all patients (98.5%) had 11-deoxycortisol levels 
within the normal range (0 - 2017 pmol/L). 
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Figure 9-1. Box and whisker plot of 11-deoxycortisol concentrations showing the 2.5, 25, 
50, 75 and 97.5
 
centiles 
 
 
 
 
 
3 0 0 0 2 4 0 0 1 8 0 0 1 2 0 0 6 0 0 0 
1 8 
1 6 
1 4 
1 2 
1 0 
8 
6 
4 
2 
0 
1 1 - d e o x y c o r t i s o l  ( p m o l / l ) 
N
 u
 m
 b
 e
 r  
 o
 f  
 p
 a
 t i
 e
 n
 t s
 
1 1 - d e o xy c o r t i s o l  ( p o l / L)  
N
u
m
b
e
r
 o
f
 p
a
t
ie
n
t
s
 
Figure 9-2. Frequency distribution histogram of 11-deoxycortisol concentrations 
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9.3.3.1 Cortisol 
A cortisol level measured during follow-up was available in 73 of the 76 patients. The 
median (IQR) cortisol was 223.3 (153.7 - 310.4) nmol/L (Figure 9-3) and the mean (SD) 
cortisol was 262.4 (185.1) nmol/L. A frequency distribution histogram of cortisol levels in 
these patients is displayed in Figure 9-4. The minimum cortisol concentration was 12.1 
nmol/L and the maximum cortisol concentration was 1166.4 nmol/L. The majority of patients 
(97.5%) had cortisol levels within the normal range (0 – 823nmol/L). 
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Figure 9-3. Box and whisker plot of cortisol concentrations showing the 2.5, 25, 50, 75 
and 97.5
 
centiles 
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9.3.3.2 11-deoxycortisol to cortisol ratio 
An 11-deoxycortisol to cortisol ratio could be calculated for 68 of the 76 patients studied. 
The median (IQR) 11-deoxycortisol to cortisol ratio was 2.06 (1.32 - 3.45) x10
-3
 (Figure 9-5) 
and the mean (SD) 11-deoxycortisol to cortisol ratio was 2.70 (2.17) x10
-3
. A frequency 
distribution histogram of 11-deoxycortisol to cortisol ratio in these patients is displayed in 
Figure 9-6. The minimum 11-deoxycortisol to cortisol ratio was 0.07 x10
-3
 and the maximum 
11-deoxycortisol to cortisol ratio was 13.5 x10
-3
. 
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Figure 9-5. Box and whisker plot of 11-deoxycortisol/cortisol showing the 2.5, 25, 50, 75 
and 97.5 centiles 
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Figure 9-6. Frequency distribution histogram of 11-deoxycortisol to cortisol ratio 
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9.3.4 Patient characteristics according to glucocorticoid levels 
The characteristics of patients not receiving a RAAS inhibitor or oral glucocorticoid therapy 
during follow-up were stratified according to the levels of 11-deoxycortisol and cortisol and 
the 11-deoxycortisol to cortisol ratio.  
 
9.3.4.1 Patient characteristics according to 11-deoxycortisol levels 
The cohort of 68 patients with measured 11-deoxycortisol levels was divided into two groups 
according to the median 11-deoxycortisol; patients with 11-deoxycortisol <468.7 pmol/L and 
patients with 11-deoxycortisol levels ≥ 468.7 pmol/L (Table 9-2).  
 
Patients with lower 11-deoxycortisol levels were more likely to have lower cortisol and 11-
deoxycortisol to cortisol ratio compared to patients with higher 11-deoxycortisol levels. In 
addition, a trend for higher PRC and aldosterone and lower SBP and eGFR was evident in 
these patients. 
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Table 9-2. Characteristics of patients not taking a RAAS inhibitor* or oral 
glucocorticoid therapy according to the median 11-deoxycortisol 
Variable 11-deoxycortisol  
< 468.7 pmol/L  
(n=34) 
11-deoxycortisol 
 ≥ 468.7 pmol/L  
 (n=34) 
p-value† 
Age (years) 75.5 (69.75 - 83.25) 75 (67.75 - 80) 0.280 
Female gender 19 (55.88) 18 (52.94) 0.808 
NYHA class    
I 2 (5.88) 1 (2.94) 0.555 
II 24 (70.59) 21 (61.76) 0.442 
III 8 (23.53) 12 (35.29) 0.287 
Medical history    
HF 13 (38.24) 12 (35.29) 0.801 
MI 13 (38.24) 15 (44.12) 0.622 
Angina 15 (44.12) 15 (44.12) 1.000 
Diabetes mellitus 4 (11.76) 10 (29.41) 0.072 
Hypertension 25 (73.53) 25 (73.53) 1.000 
AF 18 (52.94) 23 (67.65) 0.215 
CVA/TIA 9 (26.47) 5 (14.71) 0.230 
Physiological measurements    
BMI (kg/m
2
) 26.36 (23.38 - 32.73) 26.34 (24.21 - 32.28) 0.835 
Pulse rate (bpm) 77 (63.75 - 90.0) 74 (67 - 94) 0.628 
SBP (mmHg) 134 (123.75 – 145.5) 140 (123 – 154.25) 0.310 
DBP (mmHg) 69 (53.75 - 74.5) 71.5 (62.75 - 82) 0.170 
Signs of fluid congestion    
Elevated JVP 2 (6.5) 3 (10) 0.614 
Peripheral oedema 14 (41.2) 13 (37.1) 0.731 
ECG rhythm    
SR 23 (67.65) 17 (50.0) 0.139 
AF 10 (29.41) 14 (41.18) 0.310 
Echocardiography  measurements   
LVEF 45.5 (38.75 - 53.5) 46 (33 – 55.25) 0.797 
LVEF <45% 16 (47) 14 (40) 0.478 
Laboratory measurements (blood)   
BNP (pg/ml) 442.5 (213 – 858) 526.5 (231 - 787) 0.677 
Troponin I ≥ 0.04 (µg/L) 5 (14.71) 9 (26.47) 0.230 
Sodium (mmol/L) 138.5 (137 - 141) 140 (138 - 141) 0.187 
Potassium (mmol/L) 3.8 (3.5 - 4.1) 3.95 (3.78 - 4.13) 0.119 
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Variable 11-deoxycortisol  
< 468.7 pmol/L  
(n=34) 
11-deoxycortisol 
 ≥ 468.7 pmol/L  
 (n=34) 
p-value† 
Urea (mmol/L) 9.35 (6.95 - 10.7) 9.8 (6.15 - 13.03) 0.893 
Creatinine (µmol/L) 115 (92 - 141.25) 111.5 (84.25 – 153.5) 0.650 
eGFR (ml/min/1.73m
2
) 50 (34 - 60) 56.5 (34 - 60) 0.440 
eGFR <60ml/min/1.73m
2
 24 (70.59) 18 (52.94) 0.134 
Cholesterol (total) (mmol/L) 3.9 (3.38 - 4.8) 4.0 (3.58 - 5.53) 0.521 
HDL (mmol/L) 1.3 (1.0 - 1.4) 1.05 (0.8 - 1.33) 0.070 
CRP (mg/L) 5.65 (3.05 - 25.25) 5.85 (3.4 - 17.0) 0.813 
TSH (mIU/L) 1.5 (0.75 - 2.85) 1.6 (0.89 - 3.03) 0.598 
Cortisol (nmol/L) 200.4 (131.7 - 263.6) 291.2 (196 - 389.9) 0.006 
11-deoxycortisol/cortisol (10
-3
) 1.47 (0.99 - 2.38) 3.07 (1.64 - 4.68) <0.001 
Aldosterone (pmol/L) 195.3 (106.8 - 342.2) 172.4 (87.7 - 319.8) 0.615 
PRC (mIU/L) 47.45 (17 - 109.2) 33.30 (18.1 - 104.1) 0.659 
Aldosterone/PRC 4.17 (1.94 - 9.62) 3.74 (1.83 - 12.63) 0.912 
Haemoglobin (g/dl) 11.7 (11.3 - 13.3) 12.85 (11.3 - 13.7) 0.202 
Cardiovascular medication    
Diuretic  33 (97.06) 34 (100) - ¥ 
Beta-blocker 19 (55.88) 20 (58.82) 0.806 
Digoxin 4 (11.76) 10 (29.41) 0.072 
Anti-arrhythmic   4 (11.76) 2 (5.88) 0.393 
Aspirin 21 (61.76) 18 (52.94) 0.462 
Statin 26 (76.47) 26 (76.47) 1.000 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
* ACE inhibitor/ARB or aldosterone blocker. 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid.  
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9.3.4.2 Patient characteristics according to cortisol levels  
The cohort of 73 patients with measured cortisol levels was divided into two groups 
according to the median cortisol; patients with cortisol <223.3 pmol/L and patients with 
cortisol levels ≥ 223.3 pmol/L (Table 9-3).  
 
Patients with higher cortisol levels were more likely to have higher 11-deoxycortisol, 
aldosterone, PRC and urea and lower 11-deoxycortisol to cortisol ratio. There was also a 
trend for higher BNP elevated troponin and lower eGFR in these patients. Patients with 
higher cortisol levels were more often in NHYA class III and less often in NYHA class II 
compared to patients with lower cortisol levels. Beta-blockers were more often prescribed in 
patients of the former group compared to patients of the latter group.  
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Table 9-3. Characteristics of patients not taking a RAAS inhibitor* or oral 
glucocorticoid therapy according to the median cortisol 
Variable Cortisol   
< 223.3 nmol/L 
(n=37) 
Cortisol   
≥ 223.3 nmol/L 
 (n=36) 
p-value† 
Age (years) 75 (67.5 – 82) 75.5 (69 – 82.5) 0.551 
Female gender 19 (51.35) 23 (63.89) 0.279 
NYHA class    
I 2 (5.41) 1 (2.78) 0.572 
II 28 (75.68) 22 (58.33) 0.115 
III 7 (18.92) 14 (38.89) 0.060 
Medical history    
HF 14 (37.84) 13 (36.11) 0.879 
MI 15 (40.54) 13 (36.11) 0.697 
Angina 15 (40.54) 16 (44.44) 0.736 
Diabetes mellitus 5 (13.51) 10 (27.78) 0.132 
Hypertension 25 (67.57) 29 (80.56) 0.206 
AF 25 (67.57) 20 (55.56) 0.291 
CVA/TIA 10 (27.03) 4 (11.11) 0.084 
Physiological measurements   
BMI (kg/m
2
) 26.52 (24.0 – 31.9) 26.11 (22.91 – 33.42) 0.860 
Pulse rate (bpm) 79 (61.5 – 90) 74 (68 – 91.75) 0.540 
SBP (mmHg) 140 (126.5 – 152) 134.5 (120 – 147) 0.270 
DBP (mmHg) 73 (61.5 – 81) 67 (54.25 – 75.5) 0.229 
Signs of fluid congestion    
Elevated JVP 3 (9.1) 3 (9.1) 1.000 
Peripheral oedema 10 (27) 19 (51.4) 0.032 
ECG rhythm    
SR 23 (62.16) 20 (52.78) 0.417 
AF 12 (32.43) 15 (41.67) 0.414 
Echocardiography measurements   
LVEF 46 (39.25 – 55) 46 (33.75 – 54.5) 0.991 
LVEF <45% 20 (55.6) 21 (56.8) 0.918 
Laboratory measurements (blood)   
BNP (pg/ml) 340 (193.5 – 700) 536 (298 – 1038) 0.105 
Troponin I ≥ 0.04 (µg/L) 5 (13.51) 9 (25) 0.213 
Sodium (mmol/L) 139 (137 – 141) 140 (138 – 141) 0.360 
Potassium (mmol/L) 3.9 (3.6 – 4.15) 3.9 (3.6 – 4.1) 0.882 
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Variable Cortisol   
< 223.3 nmol/L 
(n=37) 
Cortisol   
≥ 223.3 nmol/L 
 (n=36) 
p-value† 
Urea (mmol/L) 8.1 (5.9 – 10.3) 10.4 (7.25 – 12.45) 0.029 
Creatinine (µmol/L) 102 (88 – 125.5) 112.5 (92 – 153) 0.265 
eGFR (ml/min/1.73m
2
) 55 (39 – 60) 43 (33.25 – 60) 0.111 
eGFR <60ml/min/1.73m
2
 20 (54.05) 25 (69.44) 0.176 
Cholesterol (total) (mmol/L) 3.9 (3.6 – 5.35) 4.05 (3.43 – 505) 0.683 
HDL (mmol/L) 1.3 (1.0 – 1.4) 1.0 (0.9 – 1.4) 0.260 
CRP (mg/L) 5.8 (3.3 – 26.0) 6.8 (3.9 – 17.0) 0.932 
TSH (mIU/L) 1.5 (0.91 – 3.2) 1.7 (0.66 – 2.6) 0.783 
11-deoxycortisol (pmol/L) 422.7 (200.8 – 634.4) 625.3 (337.4 – 943.6) 0.015 
11-deoxycortisol/cortisol (10
-3
) 3.05 (1.63 – 4.04) 1.59 (1.19 – 2.62) 0.004 
Aldosterone (pmol/L) 128.2 (81.5 – 257.6) 224.8 (128.6 – 363.1) 0.025 
PRC (mIU/L) 33.8 (13.1 – 52.9) 61.9 (24.3 – 125.4) 0.016 
Aldosterone/PRC 4.34 (1.82 – 10.48) 3.62 (1.99 – 9.86) 0.753 
Haemoglobin (g/dl) 12.7 (11.5 – 13.4) 11.8 (10.73 – 13.08) 0.144 
Cardiovascular medication   
Diuretic  36 (97.3) 36 (100) - ¥ 
Beta-blocker 16 (43.24) 24 (66.67) 0.044 
Digoxin 7 (18.92) 10 (27.78) 0.371 
Anti-arrhythmic   3 (8.11) 4 (11.11) 0.663 
Aspirin 20 (54.05) 21 (58.33) 0.713 
Statin 26 (70.27) 29 (77.78) 0.465 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
*ACE inhibitor/ARB or aldosterone blocker. 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid. 
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9.3.4.3 Patient characteristics according to 11-deoxycortisol to cortisol ratio 
The cohort of 68 patients with calculated 11-deoxycortisol to cortisol ratio was divided into 
two groups according to the median 11-deoxycortisol to cortisol ratio; patients with 11-
deoxycortisol to cortisol < 2.06 x10
-3
 and patients with 11-deoxycortisol levels ≥ 2.06 x10-3 
(Table 9-4).  
 
Patients with lower 11-deoxycortisol to cortisol ratio were more likely to have lower 11-
deoxycortisol, SBP and haemoglobin and higher BNP and cortisol compared to patients with 
higher 11-deoxycortisol to cortisol ratio. There was also a trend for higher PRC and 
aldosterone, urea and CRP and elevated troponin in these patients. Patients with lower higher 
11-deoxycortisol to cortisol ratio cortisol were also more often in NYHA class III compared 
to patients with higher 11-deoxycortisol to cortisol ratio.  
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Table 9-4. Characteristics of patients not taking a RAAS inhibitor* or oral 
glucocorticoid therapy according to the median 11-deoxycortisol to cortisol 
Variable 11-deoxycortisol/ 
cortisol  
 < 2.06  
(n=34) 
11-deoxycortisol/  
cortisol  
 ≥ 2.06  
 (n=34) 
p-value† 
Age (years) 75.50 (72 – 83.25) 74.50 (67.75 – 80) 0.234 
Female gender 21 (61.76) 16 (47.06) 0.223 
NYHA class    
I 0 (0) 3 (8.82) 0.076 
II 20 (58.82) 25 (73.53) 0.200 
III 14 (41.18) 6 (17.65) 0.033 
Medical history    
HF 12 (35.29) 13 (38.24) 0.801 
MI 13 (34.24) 15 (44.12) 0.622 
Angina 13 (38.24) 17 (50) 0.329 
Diabetes mellitus 7 (20.59) 7 (20.59) 1.000 
Hypertension 26 (76.47) 24 (70.59) 0.582 
AF 17 (50) 24 (70.59) 0.083 
CVA/TIA 6 (17.65) 8 (23.53) 0.549 
Physiological measurements    
BMI (kg/m
2
) 25.48 (22.86 – 32.75) 27.36 (24.41 – 32.37) 0.275 
Pulse rate (bpm) 80 (67.75– 91.25) 73.5 (59.75 – 91) 0.585 
SBP (mmHg) 131.5 (119.5 – 145.5) 143 (129 – 154.5) 0.032 
DBP (mmHg) 69 (58 – 75.5) 73 (62.25 – 82) 0.377 
Signs of fluid congestion    
Elevated JVP 2 (6.1) 3 (10.7) 0.509 
Peripheral oedema 16 (45.7) 26 (76.5) 0.009 
ECG rhythm    
SR 22 (64.71) 18 (52.94) 0.324 
AF 10 (29.41) 14 (41.18) 0.310 
Echocardiography measurements    
LVEF 43 (32.88 – 50.50) 47.5 (39.75 – 56) 0.119 
LVEF <45% 17 (48.6) 22 (64.7) 0.176 
Laboratory measurements (blood)   
BNP (pg/ml) 622.5 (289 – 1083) 436.5 (184.5 – 639.8) 0.047 
Troponin I ≥ 0.04 (µg/L) 9 (26.47) 5 (14.71) 0.230 
Sodium (mmol/L) 139 (138 – 141) 140 (137 – 141) 0.801 
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Variable 11-deoxycortisol/ 
cortisol  
 < 2.06  
(n=34) 
11-deoxycortisol/  
cortisol  
 ≥ 2.06  
 (n=34) 
p-value† 
Potassium (mmol/L) 3.8 (3.5 – 4.1) 4.0 (3.7 – 4.2) 0.116 
Urea (mmol/L) 10.05 (7.78 – 11.85) 7.35 (5.68 – 11.23) 0.092 
Creatinine (µmol/L) 118 (92.75 – 153) 106 (81.75 – 143.5) 0.215 
eGFR (ml/min/1.73m
2
) 46 (33.75 – 60) 59 (37.75 – 60) 0.108 
eGFR <60ml/min/1.73m
2
 25 (73.53) 17 (50) 0.046 
Cholesterol (total) (mmol/L) 3.9 (3.38 – 5.43) 3.95 (3.58 – 4.8) 0.793 
HDL (mmol/L) 1.3 (1.0 – 1..65) 1.1 (0.9 – 1.3) 0.116 
CRP (mg/L) 8.5 (3.85 – 25.5) 4.7 (3.3 – 15.0) 0.162 
TSH (mIU/L) 1.7 (0.66 – 3.65) 1.45 (0.86 – 2.68) 0.707 
Cortisol (nmol/L) 279 (208.4 – 395.4) 189.5 (116.4 – 280.8) <0.001 
11-deoxycortisol (pmol/L) 329.5 (240.6 – 494.8) 686.6 (454.9 – 893.8) <0.001 
Aldosterone (pmol/L) 208.4 (120.2 – 375.9) 142.1 (85.1 – 289.3) 0.166 
PRC (mIU/L) 53.6 (20.9 – 131.8) 34.95 (12.2 – 93.3) 0.131 
Aldosterone/PRC 3.71 (2.17 – 8.80) 4.19 (1.65 – 13.18) 0.980 
Haemoglobin (g/dl) 11.7 (10.93 - 13.1) 12.5 (11.5 - 13.75) 0.048 
Cardiovascular medication    
Diuretic  34 (100) 33 (97.06) - ¥ 
Beta blocker 18 (52.94) 21 (61.76) 0.462 
Digoxin 6 (17.65) 8 (23.53) 0.549 
Anti-arrhythmic   5 (14.71) 1 (2.94) 0.087 
Aspirin 20 (58.82) 19 (55.88) 0.806 
Statin 22 (64.71) 30 (88.24) 0.022 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
*ACE inhibitor/ARB or aldosterone blocker 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
 
¥ Chi-Square approximation probably invalid  
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9.3.5 Levels of glucocorticoids during hospital admission and follow-up in patients not 
receiving a RAAS inhibitor or oral glucocorticoid therapy   
 
Of the 75 patients not taking a RAAS inhibitor or oral glucocorticoid therapy during follow-
up, 55 were not taking the above agents prior to hospital admission with decompensated HF. 
The demographic characteristics, medical history and LVEF in these patients are presented in 
Table 9-5. 
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Patients not taking a RAAS inhibitor or oral glucocorticoid treatment were older, more often 
female and were more likely to have higher LVEF compared with patients of the overall post-
discharge cohort. This group was also less likely to have history of HF and diabetes 
compared with the overall post-discharge or hospitalised cohort.  
 
The physiological and laboratory measurements of these patients during hospital admission 
and follow-up and the medication prior to admission and after discharge are presented in 
Table 9-6. 
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Table 9-6. Clinical characteristics, physiological and laboratory measurements and 
medication in patients not taking a RAAS inhibitor* or oral glucocorticoid therapy 
during hospital admission and follow-up (n=55) 
Variable During admission  
(n=55) 
During follow-up  
(n=55) 
p-value† 
NYHA class    
I 0 (0) 2 (3.6)  - ¥ 
II 20 (36.4) 37 (67.3) 0.001 
III 29 (52.7) 16 (29.1) 0.026 
IV 6 (11) 0 (0) - ¥ 
Physiological measurements    
BMI (kg/m
2
) 28 (24.2 - 34.1) 26.5 (23 - 33.5) <0.001 
Weight (kg) 73.5 (57 - 90) 69.7 (56.4 - 87) <0.001 
Pulse rate (bpm) 86 (72 - 99) 79 (67 - 93) 0.014 
SBP (mmHg) 140 (125 - 155) 142 (128 - 153) 0.572 
DBP (mmHg) 80 (68 - 90) 70 (58 - 80) 0.001 
Signs of fluid congestion    
Elevated JVP 39 (78) 4 (8.3) <0.001 
Peripheral oedema 36 (65.5) 21 (38.2) 0.001 
Laboratory measurements (blood)   
BNP (pg/ml) 647 (256 - 1715) 457 (207 - 772) <0.001 
Sodium (mmol/L) 138 (136 - 141) 139 (137 - 141) 0.081 
Potassium (mmol/L) 4.1 (3.8 - 4.6) 3.9 (3.6 - 4.1) 0.001 
Urea (mmol/L) 8.8 (5.6 - 10.9) 9.2 (6.8 - 11) 0.175 
Creatinine (µmol/L) 112 (75 - 144) 115 (89 - 151) 0.002 
eGFR (ml/min/1.73m
2
) 53 (35 - 60) 51 (30 - 60) 0.051 
eGFR <60ml/min/1.73m
2
 34 (62) 36 (65.5) 0.727 
Cholesterol (total) (mmol/L) 3.9 (3.4 - 5.3) 4.1 (3.6 - 5.5) 0.211 
HDL (mmol/L) 1.1 (0.9 - 1.4) 1.1 (1.0 - 1.4) 0.327 
CRP (mg/L) 11 (4.6 - 37) 6.9 (3.9 - 21.3) 0.001 
TSH (mIU/L) 2.3 (1.2 - 3.8) 1.5 (0.7 - 2.5) 0.344 
Cortisol (nmol/L) 346.9 (259.7 - 460) 220.4 (151 - 297.3) <0.001 
11-deoxycortisol (pmol/L) 536 (323 - 1047) 423.8 (258.8 - 752.7) 0.433 
11-deoxycortisol/cortisol (10
-3
) 1.68 (1.14 - 3.44) 2.04 (1.30 - 3.42) 0.266 
Aldosterone (pmol/L) 118.7 (52.8 - 252.8) 185 (109.7 - 298.8) 0.111 
PRC (mIU/L) 31.2 (9.0 - 67.3) 46.5 (18.5 - 107) 0.014 
Aldosterone/PRC 3.28 (1.65 - 8.14) 3.85 (2.10 - 13.41) 0.283 
Haemoglobin (g/dl) 12 (10.3 - 13.4) 12 (11 - 13.4) 0.374 
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Variable During admission  
(n=55) 
During follow-up  
(n=55) 
p-value† 
Cardiovascular medication    
Diuretic  30 (54.5) 54 (98.2) <0.001 
Beta-blocker 27 (49) 27 (49) 1 
Digoxin 8 (14.5) 9 (16.4) 1 
Anti-arrhythmic   5 (9) 5 (9) 1 
Aspirin 31 (56) 32 (58.2) 1 
Statin 33 (60) 39 (71) 0.146 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
* ACE inhibitor/ARB or aldosterone blocker. 
 
† Wilcoxon matched pairs test was used for continuous variables and McNemars’s test was used for categorical 
variables. 
 
¶ medication prior to hospital admission for patients studied during the hospital admission. 
 
¥ Chi-Square approximation probably invalid. 
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Cortisol levels were lower at follow-up compared with the hospital admission. There was a 
trend for lower 11-deoxycortisol levels and higher 11-deoxycortisol to cortisol ratio at 
follow-up, but that did not reach statistical significance. Patients were taking diuretics more 
frequently and were more likely to have higher PRC and creatinine and lower weight, BNP 
and eGFR after discharge. The pulse rate, DBP, potassium and CRP were also lower at 
follow-up compared with hospital admission.   
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9.4 Discussion 
 
9.4.1 Patient characteristics according to glucocorticoid secretion during follow-up 
The levels of 11-deoxycortisol and cortisol and the 11-deoxycortisol to cortisol ratio in 
patients not taking a RAAS inhibitor or oral glucocorticoid therapy at follow-up were similar 
to the levels of above glucocorticoids and their ratio in the overall post-discharge cohort. 
Cortisol was associated with higher levels of RAAS mediators at the follow-up visit similar 
to the hospital admission. Apart from the associations with the RAAS mediators, cortisol 
levels were also higher in patients with higher urea levels. Glucocorticoids are normally 
excreted by the kidneys and chronic renal failure has been reported to result in prolonged 
half-life of cortisol (399). Urea is likely to reflect a decline in glomerular filtration rate due to 
renal hypoperfusion in these patients. Nevertheless, it has been suggested that in patients with 
HF, blood urea is raised not only due to the decline in glomerular filtration rate but also due 
to the increased reabsorption by the nephrons secondary to activation of RAAS and other 
neurohumoral pathways (400) (401). Under these circumstances, urea not only reflects the 
local reduction in renal perfusion but also the systemic hypoperfusion with activation of the 
RAAS and other compensatory cascades. Thus, the above pathophysiological pathways may 
explain the association between cortisol with higher urea levels at the follow-up visit. 
Alternatively, urea and cortisol may reflect a state of higher protein breakdown in these 
patients; cortisol exerts catabolic effects on protein metabolism (402), which in turn results in 
an increase of urea production. Thus, patients with higher urea and cortisol levels might 
represent a subgroup characterised by prominence of the catabolic processes. 
 
Patients with lower 11-deoxycortisol to cortisol ratio had lower SBP and higher PRC and 
aldosterone. That indicates that chronic ACTH stimulation, as reflected by the up-regulation 
of the late enzymatic step in cortisol synthesis, is associated with greater RAAS activity in 
patients with stable HF similar to patients with decompensated HF. Correspondingly, these 
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patients had higher BNP, higher levels of inflammatory markers and worse kidney function 
reflecting the stimulation of glucocorticoid secretion in patients with worse HF. These 
associations were replicated in the overall post-discharge cohort (Table 13-12 in the 
Appendix) re-iterating the notion of greater HPA activity in patients with raised prognostic 
markers. The only exception was the absence of the higher RAAS activity in patients with 
lower 11-deoxcortisol to cortisol ratio; however, this may represent a confounding effect of 
RAAS inhibitors in the overall cohort. 
 
In summary, most of the associations among glucocorticoid levels, HPA activity and markers 
of HF severity seen in patients with decompensated HF were replicated in patients with stable 
HF at the follow-up. These findings provide evidence that inhibition of 11beta-hydroxylase, 
as discussed in section 8.4.1, may be translated into clinical benefit in patients with chronic 
HF. 
 
9.4.2 Change in glucocorticoid secretion from admission to follow-up in patients not 
taking an oral glucocorticoid or a RAAS inhibitor 
Cortisol but not 11-deoxycortisol levels were lower at the follow-up visit compared with 
hospital admission in patients not taking oral glucocorticoid therapy or a RAAS inhibitor at 
both time points. Glucocorticoid levels were taken at different time periods during hospital 
admission and at the follow-up visit making the interpretation of these results not 
straightforward. Cortisol levels, as shown in section 5.3.4, were not different between 
hospital admission and follow-up in patients who had blood samples collected only in the 
morning at both time points. These findings argue against a potential impact of clinical 
improvement on the changes in cortisol levels. Thus, the lower levels of cortisol at follow-up 
in this study provide further evidence for a diurnal pattern in glucocorticoid secretion in 
patients with HF and in accordance with previous findings (section 5.3.4).  
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In summary, these findings indicate that glucocorticoid secretion in patients with HF 
maintains the characteristic circadian pattern observed in healthy subjects. 
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10. Prognostic value of RAAS mediators and 
glucocorticoid levels in patients with 
decompensated HF 
  
312
  
10.1 Introduction 
 
The prognostic importance of RAAS mediators has been extensively investigated in patients 
with chronic HF (55) (284) (285). Similarly, cortisol has been examined with respect to 
prognosis in patients with chronic HF (72) (73). Little is known about the prognostic 
significance of plasma levels of RAAS mediators and glucocorticoids in patients with 
decompensated HF (340). Moreover, their importance in patients with diastolic HF remains 
unclear. The aim of this chapter is to evaluate the prognostic value of RAAS mediators and 
plasma glucocorticoids in a cohort of patients with HFrSF and HFpSF during hospital 
admission. 
 
10.2 Methods 
 
The study design and laboratory measurements were described in sections 2.3.1 & 2.3.2. All 
patients enrolled in the study during hospital admission were included in the analyses 
irrespective of background therapy. The primary outcome in this study was all-cause 
mortality, defined as death in and out of the hospital from any cause. All-cause mortality was 
determined by the death certificates and the relevant information was linked to the study 
database through the ISD of the National Scottish Health Service. All study participants were 
linked with the ISD following consent and enrollment in the study. Survival was defined as 
the period from the enrollment in the study during hospital admission until the time of death 
or the censor date on 28
th
 of August 2011.  
 
For the outcome analyses, Kaplan-Meier event-free (time to death) survival curves were 
constructed for each of RAAS mediators and corticosteroids in the overall hospitalised 
cohort. The variables examined were PRC, aldosterone, 11-deoxycortisol, cortisol and the 
aldosterone to PRC ratio and 11-deoxycortisol to cortisol ratio. The log-rank test was used for 
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the comparison of the survival curves with each of these variables entered as quartiles or 
dichotomised according to the median (Q2) and the 75
th
 percentile (Q3). Cox proportional 
hazard models were employed to calculate the hazard ratio (HR) and confidence interval (CI) 
of all-cause mortality over time with each variable entered as categorical (quartiles and 
dichotomised according to Q2 and Q3) and continuous (log-transformed). Firstly, univariate 
analyses were performed with each (neuro)hormone and their ratio as the only variable. All 
the variables found to be significantly associated with all-cause mortality on univariate 
analyses were included separately in multivariate Cox proportional hazards models. These 
models included a set of independent markers for all-cause mortality identified by backwards 
selection in a multivariate model with predetermined variables not including the variables in 
question; the prespecified variables were age, gender, previous hospitalisation with HF, 
history of COPD, SBP, LVSD, pulse rate, serum sodium and urea, eGFR, albumin, BNP, 
troponin and haemoglobin. The univariate and multivariate models were calculated for the 
full follow-up and up to 1 year from the hospital admission. All statistical analyses were 
performed using R version 2.15.1. 
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10.3 Results 
 
10.3.1 Baseline characteristics – Follow-up  
722 patients were included in this study. The patient characteristics were described in section 
4.3.1. The median (IQR) follow-up was 998 (365 – 1217) days. 
 
10.3.2 PRC and corticosteroid levels as univariate predictors of all-cause mortality 
PRC and aldosterone concentrations, 11-deoxycortisol and cortisol levels and the aldosterone 
to PRC and 11-deoxycortisol to cortisol ratio were examined in relation to outcomes in the 
overall population. The association of each of these variables with all-cause mortality is 
presented below. 
 
PRC  
 
The Kaplan-Meier curves for all-cause mortality using PRC as quartiles are displayed in 
Figure 10-1.The rate of all-cause mortality increased across the quartiles of PRC. Patients 
with the higher PRC quartile had worse prognosis compared with the other groups (log-rank 
p-value < 0.001). 
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
PRC ≤ 13.00 173 139 120 83 10 
PRC 13.01 – 47.30 172 135 109 68 9 
PRC 47.31 – 177.30 172 129 104 64 3 
PRC > 177.30 172 114 89 52 6 
Figure 10-1. Kaplan–Meier event-free curves for patients with decompensated HF 
according to PRC quartiles  
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Likewise, patients with PRC above median had worse prognosis compared to patients with 
PRC below median (log-rank p-value < 0.001) (Figure 10-2 below). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
PRC ≤ 47.30 345 274 229 151 19 
PRC > 47.30 344 243 193 116 9 
Figure 10-2. Kaplan–Meier event-free curves for patients with decompensated HF 
according to median PRC  
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Similar results were produced when PRC was dichotomised according to the 75
th
 percentile 
(log-rank p-value < 0.001) (Figure 10-3 below). 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
PRC ≤ 177.3 517 403 333 215 22 
PRC > 177.3 172 114 89 52 6 
Figure 10-3. Kaplan–Meier event-free curves for patients with decompensated HF 
according to PRC 75
th
 percentile  
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The univariate analyses of the Cox proportional hazard model for PRC as a predictor of all-
cause mortality analysed as a categorical variable (quartiles or dichotomised by Q2 and Q3) 
or continuous variable (log-normalised) are presented in Table 10-1 below. PRC was 
positively associated with all-cause mortality with a HR of 0.474 (0.351, 0.642) for the 
lowest versus the highest PRC quartile and a HR of 0.620 (0.501, 0.766) for patients with 
PRC below median versus patients with PRC above median. 
 
 
Table 10-1. Univariate Cox regression analysis of PRC at baseline for all-cause mortality 
with PRC entered as categorised (quartiles/dichotomised according to Q2 and Q3) and 
continuous (log-transformed variable). 
Variable HR (95% CI) p-value 
PRC (Quartiles) (mIU/L)  <0.001 
≤ 13.00 0.474 (0.351, 0.642) <0.001 
13.01 – 47.30 0.588 (0.441, 0.785) <0.001 
47.31 – 177.30 0.730 (0.554, 0.960) 0.0246 
> 177.30 1 (-)  
PRC (Split by Q2) (mIU/L)  <0.001 
≤ 47.30 0.620 (0.501, 0.766)  
> 47.30 1  (-)  
PRC (Split by Q3) (mIU/L)  <0.001 
≤ 177.30 0.593 (0.574, 0.743)  
> 177.30 1 (-)  
Log(PRC) 1.104 (1.064, 1.145) <0.001 
 
 
 
Univariate results for PRC as a predictor of all-cause mortality censoring the outcomes at 1 
year after hospital admission is presented in Table 10-2. 
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Table 10-2. Univariate Cox regression analysis of PRC at baseline for all-cause mortality 
with PRC entered as categorised (quartiles/dichotomised according to Q2 and Q3) and 
continuous (log-transformed variable) censoring the outcomes at 1 year after hospital 
admission. 
Variable HR (95% CI) p-value 
PRC (Quartiles) (mIU/L)  0.0038 
≤ 13.00 0.497 (0.326, 0.760) 0.0012 
13.01 – 47.30 0.556 (0.368, 0.840) 0.0053 
47.31 – 177.30 0.663 (0.447, 0.984) 0.0411 
> 177.30 1 (-)  
PRC (Split by Q2) (mIU/L)  0.0040 
≤ 47.30 0.640 (0.473, 0.868)  
> 47.30 1 (-)  
PRC (Split by Q3) (mIU/L)  <0.001 
≤ 177.30 0.571 (0.416, 0.783)  
> 177.30 1 (-)  
Log(PRC) 1.107 (1.051, 1.166) <0.001 
 
 
 
Aldosterone  
Kaplan-Meier curves for all-cause mortality using aldosterone in quartiles is presented in 
Figure 10-4. No association of aldosterone with all-cause mortality was seen in this cohort 
(log-rank p-value = 0.46). There was a trend for worse prognosis in patients with lower 
aldosterone levels compared to patients with higher aldosterone levels.
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone ≤ 31.692 139 99 80 51 2 
Aldosterone 31.693 – 72.280 137 105 81 50 1 
Aldosterone 72.281 – 151.649 137 108 95 58 3 
Aldosterone > 151.649 138 101 83 60 2 
Figure 10-4. Kaplan–Meier event-free curves for patients with decompensated HF 
according to aldosterone quartiles 
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Correspondingly, no association of aldosterone with mortality was present when aldosterone 
was analysed as binary variable according to median (log-rank p-value = 0.185) (Figure 10-5 
below) and 75
th
 percentile (log-rank p-value = 0.946) (Figure 10-6). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone ≤ 72.280 276 204 161 101 3 
Aldosterone > 72.280 275 209 178 118 5 
Figure 10-5. Kaplan–Meier event-free curves for patients with decompensated HF 
according to median aldosterone 
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone ≤ 151.649 413 204 161 101 3 
Aldosterone > 151.650 138 209 178 118 5 
Figure 10-6. Kaplan–Meier event-free curves for patients with decompensated HF 
according to aldosterone 75
th
 centile 
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The results of univariate Cox analyses for aldosterone as a predictor of all cause-mortality are 
displayed in Table 10-3. 
 
 
Table 10-3. Univariate Cox regression analysis of aldosterone at baseline for all-cause 
mortality with aldosterone entered as categorised (quartiles/dichotomised according to 
Q2 and Q3) and continuous (log-transformed variable).  
Variable HR (95% CI) p-value 
Aldosterone (Quartiles) (pmol/L)  0.4626 
≤ 31.692 1.123 (0.811, 1.554) 0.4856 
31.693 - 72.280 1.055 (0.760, 1.465) 0.7476 
72.281 - 151.649 0.863 (0.615, 1.212) 0.3952 
> 151.649 1 (-)  
Aldosterone (Split by Q2) (pmol/L)  0.1852 
≤ 72.280 1.171 (0.927, 1.479)  
> 72.281 1 (-)  
Aldosterone (Split by Q3) (pmol/L)  0.9465 
≤ 151.649 1.009 (0.770, 1.322)  
> 151.650 1 (-)  
Log(Aldosterone) 0.956 (0.895, 1.021) 0.1794 
 
 
 
Univariate results for aldosterone as a predictor of all-cause mortality censoring the outcomes 
at 1 year after the hospital visit are presented in Table 10-4. 
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Table 10-4. Univariate Cox regression analysis of aldosterone at baseline for all-cause 
mortality with aldosterone entered as categorised (quartiles/dichotomised according to 
Q2 and Q3) and continuous (log-transformed variable) censoring the outcomes at 1 year 
after hospital admission. 
Variable HR (95% CI) p-value 
Aldosterone (Quartiles) (pmol/L)  0.4782 
≤ 31.692 1.060 (0.678, 1.657) 0.7987 
31.693 - 72.280 0.840 (0.523, 1.349) 0.4706 
72.281 - 151.649 0.753 (0.463, 1.225) 0.2529 
> 151.649 1 (-)  
Aldosterone (Split by Q2) (pmol/L)  0.6274 
≤ 72.280 1.086 (0.778, 1.517)  
> 72.280 1 (-)  
Aldosterone (Split by Q3) (pmol/L)  0.0461 
≤ 151.649 0.791 (0.638, 0.996)  
> 151.650 1 (-)  
Log(Aldosterone) 0.970 (0.883, 1.066) 0.5273 
 
 
Aldosterone to PRC ratio 
Kaplan-Meier curves for all-cause mortality using the aldosterone to PRC ratio in quartiles 
are presented in Figure 10-7 (log-rank p-value <0.001). The aldosterone to renin ratio was 
inversely related with all-cause mortality; patients with the higher aldosterone to PRC ratio 
had better prognosis than the other groups. However, mortality risk did not decrease in an 
absolute stepwise inverse fashion across the quartiles of the aldosterone to renin ratio; 
patients with aldosterone to PRC ratio in the lowest quartile had better prognosis than 
patients with aldosterone to PRC ratio in the second quartile, who had the worst prognosis.  
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone:PRC ≤ 0.2959 136 97 75 45 3 
Aldosterone:PRC 0.2960 – 1.5294 135 87 69 38 0 
Aldosterone:PRC 1.5295 – 4.9484 135 107 88 58 1 
Aldosterone:PRC > 4.9484 136 113 100 72 4 
Figure 10-7. Kaplan–Meier event-free curves for patients with decompensated HF 
according to aldosterone to PRC quartiles 
  
326
  
When the aldosterone to PRC ratio was dichotomised according to median, patients with the 
lowest aldosterone to renin ratio had worse prognosis than patients with the higher 
aldosterone to PRC ratio (log-rank p-value p <0.001) (Figure 10.8).  
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone ≤ 1.5294 271 184 144 83 3 
Aldosterone > 1.5294 271 220 188 130 5 
Figure 10-8. Kaplan–Meier event-free curves for patients with decompensated HF 
according to median aldosterone to PRC 
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Likewise, patients with lower aldosterone to PRC ratio had higher mortality rate when the 
ratio was dichotomised according to the 75
th
 percentile (log-rank p-value <0.001) (Figure 10-
9). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Aldosterone ≤ 4.984 406 291 232 141 4 
Aldosterone > 4.984 136 113 100 72 4 
Figure 10-9. Kaplan–Meier event-free curves for patients with decompensated HF 
according to aldosterone to PRC 75
th
 percentile 
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The univariate analyses of the Cox proportional hazard model for the aldosterone to PRC 
ratio as a predictor of all-cause mortality as a categorical (quartiles or binary) or continuous 
variable (log-normalised) are presented in Table 10-5. 
 
 
Table 10-5. Univariate Cox regression analysis of aldosterone to PRC ratio at baseline 
for all-cause mortality with aldosterone to PRC ratio entered as categorised (quartiles/ 
dichotomised according to Q2 and Q3) and continuous (log-transformed variable).  
Variable HR (95% CI) p-value 
Aldosterone:PRC (Quartiles)  <0.001 
≤ 0.2959 1.950 (1.377, 2.762) <0.001 
0.2960 – 1.5294 2.210 (1.565, 3.121) <0.001 
1.5295 – 4.9484 1.273 (0.880, 1.844) 0.2004 
4.9484 1 (-)  
Aldosterone:PRC (Split by Q2) 1.834 (1.444, 2.329) <0.001 
≤ 1.5294 1 (-)  
> 1.5294   
Aldosterone:PRC (Split by Q3)  <0.001 
≤ 4.984 1.775 (1.313, 2.399)  
> 4.984 1 (-)  
Log(Aldosterone:PRC) 0.877 (0.831 – 0.927) <0.001 
 
 
Univariate results for the aldosterone to PRC ratio as a predictor of all-cause mortality at 1 
year after the hospital visit are displayed in Table 10-6. 
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Table 10-6. Univariate Cox regression analysis of aldosterone to PRC ratio at baseline 
for all-cause mortality with aldosterone to PRC ratio entered as categorised (quartiles/ 
dichotomised according to Q2 and Q3) and continuous (log-transformed variable) 
censoring the outcomes at 1 year after hospital admission. 
Variable HR (95% CI) p-value 
Aldosterone:PRC (Quartiles)  0.0019 
≤ 0.2959 1.889 (1.128, 3.162) 0.0156 
0.2960 – 1.5294 2.383 (1.450, 3.918) <0.001 
1.5295 – 4.9484 1.261 (0.726, 2.189) 0.4101 
4.9484 1 (-)  
Aldosterone:PRC (Split by Q2)  <0.001 
≤ 1.5294 1.834 (1.444, 2.329)  
> 1.5294   
Aldosterone:PRC (Split by Q3)  0.0085 
≤ 4.984 1.825 (1.166, 2.865)  
> 4.984   
Log(Aldosterone:PRC) 0.923 (0.874, 0.974) 0.0038 
 
 
 
Cortisol 
Kaplan-Meier curves for all-cause mortality using cortisol in quartiles is presented in Figure 
10-10. Patients with higher cortisol levels had worse prognosis, however that failed to reach 
statistical significance (log-rank p-value = 0.103). 
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Cortisol ≤ 226.044 154 124 104 58 4 
Cortisol 226.045 - 322.644 153 118 99 66 4 
Cortisol 322.645 - 444.360 153 117 96 57 0 
Cortisol > 444.360 153 104 81 52 2 
Figure 10-10. Kaplan–Meier event-free curves for patients with decompensated HF 
according to cortisol quartiles 
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Cortisol was associated with all-cause mortality when analysed as a binary variable according 
to median; patients with higher cortisol levels were at higher risk of death (log-rank p-value 
p=0.046). The survival curve for these patients appears to be steeper in the first 6 months after 
the hospital visit compared to patients with lower cortisol levels; thereafter the hazards appear 
proportional (Figure 10-11). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Cortisol ≤ 322.644 307 242 203 124 8 
Cortisol > 322.644 306 221 177 109 2 
Figure 10-11. Kaplan–Meier event-free curves for patients with decompensated HF 
according to median cortisol  
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Similarly, when cortisol was dichotomised according to 75
th
 percentile, patients with higher 
cortisol levels had worse prognosis (log-rank p-value =0.0193) (Figure 10-12). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
Cortisol ≤ 444.360 460 359 299 181 8 
Cortisol > 444.360 153 104 81 52 2 
Figure 10-12. Kaplan–Meier event-free curves for patients with decompensated HF 
according to cortisol 75
th
 percentile  
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Table 10-7 below summarises the results of Cox univariate analyses of cortisol as a predictor 
of all-cause mortality analysed as a categorical variable (quartiles or binary) and continuous 
variable (log transformed). 
 
 
Table 10-7. Univariate Cox regression analysis of cortisol at baseline for all-cause 
mortality with cortisol entered as categorised (quartiles/ dichotomised according to Q2 
and Q3) and continuous (log-transformed variable). 
Variable HR (95% CI) p-value 
Cortisol (Quartiles)(nmol/L)  0.1049 
≤ 226.044 0.730 (0.536, 0.995) 0.0463 
226.045 - 322.644 0.702 (0.514, 0.960) 0.0268 
322.645 - 444.360 0.807 (0.595, 1.094) 0.1670 
> 444.360 1.00 (-)  
Cortisol (Split by Q2) (nmol/L)  0.046 
≤ 322.644 0.797 (0.638, 0.996)  
> 322.644 1.00 (-)  
Cortisol (split by Q3) (nmol/L)  0.0197 
≤ 444.360 0.746 (0.583, 0.954)  
> 444.360 1.00 (-)  
Log(Cortisol) 1.066 (0.896, 1.268) 0.4738 
 
 
 
Univariate results for cortisol as a predictor of all-cause mortality censoring the outcomes at 
1 year after hospital admission are displayed in Table 10-8. 
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Table 10-8. Univariate Cox regression analysis of cortisol at baseline for all-cause 
mortality with cortisol entered as categorised (quartiles/ dichotomised according to Q2 
and Q3) and continuous (log-transformed variable) censoring the outcomes at 1 year 
after hospital admission. 
Variable HR (95% CI) p-value 
Cortisol (Quartiles) (nmol/L)  0.0465 
≤ 226.044 0.548 (0.348, 0.863) 0.0095 
226.045 - 322.644 0.648 (0.420, 1.001) 0.0504 
322.645 - 444.360 0.682 (0.444, 1.049) 0.0815 
> 444.360 1.00 (-)  
Cortisol (Split by Q2) (nmol/L)  0.043 
≤ 322.644 0.716 (0.518, 0.989)  
> 322.644 1.00 (-)  
Cortisol (split by Q3) (nmol/L)  0.0071 
≤ 444.360 0.626 (0.445, 0.880)  
> 444.360 1 (-)  
Log(Cortisol) 1.227 (0.939, 1.603) 0.1347 
 
 
No association was found between 11-deoxycortisol and mortality (log-rank p = 0.941) 
(Figure 10-13). 
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 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
11-Deoxycortisol ≤ 275.5238 150 110 95 58 4 
11-Deoxycortisol 275.5239 – 492.6225 150 111 92 55 3 
11-Deoxycortisol 492.6226 – 929.5988 150 123 98 51 1 
11-Deoxycortisol > 929.5988 150 109 89 64 2 
Figure 10-13. Kaplan–Meier event-free curves for patients with decompensated HF 
according to 11-deoxycortisol quartiles 
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Similar to 11-deoxycortisol, the 11-deoxycortisol to cortisol ratio was not associated with 
prognosis (log-rank p-value = 0.427) (Figure 10-14). 
 
 
 No. at risk 
 Time = 0 1 year 2 year 3 year 4 year 
11-Deoxycortisol:Cortisol ≤ 0.9629 150 102 86 53 3 
11-Deoxycortisol:Cortisol 0.9630 – 1.6454 150 119 96 55 3 
11-Deoxycortisol:Cortisol 1.6455 – 2.8842 150 121 95 57 2 
11-Deoxycortisol:Cortisol > 2.8842 150 111 97 63 2 
Figure 10-14. Kaplan–Meier event-free curves for patients with decompensated HF 
according to the 11-deoxycortisol to cortisol ratio quartiles 
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10.3.3 Multivariate predictors of all-cause mortality 
To examine further if cortisol and renin confer prognostic value over and above established 
prognostic factors in patients with decompensated HF, they were included individually into 
models, which included independent predictors of all-cause mortality in the overall 
population identified in multivariable models with predefined variables not including renin or 
cortisol. These independent predictors were age, SBP, previous history of COPD, 
haemoglobin, urea, troponin, log(BNP) for the models had PRC added in and age, SBP, 
previous history of COPD, previous hospitalisation with HF, haemoglobin, urea, troponin and 
log(BNP) for the models that included cortisol.  
 
PRC 
When PRC was included in multivariate Cox analysis as a quartile, there was an overall trend 
for higher of all-cause mortality in patients with higher PRC levels (p=0.0545) with a HR of 
0.6433 (95% CI , 0.4457 to 0.9284) for lowest versus highest PRC quartile and a HR of 
0.6591 (95% CI , 0.4688, 0.9627) for patients in the second PRC quartile compared with 
patients in the highest PRC quartile (Table 10-9). Further analysis with PRC analysed as 
binary variable according to median and 75
th
 percentile showed a positive association of PRC 
with all-cause mortality. Similarly, PRC as a continuous variable (log-transformed) was 
associated with death; an increase of 1 unit of log(PRC) was correlated with approximately 
8% higher risk of all-cause mortality. Other independent predictors of all-cause mortality in 
these models were increasing age, lower SBP and haemoglobin, history of COPD and 
elevated urea and BNP (Table 13-13 to Table 13-16 in the Appendix).   
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Unadjusted and adjusted Kaplan-Meier plots for all-cause mortality using PRC in quartiles 
and as a binary variable (split by Q2 and Q3) are displayed in Figure 10-15 to Figure 10-17.  
 
Figure 10-15. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to PRC (quartiles) at baseline 
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Figure 10-16. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to PRC (dichotomised according to median,Q2) at baseline 
341
  
 
Figure 10-17. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to PRC (dichotomised according to 75
th
 centile, Q3) at baseline 
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Censoring at 1 year after hospital admission 
In contrast to the prognostic value of PRC for the full follow-up, no prognostic significance 
was identified when PRC was included in a Cox multivariate model censoring at 1 year after 
hospital admission (Table 10-10). 
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Kaplan Meier curves for PRC censoring at 1 year unadjusted and adjusted for 
independent prognostic markers are displayed in Figure 10-18 to Figure 10-20. 
 
 
 
Figure 10-18. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to PRC (quartiles) at baseline 
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Figure 10-19. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to PRC (dichotomised according to median, Q2) 
at baseline 
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Figure 10-20. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to PRC (dichotomised according to 75
th
 centile, 
Q3) at baseline 
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Cortisol 
When Cortisol was considered along with independent prognostic factors in a Cox 
multivariate regression analysis, expressed either as quartiles, binary (split by median and 75
th
 
centile) variable or continuous (log-transformed) variable, it was not associated with all-cause 
mortality (Table 10-11). The independent predictors of all-cause mortality in these models 
were age, SBP, history of previous HF hospitalisation, history of COPD, urea, troponin and 
log(BNP) (Table 13-17 to Table 13-20 in the Appendix).  
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Kaplan-Meier plots for all-cause mortality using cortisol in quartiles and as a binary variable 
(both split by Q2 and Q3) are presented in Figure 10-21 to Figure 10-23.  
 
Figure 10-21. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to quartiles of plasma cortisol at baseline 
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Figure 10-22. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to plasma cortisol (dichotomised according to median, Q2) at baseline 
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Figure 10-23. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality 
according to plasma cortisol (dichotomised according to 75
th
 centile, Q3) at baseline 
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Censoring at 1 year after hospital admission 
Similarly, when cortisol was included in a Cox multivariate model censoring at 1 year after 
hospital admission no prognostic importance was elucidated for this glucocorticoid (Table 10-
12). 
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Kaplan Meier curves for cortisol censoring at 1 year unadjusted and adjusted for 
independent prognostic markers are displayed in Figure 10-24 to Figure 10-26. 
 
 
Figure 10-24. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to quartiles of plasma cortisol at baseline 
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Figure 10-25. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to plasma cortisol (dichotomised according to 
median, Q2) at baseline 
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Figure 10-26. Unadjusted and adjusted Kaplan-Meier curves for all-cause mortality at 1 
year after hospital admission according to plasma cortisol (dichotomised according to 
75
th
 percentile, Q3) at baseline 
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10.4 Discussion 
 
10.4.1 RAAS mediators and prognosis 
To my knowledge this is the first study to examine the prognostic value of PRC in a wide 
spectrum of patients with acute decompensated HF. The prognostic importance of renin was 
previously examined in patients with chronic HF with LVSD (353) (354) (403). In these 
studies plasma renin, measured either as activity or concentration, was positively associated 
with increased risk of mortality. In a similar fashion, higher PRC showed prognostic value in 
patients with decompensated HF over-and-above other independent prognostic markers in the 
current study.  
 
What are the potential links which account for the association of PRC with all-cause mortality 
in patients with decompensated HF? Firstly, high renin concentrations may represent a marker 
of worse cardiac and/or renal disease. Indeed, PRC was associated with lower blood pressure, 
indexes of LV remodeling and markers of renal function in patients during hospital 
admission. However, renin retained its prognostic significance when adjusted for markers of 
haemodynamic status and renal function in most of the models, indicating that other factors 
likely to contribute additionally to its prognostic importance. A potential alternative link 
might be the deleterious effects of renin on the cardiovascular system through RAAS 
activation in the long term; as previously discussed, aldosterone levels in patients with 
worsening HF were higher in patients with higher PRC despite treatment with a RAAS 
inhibitor, indicating that the secretion of the down-stream components of RAAS continues to 
be primarily driven by renin despite the treatment with an ACE inhibitor/ARB. Moreover, the 
reactive rise of renin due to RAAS may overcome RAAS inhibition leading to further disease 
progression. On the other hand, higher renin concentrations might be of additional 
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physiological importance, as there is growing evidence that renin exerts direct inflammatory 
and fibrotic effects independent of angiotensin II through prorenin/renin receptors (404) (405)   
 
Apart from the potential direct and indirect effects of renin on disease progression and clinical 
outcomes, other factors might also account for the observed association between renin and all-
cause mortality. Higher PRC levels may reflect the inhibition of RAAS with an ACE 
inhibitor/ARB or an aldosterone blocker. Indeed, as was shown previously PRC was higher in 
patients taking a RAAS inhibitor prior to admission. On the other hand, prior treatment with a 
RAAS inhibitor reflects history of established cardiovascular disease and that may have 
further contributed to worse outcomes seen in patients with higher renin levels. However, it is 
likely that a number of patients with a history of HF, especially those with advanced HF, were 
not treated with a RAAS inhibitor prior to hospital admission due to haemodynamic 
instability or kidney dysfunction. PRC rise in these patients due to disease progression might 
not be as prominent as in patients treated with RAAS inhibitors; nevertheless, it is generally 
accepted that patients with advanced HF not taking RAAS inhibitors have worse prognosis 
and higher short-term mortality. That might account for the difference in the prognostic value 
of PRC in 12 months after hospital admission and in the overall follow-up in the current 
study. 
 
Finally, other unmeasured variates may contribute to the increased risk of death in patients 
with higher PRC during hospital admission in the current study. One of the principal 
regulators of renin secretion is the SNS activation. Plasma norepinephrine has been associated 
with worse outcomes in patients with severe HF (384). Thus, greater SNS activity promotes 
RAAS activation and may contribute to the higher mortality risk in patients with higher PRC 
and worsening HF.  
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In contrast to PRC, plasma aldosterone was not associated with prognosis in the current study. 
In patients with congestive HF not taking an ACE inhibitor or ARB aldosterone levels were 
associated with worse medium-term prognosis in CONSENSUS trial (55). Moreover, in 
patients with decompensated HF in the EVEREST trial, aldosterone was univariately 
associated with all-cause mortality (340). Aldosterone was also associated with all-cause 
mortality after adjustment for established prognostic factors in that study (Prof Faiez Zannad, 
personal communication, November 2012). However, it should be mentioned that 
approximately half of these patients were taking an aldosterone blocker; that is likely to affect 
the association between aldosterone levels and survival, as aldosterone blockers increase 
aldosterone levels and their prescription is targeted to patients with severe HF and hence 
worse prognosis. Alternatively, as previously discussed different methods were employed for 
aldosterone measurement and that may contribute to the differences in aldosterone levels and 
their associations with mortality between the current and the EVEREST study. Aldosterone 
levels were measured in the current study by LCMS, which has been recognised for its 
specificity over immunoassays, specifically with regards to aldosterone measurements (323). 
Overall, in contrast to previous studies aldosterone levels in the current study were not found 
to be a prognostic indicator in patients with decompensated HF.  
 
Finally, the aldosterone to renin ratio was univariately associated with outcomes; however, 
that was not in a stepwise fashion and although the mortality risk was higher in patients with 
the highest aldosterone to renin ratio quartile, the worst prognosis was not seen in patients in 
lowest quartile. As discussed in chapter 6, the aldosterone to renin ratio is principally driven 
by renin in patients with HF and that is likely to account for the better outcomes in patients 
with the higher ratio. Nevertheless, treatment with RAAS inhibitors exerts discordant effects 
on RAAS mediators with variable effects on the aldosterone to renin ratio which potentially 
reduce its prognostic significance. Thus, despite the stronger association with features of HF 
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severity in patients not taking a RAAS inhibitor, as previously shown in chapter 7, the 
aldosterone to renin ratio is not as discriminating as PRC in identifying HF patients with 
worse prognosis following RAAS inhibition.  
 
10.4.2 Glucocorticoid levels and survival 
11-deoxycortisol levels were not associated with all-cause mortality in the current cohort. 
That is not entirely surprising given that 11-deoxycortisol is an intermediate corticosteroid 
with weak mineralocorticoid activity. In addition, the 11-deoxycortisol to cortisol ratio, an 
index of 11beta-hydroxylase activity, was not associated with increased risk of mortality in 
the overall population. The association of 11-deoxycortisol to cortisol ratio with prognostic 
markers of HF but no with outcomes indicates that 11beta-hydroxylase was up-regulated in 
patients with features of severe HF, however, the greater activity of this enzyme was not 
related with mortality. Nevertheless, as all-cause mortality was the only end point in the 
current study, an impact of greater 11beta-hydroxylase activity on HF progression and 
hospitalisation or combined end points cannot be excluded.  
 
Cortisol was associated with all-cause mortality at 1year after hospitalisation in univariate 
but not with long term prognosis in the current study; 6 months after hospital admission the 
survival curves of cortisol quartiles were almost parallel and the hazards were proportional. 
These findings indicate that cortisol levels in patients with decompensated HF represent 
mainly the HF severity and comorbidity during hospital admission with decompensated HF. 
In other words cortisol levels are likely to reflect the stress of acute illness but do not confer 
prognostic importance in the long term. That is in accordance with the finding that the risk 
of death is higher early after a hospitalisation for HF and is affected by the length of stay 
which is influenced mainly by HF severity and comorbidity (346). On the other hand, 
whether cortisol is associated with long term prognosis in patients with stable HF has not 
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been examined in this thesis; previous studies reported on the independent prognostic 
significance of cortisol in patients with chronic HF, suggesting a patho-physiological role of 
glucocorticoids in HF progression through the activation of MRs (72) (73). The discrepancy 
in the findings between the current and the above mentioned studies indicate that the 
prognostic cortisol role might be different depending on HF stage.  
 
Finally, the effect of diurnal rhythm on glucocorticoid levels, should be taken into account in 
the interpretation of the findings in the current study. In the studies with the healthy subjects, 
there was a significant decline in cortisol levels from 8am to 12pm during ambulatory blood 
sampling. Blood samples were collected between 8-11am in patients with HF during 
hospital admission; thus, the circadian rhythm is likely to have a prominent effect on the 
association between glucocorticoids and outcomes and potentially limit the prognostic 
power of cortisol. Future studies examining the prognostic value of cortisol with collection 
of blood samples within a narrower time frame in the morning or evening will give further 
insights into the prognostic value of corticosteroids  
 
In conclusion, PRC showed an independent prognostic value in a broad spectrum of patients 
with decompensated HF over and above variables that represent distinct pathophysiological 
pathways, such as age, SBP, urea, history of COPD, haemoglobin, troponin and log(BNP). 
In contrast, cortisol although showed a medium-term prognostic value, it did not remain 
significant following adjustment for similar factors. Renin is the principal regulator of 
RAAS and might contribute directly or indirectly in HF development and progression 
despite treatment with a RAAS inhibitor. Moreover, renin is linked with other pathways, 
such as SNS, playing a pivotal which in HF progression. Measurement of renin in patients 
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with decompensated HF may help identifying those who need further therapeutic measures. 
Future studies will clarify if such a strategy is translated into clinical benefit.  
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11. Chapter Eleven - Associations of CYP11B2 
polymorphisms with mineralo- and gluco-
corticoid secretion and prognosis in patients 
with HF  
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11.1 Introduction 
 
Higher levels of cortisol and aldosterone have been found to be associated with worse 
prognosis in HF (62, 63). The final step in cortisol synthesis from 11-deoxycortisol in adrenal 
ZF is catalysed by the enzyme 11beta-hydroxylase, which is encoded by the CYP11B1 gene. 
Aldosterone synthase, catalyses the final steps of aldosterone production in ZG and is 
encoded by CYP11B2. A common polymorphism (-344C/T) in the promoter region of 
CYP11B2 has been shown to be associated with aldosterone levels and blood pressure (298) 
(301). The -344T allele, moreover, has been consistently associated with a higher 11-
deoxycortisol to cortisol ratio in urine and plasma, which represent an index of impaired 
11beta-hydroxylase efficiency (299) (311).   
 
In patients with HF, the CYP11B2 -344TT genotype has been found to be linked with better 
event-free survival in African-Americans (315). In addition, the same genotype has been 
shown to be associated with better outcomes in patients of European ethnicity following MI 
(317). However, the prognostic significance of CYP11B2 polymorphisms in patients with HF 
of Caucasian origin remains unknown.  
 
The aim of this chapter is to explore the potential impact of CYP11B2 -344 T/C 
polymorphism and IC on mineralo- and gluco- corticoid levels and the 11-deoxycortisol to 
cortisol and aldosterone to PRC ratio in patients of Caucasian origin with decompensated HF. 
In this chapter, I also examine the prognostic significance of CYP11B2 polymorphisms in this 
cohort of patients. 
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11.2 Methods 
 
11.2.1 Study design and laboratory measurements 
The study design and laboratory measurements in the overall hospitalised cohort were 
described in sections 2.3.1 & 2.3.2.  
 
11.2.2 DNA extraction and genotyping 
The methodology of DNA extraction and genotyping of CYP11B2 -344T/C and IC 
polymorphisms was described in section 2.3.3. Genotyping was performed in 699 (96.8%) 
patients for the CYP11B2 -344 T/C polymorphism and in 696 (96.3%) patients for the 
CYP11B2 IC.  
 
11.2.3 Follow-up  
The primary outcome in this study was all-cause mortality, defined as death in and out of the 
hospital from any cause. Survival was defined as the period from the enrollment in the study 
during hospital admission until the time of death or the censor date on 31
st
 of August 2010.  
 
11.2.4 Statistical analysis 
All patient characteristics were expressed as median (IQR) for continuous and as absolute 
number (percentage) for categorical variables. The comparisons among the different 
genotype groups were carried out by the Mann-Whitney and Kruskal-Wallis test for 
continuous variables as appropriate and by the χ2 test for categorical variables. For the 
outcome analyses, Kaplan-Meier event-free (time to death) survival curves were constructed 
for each of the CYP11B2 -344T/C and IC genotypes in the overall hospitalised cohort. The 
log-rank test was used for the comparison of the survival curves by genotypes. Cox 
regression analysis was employed to calculate the HR of all-cause mortality over time 
according to a reference genotype. In addition, given the data from previous studies showing 
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that homozygotes for the -344T allele had better prognosis compared to heterozygotes or 
homozygotes for the -344C allele, CC and TC patients were pooled in one group (CC + TC) 
and compared with TT patients in a separate Kaplan-Meier survival analysis. A p-value <0.05 
was considered significant for all the analyses.  
 
11.3 Results 
 
11.3.1 Genotype distribution  
The clinical characteristics of the 722 patients enrolled in the study during the hospital 
admission were presented in section 4.3.1. The majority of patients (n=714; 98.9%) were of 
Caucasian origin and the rest of the patients were of South Asian and African-Caribbean 
origin. Genotyping for the CYP11B2 -344 T/C polymorphism classified 154 (22%) patients 
as homozygous for the C allele (CC), 345 (49%) as heterozygous (CT) and 200 (29%) as 
homozygous for the T allele (TT). The above genotype frequencies (% CC/CT/TT = 
22%/49%/29%) were consistent with the Hardy-Weinberg equilibrium. Moreover, they were 
very similar to CYP11B2 -344T/C genotype frequencies identified in the Prospective Study 
of Pravastatin in the Elderly at Risk (PROSPER) (% CC/CT/TT = 23%/50%/27%) (Prof Ian 
Ford, personal communication, December 2011). The PROSPER study recruited patients of 
Caucasian origin in Scotland, Ireland and the Netherlands, who had or were at high risk for 
vascular disease (406). In contrast, the genotype frequencies in my study differed markedly 
from the frequencies of -344T/C polymorphism reported in a cohort of African Americans 
from the GRAHF study, a genetic sub-study of the A-HeFT study (% CC/CT/TT = 
6%/32%/62%). That is expected as the 344T allele has been reported to be more prevalent in 
African-Americans (301). 
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Genotyping for the CYP11B2 IC revealed 137 (20%) homozygotes for the conversion allele 
(CON), 321 (46%) heterozygotes (HTZ) and 238 (34%) homozygotes for the wild-type allele 
(WT). The above genotype distribution was consistent with Hardy-Weinberg equilibrium.  
 
11.3.2 Patient characteristics according to CYP11B2 -344T/C genotypes 
The clinical characteristics during hospital admission in patients of the overall cohort 
according to CYP11B2 -344T/C genotypes (CC/TC/TT) are presented in Table 11-1. Patients 
with the CC genotype were more likely to have a history of previous MI compared to patients 
with the TT and TC genotypes. Serum sodium levels were lower in patients with CC and TC 
genotypes and higher in patients with TT genotype. Homozygotes for the C allele were more 
often in NYHA class IV and less often in NYHA class II compared to heterozygotes and 
homozygotes for the T allele, although the above differences failed to reach statistical 
significance. 
 
With regards to plasma glucocorticoid levels, 11-deoxycortisol levels and 11-deoxycortisol to 
cortisol ratio increased in a stepwise fashion according to the increasing number of T alleles. 
Indeed, TT patients were more likely to have higher 11-deoxycortisol levels and 11-
deoxycortisol to cortisol ratio and CC patients were more likely to have lower 11-
deoxycortisol levels and 11-deoxycortisol to cortisol ratio, with TC patients being 
intermediate. No differences in cortisol levels were detected among the three genotype 
subgroups.  
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Looking further at the inter-group differences in 11-deoxycortisol levels and 11-
deoxycortisol to cortisol ratio, 11-deoxycortisol was significantly higher in patients with the 
TT genotype compared to patients with the CC genotype (Figure 11-1 below). Similarly, 11-
deoxycortisol levels remained significantly higher in TC patients compared to CC patients. In 
contrast, TT patients had numerically but not statistically higher 11-deoxycortisol compared 
to TC patients.  
 
 
 
Figure 11-1. 11-deoxycortisol levels in all subjects of the hospitalised cohort according to 
CYP11B2 -344T/C genotypes. Inter-group comparisons performed by Mann-Whitney 
nonparametric testing 
  
373
  
Similar to 11-deoxycortisol, the 11-deoxycortisol to cortisol ratio was found to be 
significantly higher in patients with TT genotype compared with patients with CC genotype 
(Figure 11-2 below). TC patients were more likely to have higher 11-deoxycortisol to cortisol 
ratio compared to CC patients, and TT patients were more likely to have higher 11-
deoxycortisol to cortisol ratio compared to TC patients, but these differences failed to reach 
statistical significance. 
 
 
 
Figure 11-2. 11-deoxycortisol to cortisol ratio in the hospitalised cohort according to 
CYP11B2 -344T/C genotypes. Inter-group comparisons performed by Mann-Whitney 
nonparametric testing 
 
 
 
 
In contrast to 11-deoxycortisol levels and the 11-deoxycortisol to cortisol ratio, plasma 
aldosterone and renin concentrations and the aldosterone to PRC ratio were not different 
among the CYP11B2 -344T/C genotype subgroups. Given the impact of background therapy 
374
  
with a RAAS inhibitor on PRC and aldosterone levels (section 4.3.2.4), I explored further if 
potential associations of CYP11B2 -344T/C polymorphism with aldosterone and the 
aldosterone to PRC ratio (or other clinical characteristics) exist in the absence of background 
treatment with an ACE inhibitor/ARB or aldosterone antagonist (Table 11-2). Aldosterone, 
PRC and the aldosterone to PRC ratio were not different among the genotype groups. In 
contrast to the overall hospitalised cohort, there were no differences in 11-deoxycortisol 
levels and the 11-deoxycortisol to cortisol ratio among patients with different genotypes, 
likely due to the markedly smaller study cohort 
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11.3.3 Patient characteristics according to CYP11B2 IC genotypes 
The clinical characteristics during the hospital admission in patients of the overall cohort 
according to CYP11B2 IC genotypes (Con/Htz/Wt) are presented in Table 11-3. Patients with 
the Con genotype were more likely to be in NYHA functional class II and less likely to be in 
NYHA functional class IV compared to patients with the Htz and Wt genotypes. There was 
also a trend for higher sodium and lower prevalence of elevated troponin in Con patients 
compared to Htz and Wt patients.  
 
With regards to plasma glucocorticoid levels, a trend for higher 11-deoxycortisol and 11-
deoxycortisol to cortisol ratio was present in patients with Con genotype compared to patients 
with Htz and Wt genotypes, however, the differences were not significant.  
 
Similar to the -344T/C genotypes in the hospitalised cohort, no differences in plasma 
aldosterone and renin concentrations and the aldosterone to PRC ratio were seen among the 
CYP11B2 IC genotypes.  
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11.3.4 Association of the CYP11B2 -344T/C polymorphism with prognosis  
During the course of follow-up, 292 deaths occurred in the patients of the overall hospitalised 
cohort. The distribution of the events according to -344T/C genotypes in these patients is 
displayed in Table 11-4 below.  
 
 
Table 11-4. Number and percentage (%) of events according to CY11B2 -344T/C 
genotypes 
CYP11B2 -344 T/C genotype TT TC TT 
Total number of events (%) 58 (37.7%) 148 (42.9) 86 (43%) 
 
 
 
The Kaplan-Meier survival curves for all-cause mortality were not significantly different 
among the three genotypes (TT versus TC versus CC) (Figure 11-3). A corresponding Cox 
regression analysis with the CC genotype as the reference genotype revealed no difference in 
the HR among patients with the TC genotype (HR, 1.141; 95% CI, 0.842 to 1.546; p=0.39) 
and patients with the TT genotype (HR, 1.149; 95% CI, 0.823 to 1.603; p=0.41).  
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Figure 11-3. Event-free survival by CYP11B2 -344 T/C genotypes in the overall 
hospitalised cohort 
 
 
 
When patients with the C allele were pooled in one group (CC + TC) and compared with the 
TT patients, the Kaplan-Meier curves for all-cause mortality were not different (CC + TC 
versus TT) (HR, 1.047; 95% CI, 0.814 to 1.347; p=0.72).  
 
11.3.5 Association of the CYP11B2 IC with prognosis  
For the entire cohort, the Kaplan-Meier survival curves for all-cause mortality were not 
significantly different among the three genotypes (Wt versus Htz versus Con) (Figure 11-4).  
 
A corresponding Cox regression analysis with the Con genotype as the reference category 
revealed no difference in HR among patients with the Htz genotype (HR, 0.976; 95% CI, 
p=0.649 
385
  
0.722 to 1.319); p=0.87) and patients with the Wt genotype (HR, 0.833; 95% CI, 0.638 to 
1.221; p=0.45). 
 
Time (day s)
C
u
m
u
la
ti
v
e
 S
u
rv
iv
a
l 
P
ro
b
a
b
ili
ty
0 200 400 600 800 1000
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
con
htz
wt
 
Figure 11-4. Event-free survival by CYP11B2 IC genotypes in the overall hospitalised 
cohort 
  
p=0.685 
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11.4 Discussion 
 
11.4.1 Associations of CYP11B2 polymorphisms with gluco- and mineralo- corticoid 
secretion 
To the best of my knowledge, this is the first study in patients with HF to show an association 
between the CYP11B2 -344T/C polymorphism and 11-deoxycortisol levels and the 11-
deoxycortisol to cortisol ratio, which is an index of 11beta-hydroxylase efficiency. It has 
been consistently shown that the -344TT genotype is associated with increased basal and 
ACTH stimulated levels of plasma and urine 11-deoxycortisol and 11-deoxycortisol to 
cortisol ratio in healthy subjects (295) (299) (407) (408). Similarly, the TT genotype has been 
correlated with higher urine 11-deoxycortisol to cortisol ratio in patients with hypertension 
(311). The above associations have now been replicated and further extended in a population 
of patients with HF. Both 11-deoxycortisol levels and 11-deoxycortisol to cortisol ratio were 
higher in homozygotes for the T allele compared to homozygotes for the C allele, with 
heterozygotes being intermediate, during the hospital admission. 11-deoxycortisol is 
converted to cortisol by 11beta-hydroxylase in ZF. Classic 11beta-hydroxylase deficiency is 
characterised by a decrease in the synthesis of cortisol and a secondary increase in the 
secretion of 11-deoxycortisol in circulation and a higher 11-deoxycortisol to cortisol ratio. 
The higher 11-deoxycortisol levels and the 11-deoxycortisol to cortisol ratio seen in patients 
with the -344T allele are likely to reflect a relative impairment in 11beta-hydroxylase 
efficiency in these patients.  
 
In contrast to 11-deoxycortisol, no differences were seen in cortisol levels among the 
genotype subgroups. This is in keeping with previous studies in healthy subjects and patients 
with hypertension, where an altered plasma level of 11-deoxycortisol but not cortisol was 
found among the genotypes (295) (299). Under the greater ACTH stimulation in the morning, 
homozygotes for the T allele appear to achieve levels of cortisol similar to heterozygotes and 
387
  
homozygotes of the C allele in expense of higher 11-deoxycortisol levels. In this way, the 
relatively impaired efficiency of 11beta-hydroxylase is not translated into lower levels of the 
biologically active end product but results in higher levels of the precursor.    
 
The association between CYP11B2 -344 T/C polymorphism and 11beta-hydroxylase activity 
seen in patients with HF is in keeping with previous studies in normotensive and 
hypertensive individuals. CYP11B2 and CYP11B1 are homologous and lie in close proximity 
on chromosome 8 in humans. It was initially hypothesized that -344T/C polymorphism is not 
directly linked with the intermediate glucocorticoid phenotype and the causative locus would 
be probably located within CYP11B1; thus, a LD between the two loci would account for the 
above observations (299) (409). Indeed, LD has been demonstrated across the two gene 
regions in normal subjects and patients with hypertension resulting in three common 
haplotypes (312) (313). In these studies, higher 11-deoxycortisol levels were associated with 
the haplotypes that included the -344T allele. Two polymorphisms were further identified in 
the promoter coding region of CYP11B1 in close LD with -344T/C polymorphism (314). 
These polymorphisms were associated with altered gene transcription in response to ACTH 
in vitro and 11beta-hydroxylase activity in patients with hypertension.  
 
In contrast to the associations with glucocorticoid levels, the -344T/C polymorphism was not 
associated with aldosterone levels or the aldosterone to renin ratio in the current study. The  
-344T allele has been previously associated with higher plasma and urine levels of 
aldosterone (298) (300). Moreover, the same allele has been associated with a raised 
aldosterone to renin ratio (410). However, the genotype-phenotype associations between  
-344T/C polymorphism and aldosterone secretion have not been always consistent, with other 
studies reporting no correlation or reporting the CC genotype to be associated with increased 
aldosterone secretion (303) (304) (411). The reasons for the above discrepancies in the 
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literature are not clear and many contributing factors, as differences in the size of studies, 
ethnic and demographic diversity, as well as variation in the background medication, might 
be implicated (412). Nevertheless, in a recent meta-analysis including 2872 patients with 
hypertension, no correlation between the 344T/C polymorphism and aldosterone levels was 
shown (413).  
 
Overall, in this study I demonstrated an association between CYP11B2 -344 T/C 
polymorphism with 11beta-hydroxylase activity in patients with decompensated HF. 
However, no associations were seen between this polymorphism and aldosterone levels or the 
aldosterone to renin ratio. To my knowledge, this is the first study that reports on mineralo- 
and gluco-corticoid levels with respect to CYP11B2 polymorphisms in patients with HF of 
Caucasian origin. 
 
11.4.2 CYP11B2 polymorphisms and prognosis 
No association between CYP11B2 promoter -344T/C polymorphism and mortality was found 
in this cohort of Caucasian patients admitted to hospital with decompensated HF. The results 
of my study do not confirm the previously reported associations between CYP11B2 -344 T/C 
polymorphism and survival in African-American patients with advanced HF as well as in 
patients with MI. Apart from the CYP11B2 -344 T/C polymorphism, the CYP11B2 IC, which 
is in close LD with the -344T/C and has been previously linked with increased aldosterone 
secretion, was not associated also with all-cause mortality in my study.  
 
In a genetic sub-study (GRAHF) (315) of the A-HeFT (316), the CYP11B2 -344C allele was 
associated with worse event-free survival in African-Americans with severe HF. The A-
HeFT was a double-blinded randomised trial of the addition of a fixed combination of 
isosorbide dinitrate and hydralazine or placebo on top of standard therapy in African-
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Americans with advanced HF. All patients were in NYHA class III-IV with LVEF of <35% 
and were taking an ACE inhibitor, diuretic or digoxin. The trial was additionally stratified to 
include patients receiving or not a beta-blocker. The GRAHF was an A-HeFT sub-study 
designed to investigate potential associations of genetic polymorphisms with survival and 
interaction with the pharmacological treatment. The CYP11B2 promoter polymorphism  
-344T/C was one of the first single nucleotide polymorphisms studied in the GRAHF study. 
Patients with the CC genotype reported to have worse and patients with the TT genotypes 
better hospitalisation-free survival among the -344T/C genotypes. In addition, the mortality 
rate was significantly lower in homozygotes for the T allele compared to heterozygotes and 
homozygotes for the C allele. 
 
Similar results were reported in a cohort of patients following MI. The cohort in this study 
was an admixture of different ethnic background groups with those of European ethnicity 
comprising the majority of participants. Interestingly, the genotype frequencies in patients of 
European ethnicity were similar to the genotype distribution in the current study. The 
common finding with the GRAHF, although reporting on patients following MI, was that TT 
patients found to have better survival compared to patient with the CC and TC genotypes. 
 
The reasons for the differences between the current and the above mentioned studies with 
regards to CYP11B2 -344T/C polymorphism and prognosis can only be speculated. Firstly, 
differences in the ethnic background may account for the discrepancy in the results between 
this and the GRAHF study. HF phenotype differs in African-American and Caucasian 
patients, with history of hypertension being more prevalent in the former compared with the 
latter (414). Correspondingly, the genotype frequencies with regards to  
-344T/C polymorphism are different among patients of different ethnic background; the  
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-344T allele is more prevalent in African-Americans (315) and might exert more deleterious 
effects in these patients compared to Caucasians. Indeed, in patients with hypertension 
aldosterone blockers were more effective in lowering blood pressure compared to ARBs in 
African-Americans but not in Caucasians (415). Secondly, differences in the background 
therapy and potential pharmacogenetic interactions might contribute to the different results 
between my study and previous ones. In the GRAHF study homozygotes for the T allele had 
a better response to the combination of isosorbide dinitrate and hydralazine, in terms of 
survival, HF hospitalisation and change in quality of life. Hence, the better survival in 
patients with TT in the GRAHF study might at least partially represent the better response to 
the above agents. In contrast, my study population was predominantly treated with a beta-
blocker, ACE inhibitor or ARB, which to my knowledge have not been shown to exert any 
pharmacogenetic interaction with CYP11B2 polymorphisms. Finally, as the results of the 
GRAFH study were not further replicated by another study in HF patients, a false positive 
result cannot be excluded regarding the associations of CYP11B2 -344 T/C polymorphism 
with outcomes. 
 
None of the previous studies reporting on CYP11B2 polymorphisms and outcomes included 
measurements of mineralo- and gluco-corticoids. The GRAHF study group aiming to identify 
a mechanistic link for the association between the -344T/C polymorphism and prognosis, 
explored the association between the above polymorphism and LV remodeling instead. The -
344C allele was associated with worse LV remodeling at 6 months in patients randomised to 
placebo, whilst the above association was not present in patients of the treatment arm. In 
keeping with that finding, C allele has been associated with increased LV volumes in 
Japanese patients with dilated cardiomyopathy (416). However, similar to the associations of 
CYP11B2 -344 T/C polymorphism with aldosterone secretion, the data regarding the effect of 
the above polymorphism on LV remodeling are conflicting; in a study of Black South 
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African patients with dilated cardiomyopathy, serial echocardiography showed that treatment 
with an ACE inhibitor, diuretic and digoxin (similar to the treatment of the placebo arm in the 
GRAHF study) resulted in improvement of LVEF in CC and TC patients compared to TT 
patients (417). Moreover, in a cohort of African-Americans on standard therapy for HF, the C 
allele predicted improved LV dimensions compared to the T allele (418). In my patients, LV 
remodeling was not examined and any comparisons with the above studies are not applicable. 
However, the discordant results with regards to associations of CYP11B2 -344 T/C 
polymorphism with LV remodeling in the aforementioned studies, even within study groups 
of the same ethnic background, re-emphasise the possibility that other candidate 
polymorphisms within or near the CYP11B2 and in LD with the above polymorphism exert a 
principal functional role. Although CYP11B2 polymorphisms and specifically -344T/C have 
been extensively studied in the past, the impact of the above polymorphism on aldosterone 
secretion is uncertain, not only in molecular but also on clinical level (413). Nevertheless, the 
above polymorphism has been found to be in LD with polymorphisms in the CYP11B1 and 
has additionally been associated with impaired activity of 11beta-hydroxylase. Thus, part of 
the associations previously attributed to CYP11B2 polymorphisms, might be due to 
polymorphisms in CYP11B1, which lies in close proximity to CYP11B2. 11beta-hydroxylase, 
as mentioned before, mediates the final step in cortisol production from 11-deoxycortisol. 
Interestingly, cortisol has been associated with higher blood pressure, LV remodeling 
following MI and worse prognosis in HF (72) (270) (320). Future studies examining both 
CYP11B2 and CYP11B1 polymorphisms with respect to mineralo- and gluco- corticosteroid 
secretion will give further insight into corticosteroid secretion in patients with HF.   
 
In summary, I have demonstrated no association between the CYP11B2 -344 T/C 
polymorphism and survival in a cohort of Caucasian patients with HF. 
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Furthermore, I have identified no correlation between CYP11B2 IC, previously linked with 
aldosterone secretion, and mortality in these patients. Overall, this study does not support the 
application of the above CYP11B2 polymorphisms in clinical practice for the identification of 
Caucasian patients with HF at higher risk of death. 
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12. General Discussion 
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RAAS activity, mineralocorticoid secretion and prognosis in patients with HF 
Although neurohumoral activation is considered as one of the fundamental 
pathophysiological features in patients with chronic HF, RAAS activity in patients with 
decompensated HF has yet to be fully characterised. What little information has been 
reported so far, comes from studies which included patients treated with some form of a 
RAAS inhibitor or diuretic (55) (339) (340), perplexing the interpretation of the findings. 
Indeed, as demonstrated in chapter 4, treatment with an ACE inhibitor/ARB or aldosterone 
blocker exerts discordant effects on the levels of RAAS mediators. Hence, RAAS activity 
during hospitalisation was described in detail in the subgroup of patients not taking a RAAS 
inhibitor in chapter 6. Surprisingly, there was no evidence of increased activation of RAAS in 
these patients, with PRC and aldosterone levels lying on average within the normal range. 
These findings are in keeping with previous reports showing that RAAS is not universally 
activated in untreated patients with congestive HF (57) (58) (60).These studies, however, 
included a small number of patients and did not always reported consistent results. On the 
other hand, the results of my study call into question the generally accepted concept of RAAS 
activation in patients with decompensated HF. Neurohumoral activation was reported in the 
early landmark trials of ACE inhibitors in advanced congestive HF, which although included 
patients on high doses of diuretics, led partially to the undisputed notion of RAAS activation 
in patients with congestive HF.  
 
Why is RAAS activation not prominent in patients with worsening HF? In order to explain 
the previously reported variability of RAAS activation in patients with congestive HF, it has 
been suggested that the RAAS activity depends on the severity of haemodynamic 
compromise and the stage of HF (59). RAAS activity is greater in patients with 
decompensated HF with reduced cardiac output and low blood pressure. Indeed, patients with 
higher PRC had lower blood pressure, more frequently LVSD and remodeling during hospital 
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admission in this study. On the other hand, extracellular volume expansion and normal blood 
pressure are associated with normal or low RAAS activity. Patients included in the current 
study were normotensive or hypertensive with the vast majority having signs of fluid 
overload, features that are likely to account for the normal levels of renin and aldosterone. In 
addition, BNP levels were elevated during hospital admission; raised levels of natriuretic 
peptides are likely to contribute to the lower levels of RAAS mediators, as apart from the 
vasodilating and natriuretic effects, they suppress the activation of the SNS and RAAS (30) 
(124) (127). Overall, the expansion of extracellular fluid volume is likely to exert in 
combination with the activation of natriuretic counter-regulatory system, a prevailing 
inhibiting effect on RAAS activity, overriding the effects of RAAS stimulators during 
hospital admission in the current studies. 
 
Clinical and prognostic markers of HF severity were also examined in relation to RAAS 
activity in patients during hospital admission in chapter 6. RAAS activity was greater, as 
previously mentioned, in patients with lower SBP, LVSD and dilatation, as well as with 
markers of renal dysfunction, showing that higher neurohumoral activity is a characteristic of 
patients with decompensated HF and cardiorenal syndrome. The management of these 
patients in clinical practice remains challenging. Reduction of fluid overload and intracardiac 
filling pressures with diuretics along with haemodynamic support with inotropes, if 
necessary, remains the initial therapeutic approach in the majority of these patients. However, 
this strategy is not necessarily translated into better outcomes in patients with decompensated 
HF despite the symptomatic relief of fluid congestion (419). Unfortunately, newer therapeutic 
agents failed to show mortality benefit in these patients (420). MR activation may contribute 
to decompensation and cardiorenal dysfunction during worsening HF. Indeed, aldosterone 
promotes sodium and water retention through MRs in the kidneys. Alternatively, cortisol 
under conditions of reduced inactivation by 11beta- HSD2 in patients with cardiorenal 
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syndrome may contribute to the fluid retention and worsening of HF through the epithelial 
MRs. Moreover, aldosterone and cortisol (the latter under conditions of altered redox state), 
promote vascular inflammation, oxidative stress, myocardial and renal interstitial fibrosis and 
exert in parallel pro-arrhythmic effects on myocardium by activation of non-epithelial MRs. 
In addition, MR expression is up-regulated in patients with HF and may be associated with 
augmented corticosteroid-induced effects (421). Thus, aldosterone blocker by attenuating the 
MR-induced epithelial and non-epithelial deleterious effects may be beneficial in patients 
with decompensated HF by reducing the risk of progressive pump failure and sudden cardiac 
death and potentially the worsening of renal function in the long term. However, the potential 
benefits of these agents might be compromised by the potential risk of hyperkalaemia or 
early deterioration of renal function especially in patients with chronic kidney disease. 
Appropriate patient selection and serial measurements of electrolytes might overcome these 
issues. 
 
Diuretic therapy leads to reactive neurohumoral activation secondary to reduction in 
intravascular volume and in parallel to a reduction in natriuretic peptide levels due to 
decrease in cardiac filling pressures. These changes are seen early following diuretic 
treatment. It remains unclear, however, whether the dissociation between natriuretic peptides 
and RAAS seen after initiation of diuretic therapy persists in the long term.  
 
In Chapter 7, I demonstrated that PRC  and aldosterone levels were higher 4 to 6 weeks after 
discharge compared with hospital admission secondary to effective diuresis. In parallel, there 
was an improvement in natriuretic peptide levels as reflected by the decline in BNP 
concentration. Natriuretic peptides, as mentioned above, promote diuresis and vasodilation, 
suppress RAAS and SNS activity and enhance parasympathetic action; thus, the decline in 
their levels might have additionally contributed to greater RAAS activity in the medium to 
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long term. Increased RAAS activity is associated with volume expansion, peripheral vascular 
resistance and worse prognosis in patients with HF (55) (285) (353). These findings provide 
evidence that further suppression of RAAS by enhancing the natriuretic peptide system might 
be of therapeutic benefit in patients with chronic HF. Inhibition of natriuretic peptide 
degradation has been examined in combination with an ACE inhibitor as an alternative 
therapeutic strategy in patients with HF (378) (379). However, although this approach 
resulted in an improvement in haemodynamic parameters, it was not further developed 
because of an increase in the frequency of angioedema due to inhibition of bradykinin 
metabolism. Similar approach of inhibiting the breakdown of natriuretic peptides in 
combination with an ARB rather than an ACE inhibitor has been shown to decrease 
natriuretic peptide levels and was associated with improvement in NHYA clinical status and 
left atrial reverse remodeling in patients with HFpSF (380). The same strategy is currently 
being tested in patients with HFrSF and results with regards to potential benefit are awaited.  
 
In chapter 7, I also showed that lower aldosterone to renin ratio in patients with stable HF not 
taking a RAAS inhibitor is associated with markers of HF severity. Moreover, the 
aldosterone to renin ratio was more discriminating than PRC alone in classifying patients 
according to markers of HF severity. Information with regards to the aldosterone to PRC ratio 
in patients with HF is sparse and to my knowledge this is a novel finding. Interestingly, 
aldosterone levels were lower in patients with higher PRC in the subgroup with lower 
aldosterone to renin ratio compared with patients with higher aldosterone and lower PRC in 
the higher aldosterone to renin ratio subgroup. Conversely, BNP was higher in the former 
compared with the latter group indicating that natriuretic peptides may suppress more the 
downstream rather than the upstream components of RAAS. Thus, the aldosterone to renin 
ratio in HF incorporates information about neurohumoral activation, as reflected by the 
higher PRC, and extracellular volume expansion with raised natriuretic peptides, as reflected 
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by lower aldosterone levels, and might exert prognostic significance in patients with chronic 
HF not treated with a RAAS inhibitor. 
 
Finally, chapter 10 examined the prognostic significance of RAAS mediators in the overall 
cohort of patients with decompensated HF. The first important result was that PRC is a risk 
marker for all-cause mortality in patients with decompensated HF among a set of independent 
clinical and laboratory predictors. Renin through direct and indirect effects might affect HF 
progression and clinical outcomes. Moreover, background therapy prior to admission 
modified the PRC-related risk of all-cause mortality. However, treatment with a RAAS 
inhibitor reflects mainly existing cardiovascular disease and co-morbidities rather than the 
medication per se and that may contribute to the prognostic value of PRC. Lastly, the notion 
that further RAAS inhibition with renin inhibitor may exert beneficial effects in patients with 
worsening HF cannot be fully supported by the current findings; the hazard ratios observed 
for PRC, either as continuous or categorical variable, do not provide strong justification for 
that. Interestingly, the results of the ASTRONAUT study were recently published and showed 
that the addition of aliskiren on top of standard medical treatment in hospitalised patients with 
HFrSF had no effect on cardiovascular mortality or HF hospitalisation after 6 or 12 months 
(377). Nevertheless, a subgroup analysis revealed a potential benefit from aliskiren in 
combination with other RAAS inhibitors in non-diabetics with HFrSF and that remains to be 
further investigated in future studies. 
 
The second result of interest in this chapter was that patients with higher aldosterone levels 
did not have worse prognosis compared to patients with lower aldosterone levels. That is in 
contrast to previous findings in patients with worsening HF. However, approximately half of 
these patients were taking an aldosterone blocker. This class of RAAS inhibitors is often 
targeted in patients with severe HF representing a marker of worse prognosis. Given in 
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addition that it increases aldosterone levels, it is likely to contribute to the prognostic 
significance of aldosterone seen in previous studies.  
 
Glucocorticoid secretion and prognosis in patients with HF  
Glucocorticoid levels were normal 24-48 hours after hospital admission in patients with 
decompensated HF as shown in chapter 4. Cortisol is a non-specific indicator of stress and 
someone would expect cortisol levels to be elevated in patients with worsening HF requiring 
in-hospital treatment. Previous studies reported raised cortisol levels in untreated patients 
with severe congestive HF (69) (70). However, other reports showed that cortisol levels were 
elevated one hour after admission and returned to normal twelve hours after initiation of 
treatment in patients with acute cardiogenic pulmonary oedema (343). Thus, it might be 
possible that cortisol levels were higher in my patients on hospital admission and gradually 
normalised one to two days after hospitalisation.  
 
The differences in RAAS activity and other prognostic markers according to glucocorticoid 
secretion during hospital admission were examined in chapter 8. Cortisol levels were 
associated with markers of myocardial wall stress and necrosis as well as with NYHA 
function class. These associations are likely to reflect the stress response according to the 
severity of HF; however, direct effects of glucocorticoids on cardiovascular system might 
represent a mechanistic link between higher levels of cortisol and markers of HF severity. 
Indeed, cortisol has been shown to activate MRs under conditions of altered redox state, 
leading to vascular inflammation, myocardial necrosis and apoptosis. In addition 
glucocorticoids in patients with cardiorenal syndrome potentially activate MRs in epithelial 
tissues promoting fluid retention. The associations of “normal” cortisol levels with strong 
prognostic markers of HF in my study call into question the “normal range” of cortisol in 
patients with HF. In fact, should we reconsider what we mean by “normal” cortisol levels in 
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HF? Alternatively, these findings re-emphasise the potential benefit of MR antagonists, 
which block aldosterone- and cortisol-induced MR activation, in patients with 
decompensated HF.  
 
Interestingly, patients with lower 11-deoxycortisol to cortisol ratio had lower blood pressure, 
higher RAAS activity and LV remodeling during hospital admission. A lower 11-
deoxycortisol to cortisol ratio reflects a higher activity of the late step in glucocorticoid 
synthesis. Chronic ACTH stimulation has been shown to result in up-regulation of 11beta-
hydroxylase activity with more efficient conversion of the substrate to the biologically active 
end product (388) (389). Thus, patients at a more advanced stage of LV remodeling with 
worse haemodynamic status, show apart from RAAS activation, chronic stimulation of the 
glucocorticoid synthetic pathway. This is a novel finding suggesting the presence of HPA 
axis stimulation in patients with features of severe HF. Glucocorticoids up-regulate the 
expression of alpha-1 adrenergic receptors and angiotensin II type I receptor in VSMCs, 
augmenting the effects of noradrenaline and angiotensin II (422) (423). That might be 
teleologically useful in order to maintain tissue perfusion in patients with features of worse 
HF as glucocorticoids exert synergistic effects with the sympathetic system and RAAS 
mediators on the vasculature.  
 
Similar to the overall hospitalised cohort, glucocorticoid levels were on average within the 
normal range in the overall post-discharge cohort as shown in chapter 5. Cortisol levels were 
significantly higher in the small subgroup of patients with glucocorticoid measurements in 
the morning compared with the majority of patients who had blood samples collected in the 
afternoon at follow-up. That indicates that the circadian rhythm continues to operate in 
patients with chronic HF and is in contrast to previous studies that showed abolishment of the 
diurnal rhythm in untreated patients with chronic HF (70). Moreover, this chapter showed no 
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significant change in glucocorticoid secretion between hospital admission and follow-up in 
patients who had blood samples collected only in the morning at both time points.  
 
The findings in chapter 5 elucidate additionally that the lower cortisol levels at the follow-up 
visit compared with hospital admission in the subgroup of patients not taking an oral 
glucocorticoid therapy or RAAS inhibitor both during hospital admission and follow-up, as 
shown in chapter 9, are principally due to the diurnal rhythm effect on glucocorticoid 
secretion. In this latter chapter, patients with stable HF with lower 11-deoxycortisol to 
cortisol ratio had lower blood pressure as well as higher RAAS activity, BNP levels and 
worse kidney function. These findings indicate that the HPA stimulation remained 
chronically higher in patients with features of worse HF. That might be important as 
glucocorticoids exert detrimental effects on the cardiovascular system through activation of 
the GRs and MRs. The deleterious effects of chronic RAAS and SNS activation were not 
fully recognised until introduction of RAAS inhibitors and beta-blockers was shown to 
improve survival and improve re-hospitalisation in patients with chronic HF. The results of 
the current study indicate that the same might apply for the HPA axis. Aldosterone synthase 
inhibitors exert a partial inhibiting effect on 11beta-hydroxylase (351). Thus, apart from 
suppressing aldosterone levels, they could also partially suppress cortisol secretion, 
alleviating thus the detrimental glucocorticoid effects on cardiovascular system. There are, 
however, concerns about inhibition of glucocorticoid secretion in the long term and safety 
and efficacy studies will give answers to these issues.  
  
Finally, in chapter 10 I examined the prognostic value of glucocorticoids in patients with 
decompensated HF. The first result of interest with regards to glucocorticoids was that the 
11-deoxycortisol to cortisol ratio, an index of 11beta-hydroxylase activity, was not correlated 
with prognosis. That is also keeping in line with the finding that CYP11B2 polymorphisms, 
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which were associated with 11beta-hydroxylase activity, were not associated with all-cause 
mortality in patients with decompensated HF. Although greater 11beta-hydroxylase activity 
during worsening HF was associated with markers of HF severity that was not translated into 
worse outcomes. The activity of 11beta-hydroxylase activity might be associated with HF 
progression and hospitalisation rather than hard end points as death, but that cannot be 
answered by the current study. In the same fashion, higher cortisol levels in patients during 
hospital admission were not indicators of worse prognosis in the long term. These findings 
are in contrast to previous reports showing the prognostic value of cortisol in patients with 
chronic HF (72) (73). Thus, higher cortisol levels in patients with decompensated HF might 
represent an indicator of acute illness; indeed cortisol was univariately associated with all-
cause mortality at 1 year after hospital admission. On the other hand, in patients with chronic 
HF they are likely to reflect the greater glucocorticoid secretion in the long term; hence, 
chronic exposure to higher cortisol levels might contribute to increased mortality in these 
patients. 
 
CYP11B2 polymorphisms, corticosteroid secretion and prognosis in patients with HF 
In chapter 11, I examined the differences in corticosteroid levels during hospital admission 
according to CYP11B2 -344T/C and IC polymorphisms in patients of predominantly 
Caucasian origin with HF. This study demonstrated that indexes of relative 11beta-
hydroxylase deficiency, such as higher plasma 11-deoxycortisol levels and 11-deoxycortisol 
to cortisol ratio, were higher in patients with the TT genotype compared to patients with the 
CC genotype. To the best of my knowledge this is a novel finding, extending previous 
findings from patients with hypertension to patients with HF.  
 
The associations between CYP11B2 -344T/C polymorphism and markers of 11beta-
hydroxylase efficiency are likely to be due to variants within the CYP11B1 gene, which lies 
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in close proximity with the CYP11B2 gene. Indeed, tight LD along the CYP11B2/CYP11B1 
locus has been confirmed in previous studies; moreover, specific variants in the 5’ promoter 
region of CYP11B1 gene were found to be in linkage with -344T/C and IC polymorphisms 
and were associated with altered activity of 11beta-hydroxylase. It has been previously 
hypothesised that the impaired 11beta-hydroxylase activity due to specific alleles (T and con) 
of the above polymorphisms results in chronic compensatory increase in ACTH drive, in 
order to maintain cortisol within normal levels (298) (409). These subtle changes in ACTH 
drive, under the synergism of other genetic and environmental factors could potentially result 
in altered response of the ZG cells to other trophins with higher secretion of aldosterone and 
a higher aldosterone to renin ratio in the long term (409).  
 
In this study, I demonstrated no differences in aldosterone levels or the aldosterone to renin 
ratio according to CYP11B2 -344T/C or IC genotypes in patients with HF during hospital 
admission. It is possible that under these circumstances RAAS override any of the ACTH-
stimulating effects on aldosterone secretion. Indeed, there was a significant association 
between aldosterone and PRC levels, indicating that RAAS exerts a dominant role in 
aldosterone secretion in patients with decompensated HF. In contrast aldosterone and cortisol 
were not strongly associated, indicating that ACTH exerts a less dominant effect on the 
regulation of aldosterone secretion in these patients. Moreover, greater ACTH drive, as 
indicated by the lower 11-deoxycortisol to cortisol ratio, was evident in patients with RAAS 
activation and features of HF severity. Thus, any potential effects of subtle changes in ACTH 
drive, potentially driven by CYP11B2 polymorphisms, on aldosterone secretion might be 
overshadowed by the chronic RAAS and ACTH stimulation in patients with HF. Moreover, 
the impact of counter-regulatory pathways, such as the natriuretic peptides, on RAAS and 
aldosterone secretion becomes more prominent in states of fluid overload and systemic 
congestion. Natriuretic peptides inhibit angiotensin- and ACTH-induced aldosterone 
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secretion and thus, the interplay between stimulating and suppressing pathways related to 
mineralocorticoid secretion, may surpass any effects on aldosterone secretion due to subtle 
changes in ACTH levels. Finally, treatment with a RAAS inhibitor exerts discordant effects 
on the levels of RAAS mediators, resulting in dissociation between the up-stream and down-
stream components of the pathway, affecting both aldosterone levels and aldosterone to renin 
ratio. Following the exclusion of patients receiving a RAAS inhibitor, no differences in 
aldosterone levels were identified among patients with different genotypes. However, it 
should be noted that almost all patients were treated with diuretics during hospital admission. 
The doses of diuretic treatment have not been documented in this study and likely to affect 
variably RAAS activity and aldosterone secretion. However, when the aldosterone secretion 
was studied in relation to PRC no differences in the aldosterone to renin ratio were identified 
among the CYP11B2 -344T/C and IC genotypes.  
 
The CYP11B2 polymorphisms were further examined with regards to prognosis in patients 
hospitalised with HF in chapter 11. Both -344T/C and IC polymorphisms were not associated 
with all-cause mortality in these patients. That is in contrast with findings from the GRAHF 
study, which showed that -344 TT genotype is associated with better prognosis in patients of 
African-American origin with severe HF (315). It might be possible that differences in the 
ethnic background might account for the discordance in the results with the previous studies. 
The CYP11B2 -344T allele is more common in African Americans than Caucasians and 
might exert more deleterious phenotypic effects in the former compared with the latter group. 
The -344TT genotype has been associated with aldosterone excess and higher aldosterone to 
renin ratio in African-Americans (301). Aldosterone excess in turn has been associated with 
endothelial dysfunction and this might account partially for the better response of TT patients 
to nitric oxide donor therapy in the A-HeFT substudy. In contrast, in the current study, 
patients were not randomised to any treatment and were predominantly treated with an 
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ACE/ARB and beta-blocker. Pharmacogenetic interactions were not examined in the current 
study; however, no known interactions between CYP11B2 -344T/C polymorphism and these 
agents have been previously reported. Thus, the lack of impact of CYP11B2 polymorphisms 
on the therapeutic benefit of HF modifying disease agents in the current study may contribute 
to the differences with previous findings.  
 
Limitations 
Several limitations should be noted in the discussion of the results of the current thesis. 
RAAS, mineralo- and glucocorticoid secretion was examined in a heterogeneous group of 
patients with HFrSF and HFpSF. Removing the “noise” by excluding patients on a RAAS 
inhibitor led to a modest sample size, especially at the follow-up visit that could potentially 
limit the power of the analyses. Plasma corticosteroid levels were only examined once during 
admission and at follow-up, which might not efficiently reflect the average corticosteroid 
synthesis, which is a highly dynamic process. Corticosteroids exert a diurnal pattern with 
higher levels in the morning and lower levels at night. Although blood samples were 
collected only in the morning (8am - 11am) during hospital admission and mainly in the 
afternoon (1pm -4pm) at the follow-up visit, that is unlikely to have fully prevented the 
impact of diurnal rhythm on the variation of corticosteroid levels measured in patients with 
HF. Indeed, in the studies with healthy volunteers a significant decline in glucocorticoid 
levels was not only seen between morning and afternoon or evening hours but also between 
earlier and later time points during the morning. On the other hand, 24-hour urine collections 
for measurements of corticosteroid excretion rates reflect better the adrenal steroid synthetic 
capacity; however, this is a laborious approach and cumbersome to organise in a “real world” 
study.  
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Furthermore, the timing of blood sampling was not totally standardised with relation to the 
duration of hospitalisation since admission. Blood samples were collected within 24-72 hours 
following admission; most of the patients had blood samples collected within 24 hours with 
the exception of patients admitted to hospital between Friday afternoon and Monday morning 
who had blood samples collected within 24 – 72 hours following hospital admission. That 
might have further increased the variation in glucocorticoid levels due to the different degree 
of improvement in clinical status and HF decompensation- induced stress among patients 
enrolled in the study. Moreover, the lack of standardisation of blood sampling timing with 
relation to the duration of hospitalisation likely contributed to a greater variation in the levels 
of RAAS mediators due to in-hospital treatment with diuretics and RAAS inhibitors.  
 
No echocardiographic measurements related to LV structure were undertaken during the 
follow-up visit; that would allow for assessment if the associations between LV morphology 
parameters and markers of RAAS activity and glucocorticoid secretion identified during the 
hospital admission would be replicated in patients with stable HF. Moreover, ACTH was not 
measured and that might have provided additional information about the HPA axis activity in 
the current studies. Furthermore, there was no control for sodium intake in this study; 
however, my patients were under low-normal salt diet during their hospitalisation.  
 
All cause-mortality has been used as the sole primary end-point in the survival studies of this 
thesis. All-cause mortality is easy to obtain in patients over long term periods of follow-up. 
Moreover, it is objective and unlikely to have been exposed to bias in the ascertainment of the 
events. Nevertheless, prognostic markers that are related with pathophysiological pathways in 
HF and all-cause mortality might be associated with cardiovascular but not necessarily with 
non-cardiovascular deaths. That might be of importance as non-cardiovascular deaths 
comprise a considerable proportion of all-cause mortality in patients with HFrSF following 
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numerous beneficial HF modifying disease therapies (424). In addition, a higher proportion of 
patients with HFpSF would be expected to die from non-cardiovascular causes (425); thus, 
the use of cardiovascular mortality as a secondary end point, especially as a composite of 
cardiovascular death or HF hospitalisation, might have increased sensitivity in the current 
studies. Nevertheless, the information provided by the ISD regarding outcomes was based on 
documentation of the death certificates. The lack of information from medical notes, as well 
as from next of kin, and the lack of cause-specific mortality adjudication led to the selection 
of all-cause mortality as the only end point in the current analyses. Finally, as morbidity data 
were not examined, combined morbidity/mortality outcomes were not used in the current 
studies. 
 
Strengths 
The study population was well-characterised during the hospital admission and at follow-up 
visit in these studies. Patients on RAAS inhibitors were excluded in the studies examining 
RAAS activity, glucocorticoid secretion and their inter-relations, preventing thus any 
alteration of existing relationships and potential confounding findings. Corticosteroids were 
analysed by LCMS, which has been increasingly recognised for its sensitivity and specificity, 
especially with regards to aldosterone, over radioimmunoassays. In addition, PRC was 
measured instead of PRA in this study. As PRC has been reported to be superior to PRA for 
evaluating HF severity (337), this represents another strength in these studies. Finally, 
patients with multiple comorbid conditions were not excluded in the current studies, 
representing a real world population.  
 
Future studies 
Future work relevant to the studies of this thesis would aim to explore: 
 
408
  
 The prognostic significance of RAAS mediators and corticosteroids including 
cardiovascular outcomes, as cardiovascular death, HF hospitalisation or combined end 
points in patients with decompensated HF.  
 The prognostic significance of corticosteroid levels in patients with HF measured in 
the evening or at night. That would potentially increase the prognostic power of 
glucocorticoids as the intra-individual variability in corticosteroid levels due to 
circadian rhythm is smaller in the evening compared with the morning.  
 Associations of variants in the CYP11B1 locus with markers of 11beta-hydroxylase 
activity and mineralocorticoid secretion. 
 Associations of variants in the CYP11B1 locus with prognostic markers  
  
409
  
Conclusions 
Levels of RAAS mediators in patients with decompensated HF not taking a RAAS inhibitor 
were on average within normal levels during hospital admission. PRC and aldosterone levels 
were higher 4-6 weeks after discharge compared to hospital admission in patients not taking a 
RAAS inhibitor at both time points due to decline in the extracellular fluid volume and 
natriuretic peptide levels. Glucocorticoid levels measured 24-48 hours after hospital 
admission were also within the normal range. However, higher cortisol levels were associated 
with strong prognostic markers in patients with decompensated HF. Moreover, lower systolic 
blood systolic pressure, indexes of LV remodeling and higher PRC and BNP levels were 
present in patients with greater HPA activation, as reflected by the lower 11-deoxycortisol to 
cortisol ratio. Most of these associations were also present in patients with stable HF at 
follow-up. PRC but not plasma aldosterone or cortisol, was an independent predictor of all-
cause mortality in patients with decompensated HF. With regards to CYP11B2 
polymorphisms, -344T/C but not IC polymorphism was associated with markers of 11beta-
hydroxylase efficiency during hospital admission. Finally, none of these polymorphisms was 
correlated with aldosterone levels or prognosis in patients with decompensated HF.   
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Table 13-7. Patient (n=453) characteristics of the overall cohort by the median 
aldosterone concentration during follow-up 
Variable Aldosterone 
< 143 pmol/L 
(n=214) 
aldosterone 
≥ 143 pmol/L 
(n=214) 
p-value† 
Age (years) 73 (66 - 78) 71 (65 – 77) 0.328 
Female gender 79 (36.9) 92 (43) 0.200 
NYHA class    
I 5 (2.3) 7 (3.3) 0.558 
II 140 (65.4) 139 (65) 0.919 
III 67 (31.3) 67 (31.3) 1 
IV 2 (0.9) 1 (0.5) 0.562 
Medical history    
HF 88 (41.1) 88 (41.1) 1 
MI 90 (42.1) 94 (43.9) 0.696 
Angina 118 (55.1) 117 (54.7) 0.923 
Diabetes mellitus 61 (28.5) 73 (34.1) 0.211 
Hypertension 130 (60.8) 145 (67.8) 0.130 
AF 105 (49.1) 117 (54.7) 0.246 
CVA/TIA 42 (19.6) 42 (19.6) 1 
Physiological measurements   
BMI (kg/m
2
) 27.8 (24.1 - 32.9) 27.4 (23.6 - 32.2) 0.437 
Pulse rate (bpm) 72 (64 - 82) 74 (65 - 88.3) 0.075 
SBP (mmHg) 129 (115 - 144) 129 (113.8 - 145) 0.818 
DBP (mmHg) 66 (58 - 74) 69 (58 - 79) 0.036 
Signs of fluid congestion    
Elevated JVP 28 (15.4) 29 (15.7) 0.939 
Peripheral oedema 71 (33.2) 71 (33.2) 1.000 
ECG rhythm    
SR 133 (62.2) 125 (58.4) 0.429 
AF 72 (33.6) 79 (36.9) 0.479 
Echo measurements    
LVEF 40 (32 - 48) 41 (30 - 48) 0.990 
Laboratory measurements (blood)   
BNP (pg/ml) 405.5 (237 - 808.8) 394 (177.8 - 816.8) 0.223 
Troponin I ≥ 0.04 (μg/L) 36 (16.8) 39 (18.2) 0.703 
Sodium (mmol/L) 140 (137 – 141) 139 (137 - 141) 0.042 
Potassium (mmol/L) 4.1 (3.8 - 4.4) 4 (3.7 - 4.3) 0.042 
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Variable Aldosterone 
< 143 pmol/L 
(n=214) 
aldosterone 
≥ 143 pmol/L 
(n=214) 
p-value† 
Urea (mmol/L) 9.1 (6.4 - 12.2) 8.2 (6.7 - 11.5) 0.503 
Creatinine (μmol/L) 105.5 (88 - 130) 105.5 (87 - 134.5) 0.924 
eGFR (ml/min/1.73m
2
) 60 (43 - 60) 58 (43 - 60) 0.672 
eGFR <60ml/min/1.73m
2
 106 (49.5) 111 (51.9) 0.629 
Cholesterol (total) (mmol/L) 3.9 (3.3 - 4.8) 4.1 (3.3 - 4.9) 0.549 
HDL (mmol/L) 1.1 (0.9 - 1.3) 1 (0.8 - 1.4) 0.888 
CRP (mg/L) 5 (2.6 - 12.3) 5.4 (2.6 - 12) 0.919 
Cortisol (nmo/L) 195.7 (137.7 - 269.6) 241.1 (164.4 - 334.8) <0.001 
11-deoxycortisol (pmol/L) 457.6 (295 – 668) 484.2 (287.9 - 781.2) 0.215 
11-deoxycortisol/cortisol (10
-3
) 2.54 (1.47 - 3.84) 2.11 (1.27 - 3.55) 0.071 
PRC (mIU/L) 62.8 (24.3 - 284.6) 116.5 (37.7 - 368.3) 0.021 
Aldosterone/PRC 1.01 (0.20 - 3.62) 2.28 (0.62 - 9.39) <0.001 
TSH (mIU/L 1.6 (0.9 - 2.3) 1.5 (0.9 - 2.4) 0.780 
Haemoglobin (g/dl) 12.5 (11.1 - 13.6) 12.5 (11.4 - 13.6) 0.497 
Cardiovascular medication   
Diuretic  209 (97.7) 212 (99.1) 0.253 
ACE inhibitor 167 (78) 142 (66.4) 0.007 
ACE inhibitor or ARB 181 (84.6) 160 (74.8) 0.012 
Beta-blocker 158 (73.8) 134 (62.6) 0.013 
Aldosterone antagonist 18 (8.4) 41 (19.2) 0.001 
Digoxin 49 (22.9) 55 (25.7) 0.499 
Anti-arrhythmic   6 (2.8) 17 (7.9) 0.018 
Aspirin 125 (58.4) 117 (54.7) 0.435 
Statin 163 (76.2) 157 (73.4) 0.504 
Continuous variables are presented as median (IQR). Categorical variables are presented as number 
(percentage). 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
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Table 13-8. Patient (n=453) characteristics of the overall cohort by the median PRC 
during follow-up 
Variable PRC 
< 92.8 mIU/L 
(n=222) 
PRC 
≥ 92.8 mIU/L 
(n=223) 
p-value† 
Age (years) 73 (66 - 78) 71 (64 – 78) 0.109 
Female gender 101 (45.5) 76 (34.1) 0.014 
NYHA class    
I 9 (4) 3 (1.4) 0.078 
II 147 (66.2) 138 (61.9) 0.341 
III 64 (28.8) 80 (35.9) 0.112 
IV 2 (0.9) 2 (0.9) 0.996 
Medical history    
HF 75 (33.8) 108 (48.4) 0.002 
MI 79 (35.6) 114 (51.1) 0.001 
Angina 115 (51.8) 129 (57.9) 0.200 
Diabetes mellitus 68 (30.6) 72 (32.3) 0.707 
Hypertension 147 (66.2) 142 (63.7) 0.575 
AF 127 (57.2) 105 (47.1) 0.033 
CVA/TIA 46 (20.7) 42 (18.8) 0.617 
Physiological measurements   
BMI (kg/m
2
) 27.9 (24.1 - 33.1) 27.4 (23.5 - 31.6) 0.262 
Pulse rate (bpm) 74 (64 - 87.3) 74 (65 - 85) 0.850 
SBP (mmHg) 137 (122 - 151) 121 (109 - 135) <0.001 
DBP (mmHg) 70.5 (61 - 81) 63 (56 - 71) <0.001 
Pulse pressure (mmHg) 63.5 (50 - 81) 58 (42 - 71) <0.001 
Signs of fluid congestion    
Elevated JVP 23 (12.3) 37 (19.1) 0.070 
Peripheral oedema 79 (35.6) 72 (32.3) 0.462 
ECG rhythm    
SR 125 (56.3) 140 (62.8) 0.164 
AF 90 (40.5) 71 (31.8) 0.056 
Echo measurements    
LVEF 41 (33 - 48) 39.5 (29.8 - 47) 0.099 
Laboratory measurements (blood)   
BNP (pg/ml) 419 (214.3 - 822.3) 349 (191 - 810) 0.152 
Troponin I ≥ 0.04 (μg/L) 41 (18.5) 40 (17.9) 0.885 
Sodium (mmol/L) 140 (138 - 142) 138 (136 - 140) <0.001 
433
  
Variable PRC 
< 92.8 mIU/L 
(n=222) 
PRC 
≥ 92.8 mIU/L 
(n=223) 
p-value† 
Potassium (mmol/L) 4.1 (3.7 - 4.3) 4.1 (3.8 - 4.3) 0.372 
Urea (mmol/L) 8 (6.3 - 10.7) 9.2 (6.7 - 12.8) 0.006 
Creatinine (μmol/L) 101.5 (86 - 122) 110 (89 - 140) 0.004 
eGFR (ml/min/1.73m
2
) 60 (46 - 60) 55 (40 - 60) 0.010 
eGFR <60ml/min/1.73m
2
 97 (43.7) 127 (57) 0.005 
Cholesterol (total) (mmol/L) 3.9 (3.3 - 5.1) 4.1 (3.4 - 4.8) 0.605 
HDL (mmol/L) 1.1 (0.9 - 1.3) 1 (0.8 - 1.3) 0.131 
CRP (mg/L) 5 (2.7 - 14) 5.5 (2.5 - 11) 0.707 
Cortisol (nmo/L) 212 (138.6 - 294.2) 218.2 (154.4 - 298.4) 0.379 
11-deoxycortisol (pmol/L) 460.3 (288.4 - 749.3) 468.5 (289.6 - 707.7) 0.948 
11-deoxycortisol/cortisol (10
-3
) 2.30 (1.49 - 3.65) 2.36 (1.28 - 3.79) 0.487 
Aldosterone (pmol/L) 120.7 (68.9 - 216.3) 168.2 (86.6 - 329.2) 0.001 
Aldosterone/PRC 4.76 (2.15 - 13.7) 0.44 (0.12 - 1.24) <0.001 
TSH (mIU/L 1.5 (0.9 - 2.4) 1.6 (0.9 - 2.4) 0.689 
Haemoglobin (g/dl) 12.4 (11.2 - 13.5) 12.6 (11.2 - 13.7) 0.542 
Cardiovascular medication    
Diuretic  216 (97.3) 222 (99.6) 0.056 
ACE inhibitor 150 (67.6) 175 (78.5) 0.010 
ACE inhibitor or ARB 167 (75.2) 189 (84.8) 0.012 
Beta-blocker 159 (71.6) 146 (65.5) 0.162 
Aldosterone antagonist 14 (6.3) 49 (22) <0.001 
Digoxin 54 (24.3) 57 (25.6) 0.763 
Anti-arrhythmic   11 (5) 14 (6.3) 0.544 
Aspirin 115 (51.8) 135 (60.6) 0.063 
Statin 158 (71.2) 171 (76.7) 0.186 
Continuous variables are presented as median (IQR). Categorical variables are presented as number 
(percentage). 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables. 
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Table 13-9. Patient (n=453) characteristics of the overall cohort by the median 
aldosterone to PRC during follow-up 
Variable aldosterone to PRC 
<1.51 
(n=213) 
aldosterone to PRC 
≥1.51 
(n=213) 
p-value† 
Age (years) 71 (63 - 77) 73 (67 - 79) 0.021 
Female gender 69 (32.4) 101 (47.4) 0.002 
NYHA class    
I 3 (1.4) 9 (4.2) 0.079 
II 133 (62.4) 144 (67.6) 0.264 
III 75 (35.2) 59 (27.7) 0.095 
IV 2 (0.9) 1 (0.5) 0.562 
Medical history    
HF 100 (47) 75 (35.2) 0.014 
MI 104 (48.8) 80 (37.6) 0.019 
Angina 125 (58.7) 110 (51.6) 0.144 
Diabetes mellitus 75 (35.2) 58 (27.2) 0.075 
Hypertension 134 (62.9) 139 (65.3) 0.614 
AF 100 (47) 120 (56.3) 0.052 
CVA/TIA 43 (20.2) 40 (18.8) 0.714 
Physiological measurements   
BMI (kg/m
2
) 27.5 (23.7 - 32) 27.6 (23.9 - 33) 0.687 
Pulse rate (bpm) 72 (65 - 82) 75 (64 - 88) 0.124 
SBP (mmHg) 122 (109 - 136) 137 (131.5 - 151) <0.001 
DBP (mmHg) 64 (56 - 72) 70 (60 - 80) <0.001 
Signs of fluid congestion    
Elevated JVP 36 (19.9) 21 (11.4) 0.026 
Peripheral oedema 66 (31) 75 (35.2) 0.354 
ECG rhythm    
SR 137 (64.3) 120 (56.3) 0.092 
AF 64 (30.1) 86 (40.4) 0.026 
Echo measurements    
LVEF 39 (30 - 46) 41 (33 - 49) 0.014 
Laboratory measurements (blood)   
BNP (pg/ml) 392 (208.5 - 828.5) 415 (207 - 810.5) 0.655 
Troponin I ≥ 0.04 (μg/L) 36 (16.9) 39 (18.3) 0.703 
Sodium (mmol/L) 139 (136 – 141) 140 (138 - 141) <0.001 
Potassium (mmol/L) 4.1 (3.8 - 4.4) 4 (3.7 - 4.2) 0.001 
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Variable aldosterone to PRC 
<1.51 
(n=213) 
aldosterone to PRC 
≥1.51 
(n=213) 
p-value† 
Urea (mmol/L) 9.2 (6.8 - 13.2) 8.1 (6.3 - 10.7) 0.014 
Creatinine (μmol/L) 110 (91.5 - 137.5) 101 (84 – 127) 0.004 
eGFR (ml/min/1.73m
2
) 56 (42 - 60) 60 (44 - 60) 0.111 
eGFR <60ml/min/1.73m
2
 120 (56.3) 96 (45.1) 0.020 
Cholesterol (total) (mmol/L) 4 (3.3 - 4.8) 4 (3.5 - 4.9) 0.243 
HDL (mmol/L) 1 (0.8 - 1.3) 1.1 (0.9 - 1.4) 0.007 
CRP (mg/L) 5.5 (2.5 - 11.8) 5 (2.6 - 12) 0.682 
Cortisol (nmo/L) 209.2 (154.4 - 288.1) 220.2 (144.1 - 306.6) 0.780 
11-deoxycortisol (pmol/L) 468.8 (309.5 - 729.6) 454.3 (257.9 - 735.2) 0.403 
11-deoxycortisol/cortisol (10
-3
) 2.48 (1.38 - 3.78) 2.16 (1.38 - 3.67) 0.411 
Aldosterone (pmol/L) 107.3 (50.7 - 220.9) 180.7 (101.9 - 299.7) <0.001 
PRC (mIU/L) 318.5 (118 - 961) 29.5 (11 – 68) <0.001 
TSH (mIU/L 1.6 (0.9 - 2.2) 1.5 (0.9 - 2.5) 0.986 
Haemoglobin (g/dl) 12.6 (11.2 - 13.7) 12.4 (11.3 - 13.5) 0.973 
Cardiovascular Medication    
Diuretic  211 (99.1) 208 (97.7) 0.253 
ACE inhibitor 179 (84) 130 (61) <0.001 
ACE inhibitor or ARB 194 (91.1) 146 (68.5) <0.001 
Beta-blocker 146 (68.5) 145 (68.1) 0.917 
Aldosterone antagonist 38 (17.8) 21 (9.9) 0.017 
Digoxin 49 (23) 54 (25.4) 0.572 
Anti-arrhythmic   10 (4.7) 13 (6.1) 0.520 
Aspirin 129 (60.6) 113 (53.1) 0.118 
Statin 165 (77.5) 153 (71.8) 0.181 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables.  
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Table 13-10. Patient (n=453) characteristics of the overall cohort according to the 
median cortisol value during follow-up 
Variable cortisol 
<215.8 nmol/L 
(n=213) 
cortisol 
<215.8 nmol/L 
(n=214) 
p-value† 
Age (years) 71 (65 - 77) 73 (66 - 79) 0.082 
Female gender 90 (42.3) 80 (37.4) 0.304 
NYHA class    
I 8 (3.8) 4 (1.9) 0.238 
II 141 (66.2) 137 (64) 0.637 
III 63 (29.6) 71 (33.2) 0.423 
IV 1 (0.5) 2 (0.9) 0.565 
Medical history    
HF 92 (43.2) 83 (38.8) 0.354 
MI 89 (41.8) 95 (44.4) 0.586 
Angina 117 (54.9) 118 (55.1) 0.965 
Diabetes mellitus 55 (25.8) 78 (36.5) 0.018 
Hypertension 129 (60.6) 145 (67.8) 0.121 
AF 112 (52.6) 109 (50.9) 0.733 
CVA/TIA 46 (21.6) 38 (17.8) 0.318 
Physiological measurements   
BMI (kg/m
2
) 28 (24.5 - 32.8) 27 (23.2 - 32.2) 0.062 
Pulse rate (bpm) 74 (63 - 84) 73 (65 - 87.3) 0.846 
SBP (mmHg) 129 (116 - 145) 129 (111 - 144) 0.432 
DBP (mmHg) 67 (59 - 76) 67 (57 – 76) 0.643 
Signs of fluid congestion    
Elevated JVP 152 (84.4) 150 (84.6) 0.973 
Peripheral oedema 152 (71.4) 133 (62.2) 0.043 
Signs of fluid congestion    
Elevated JVP 28 (15.6) 29 (15.4) 0.973 
Peripheral oedema 61 (28.6) 81 (37.9) 0.043 
ECG rhythm    
SR 127 (59.6) 131 (61.2) 0.737 
AF 77 (36.2) 73 (34.1) 0.659 
Echo measurements    
LVEF 41 (41 - 48) 40 (30 - 47.8) 0.166 
Laboratory measurements (blood)   
BNP (pg/ml) 334 (179 - 783) 471 (245.8 - 892.3) 0.006 
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Variable cortisol 
<215.8 nmol/L 
(n=213) 
cortisol 
<215.8 nmol/L 
(n=214) 
p-value† 
Troponin I ≥ 0.04 (μg/L) 33 (15.5) 42 (19.6) 0.262 
Sodium (mmol/L) 139 (137 - 141) 139 (137 - 141) 0.688 
Potassium (mmol/L) 4 (3.8 - 4.3) 4.1 (3.7 - 4.5) 0.092 
Urea (mmol/L) 7.8 (6.0 - 10.7) 9.9 (7.2 - 12.6) <0.001 
Creatinine (μmol/L) 99 (84 - 119) 114 (91 - 141.3) <0.001 
eGFR (ml/min/1.73m
2
) 60 (49 - 60) 53 (39 - 60) <0.001 
eGFR <60ml/min/1.73m
2
 83 (39) 132 (61.7) <0.001 
Cholesterol (total) (mmol/L) 4.1 (3.5 - 4.8) 4 (3.1 - 4.9) 0.299 
HDL (mmol/L) 1.1 (0.9 - 1.3) 1 (0.8 - 1.3) 0.273 
CRP (mg/L) 4.3 (2.5 – 9.0) 7.4 (3.1 - 16.3) <0.001 
11-deoxycortisol (pmol/L) 384.2 (209.2 - 595.4) 605.5 (342.8 - 939.1) <0.001 
11-deoxycortisol/cortisol (10
-3
) 2.91 (1.85 - 4.3) 1.79 (1.2 - 3.1) <0.001 
Aldosterone (pmol/L) 120.5 (68.9 - 225.5) 171.1 (85.3 - 301) 0.003 
PRC (mIU/L) 85.4 (233.3 - 365.5) 92.8 (29.4 - 276.4) 0.887 
Aldosterone/PRC 1.45 (0.34 - 5.32) 1.59 (0.46 - 4.94) 0.360 
TSH (mIU/L 1.4 (0.9 - 2.4) 1.6 (0.9 - 2.4) 0.171 
Haemoglobin (g/dl) 12.6 (11.4 - 13.7) 12.3 (11.1 - 13.5) 0.085 
Cardiovascular medication    
Diuretic  209 (98.1) 211 (98.6) 0.698 
ACE inhibitor 157 (73.7) 151 (70.6) 0.468 
ACE inhibitor or ARB 174 (81.7) 166 (77.6) 0.291 
Beta blocker 145 (68.1) 145 (67.8) 0.944 
Aldosterone antagonist 30 (14.1) 29 (13.6) 0.873 
Digoxin 52 (24.4) 53 (24.8) 0.932 
Anti-arrhythmic   10 (4.7) 13 (6.1) 0.528 
Aspirin 119 (55.9) 122 (57) 0.812 
Statin 154 (72.3) 166 (77.6) 0.209 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables.  
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Table 13-11. Patient (n=453) characteristics of the overall cohort by the median 11-
deoxycortisol value during follow-up 
Variable 11-deoxycortisol 
<465.7 pmol/L 
(n=209) 
11-deoxycortisol 
≥465.7 pmol/L 
(n=208) 
p-value† 
Age (years) 72(65 - 78) 71 (66 - 78) 0.952 
Female gender 89 (42.6) 74 (35.6) 0.143 
NYHA class    
I 9 (4.3) 3 (1.4) 0.080 
II 142 (67.9) 129 (62) 0.205 
III 151 (72.3) 135 (64.9) 0.106 
IV 0 (0) 3 (1.4) 0.081 
Medical history    
HF 80 (38.3) 91 (43.8) 0.256 
MI 90 (43.1) 91 (43.8) 0.887 
Angina 117 (56) 112 (53.9) 0.661 
Diabetes mellitus 57 (27.3) 75 (36.1) 0.054 
Hypertension 137 (65.6) 131 (63) 0.584 
AF 98 (46.9) 115 (55.3) 0.086 
CVA/TIA 44 (21.1) 39 (18.8) 0.556 
Physiological measurements   
BMI (kg/m
2
) 27.6 (23.3 - 32.2) 27.6 (24.3 - 32.9) 0.497 
Pulse rate (bpm) 74 (64 - 86.5) 73 (65 - 84.8) 0.979 
SBP (mmHg) 129 (113 - 143.5) 129 (114 - 144.8) 0.665 
DBP (mmHg) 66 (56 - 76) 68 (59 - 76) 0.194 
Signs of fluid congestion    
Elevated JVP 26 (14.7) 30 (16.7) 0.607 
Peripheral oedema 67 (32.1) 72 (34.6) 0.580 
ECG rhythm    
SR 134 (64.1) 121 (58.2) 0.213 
AF 66 (31.6) 77 (37) 0.242 
Echo measurements    
LVEF 42 (50-31) 39 (46-31) 0.032 
Laboratory measurements (blood)   
BNP (pg/ml) 361 (203.5 - 776) 472 (206.3 - 950.8) 0.083 
Troponin I ≥ 0.04 (μg/L) 31 (14.8) 41 (19.7) 0.187 
Sodium (mmol/L) 139 (137 - 141) 140 (137 - 141) 0.658 
Potassium (mmol/L) 4 (3.7 - 4.3) 4.1 (3.8 - 4.3) 0.188 
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Variable 11-deoxycortisol 
<465.7 pmol/L 
(n=209) 
11-deoxycortisol 
≥465.7 pmol/L 
(n=208) 
p-value† 
Urea (mmol/L) 8 (6.2 - 11.6) 9 (6.8 - 12.3) 0.190 
Creatinine (μmol/L) 103 (87 - 129) 105.5 (88 - 133.5) 0.579 
eGFR (ml/min/1.73m
2
) 59 (43 - 60) 60 (44 - 60) 0.877 
eGFR <60ml/min/1.73m
2
 106 (50.7) 103 (49.5) 0.807 
Cholesterol (total) (mmol/L) 4.1 (3.4 - 4.8) 3.9 (3.2 - 4.8) 0.426 
HDL (mmol/L) 1.1 (0.9 - 1.3) 1 (0.8 - 1.3) 0.087 
CRP (mg/L) 5.3 (2.7 - 11) 4.6 (2.4 - 13.8) 0.730 
Cortisol (nmo/L) 186.3 (123.9 - 255.6) 265.5 (181.7 - 360.2) <0.001 
11-deoxycortisol/cortisol (10
-3
) 1.46 (0.89 - 2.44) 3.32 (2.26 - 4.9) <0.001 
Aldosterone (pmol/L) 129.3 (67.7 - 266.2) 147.8 (84 - 269.9) 0.229 
PRC (mIU/L) 94.3 (28.9 - 302.9) 94.4 (24.8 - 400.2) 0.689 
Aldosterone/PRC 1.55 (0.42 - 4.97) 1.40 (0.36 - 6.3) 0.972 
TSH (mIU/L 1.5 (0.85 - 2.3) 1.6 (0.9 - 2.4) 0.294 
Haemoglobin (g/dl) 12.4 (11.2 - 13.4) 12.7 (11.4 - 14.1) 0.039 
Cardiovascular medication   
Diuretic  203 (97.1) 207 (99.5) 0.057 
ACE inhibitor 144 (68.9) 161 (77.4) 0.050 
ACE inhibitor or ARB 165 (79) 170 (81.7) 0.475 
Beta-blocker 134 (64.1) 153 (73.6) 0.037 
Aldosterone antagonist 28 (13.4) 31 (14.9) 0.659 
Digoxin 43 (20.6) 57 (27.4) 0.102 
Anti-arrhythmic 12 (5.7) 10 (4.8) 0.670 
Aspirin 121 (57.9) 117 (56.3) 0.734 
Statin 153 (73.2) 161 (77.4) 0.320 
Continuous variables are presented as median (IQR). Categorical variables are presented as number (percentage) 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables.  
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Table 13-12. Patient (n=453) characteristics of the overall cohort by the median 11-
deoxycortisol to cortisol during follow-up 
Variable 11-deoxycortisol to 
cortisol <2.33 x10
-3
 
(n=207) 
11-deoxycortisol to 
cortisol ≥2.33 x10-3 
(n=208) 
p-value† 
Age (years) 72 (66 - 79) 71 (65 – 77) 0.317 
Female gender 85 (41.1) 76 (36.5) 0.344 
NYHA class    
I 6 (2.9) 6 (2.9) 0.993 
II 132 (63.8) 137 (65.9) 0.655 
III 68 (32.9) 63 (30.3) 0.575 
IV 1 (0.5) 2 (0.96) 0.565 
Medical history    
HF 80 (38.7) 90 (43.3) 0.338 
MI 89 (43) 92 (44.2) 0.800 
Angina 115 (55.6) 114 (54.8) 0.878 
Diabetes mellitus 65 (31.4) 66 (31.7) 0.942 
Hypertension 137 (66.2) 129 (62) 0.377 
AF 99 (47.8) 112 (53.9) 0.220 
CVA/TIA 41 (19.8) 42 (20.2) 0.922 
Physiological measurements   
BMI (kg/m
2
) 26.8 (23.2 - 31.5) 28 (24.6 - 33.7) 0.030 
Pulse rate (bpm) 73 (65 - 86) 73 (65 - 85.8) 0.672 
SBP (mmHg) 125 (110 - 140) 131.5 (117.3 - 147) 0.008 
DBP (mmHg) 66 (56 - 76) 68 (59 - 76) 0.165 
Signs of fluid overload    
Elevated JVP 23 (12.5) 33 (19.1) 0.088 
Peripheral oedema 78 (37.7) 60 (28.9) 0.056 
ECG rhythm    
SR 135 (65.2) 120 (57.7) 0.115 
AF 62 (30) 79 (38) 0.084 
Echo measurements    
LVEF 41 (32 - 49) 40 (30 - 47) 0.228 
Laboratory measurements (blood)   
BNP (pg/ml) 429 (245 - 920) 345.5 (175.5 - 790.8) 0.050 
Troponin I ≥ 0.04 (μg/L) 37 (17.9) 35 (16.8) 0.778 
Sodium (mmol/L) 139 (137 - 141) 140 (137 - 141) 0.770 
Potassium (mmol/L) 4.0 (3.7 - 4.3) 4.1 (3.8 - 4.3) 0.228 
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Variable 11-deoxycortisol to 
cortisol <2.33 x10
-3
 
(n=207) 
11-deoxycortisol to 
cortisol ≥2.33 x10-3 
(n=208) 
p-value† 
Urea (mmol/L) 9.3 (7.0 - 12.3) 8.1 (6.0 - 11.2) 0.009 
Creatinine (μmol/L) 112 (86 - 123) 102 (86 - 123) 0.005 
eGFR (ml/min/1.73m
2
) 54 (40- 60) 60 (48 - 60) 0.001 
eGFR <60ml/min/1.73m
2
 122 (58.9) 85 (40.9) <0.001 
Cholesterol (total) 
(mmol/L) 
3.9 (3.2 - 4.8) 4 (3.4 - 4.8) 0.446 
HDL (mmol/L) 1.1 (0.85 - 1.3) 1 (0.8 - 1.3) 0.609 
CRP (mg/L) 6.2 (2.8 - 14) 4.3 (2.5 - 9.1) 0.011 
Cortisol (nmo/L) 255.6 (190.4 - 325.4) 180.1 (112.8 - 269.4) <0.001 
11-deoxycortisol (pmol/L) 322.1 (196.7 - 476.5) 674.3 (450 - 980) <0.001 
Aldosterone (pmol/L) 156.8 (71.4 - 293.3) 134.1 (79.6 - 232.2) 0.084 
PRC (mIU/L) 92.8 (30.2 - 297.5) 94.4 (23.4 - 372.8) 0.933 
Aldosterone/PRC 1.66 (0.46 - 4.72) 1.33 (0.34 - 6.21) 0.338 
TSH (mIU/L 1.6 (0.9 - 2.6) 1.4 (0.85 - 2.2) 0.137 
Haemoglobin (g/dl) 12.2 (11.1 - 13.4) 12.9 (11.5 - 14.2) <0.001 
Cardiovascular medication   
Diuretic  202 (97.6) 206 (99) 0.250 
ACE inhibitor 146 (70.5) 157 (75.5) 0.256 
ACE inhibitor or ARB 159 (76.8) 174 (83.7) 0.080 
Beta-blocker 131 (63.3) 154 (74) 0.018 
Aldosterone antagonist 30 (14.5) 29 (13.9) 0.872 
Digoxin 43 (20.8) 57 (27.4) 0.114 
Anti-arrhythmic   16 (7.7) 6 (2.9) 0.028 
Aspirin 120 (58) 117 (56.3) 0.723 
Statin 156 (75.4) 157 (75.5) 0.978 
Continuous variables are presented as median (IQR). Categorical variables are presented as number 
(percentage). 
 
† Mann-Whitney test was used for continuous variables and χ2 test for categorical variables.  
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